Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein

Abstract

The disclosure is directed to compounds of Formula I

Description

TECHNICAL FIELD

The disclosure is directed to MCL-1 inhibitors and methods of their use.

BACKGROUND

Apoptosis (programmed cell death) is a highly conserved cellular process that is required for embryonic development and normal tissue homeostasis (Ashkenazi A. et al., Nat. Rev. Drug Discov. 2017, 16, 273-284). Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation as well as biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, resulting in its disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signaling pathways (Cory S. et al., Nature Review Cancer 2002, 2, 647-656; Thomas L. W. et al., FEBS Lett. 2010, 584, 2981-2989; Adams J. M. et al., Oncogene 2007, 26, 1324-1337)

The Bcl-2 protein family, which includes both pro-apoptotic and anti-apoptotic members, plays a pivotal role in the regulation of the apoptosis process (Youle R. J. et al., Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59; Kelly G. L. et al., Adv. Cancer Res. 2011, 111, 39-96). Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1 are anti-apoptotic proteins and they share a common BH regions. In contrast, the pro-apoptotic family members are divided into two groups. The multi-region pro-apoptotic proteins, such as Bax, Bak and Bok, are conventionally thought to have BH1-3 regions, whereas the BH3-only proteins are proposed to share homology in the BH3 region only. Members of BH3-only proteins include Bad, Bim, Bid, Noxa, Puma, Bik/Blk, Bmf, Hrk/DP5, Beclin-1 and Mule (Xu G. et al., Bioorg. Med. Chem. 2017, 25, 5548-5556; Hardwick J. M. et al., Cell. 2009, 138, 404; Reed J. C., Cell Death Differ. 2018, 25, 3-6; Kang M. H. et al., Clin Cancer Res 2009, 15, 1126-1132). The pro-apoptotic members (such as BAX and BAK), upon activation, form a homo-oligomer in the outer mitochondrial membrane that leads to pore formation and the escape of mitochondrial contents, a step into triggering apoptosis. Antiapoptotic members of the Bcl-2 family (such as Bcl-2, Bel-XL, and Mcl-1) block the activity of BAX and BAK. In normal cells, this process is tightly regulated. Abnormal cells can dysregulate this process to avoid cell death. One of the ways that cancer cells can accomplish this is by upregulating the antiapoptotic members of the Bcl-2 family of proteins. Overexpression or up-regulation of the anti-apoptotic Bcl-2 family proteins enhance cancer cell survival and cause resistance to a variety of anticancer therapies.

Aberrant expression or function of the proteins responsible for apoptotic signaling contributes to numerous human pathologies including auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer (such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc.) (Hanahan D. et al., Cell 2000, 100. 57-70). Herein, it is prospective to target key apoptosis regulators for cancer treatment (Kale J. et al., Cell Death Differ. 2018, 25, 65-80; Vogler M. et al., Cell Death Differ. 2009, 16, 360-367).

By overexpressing one or more of these pro-survival proteins, cancer cells can evade elimination by normal physiological processes and thus gain a survival advantage. Myeloid Cell Leukemia-1 (Mcl-1) is a member of the pro-survival Bcl-2 family of proteins. Mcl-1 has the distinct trait of being essential for embryonic development as well as the survival of all hematopoietic lineages and progenitor populations. Mcl-1 is one of the most common genetic aberrations in human cancer and is highly expressed in many tumor types. Mcl-1 overexpression in human cancers is associated with high tumor grade and poor survival (Beroukhim R. et al., Nature 2010, 463, 899-905). Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing the cells to survive despite widespread genetic damage. Further, its amplification is associated with both intrinsic and acquired resistance to a wide variety of antitumorigenic agents including chemotherapeutic agents such as microtubule binding agents, paclitaxel and gemcitabine, as well as apoptosis-inducing agents such as TRAIL, the Bcl-2 inhibitor, venetoclax, and the Bcl-2/Bcl-XL dual inhibitor navitoclax. Not only do gene silencing approaches that specifically target Mcl-1 circumvent this resistance phenotype, but certain cancer cell types frequently undergo cell death in response to Mcl-1 silencing, indicating a dependence on Mcl-1 for survival. Consequently, approaches that inhibit Mcl-1 function are of considerable interest for cancer therapy (Wertz I. E et al., Nature 2011, 471, 110-114; Zhang B. et al., Blood 2002, 99, 1885-1893).

SUMMARY

The disclosure is directed to compounds of Formula I:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • Z is CH or N;
  • Q is —O—, —S—, —S(O)—, or —S(O)₂—;
  • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —NR^2B—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—NR^2B, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—;
  • L¹ is absent or is optionally substituted —C₁-C₆alkylene-;
  • L² is absent or is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁴ is absent, or is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; or is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • L⁵ is absent, or is —C₁-C₆ alkylene-, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein said C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene, arylene, heteroarylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, —(CR⁷R⁸)_sO(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t—; —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t—, —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—;
  • each n is independently 0-3;
  • each m is independently 0-2;
  • each p is independently 0-4;
  • each q is independently 0-4;
  • each s is independently 0-3;
  • each t is independently 0-4;
  • each R is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, -cycloalkyl, —OR^a, —SR^a, —C(O)R^b, —C(O)OR^a, —NR^cR^d, —C(O)NR^cR^d, or —S(O)₂R^a; wherein said —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, or -cycloalkyl is optionally substituted;
  • each R¹ is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OR^a, —SR^a, —NR^cR^d, —C(O)R^b, —OC(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)₂R^a; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein said —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted;
  • each R², R^2A, or R^2a is independently H, D, halo, OR^a, optionally substituted C₁-C₆alkyl, or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
  • each R^2B and R^2C is independently H, D, optionally substituted C₁-C₆alkyl, or R^2B and R^2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
  • R³ is H, D, —C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, heterocycloalkyl, C(O)R^b, C(O)OR^a, or C(O)NR^cR^d; wherein said C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R³ is —C₁-C₆alkyl substituted at the C₁ carbon atom with —OR^3A wherein R^3A is C₁-C₆alkyl, —PO₃H, —C(O)OR^2C, or —C(O)NR^3AR^3B wherein R^3A and R^3B are each independently H, D, optionally substituted C₁-C₆alkyl;
  • each R⁴ or R⁷ is independently H, D, halo, —OH, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —OR^a, —SR^a, —NR^cR^d, —NR^aR^c, —C(O)R^b, —OC(O)R^a, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b, or —S(O)₂R^b, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkenyl, or heterocycloalkyl is optionally substituted;
  • each R^4A or R^4B is independently H, D, -Me, —CF₃ or —F;
  • each R⁵ or R⁸ is independently H, D, fluoro, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • or R⁴ and R⁵ together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • or an R⁴ and an R⁵ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • or R⁷ and R⁸ together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted;
  • or an R⁷ and an R⁸ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • each R⁶ or R⁹ is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b or —S(O)₂R^b, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted;
  • or R⁹ together with an R⁷ or an R⁸ forms an optionally substituted heterocyclic alkylene;
  • each R^6A, R^6B, R^9A, or R^9B is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • or R^6A and R^6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
  • or R^9A and R^9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
  • each R^a is independently H, D, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —P(OR^c)₂, —P(O)R^cR^b, P(O)OR^cOR^b, —S(O)R^b, —S(O)NR^cR^d, —S(O)₂R^b, —S(O)₂NR^cR^d, —B(OR^c)(OR^b), SiR^b₃, —C₁-C₁₀alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • each R^b, is independently H, D, —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • each R^c or R^d is independently H, D, —C₁-C₁₀ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted;
  • or R^c and R^d, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.

Stereoisomers of the compounds of Formula I and the pharmaceutical salts and solvates thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula I are described, as well as pharmaceutical compositions including the compounds of Formula I.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an ORTEP representation of the compound of Example 34.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The disclosure may be more fully appreciated by reference to the following description, including the following definitions and examples. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any subcombination.

The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C₁-C₁₂”), preferably 1 to 6 carbons atoms (“C₁-C₆”), in the group. Examples of alkyl groups include methyl (Me, C₁alkyl), ethyl (Et, C₂alkyl), n-propyl (C₃alkyl), isopropyl (C₃alkyl), butyl (C₄alkyl), isobutyl (C₄alkyl), sec-butyl (C₄alkyl), tert-butyl (C₄alkyl), pentyl (C₅alkyl), isopentyl (C₅alkyl), tert-pentyl (C₅alkyl), hexyl (C₆alkyl), isohexyl (C₆alkyl), and the like.

The term “haloalkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C₁-C₁₂”), preferably 1 to 6 carbons atoms (“C₁-C₆”), in the group, wherein one or more of the hydrogen atoms in the group have been replaced by a halogen atom. Examples of haloalkyl groups include trifluoromethyl (—CF₃, C₁haloalkyl), trifluoroethyl (—CH₂CF₃, C₂haloalkyl), and the like.

The term “alkylene” when used alone or as part of a substituent group, refers to an alkyl diradical, i.e., a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C₁-C₁₂”), preferably 1 to 6 carbons atoms (“C₁-C₆”), in the group, wherein the group is directly attached to two other variable groups.

As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and/or alkenyl groups. Cycloalkyl groups thus also encompass cycloalkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2 fused rings) groups, spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)). Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (C3-10). In some embodiments, the cycloalkyl is a C3-10 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C_3-10 monocyclic or bicyclic cycloalkyl which is optionally substituted by CH₂F, CHF₂, CF₃, and CF₂CF₃. In some embodiments, the cycloalkyl is a C_3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-10 spirocycle or bridged cycloalkyl. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, cycloalkyl are cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 12 carbon atoms (“C₃-C₁₂”), preferably from 3 to 6 carbon atoms (“C₃-C₆”). Examples of cycloalkyl groups include, for example, cyclopropyl (C₃; 3-membered), cyclobutyl (C₄; 4-membered), cyclopropylmethyl (C₄), cyclopentyl (C₅), cyclohexyl (C₆), 1-methylcyclopropyl (C₄), 2-methylcyclopentyl (C₄), adamantanyl (C₁₀), and the like.

The term “cycloalkylene” when used alone or as part of a substituent group refers to a cycloalkyl diradical, i.e., a cyclic-containing, non-aromatic hydrocarbon group having from 3 to 14 carbon atoms (“C₃-C₁₄”; or 3-14 membered), for example 3 to 12 carbon atoms (“C₃-C₁₂”), preferably from preferably from 3 to 7 carbon atoms (“C₃-C₇”, or 3-7 membered) or 3 to 6 carbon atoms (“C₃-C₆”), wherein the group is directly attached to two other variable groups. Cycloalkylene groups include spirocycloalkylene groups.

The term “cycloalkenylene” refers to a cycloalkenylene diradical.

The term “spirocycloalkyl” when used alone or as part of a substituent group refers to a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common.

The term “spirocycloalkylene” when used alone or as part of a substituent group refers to a spirocycloalkyl diradical, i.e., a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.

As used herein, “heterocycloalkyl” refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, O, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(O)2, etc.). Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10, 4-10, 3-7, 4-7, and 5-6 membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds.

Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom. In some embodiments, the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, S and B and having one or more oxidized ring members.

Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline, azabicyclo[3.1.0]hexanyl, diazabicyclo[3.1.0]hexanyl, oxabicyclo[2.1.1]hexanyl, azabicyclo[2.2.1]heptanyl, diazabicyclo[2.2.1]heptanyl, azabicyclo[3.1.1]heptanyl, diazabicyclo[3.1.1]heptanyl, azabicyclo[3.2.1]octanyl, diazabicyclo[3.2.1]octanyl, oxabicyclo[2.2.2]octanyl, azabicyclo[2.2.2]octanyl, azaadamantanyl, diazaadamantanyl, oxa-adamantanyl, azaspiro[3.3]heptanyl, diazaspiro[3.3]heptanyl, oxa-azaspiro[3.3]heptanyl, azaspiro[3.4]octanyl, diazaspiro[3.4]octanyl, oxa-azaspiro[3.4]octanyl, azaspiro[2.5]octanyl, diazaspiro[2.5]octanyl, azaspiro[4.4]nonanyl, diazaspiro[4.4]nonanyl, oxa-azaspiro[4.4]nonanyl, azaspiro[4.5]decanyl, diazaspiro[4.5]decanyl, diazaspiro[4.4]nonanyl, oxa-diazaspiro[4.4]nonanyl and the like.

In some embodiments, heterocycloalkyl refers to any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure. Examples of suitable heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, and the like.

The term “heterocycloalkylene” when used alone or as part of a substituent group refers to a heterocycloalkyl diradical. In some embodiments heterocycloalkylene any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S, wherein the ring structure is directly attached to two other variable groups.

In some embodiments, the term “spiroheterocycloalkyl” when used alone or as part of a substituent group refers to a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common.

In some embodiments, the term “spirocycloalkylene” when used alone or as part of a substituent group refers to a spirocycloalkyl diradical. In some embodiments, spirocycloalkylene is a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.

The term “alkenyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C₂-C₁₂”), preferably 2 to 4 carbons atoms (“C₂-C₄”), in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (—CH═CH₂; C₂alkenyl), allyl (—CH₂— CH═CH₂; C₃alkenyl), propenyl (—CH═CHCH₃; C₃alkenyl); isopropenyl (—C(CH₃)═CH₂; C₃alkenyl), butenyl (—CH═CHCH₂CH₃; C₄alkenyl), sec-butenyl (—C(CH₃)═CHCH₃; C₄alkenyl), iso-butenyl (—CH═C(CH₃)₂; C₄alkenyl), 2-butenyl (—CH₂CH═CHCH₃; C₄alkyl), pentenyl (CH═CHCH₂CH₂CH₃ or CH₂═CHCH₂CH₂CH₂—; C₅alkenyl), and the like.

The term “alkenylene” when used alone or as part of a substituent group refers to a alkenyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C₂-C₁₂”), preferably 2 to 4 carbons atoms (“C₂-C₄”), in the group, wherein the group includes at least one carbon-carbon double bond, and wherein the group is directly attached to two other variable groups.

The term “alkynyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C₂-C₁₂”), preferably 2 to 4 carbons atoms (“C₂-C₄”), in the group, wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (—C≡CH; C₂alkynyl), propragyl (—CH₂—CH≡CH; C₃alkynyl), and the like.

The term “alkynylene” when used alone or as part of a substituent group refers to an alkynyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C₂-C₁₂”), preferably 2 to 4 carbons atoms (“C₂-C₄”), in the group, wherein the group includes at least one carbon-carbon triple bond, and wherein the group is directly attached to two other variable groups.

The term “aryl” when used alone or as part of a substituent group refers to a monocyclic all carbon aromatic ring or a multicyclic all carbon ring system wherein the rings are aromatic. Thus, aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 aryl rings) having about 9 to 14 carbon atoms. In some embodiments, “aryl” refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. Exemplary substituents include halogen atoms, —C₁-C₃ alkyl groups, and C₁-C₃haloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine. C₁-C₃haloalkyl groups include, for example, —CF₃, —CH₂CF₃, and the like.

The term “arylene” when used alone or as part of a substituent group refers to an aryl diradical. In some embodiments, “arylene” refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted, and wherein the ring structure is directly attached to two other variable groups.

The term “heteroaryl” when used alone or as part of a substituent group, the term “heteroaryl” as used herein refers to a monocyclic aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multicyclic ring systems that have at least one such aromatic ring. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group is condensed with one or more rings selected from heteroaryls or aryls. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring system. A heteroaryl (a monocyclic aromatic ring or multicyclic condensed ring system) can also have about 5 to 12 or about 5 to 10 members within the heteroaryl ring. The rings of a multicyclic ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. In some embodiments, “heteroaryl” refers to a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur. In such embodiments, heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. The heteroaryl moiety can be optionally substituted. Exemplary substituents include halogen atoms; —C₁-C₃ alkyl groups, and C₁-C₃haloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine.

The term “heteroarylene” when used alone or as part of a substituent group refers to a heteroaryl diradical. In some embodiments, heteroarylene is a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring structure is directly attached to two other variable groups.

The term “halo” refers to a halogen substituent (i.e., —F, —Cl, —Br, or —I).

The term “oxo” refers to an oxygen substituent that is connected by a double bond (i.e., ═O).

The term “alkoxy” when used alone or as part of a substituent group refers to an oxygen radical attached to an alkyl group by a single bond. Examples of alkoxy groups include methoxy (—OCH₃), ethoxy (—OCH₂CH₃), isopropoxy (—OCH(CH₃)₂) and the like.

The term “haloalkoxy” when used alone or as part of a substituent group refers to an oxygen radical attached to a haloalkyl group by a single bond. Examples of haloalkoxy groups include —OCF₃, —OCH₂CF₃, —OCH(CF₃)₂, and the like.

When a range of carbon atoms is used herein, for example, C₁-C₆, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C₁-C₃” includes C₁-C₃, C₁-C₂, C₂-C₃, C₁, C₂, and C₃.

The term “C₁-C₆alk” when used alone or as part of a substituent group refers to an aliphatic linker having 1, 2, 3, 4, 5, or 6 carbon atoms and includes, for example, —CH₂—, —CH(CH₃)—, —CH(CH₃)—CH₂—, and —C(CH₃)₂—. The term “—C₀alk-” refers to a bond. In some aspects, the C₁-C₆alk can be substituted with one or more substituents.

In some embodiments wherein a group is described as “optionally substituted” (e.g., when a C₁-C₆alkyl, —C₁-C₆alkylene-, C₁-C₁₀ alkyl, —C₂-C₁₀alkenyl, —C₂-C₁₀alkynyl, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, cycloalkyl, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, heteroaryl, or heteroarylene group is optionally substituted), the optional substituent may be one or more of D, halo, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl-NR^c1R^d1, —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10; C_2-6 alkenyl-NR^c1R^d1, C_2-6 alkynyl-NR^c1R^d1, OC_2-6 alkyl-NR^c1R^d1, CN, NO₂, N₃, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, —CH₂C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, —NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)NR^c1R^d1, NR^c1C(O)OR^a1, C(═NR^g1)NR^c1R^d1, NR^c1C(═NR^g1)NR^c1R^d1, P(R_f1)₂, P(OR^e1)₂, P(O)R^e1R^f1, P(O)OR^e1OR^f1, S(O)R^b1, >SO(═NR^b1); S(O)NR^c1R^d1, S(O)₂R^b1, NR^c1S(O)₂R^b1, S(O)₂NR^c1R^d1; aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl, wherein the aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl are optionally substituted with D, halo, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl-NR^c1R^d1, C_2-6 alkenyl-NR^c1R^d1, C_2-6 alkynyl-NR^c1R^d1, OC_2-6 alkyl-NR^c1R^d1, CN, NO₂, N₃, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, —CH₂C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, —NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)NR^c1R^d1, NR^c1C(O)OR^a1, C(═NR^g1)NR^c1R^d1, NR^c1C(═NR^g1)NR^c1R^d1, P(R^f1)₂, P(OR^e1)₂, P(O)R^e1R^f1, P(O)OR^e1OR^f1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, NR^c1S(O)₂R^b1, S(O)₂NR^c1R^d1.

In these optional substituents, each R^a1 is independently H, D, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In these optional substituents each R^b1 is independently H, D, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In these optional substituents R^c1 or R^d1 is independently H, C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR^a1, C(O)R^b1, S(O)₂R^b1, alkoxyalkyl, and alkoxyalkoxy;

Alternatively, in some embodiments, these optional substituents R^c2 and R^d2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR^a1, C(O)R^b1, S(O)₂R^b1, alkoxyalkyl, and alkoxyalkoxy;

In these optional substituents R^e1 is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, (C₁-C₆ alkoxy)-C₁-C₆ alkyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.

In these optional substituents R^f1 is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl.

In these optional substituents R^g1 is independently H, CN, or NO₂.

“Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

A “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.

“Subject” includes humans. The terms “human,” “patient,” and “subject” are used interchangeably herein.

“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

“Compounds of the present disclosure,” and equivalent expressions, are meant to embrace compounds of Formula I or Formula II as described herein, as well as their respective subgenera, which expression includes the stereoisomers (e.g., entaniomers, diastereomers) and constitutional isomers (e.g., tautomers) of compounds of Formula I or Formula II as well as the pharmaceutically acceptable salts, where the context so permits.

As used herein, the term “isotopic variant” refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance. For example, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more radioactive isotopes, or can be labeled with non-radioactive isotopes such as for example, deuterium (²H or D), carbon-13 (¹³C), nitrogen-15 (¹⁵N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be ²H/D, any carbon may be ¹³C, or any nitrogen may be ¹⁵N, and that the presence and placement of such atoms may be determined within the skill of the art.

It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers,” for example, diastereomers, enantiomers, and atropisomers. The compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers at each asymmetric center, or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include all stereoisomers and mixtures, racemic or otherwise, thereof. Where one chiral center exists in a structure, but no specific stereochemistry is shown for that center, both enantiomers, individually or as a mixture of enantiomers, are encompassed by that structure. Where more than one chiral center exists in a structure, but no specific stereochemistry is shown for the centers, all enantiomers and diastereomers, individually or as a mixture, are encompassed by that structure. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

In some aspects, the disclosure is directed to a compound of Formula I:

or a pharmaceutically acceptable salt or solvate thereof.

In some aspects, Z in Formula I is CH or N. In some embodiments, Z is CH. In other embodiments, Z is N.

In some aspects, Q in Formula I is —O—, —S—, —S(O)—, or —S(O)₂—. In some embodiments, Q is —O—. In some embodiments, Q is —S—. In some embodiments, Q is —S(O)—. In some embodiments, Q is —S(O)₂—.

In some aspects, the moiety —W¹—W²—W³ in Formula I is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —NR^2B—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—NR^2B—, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—.

In some embodiments, the moiety —W¹—W²—W³ in Formula I is —CR²R^2A—CR²R^2A—CR²R^2A—. In some embodiments, the moiety —W¹—W²—W³ in Formula I is —O—CR^2BR^2C—CR²R^2A—. In some embodiments, the moiety —W¹—W²—W³ in Formula I —CR²R^2A—CR^2BR^2C—O—. In some embodiments, the moiety —W¹—W²—W³ in Formula I is —NR^2B—CR^2BR^2C—CR²R^2A—. In some embodiments, the moiety —W¹—W²—W³ in Formula I —CR²R^2A—CR^2BR^2C—NR^2B—. In some embodiments, the moiety —W¹—W²—W³ in Formula I is —S—CR^2BR^2C—CR²R^2A. In some embodiments, the moiety —W¹—W²—W³ in Formula I is —CR²R^2A—CR^2BR^2C—S—.

In some aspects, L¹ in Formula I is absent, or is —C₁-C₆alkylene-, for example, —C₁alkylene, —C₂alkylene, —C₃alkylene, —C₄alkylene, —C₅alkylene, or —C₆alkylene, wherein the C₁-C₆alkylene is optionally substituted. In some embodiments, L¹ in Formula I is —C₁-C₆alkylene-, for example, —C₁alkylene, —C₂alkylene, —C₃alkylene, —C₄alkylene, —C₅alkylene, or —C₆alkylene, wherein the C₁-C₆alkylene is optionally substituted. In some embodiments, L¹ in Formula I is optionally substituted —C₁alkylene. In some embodiments, L¹ in Formula I is —CH₂—.

In some aspects, L² in Formula I is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene.

In some embodiments, L² in Formula I is 3-7 membered cycloalkylene, 4-7 membered heterocycloalkylene, arylene, or heteroarylene; each optionally substituted.

In some embodiments, L² is optionally substituted cycloalkylene or optionally substituted heterocycloalkylene.

In some embodiments, L² is optionally substituted cyclobutylene or optionally substituted pyrrolidinyl.

In some embodiments, L² in Formula I is 3-7 membered cycloalkylene, for example, 3-membered cycloalkylene, 4-membered cycloalkylene, 5-membered cycloalkylene, 6-membered cycloalkylene, or 7-membered cycloalkylene. In some embodiments, L² is 4-membered cycloalkylene. In some embodiments, L² is cyclobutylenyl.

In some embodiments, L² in Formula I is 4-7 membered heterocycloalkylene, for example, 4-membered heterocycloalkylene, 5-membered heterocycloalkylene, 6-membered heterocycloalkylene, or 7-membered heterocycloalkylene. In some embodiments, L² in Formula I is 5-membered heterocycloalkylene. In some embodiments, L² is pyrrolidinyl.

In other embodiments, L² in Formula I is heteroarylene. In some embodiments, the heteroarylene is pyrazolyl.

In some aspects, L³ in Formula I is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—.

In some embodiments, L³ in Formula I is absent. In some embodiments, L³ is —(CR⁴R⁵)_p—. In some embodiments, L³ is —(CR⁴R⁵)_pO—. In some embodiments, L³ is —O—. In some embodiments, L³ is —S—. In some embodiments, L³ is —S(O)—. In some embodiments, L³ is —S(O)₂—. In some embodiments, L³ is —C(═O)—. In some embodiments, L³ is —NR⁶—. In some embodiments, L³ is —OC(═O)—. In some embodiments, L³ is —C(═O)O—. In some embodiments, L³ is —NR^6AC(O). In some embodiments, L³ is —C(═O)NR^6A—. In some embodiments, L³ is —OC(═O)N(R^6A)—. In some embodiments, L³ is —NR^6AC(O)O—. In some embodiments, L³ is —S(═O)NR^6A—. In some embodiments, L³ is —NR^6AS(O)—. In some embodiments, L³ is —S(═O)₂NR^6A—. In some embodiments, L³ is —NR^6AS(O)₂—.

In some aspects, L⁴ in Formula I is absent, or is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; or is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—.

In some embodiments, L⁴ in Formula I is absent. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—S—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—S(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—S(O)₂—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—C(═O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR⁶—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—OC(═O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—C(═O)O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR^6AC(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—C(═O)NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR^6AC(O)R^6B—CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—OC(═O)N(R^6A)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR^6AC(O)O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—S(═O)NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR^6AS(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula I is —(CR⁴R⁵)_p—NR^6AS(O)₂—(CR⁴R⁵)_q—. In some embodiments, L⁴ is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—.

In some aspects, L⁵ in Formula I is absent, or is —C₁-C₆ alkylene-, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein the C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene, arylene, heteroarylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted.

In some embodiments, L⁵ in Formula I is absent. In other embodiments, L⁵ in Formula I is C₁-C₆ alkylene, for example, C₁alkylene, C₂alkylene, C₃alkylene, C₄alkylene, C₅alkylene, or C₆alkylene, each optionally substituted.

In other embodiments, L⁵ in Formula I is C₂-C₆ alkenylene, for example, C₂alkenylene, C₃alkenylene, C₄alkenylene, C₅alkenylene, or C₆alkenylene, each optionally substituted.

In other embodiments, L⁵ in Formula I is C₂-C₆ alkynylene, for example, C₂alkynylene, C₃alkynylene, C₄alkynylene, C₅alkynylene, or C₆alkynylene, each optionally substituted.

In other embodiments, L⁵ in Formula I is an optionally substituted arylene. In some embodiments, L⁵ in Formula I is a 6- to 10-membered arylene, for example phenylene or naphthylene. In some embodiments, L⁵ in Formula I is a phenylene.

In other embodiments, L⁵ in Formula I is an optionally substituted heteroarylene. In some embodiments, L⁵ in Formula I is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl. In some embodiments, L⁵ in Formula I is pyrazolyl. In other embodiments, L⁵ in Formula I is thiazolyl. In other embodiments, L⁵ in Formula I is imidazolyl. In some embodiments, L⁵ in Formula I is pyridinyl.

In other embodiments, L⁵ in Formula I is an optionally substituted cycloalkenylene. In some embodiments, L⁵ in Formula I is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.

In other embodiments, L⁵ in Formula I is an optionally substituted cycloalkylene. In some embodiments, L⁵ in Formula I is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like. In some embodiments, L⁵ in Formula I is cyclopentanyl.

In other embodiments, L⁵ in Formula I is a 6- to 12-membered bicyclic cycloalkylene.

In other embodiments, L⁵ in Formula I is an optionally substituted heterocycloalkylene. In some embodiments, L⁵ in Formula I is an optionally substituted 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like. In some embodiments, L⁵ in Formula I is pyrrolidinyl. In some embodiments, L⁵ in Formula I is tetrahydrofuranyl. In some embodiments, L⁵ in Formula I is piperidinyl. In some embodiments, L⁵ in Formula I is piperazinyl.

In other embodiments, L⁵ in Formula I is an optionally substituted 6- to 12-membered bicyclic heterocycloalkylene group.

In some embodiments, L⁵ is absent, or is —C₁-C₆ alkylene-, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group.

In some aspects, L⁶ in Formula I is absent, or is (CR⁷R⁸)_s, (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t; —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t, (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t- O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—.

In some embodiments, L⁶ in Formula I is absent. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_s. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sO(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sS(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula I is —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-O—. In other embodiments, L⁶ in Formula I is —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—.

In some embodiments, L⁶ is absent, or is —(CR⁷R⁸)_s—, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, —S(O)₂(CR⁷R⁸)_t—, —NR^9AC(O)(CR⁷R⁸)_t—, —C(O)NR^9A(CR⁷R⁸)_t—, —R^9AC(O)O(CR⁷R⁸)_t—, —NR^9AC(O)NR^9B(CR⁷R⁸)_t—, —NR^9AS(O)(CR⁷R⁸)_t—, —NR^9AS(O)₂(CR⁷R⁸)_t—; —CR^4A═CR^4B—(CR⁷R⁸)_t—, —C(═O)(CR⁷R⁸)_t—; —C(═O)(CR⁷R⁸)_t—O—, or —C(═O)(CR⁷R⁸)t-NR⁶—.

In some aspects, in Formula I, each n is independently 0-3. In some embodiments, n=0. In other embodiments, n=1. In other embodiments, n=2. In other embodiments, n=3.

In some aspects, in Formula I, each m is independently 0-2. In some embodiments, m=0. In other embodiments, m=1. In other embodiments, m=2.

In some aspects, in Formula I, each p is independently 0-4. In some embodiments, p=0. In other embodiments, p=1. In other embodiments, p=2. In other embodiments, p=3. In other embodiments, p=4.

In some aspects, in Formula I, each q is independently 0-4. In some embodiments, q=0. In other embodiments, q=1. In other embodiments, q=2. In other embodiments, q=3. In yet other embodiments, q=4.

In some aspects, in Formula I, each s is independently 0-3. In some embodiments, s=0. In other embodiments, s=1. In other embodiments, s=2. In other embodiments, s=3.

In some aspects, in Formula I, each t is independently 0-4. In some embodiments, t=0. In other embodiments, t=1. In other embodiments, t=2. In other embodiments, t=3. In other embodiments, t=4.

In some aspects, each R in Formula I is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, -cycloalkyl, —OR^a, —SR^a, —C(O)R^b, —C(O)OR^a, —NR^cR^d, —C(O)NR^cR^d, or —S(O)₂R^a; wherein said —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, or -cycloalkyl is optionally substituted.

In some embodiments, R is halo, for example, Cl or F. In some embodiments, R is —SR^a, for example —SCH₃. In other embodiments, R is —C₁-C₆alkyl, for example —CH₃.

In some aspects, each R¹ in Formula I is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OR^a, —SR^a, —NR^cR^d, —C(O)R^b, —OC(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)₂R^a; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein the —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted.

In some embodiments, R¹ in Formula I is halo, for example, Cl or F. In other embodiments, R¹ in Formula I is —C₁-C₆alkyl substituted with fluorine, for example —CF₃. In other embodiments, R¹ in Formula I is —C₁-C₆alkyl, for example, —C₆alkyl, —C₅alkyl, —C₄alkyl, —C₃alkyl, —C₂alkyl, —C₁alkyl. In some embodiments, R¹ in Formula I is —C₁alkyl substituted with —CN. In other embodiments, R¹ in Formula I is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R¹ in Formula I is cyclopropane substituted with —CN.

In some aspects, each R², R^2A, or R^2a is independently H, D, halo, OR^a, optionally substituted C₁-C₆alkyl, or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.

In some embodiments, R², R^2A, and R^2a in Formula I are each H.

In other embodiments, R², R^2A, or R^2a in Formula I is C₁-C₆alkyl, for example —CH₃ or —CH₂CH₃.

In other embodiments, R² and R^2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted 3-6 membered cycloalkyl ring. In some embodiments, R² and R^2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.

In other aspects, R² and R^2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted 3-6 membered cycloalkyl ring. In some embodiments, R² and R^2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.

In some aspects, each R^2B and R^2C in Formula I is independently H, D, optionally substituted C₁-C₆alkyl, or R^2B and R^2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.

In some embodiments, R^2B and R^2C in Formula I are each H.

In other embodiments, R^2B and R^2C that are attached to the same carbon atom together with the carbon atom to which they are both attached, form a cyclopropane ring.

In some aspects, R³ in Formula I is H, D, —C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, heterocycloalkyl, C(O)R^b, C(O)OR^a, or C(O)NR^cR^d; wherein said C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R³ is —C₁-C₆alkyl substituted at the C₁ carbon atom with —OR^3A wherein R^3A is C₁-C₆alkyl, —PO₃H, —C(O)OR^2C, or —C(O)NR^3AR^3B wherein R^3A and R^3B are each independently H, D, optionally substituted C₁-C₆alkyl.

In some embodiments, R³ in Formula I is H. In other embodiments, R³ in Formula I is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like.

In some aspects, each R⁴ or R⁷ in Formula I is independently H, D, halo, —OH, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —OR^a, —SR^a, —NR^cR^d, —NR^aR^c, —C(O)R^b, —OC(O)R^a, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b, or —S(O)₂R^b, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted.

In some embodiments, R⁴ is Formula I is H. In some embodiments, R⁴ is Formula I is —OH. In other embodiments, R⁴ in Formula I is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In other embodiments, R⁴ is Formula I is —OR^a, for example, —OCH₃.

In some embodiments, R⁷ in Formula I is H. In other embodiments, R⁷ in Formula I is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In some embodiments, R⁷ in Formula I is —CH₃. In other embodiments, R⁷ in Formula I is —OR^a, for example, —OCH₃.

In some aspects, each R^4A or R^4B in Formula I is independently H, D, -Me, —CF₃ or —F. In some embodiments, R^4A is H. In some embodiments, R^4B is H.

In some aspects, each R⁵ or R⁸ in Formula I is independently H, D, fluoro, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.

In some embodiments, R⁵ in Formula I is H. In other embodiments, R⁵ in Formula I is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In some embodiments, R⁵ in Formula I is —CH₃.

In some embodiments, R⁸ in Formula I is H. In other embodiments, R⁸ in Formula I is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In some embodiments, R⁸ in Formula I is —CH₃.

In some embodiments each R⁷ and each R⁸ is independently, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C₁-C₆alkyl.

In other embodiments, each R⁷ and each R⁸ is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C₁-C₆alkyl.

In other embodiments, each R⁷ and each R⁸ is independently H, —CH₃, -cyclopropyl, —CH₂CH₃, or —CH(CH₃)₂.

In other embodiments, each R⁷ and each R⁸ is independently H, or a —C₁-C₆alkyl group optionally substituted with —OH, optionally substituted —OC₁-C₆alkyl, optionally substituted —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10, or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, optionally substituted —C₁-C₆alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.

In other embodiments, each R⁷ and each R⁸ is independently H, or —C₁-C₆alkyl group is optionally substituted with —OH, —OC₁-C₆alkyl, —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10, or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, C₁-C₆alkyl, or 4-7 membered heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form a multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo, —OC₁-C₆alkyl, or —C₁-C₆alkyl optionally substituted with —OH or —OC₁-C₆alkyl.

In some aspects, R⁴ and R⁵ together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.

In other aspects, R⁴ and an R⁵ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.

In some embodiments, each R⁷ and each R⁸ is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C₁-C₆alkyl; or R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring; or R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.

In some embodiments, each R⁷ and each R⁸ is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C₁-C₆alkyl; or wherein R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring; or R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.

In some embodiments, R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring; or R⁷ and R⁸ attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.

In some embodiments, R⁷ or R⁸ are each independently H, —CH₃, -cyclopropyl, —CH₂CH₃, or —CH(CH₃)₂.

In some embodiments, R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.

In some embodiments, each R⁷ and each R⁸ is independently H, or a —C₁-C₆alkyl group optionally substituted with —OH; optionally substituted —OC₁-C₆alkyl; optionally substituted —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10; or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, optionally substituted —C₁-C₆alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.

In some embodiments, the —C₁-C₆alkyl group is optionally substituted with —OH; —OC₁-C₆alkyl; —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10; or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, C₁-C₆alkyl, or 4-7 membered heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form a monocyclic or multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo; —OC₁-C₆alkyl; or —C₁-C₆alkyl optionally substituted with —OH or —OC₁-C₆alkyl.

In some aspects, R⁷ and R⁸ together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted.

In some embodiments, R⁷ and R⁸ together with the C atom to which they are both attached form a cycloalkyl ring, for example, a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring.

In some embodiments, R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring.

In other embodiments, R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.

In other embodiments, R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring;

In other embodiments, R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.

In other embodiments, R⁷ and R⁸ attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.

In other embodiments, R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.

In some aspects, an R⁷ and an R⁸ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.

In some aspects, each R⁶ or R⁹ is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b or —S(O)₂R^b, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein the C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted.

In some embodiments, R⁶ is H. In other embodiments, R⁶ is —C₁-C₆alkyl, for example, —CH₃ or —CH₂CH₃.

In some embodiments, R⁹ is H; optionally substituted —C₁-C₆alkyl; optionally substituted —C(O)OC₁-C₆alkyl; optionally substituted —SO₂C₁-C₆alkyl; optionally substituted —C(O)C₁-C₆alkyl; optionally substituted —C(O)NR^cR^d; or wherein R⁹ together with either R⁷ or R⁸ form an optionally substituted heterocyclic alkylene.

In some embodiments, R⁹ is H; —C₁-C₆alkyl, optionally substituted with deuterium; —C(O)OC₁-C₆alkyl; —SO₂C₁-C₆alkyl; —C(O)C₁-C₆alkyl; or wherein R⁹ together with either R⁷ or R⁸ forms an optionally heterocyclic alkylene.

In other embodiments, R⁹ is H; —C₁-C₆alkyl, optionally substituted with deuterium; —C(O)OC₁-C₆alkyl; —SO₂C₁-C₆alkyl; —C(O)C₁-C₆alkyl.

In yet other embodiments, R⁹ is H; —CH₃; —CH₂CH₃, —CH₂CH₂CH₃, -CD₃, —C(O)OCH₃; —C(O)OC(CH₃)₃, —SO₂CH₃; or —C(O)CH₃.

In some aspects, R⁹ together with either an R⁷ or an R^8′ forms an optionally substituted heterocyclic alkylene. In some embodiments, R⁹ together with either R⁷ or R⁸ form a heterocyclic alkylene. In some embodiments, R⁹ together with either an R⁷ or an R^8′ forms a C₃-C₉ heterocyclic alkylene.

In some aspects, each R^6A, R^6B, R^9A, or R^9B in Formula I is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.

In some aspects, R^6A and R^6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring.

In some aspects, R^9A and R^9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;

In some aspects, each R^a in Formula I is independently H, D, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —P(OR^c)₂, —P(O)R^cR^b, —P(O)OR^cOR^b, —S(O)R^b, —S(O)NR^cR^d, —S(O)₂R^b, —S(O)₂NR^cR^d, —B(OR^c)(OR^b), SiR^b₃, —C₁-C₁₀alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.

In some embodiments, R^a is H, —C(O)R^b, —C(O)NR^cR^d, optionally substituted C₁-C₁₀alkyl, optionally substituted C₂-C₁₀alkenyl, optionally substituted C₂-C₁₀ alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl

In some embodiments, R^a is H, —C(O)R^b, —C(O)NR^cR^d, or optionally substituted C₁-C₁₀alkyl.

In some embodiments, R^a is H.

In some embodiments, R^a is —C(O)R^b.

In some embodiments, R^a is —C(O)R^b wherein R^b is optionally substituted —C₁-C₆alkyl.

In some embodiments, R^a is —C(O)R^b wherein R^b is —C₁-C₆alkyl.

In some embodiments, R^a is —C(O)R^b wherein R^b is —CH₃.

In some embodiments, R^a is —C(O)NR^cR^d.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; optionally substituted —OC₁-C₆alkyl; optionally substituted cycloalkyl; optionally substituted —C₁-C₆alkyl, or optionally substituted heterocycloalkyl.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; optionally substituted 3-7 membered cycloalkyl; —OC₁-C₆alkyl; or —C₁-C₆alkyl optionally substituted with deuterium, halo, optionally substituted cycloalkyl, optionally substituted —OC₁-C₆alkyl, —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or optionally substituted —C₁-C₆alkyl, optionally substituted 4-7 membered heterocycloalkyl, or optionally substituted 5-6 membered heteroaryl; or optionally substituted 4-7 membered heterocycloalkyl.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; 3-7 membered cycloalkyl; —C₁-C₆alkyl optionally substituted with deuterium, halo, —OC₁-C₆alkyl, cycloalkyl, —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or —C₁-C₆alkyl, 4-7 membered heterocycloalkyl (optionally substituted with halo, —C₁-C₆alkyl, —OH, or —OC₁-C₆alkyl), or -5-6 membered heteroaryl, —OC₁-C₆alkyl; or -4-7 membered heterocycloalkyl optionally substituted with —C₁-C₆alkyl or —OH.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl group optionally substituted with -halo, —OH, optionally substituted -4-7 membered heterocycle, optionally substituted 5-6 membered heteroaryl, optionally substituted —OC₁-C₆alkyl, optionally substituted —C₁-C₆alkyl; or —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or optionally substituted C₁-C₆alkyl.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic-4-10 membered heterocycloalkyl group optionally substituted with -halo, —OH, -4-7 membered heterocycle, 5-6 membered heteroaryl, —OC₁-C₆alkyl, —C₁-C₆alkyl (optionally substituted with —OH, —OC₁-C₆alkyl, or NR^c1R^d1, wherein R^c1 and R^d1 are independently H or C₁-C₆alkyl); or —NR^c1R^d1, wherein R^c1 and R^d1 are independently H or C₁-C₆alkyl.

In some embodiments, R^a is optionally substituted —C₁-C₁₀alkyl.

In some embodiments, R^a is —C₁-C₁₀alkyl optionally substituted with —C(O)NR^c1R^d1, wherein R^c1 and R^d1 are independently H, optionally substituted C₁-C₆alkyl, or optionally substituted heterocyclyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic-4-10 membered heterocycloalkyl group; —NR^c1R^d1 wherein R^c1 and R^d1 are independently H, optionally substituted C₁-C₆alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; optionally substituted heteroaryl; —C(O)OH; or optionally substituted -heterocycloalkyl.

In some embodiments, R^a is —C₁-C₁₀alkyl optionally substituted with —C(O)NR^c1R^d1, wherein R^c1 and R^d1 are independently H, C₁-C₆alkyl, or 4-7 membered heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form a monocyclic or multicyclic-4-10 membered heterocycloalkyl group (optionally substituted with halo, —OC₁-C₆alkyl, or —C₁-C₆alkyl optionally substituted with —OH or —OC₁-C₆alkyl); —NR^c1R^d1 wherein R^c1 and R^d1 are independently H, or optionally substituted C₁-C₆alkyl; —C₄-C₅heteroaryl; —C(O)OH; or -4-7 membered heterocycloalkyl optionally substituted with halo, C₁-C₆alkyl, or —OC₁-C₆alkyl.

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; —OCH₃, —CH₃, -CD₃, —CH₂CH₂OCH₃, —CH₂CH₃, —CH₂-cyclopropyl, -cyclobutyl, cyclopropyl, —CH(CH₃)₂, —CH₂—CH(CH₃)₂, —CH₂CH₂NH₂, —CH₂CH₂N(CH₃)₂, —CH₂CH₂NH(CH₃), —CH₂CHF₂,

In some embodiments, R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, are

In some embodiments, R^a is —C₁-C₆alkyl optionally substituted with —N(CH₃)₂, —CO₂H, —CONH₂, —CON(CH₃)(CH₂CH₂OCH₃),

In some aspects, each R^b in Formula I is independently H, D, —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein the —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.

In some aspects, each R^c or R^d in Formula I is independently H, D, —C₁-C₁₀ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.

In some aspects, R^c and R^d, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.

In some embodiments, compounds of Formula I are those having the Formula IA-0:

In some embodiments, compounds of Formula I are those having the Formula IA:

In some embodiments, the compounds of Formula IA are those wherein W¹ is —CH₂— and W³ is —O—, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —S—, or W¹ is —S— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —NR^2B—, or W¹ is —NR^2B— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—.

In other embodiments, the compounds of Formula I are those having Formula IA-1:

In some embodiments, the compounds of Formula IA-1 are those wherein W¹ is —CH₂— or —O—.

In some embodiments, the compounds of Formula I are those having the Formula IA-2:

In some embodiments, the compound of formula IA-2 are those wherein W³ is —CH₂— or —O—.

In some embodiments, the compounds of Formula I are those of Formula IA-3 wherein W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—:

In some embodiments, the compounds of Formula I are compound of Formula IA-4:

or a pharmaceutically acceptable salt or solvate thereof; wherein W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—; L³ is absent, or is —(CR⁴R⁵)_p—; L⁴ is absent, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; L⁵ is absent, or is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and L⁶ is absent, or is (CR⁷R⁸)_s, —O(CR⁷R⁸)_t, —NR⁹(CR⁷R⁸)_t, —S(CR⁷R⁸)_t, —S(O)(CR⁷R⁸)_t, —S(O)₂(CR⁷R⁸)_t, —NR^9AC(O)(CR⁷R⁸)_t, —C(O)NR^9A(CR⁷R⁸)_t, —R^9AC(O)O(CR⁷R⁸)_t, —NR^9AC(O)NR^9B(CR⁷R⁸)_t, —NR^9AS(O)(CR⁷R⁸)_t, —NR^9AS(O)₂(CR⁷R⁸)_t; —CR^4A═CR^4B—(CR⁷R⁸)_t, —C(═O)(CR⁷R⁸)_t; —C(═O)(CR⁷R⁸)t-O—, or —C(═O)(CR⁷R⁸)t-NR⁶—.

In some embodiments of the compounds of Formula I or Formula IA-4, L³ absent; L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; and L⁵ is absent.

In some embodiments of the compounds of Formula I or Formula IA-4, L⁶ is absent, or is —(CR⁷R⁸)_s—, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, —S(O)₂(CR⁷R⁸)_t—, —NR^9AC(O)(CR⁷R⁸)_t—, —C(O)NR^9A(CR⁷R⁸)_t—, —R^9AC(O)O(CR⁷R⁸)_t—, —NR^9AC(O)NR^9B(CR⁷R⁸)_t—, —NR^9AS(O)(CR⁷R⁸)_t—, —NR^9AS(O)₂(CR⁷R⁸)_t—; —CR^4A═CR^4B—(CR⁷R⁸)_t—, —C(═O)(CR⁷R⁸)_t—; —C(═O)(CR⁷R⁸)t-O—, or —C(═O)(CR⁷R⁸)t-NR⁶—.

In other embodiments of the compounds of Formula I or Formula IA-4, Q¹ is —CR^4A═CR^4B—; and L⁶ is absent, —O(CR⁷R⁸)_t, or —NR⁹(CR⁷R⁸)_t;

In other embodiments of the compounds of Formula I or Formula IA-4, p=1; q=1-4; and t=1.

In other embodiments of the compounds for Formula I or Formula IA-4, L³ absent; L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(═O)₂—; L⁵ is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and L⁶ is absent, or is (CR⁷R⁸)_s.

In other embodiments, the compounds of Formula I or Formula IA-4 are those wherein Q¹ is —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)N(R^6A)—, or —NR^6AC(O)O—; L⁵ is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene is optionally substituted; and L⁶ is absent, or is (CR⁷R⁸)_s.

In some embodiments, the compounds of Formula I or Formula IA-4 are those wherein L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q— wherein p=1; q=1-3, Q¹ is absent, or —CR^4A═CR^4B—; L⁶ is (CR⁷R⁸)_s wherein s=1-2, —O(CR⁷R⁸)_t, —NR⁹(CR⁷R⁸)_t, —S(CR⁷R⁸)_t, —S(O)(CR⁷R⁸)_t, or —S(O)₂(CR⁷R⁸)_t, wherein t=1.

In some embodiments, the compounds of Formula I are those of Formula IA-5

wherein X is O, NR⁹, CR⁷R⁸, S, S(O), SO₂; R is halo or C₁-C₆alkyl; represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵, an (E)-carbon-carbon double bond substituted with R^4A and R^4B, or a (Z)-carbon-carbon double bond substituted with R^4A and R^4B; and R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, P(OR^c)₂, P(O)R^cR^b, P(O)OR^cOR^b, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, S(O)₂NR^cR^d, B(OR^c)(OR^b), SiR^b₃, C₁-C₁₀alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₁₀alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted.

In some embodiments of the compound Formula IA-5, represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵.

In other embodiments of the compound Formula IA-5, represents a carbon-carbon double bond.

In some embodiments of the compound Formula IA-5, X is O, NR⁹, or CR⁷R⁸.

In some embodiments of the compound Formula IA-5, R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)NR^cR^d, or optionally substituted C₁-C₁₀alkyl, optionally substituted C₂-C₁₀alkenyl, optionally substituted C₂-C₁₀ alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

In some aspects, the compounds of Formula I are those of Formula IA-6:

or a pharmaceutically acceptable salt or solvate thereof; wherein X is —O—, —NR⁹—, or —CR⁷R⁸—; and W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂; R^a* is R^a.

In some embodiments, the compounds of Formula IA-6 are those wherein X is —CR⁷R⁸—.

In other embodiments, the compounds of Formula IA-6 are those wherein X is —O—.

In some embodiments, the compounds of Formula IA-6 are those wherein X is —NR⁹—.

In some embodiments X is —NR⁹— wherein R⁹ is H; optionally substituted —C₁-C₆alkyl; optionally substituted —C(O)OC₁-C₆alkyl; optionally substituted —SO₂C₁-C₆alkyl; optionally substituted —C(O)C₁-C₆alkyl; optionally substituted —C(O)NR^cR^d; or wherein R⁹ together with either R⁷ or R⁸ form an optionally substituted C₁-C₆alkylene group.

In other embodiments, X is —NR⁹— wherein R⁹ is H; —C₁-C₆alkyl, optionally substituted with deuterium; —C(O)OC₁-C₆alkyl; —SO₂C₁-C₆alkyl; —C(O)C₁-C₆alkyl; or wherein R⁹ together with either R⁷ or R⁸ form a C₁-C₆alkylene group.

In some embodiments, the compounds of Formula IA-6 are those having the structure (IA-7):

• • wherein W¹ is —CH₂— and W³ is —O—; or W¹ is —O— and W³ is —CH₂—; or W¹ is —CH₂— and W³ is —CH₂—.

In some embodiments, the compounds of Formula IA-7 are those wherein W¹ is —CH₂— and W³ is —CH₂—.

In some embodiments, the compounds of Formula I are those of Formula IA-8

wherein X is O, NR⁹, CR⁷R⁸, S, S(O), S02; W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—; R is halo or C₁-C₆alkyl; represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵, an (E)-carbon-carbon double bond, or a (Z)-carbon-carbon double bond; and R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, P(OR^c)₂, P(O)R^cR^b, P(O)OR^cOR^b, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, S(O)₂NR^cR^d, B(OR^c)(OR^b), SiR^b₃, C₁-C₁₀alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₁₀alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted; and R^c* is R^c wherein R^c is H, D, —C₁-C₁₀ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.

In some embodiments of the compound Formula IA-8, represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵.

In other embodiments of the compound Formula IA-8, represents a carbon-carbon double bond.

In other embodiments of the compound Formula IA-8, represents a (E)-carbon-carbon double bond substituted with R^4A and R^4B.

In some embodiments of the compound of Formula IA-8, R^a* is R^a and R^c* is R^c.

In other embodiments of the compound Formula IA-8, R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —S(O)₂R^b, or optionally substituted C₁-C₁₀alkyl; and R^c* is R wherein R^c is H or optionally substituted C₁-C₁₀alkyl.

In other embodiments of the compound Formula IA-8, R is —Cl.

In other embodiments of the compound Formula IA-8, each R⁴ and R⁵ is independently H or C₁-C₆alkyl.

In some embodiments of the compound Formula IA-8, X is O, NR⁹, or CR⁷R⁸.

In some aspects, the compounds of Formula I are those of Formula IA-9:

or a pharmaceutically acceptable salt or solvate thereof; wherein X is —O—, —NR⁹—, or —CR⁷R⁸—; and ¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—; R^a* is R^a and R^c* is R^c.

In other embodiments of the compound Formula IA-9, R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —S(O)₂R^b, or optionally substituted C₁-C₁₀alkyl; and R^c* is R^c wherein R^c is H or optionally substituted C₁-C₁₀alkyl.

In some embodiments, the compounds of Formula IA-9 are those wherein X is —CR⁷R⁸—.

In other embodiments, the compounds of Formula IA-9 are those wherein X is —O—.

In some embodiments, the compounds of Formula IA-9 are those wherein X is —NR⁹—.

In some embodiments, X is —NR⁹— wherein R⁹ is H; optionally substituted —C₁-C₆alkyl; optionally substituted —C(O)OC₁-C₆alkyl; optionally substituted —SO₂C₁-C₆alkyl; optionally substituted —C(O)C₁-C₆alkyl; optionally substituted —C(O)NR^cR^d; or wherein R⁹ together with either R⁷ or R⁸ form an optionally substituted C₁-C₆alkylene group.

In other embodiments, X is —NR⁹— wherein R⁹ is H; —C₁-C₆alkyl, optionally substituted with deuterium; —C(O)OC₁-C₆alkyl; —SO₂C₁-C₆alkyl; —C(O)C₁-C₆alkyl; or wherein R⁹ together with either R⁷ or R⁸ form a C₁-C₆alkylene group.

In some embodiments, the compounds of Formula IA-9 are those having the structure (IA-10):

In some aspects, the disclosure is directed to compounds of Formula II:

or a pharmaceutically acceptable salt or solvate thereof.

In some aspects, Z in Formula II is C or N. In some embodiments, Z is C. In other embodiments, Z is N.

In some aspects, Q in Formula II is —O—, —S—, —S(O)—, or —S(O)₂—. In some embodiments, Q is —O—. In some embodiments, Q is —S—. In some embodiments, Q is —S(O)—. In some embodiments, Q is —S(O)₂—.

In some aspects, the moiety —W¹—W²—W³ in Formula II is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—.

In some embodiments, the moiety —W¹—W²—W³ in Formula II is —CR²R^2A—CR²R^2A—CR²R^2A—. In some embodiments, the moiety —W¹—W²—W³ in Formula II is —O—CR^2BR^2C—CR²R²R^2A—. In some embodiments, the moiety —W¹—W²—W³ in Formula II —CR²R^2A—CR^2BR^2C—O—. In some embodiments, the moiety —W¹—W²—W³ in Formula II is —S—CR^2BR^2C—CR²R^2A. In some embodiments, the moiety —W¹—W²—W³ in Formula II is —CR²R^2A—CR^2BR^2C—S—.

In some aspects, L¹ in Formula II is —C₁-C₆alkylene-, for example, —C₁alkylene, —C₂alkylene, —C₃alkylene, —C₄alkylene, —C₅alkylene, or —C₆alkylene, wherein the C₁-C₆alkylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, oxo, CN, OR^a1, SR^a1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, and NR^c1S(O)₂R^b1. In some embodiments, L¹ in Formula II is —C₁alkylene. In some embodiments, L¹ in Formula II is —CH₂—.

In some aspects, L² in Formula II is C₃-C₇cycloalkylene, C₄-C₇heterocycloalkylene, or heteroarylene; wherein the C₃-C₇cycloalkylene, C₄-C₇heterocycloalkylene, or heteroarylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, oxo, CN, NO₂, N₃, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, NR^c2R^d2 NR^c2C(O)R^b2 NR^c2C(O)OR^a2, P(O)OR^e1OR^f1, S(O)₂R^a2, NR^c2S(O)₂R^b2, and S(O)₂NR^c2R^d2.

In some embodiments, L² in Formula II is C₃-C₇cycloalkylene, for example, C₃cycloalkylene, C₄cycloalkylene, C₅cycloalkylene, C₆cycloalkylene, or C₇cycloalkylene. In some embodiments, L² is C₄cycloalkylene. In some embodiments, L² is cyclobutylenyl.

In some embodiments, L² in Formula II is C₄-C₇heterocycloalkylene, for example, C₄heterocycloalkylene, C₅heterocycloalkylene, C₆heterocycloalkylene, or C₇heterocycloalkylene. In some embodiments, L² in Formula II is C₄heterocycloalkylene. In some embodiments, L² is pyrrolidinyl.

In other embodiments, L² in Formula II is heteroarylene. In some embodiments, the heteroarylene is pyrazolyl.

In some aspects, L³ in Formula II is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—.

In some embodiments, L³ in Formula II is absent. In some embodiments, L³ is —(CR⁴R⁵)_p—. In some embodiments, L³ is —(CR⁴R⁵)_pO—. In some embodiments, L³ is —O—. In some embodiments, L³ is —S—. In some embodiments, L³ is —S(O)—. In some embodiments, L³ is —S(O)₂—. In some embodiments, L³ is —C(═O)—. In some embodiments, L³ is —NR⁶—. In some embodiments, L³ is —OC(═O)—. In some embodiments, L³ is —C(═O)O—. In some embodiments, L³ is —NR^6AC(O). In some embodiments, L³ is —C(═O)NR^6A—. In some embodiments, L³ is —OC(═O)N(R^6A)—. In some embodiments, L³ is —NR^6AC(O)O—. In some embodiments, L³ is —S(═O)NR^6A—. In some embodiments, L³ is —NR^6AS(O)—. In some embodiments, L³ is —S(═O)₂NR^6A—. In some embodiments, L³ is —NR^6AS(O)₂—.

In some aspects, L⁴ in Formula II is absent, or is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; or is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—.

In some embodiments, L⁴ in Formula II is absent. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—S—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—S(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—S(O)₂—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—C(═O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR⁶—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—OC(═O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—C(═O)O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR^6AC(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—C(═O)NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR^6AC(O)R^6B—CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—OC(═O)N(R^6A)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR^6AC(O)O—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—S(═O)NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR^6AS(O)—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q—. In other embodiments, L⁴ in Formula II is —(CR⁴R⁵)_p—NR^6AS(O)₂—(CR⁴R⁵)_q—. In some embodiments, L⁴ is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—.

In some aspects, L⁵ in Formula II is absent, or is C₁-C₆ alkylene, C₂-C₆ alkenylene, C_2-6 alkynylene, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 5- to 12-membered spirocycloalkylene, a 5- to 12-membered spiroheterocycloalkylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or a 6- to 12-membered bicyclic cycloalkylene, or a 3- to 7-membered monocyclic heterocycloalkylene or a 6 to 12-membered bicyclic heterocycloalkylene group, wherein the heteroarylene, spiroheterocycloalkylene or heterocycloalkylene group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S; wherein the cycloalkylene, spirocycloalkylene, spiroheterocycloalkylene, and heterocycloalkylene groups may include a C═O group; wherein the spiroheterocycloalkylene, and heterocycloalkylene groups may include a S═O or SO₂; wherein said C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene, cycloalkylene, spirocycloalkylene, heterocycloalkylene, spiroheterocycloalkylene, arylene or heteroarylene are optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl NR^c3R^d3, C₂-C₆ alkenyl NR^c3R^d3, C₂-C₆ alkynyl NR^c3R^d3, OC₂-C₆ alkyl NR^c3R^d3, CN, NO₂, N₃, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, —CH₂C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)NR^c3R^d3, NR^c3C(O)OR^a3, C(═NR^g1)NR^c2R^d2 NR^c3C(═NR^g1)NR^c3R^d3, P(R^f2)₂, P(OR^e2)₂, P(O)R^e2R_f2, P(O)OR^e2OR^f2, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, NR^c3S(O)₂R^b3, and S(O)₂NR^c3R^d3.

In some embodiments, L⁵ in Formula II is absent. In other embodiments, L⁵ in Formula II is C₁-C₆ alkylene, for example, C₁alkylene, C₂alkylene, C₃alkylene, C₄alkylene, C₅alkylene, or C₆alkylene.

In other embodiments, L⁵ in Formula II is C₂-C₆ alkenylene, for example, C₂alkenylene, C₃alkenylene, C₄alkenylene, C₅alkenylene, or C₆alkenylene.

In other embodiments, L⁵ in Formula II is C₂-C₆ alkynylene, for example, C₂alkynylene, C₃alkynylene, C₄alkynylene, C₅alkynylene, or C₆alkynylene.

In other embodiments, L⁵ in Formula II is a 6- to 10-membered arylene, for example phenylene or naphthylene. In some embodiments, L⁵ in Formula II is a phenylene.

In other embodiments, L⁵ in Formula II is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl. In some embodiments, L⁵ in Formula II is pyrazolyl. In some embodiments, L⁵ in Formula II is thiazolyl. In some embodiments, L⁵ in Formula II is imidazolyl. In some embodiments, L⁵ in Formula II is pyridinyl.

In other embodiments, L⁵ in Formula II is a 5- to 12-membered spirocycloalkylene, for example, spiro[3.4]octane, or spiro[3.3]heptane.

In other embodiments, L⁵ in Formula II is a 5- to 12-membered spiroheterocycloalkylene, for example, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, or 2-azaspiro[3.3]heptane. In some embodiments, L⁵ in Formula II is 2,6-diazaspiro[3.4]octane. In some embodiments, L⁵ in Formula II is 2-azaspiro[3.4]octane. In some embodiments, L⁵ in Formula II is 2-azaspiro[3.3]heptane.

In other embodiments, L⁵ in Formula II is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.

In other embodiments, L⁵ in Formula II is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like. In some embodiments, L⁵ in Formula II is cyclopentanyl.

In other embodiments, L⁵ in Formula II is a 6- to 12-membered bicyclic cycloalkylene.

In other embodiments, L⁵ in Formula II is a 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like. In some embodiments, L⁵ in Formula II is pyrrolidinyl. In some embodiments, L⁵ in Formula II is tetrahydrofuranyl. In some embodiments, L⁵ in Formula II is piperidinyl. In some embodiments, L⁵ in Formula II is piperazinyl.

In other embodiments, L⁵ in Formula II is a 6- to 12-membered bicyclic heterocycloalkylene group.

In some aspects, L⁶ in Formula II is absent, or is (CR⁷R⁸)_s, (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t, (CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t; —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t, (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—.

In some embodiments, L⁶ in Formula II is absent. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_s. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sO(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sS(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t. In other embodiments, L⁶ in Formula II is —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-O—. In other embodiments, L⁶ in Formula II is —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—.

In some aspects, in Formula II, n=0-3. In some embodiments, n=0. In other embodiments, n=1. In other embodiments, n=2. In other embodiments, n=3.

In some aspects, in Formula II, m=0-2. In some embodiments, m=0. In other embodiments, m=1. In other embodiments, m=2.

In some aspects, in Formula II, o=1-3. In some embodiments, o=0. In other embodiments, o=1. In other embodiments, o=2. In other embodiments, o=3.

In some aspects, in Formula II, p=0-4. In some embodiments, p=0. In other embodiments, p=1. In other embodiments, p=2. In other embodiments, p=3. In other embodiments, p=⁴.

In some aspects, in Formula II, q=0-3. In some embodiments, q=0. In other embodiments, q=1. In other embodiments, q=2. In other embodiments, q=3.

In some aspects, in Formula II, s=0-3. In some embodiments, s=0. In other embodiments, s=1. In other embodiments, s=2. In other embodiments, s=3.

In some aspects, in Formula II, t=0-4. In some embodiments, t=0. In other embodiments, t=1. In other embodiments, t=2. In other embodiments, t=3. In other embodiments, t=4.

In some aspects, each R in Formula II is independently selected from halo, CN, —NO₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, —(CH₂CH₂O)_oR^a, C₁-C₆haloalkoxy, C₃-C₆cycloalkyl, OR^a, SR^a, C(O)R^b, C(O)OR^a, NR^cR^d, C(O)NR^cR^d, and S(O)₂R^a; wherein said C₁-C₆alkyl or C₃-C₆cycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR^a1, NR^c1R^d1 and C(O)NR^c1R^d1.

In some embodiments, R is halo, for example, Cl or F. In some embodiments, R is —SR^a, for example —SCH₃.

In some aspects, each R¹ in Formula II is independently selected from halo, —CN, Nitro, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, C₁-C₆haloalkyl, —(CH₂CH₂O)_oR^a, —C₁-C₆alkylC₃-C₇cycloalkyl, OR^a, SR^a, NR^cR^d, C(O)R^b, OC(O)R^b, C(O)OR^a, C(O)NR^cR^d, or S(O)₂R^a; aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO₂; wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CN, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some embodiments, R¹ in Formula II is halo, for example, Cl or F. In other embodiments, R¹ in Formula II is —C₁-C₆haloalkyl, for example —CF₃. In other embodiments, R¹ in Formula II is —C₁-C₆alkyl, for example, —C₆alkyl, —C₅alkyl, —C₄alkyl, —C₃alkyl, —C₂alkyl, —C₁alkyl. In some embodiments, R¹ in Formula II is —C₁alkyl substituted with —CN. In other embodiments, R¹ in Formula II is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R¹ in Formula II is cyclopropane substituted with —CN.

In some aspects, R² and R^2A in Formula II are each independently H, halo, OR^a, C₁-C₆alkyl, C₁-C₆haloalkyl. In some embodiments, R² and R^2A in Formula II are each H.

In other aspects, R² and R^2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted C₃-C₆cycloalkyl ring. In some embodiments, R² and R^2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.

In some aspects, R² and R^2a in Formula II are each independently H, halo, OR^a, C₁-C₆alkyl, C₁-C₆haloalkyl. In some embodiments, R² and R^2a in Formula II are each H.

In other aspects, R² and R^2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted C₃-C₆cycloalkyl ring. In some embodiments, R² and R^2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.

In some aspects, R^2B and R^2C in Formula II are each independently H, C₁-C₆alkyl, or C₁-C₆haloalkyl. In some embodiments, R^2B and R^2C in Formula II are each H.

In some aspects, R^2B and R^2C may, together with the carbon atom to which they are both attached, form an optionally substituted C₃-C₆cycloalkyl ring. In some embodiments, R^2B and R^2C that are attached to the same carbon atom together with the carbon atom to which they are both attached, form a cyclopropane ring.

In some aspects, R³ in Formula II is H, —C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, —(CH₂CH₂O)_oR^a, —C₃-C₇cycloalkyl, —C₃-C₇heterocycloalkyl, —C₁-C₆alkylC₃-C₇cycloalkyl, —C₁-C₆alkylC₃-C₇heterocycloalkyl, C(O)R^b, C(O)OR^a, or C(O)NR^cR^d; wherein the C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, halo, C_1-6 alkyl, CN, —OP(O)OR^e3OR, and OR^a4.

In some embodiments, R³ in Formula II is H. In other embodiments, R³ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like.

In some aspects, R⁴ and R⁷ in Formula II are independently selected from H, halo, OH, CN, NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C₁-C₆haloalkyl, —(CH₂CH₂O)_oR^a, C₃-C₇cycloalkyl, —C₁-C₆alkylC₃-C₇cycloalkyl, cyanoC₁-C₆alkyl-, heterocycloalkyl, C₁-C₆alk-NR^cR^d, OR^a, SR^a, NR^cR^d, C(O)R^b, OC(O)R^a, C(O)OR^a, C(O)NR^cR^d, and S(O)₂R^a, wherein said C₁-C₆alkyl, C₃-C₇cycloalkyl, heterocycloalkyl, or —C₁-C₆alkylC₃-C₇cycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CN, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some embodiments, R⁴ is Formula II is H. In other embodiments, R⁴ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In other embodiments, R⁴ is Formula II is —OR^a, for example, —OCH₃.

In some embodiments, R⁷ in Formula II is H. In other embodiments, R⁷ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In other embodiments, R⁷ is Formula II is —OR^a, for example, —OCH₃.

In some aspects, R^4A and R^4B in Formula II are independently selected from H, Me, CF₃ and F. In some embodiments, R^4A is H. In some embodiments, R^4B is H.

In some aspects, R⁵ and R⁸ in Formula II are independently selected from H, halo, OH, CN, NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C₁-C₆haloalkyl, —(CH₂CH₂O)_oR^a, —C₁-C₆alkylC₃-C₇cycloalkyl, cyanoC₁-C₆alkyl-, C₁-C₆alk-NR^cR^d, OR^c, SR^c, NR^cR^d, C(O)R^c, OC(O)R^c, C(O)OR^c, C(O)NR^cR^d, S(O)R^c, S(O)₂R_c, aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, and heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N and S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO₂, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, or —C₁-C₆alkylC₃-C₇cycloalkyl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R¹⁰, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CN, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4 NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some embodiments, R⁵ in Formula II is H. In other embodiments, R⁵ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In other embodiments, R⁵ in Formula II is —OR^a, for example, —OCH₃.

In some embodiments, R⁸ in Formula II is H. In other embodiments, R⁸ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, C₁alkyl, —CH₃, and the like. In other embodiments, R⁸ in Formula II is —OR^a, for example, —OCH₃.

In some embodiments, R⁴ and R⁵ in Formula II, together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C₁-C₆ haloalkyl, CN, and NO₂.

In some embodiments, R⁷ and R⁸ in Formula II, together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C_1-6 haloalkyl, CN, and NO₂.

In some aspects, R⁶ and R⁹ in Formula II are independently selected from H, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C₁-C₆haloalkyl, —(CH₂CH₂O)_oR^a, —C₁-C₆alkylC₃-C₇cycloalkyl, cyanoC₁-C₆alkyl-, C₁-C₆alk-NR^cR^d, C(O)R^b, C(O)OR^a, C(O)NR^cR^d, S(O)R^b S(O)₂R^b, aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, and heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO₂, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C₁-C₆alkylC₃-C₇cycloalkyl, aryl, heteroaryl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CN, N₃, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some embodiments, R⁶ in Formula II is H. In other embodiments, R⁶ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, or C₁alkyl.

In some embodiments, R⁹ in Formula II is H. In other embodiments, R⁶ in Formula II is —C₁-C₆alkyl, for example, C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, or C₁alkyl.

In some aspects, R¹⁰ in Formula II is aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO₂, wherein said aryl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —CH₂CH₂OR^a, CN, N₃, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4 NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some aspects R^6A, R^6B, R^9A, and R^9B in Formula II are each independently H, C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —(CH₂CH₂O)_oR^a, C₃-C₇cycloalkyl, —C₁-C₆alkylC₃-C₇cycloalkyl, C₄-C₇heterocycloalkyl, —C₁-C₆alkylC₄-C₇heterocycloalkyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C₃-C₇cycloalkyl, —C₁-C₆alkylC₃-C₇cycloalkyl, —C₄-C₇heterocycloalkyl, —C₁-C₆alkylC₃-C₇heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, CN, N₃, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)NR^c4R^d4, NR^c4C(O)OR^a4, P(OR^e3)₂, P(O)R^e3R^f3, P(O)OR^e3OR^f3, S(O)R^b4, S(O)NR^c4R^d4 S(O)₂R^b4, NR^c4S(O)₂R^b4, and S(O)₂NR^c4R^d4.

In some embodiments, R^6A and R^6B in Formula II, together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C₁-C₆ haloalkyl, CN, and NO₂.

In some embodiments, R^9A and R^9B in Formula II, together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C₁-C₆ haloalkyl, CN, and NO₂.

In some aspects, R^a, R^a1, R^a2, R^a3, and R^a4 in Formula II are independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some embodiments, R^a is H. In other embodiments, R^a is —C₁-C₆ alkyl, for example C₆alkyl, C₅alkyl, C₄alkyl, C₃alkyl, C₂alkyl, or C₁alkyl. In some embodiments, R^a is —CH₃.

In some aspects, R^b, R^b1, R^b2, R^b3, and R^b4 in Formula II are independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c and R^d in Formula II are independently H, C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy, or heterocycloalkyl group.

In some embodiments, R^c and R^d in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c1 and R^d1 in Formula II are independently H, C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some embodiments, R^c1 and R^d1 in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c2 and R^d2 in Formula II are independently H, C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, or biheteroaryl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR^a4, C(O)R^b4, S(O)₂R^b3, alkoxyalkyl, and alkoxyalkoxy.

In some aspects, R^c2 and R^d2 in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR^a4, C(O)R^b4, S(O)₂R^b3, alkoxyalkyl, and alkoxyalkoxy.

In some aspects, R^c3 and R^d3 in Formula II are independently H, C_1-10 alkyl, C_1-6 haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c3 and R^d3 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c4 and R^d4 in Formula II are independently H, C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C₁-C₁₀ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^c4 and R^d4 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkoxy.

In some aspects, R^e1, R^e2, and R^e3 in Formula II are independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, (C₁-C₆ alkoxy)-C₁-C₆ alkyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.

In some aspects, R^f1, R^f2, and R^f3 in Formula II are independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl.

In some aspects, R^g1 in Formula II is H, CN, or NO₂.

In some aspects, the disclosure is directed to compounds of Formula IIA:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • Q is —O—, —S—, —S(O)—, or —S(O)₂—;
  • R is halo; n=1;
  • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—;
  • R² and R^2A are each independently H, halo, or C₁-C₆alkyl,
    • or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C₃-C₆cycloalkyl ring;
  • R^2B and R^2C are each independently H or C₁-C₆alkyl,
    • or R^2B and R^2C may, together with the carbon atom to which they are both attached, form a C₃-C₆cycloalkyl ring;
  • R³ is H or C₁-C₆alkyl;
  • L¹ is —C₁-C₆alkylene-;
  • L² is C₃-C₇ cycloalkylene, C₄-C₇ heterocycloalkylene or heteroarylene;
  • L³ is absent, or is —NR^6AS(O)—, —S(═O)₂NR^6A—, —NR^6AS(O)₂—, —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —NR^6AC(O), —C(═O)NR^6A—;
  • L⁴ is absent, —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, or —O—, —S—, —S(O)—, —S(O)₂—, —NR⁶—, —NR^6AC(O), or —C(═O)NR^6A—;
  • L⁵ is absent, or is a 6-10 membered arylene or 5-10 membered heteroarylene, wherein said heteroarylene is optionally substituted with C₁-C₆ alkyl, OC₂-C₆ alkyl NR^c3R^d3, or —C₁-C₆ alkyl-C(O)NR^c3R^d3;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—;
  • p=0-4; q=0-3; s=1;
  • each R⁴ is independently H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl,
  • each R⁵ is independently selected from is H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl;
  • each R^6A is independently selected from H, or C₁-C₆alkyl;
  • each R⁷ is H, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • each R^4A and R^4B is independently H, Me, CF₃ or F; and
  • each R⁸ is H, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • R^c3 and R^d3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, or C₁-C₆ alk-C₁-C₆ alkoxy.

In some aspects, the disclosure is directed to compounds of Formula IIA-1:

or a pharmaceutically acceptable salt or solvate thereof;wherein

• • L² is C₄ cycloalkylene, C₅ heterocycloalkylene or heteroarylene;
  • L³ is absent, or is —NR^6AS(O)—, —S(═O)₂NR^6A—, —NR^6AS(O)₂—, —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —NR^6AC(O), —C(═O)NR^6A—;
  • L⁴ is absent, —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, or —O—, —S—, —S(O)—, —S(O)₂—, —NR⁶—, —NR^6AC(O), or —C(═O)NR^6A—;
  • L⁵ is absent, a 6-membered arylene, or a 5- or 6-membered heteroarylene, wherein said heteroarylene is optionally substituted with —C₁-C₆ alkyl, OC_2-6 alkyl NR^c3R^d3, or —C₁-C₆ alkyl-C(O)NR^c3R^d3;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—;
  • p=0-4; and q=0-3; s=1;
  • each R⁴ is independently selected from H, OH, —C₁-C₆alkyl, and —OC₁-C₆alkyl,
  • each R⁵ is independently selected from H, OH, —C₁-C₆alkyl, and —OC₁-C₆alkyl;
  • each R⁶ is independently selected from H and —C₁-C₆alkyl;
  • each R^6A is independently selected from H, and C₁-C₆alkyl;
  • each R⁷ is H, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • each R^4A and R^4B is independently H, Me, CF₃ or F; and
  • each R⁸ is H, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • R^c3 and R^d3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, or C₁-C₆ alk-C₁-C₆ alkoxy.

In some embodiments, the compounds of Formula IIA-1 are those wherein L² is heteroarylene, L³ is absent, L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—; L⁵ is absent, L⁶ is absent, p=1; and q=3, R⁴ and R⁵ are H; R^4A and R^4B are H.

In some aspects, the disclosure is directed to compounds of Formula IIA-2:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L³ is absent, or is —NR^6AS(O)—, —S(═O)₂NR^6A—, —NR^6AS(O)₂—, —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —NR^6AC(O), —C(═O)NR^6A—;
  • L⁴ is absent, —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, or —O—, —S—, —S(O)—, —S(O)₂—, —NR⁶—, —NR^6AC(O), or —C(═O)NR^6A—;
  • L⁵ is 6-membered arylene or 5- or 6-membered heteroarylene, wherein said heteroarylene is optionally substituted with —C₁-C₆ alkyl, —OC₂-C₆alkyl NR^c3R^d3, or —C₁-C₆ alkyl-C(O)NR^c3R^d3;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—;
  • p=0-4; q=0-3; and s=1;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl;
  • each R^6A is independently selected from H or C₁alkyl;
  • each R⁷ is H, —C₁alkyl, or —OC₁alkyl;
  • each R^4A and R^4B is H;
  • each R⁸ is H, —C₁alkyl, or —OC₁alkyl;
  • R^c3 and R^d3 together with the N atom to which they are attached form a 6-membered heterocycloalkyl group optionally substituted with —C₁-C₆ alkoxy or —C₁-C₆ alk-C₁-C₆ alkoxy.

In some aspects, the disclosure is directed to compounds of Formula IIA-3:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L³ is absent, or is —NR^6AS(O)—, —S(═O)₂NR^6A—, —NR^6AS(O)₂—, —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —NR^6AC(O), —C(═O)NR^6A—;
  • L⁴ is absent, —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, or —O—, —S—, —S(O)—, —S(O)₂—, —NR⁶—, —NR^6AC(O), or —C(═O)NR^6A—;
  • L⁵ is phenyl;
  • L⁶ is —(CR⁷R⁸)_s—;
  • p=0-4; q=0-3; and s=1
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl;
  • each R^6A is independently selected from H or C₁alkyl;
  • each R⁷ is H, —C₁alkyl, or —OC₁alkyl;
  • each R^4A and R^4B is H;
  • each R⁸ is H, —C₁alkyl, or —OC₁alkyl.

In some embodiments, the compounds of Formula IIA-3 are those wherein

• • L³ is absent,
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —O— or —S—,
  • L⁵ is phenyl;
  • L⁶ is —(CR⁷R⁸)_s—;
  • p=1-2; q=0-1; and s=1-2;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁷ is H, —C₁alkyl, or —OC₁alkyl; and
  • each R⁸ is H, —C₁alkyl, or —OC₁alkyl.

In other embodiments, the compounds of Formula IIA-3 are those wherein

• • L³ is absent;
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —O— or —S—;
  • L⁵ is phenyl;
  • L⁶ is —(CR⁷R⁸)_s—;
  • p=1; q=0; and s=1
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁷ is H, —C₁alkyl, or —OC₁alkyl; and
  • each R⁸ is H, —C₁alkyl, or —OC₁alkyl.

In other embodiments, the compounds of Formula IIA-3 are those wherein L³ is absent; L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —O— or —S—; L⁵ is phenyl; L⁶ is —(CR⁷R⁸)_s—; p=1; q=0; and s=1; each R⁴ is H; each R⁵ is H; R⁷ is H; and R⁸ is H.

In some aspects, the disclosure is directed to compounds of Formula IIB:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • Q is —O—, —S—, —S(O)—, or —S(O)₂—;
  • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—;
  • R² and R^2A are each independently H, halo, C₁-C₆alkyl,
    • or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C₃-C₆cycloalkyl ring;
  • R^2B and R^2C are each independently H or C₁-C₆alkyl,
    • or R^2B and R^2C may, together with the carbon atom to which they are both attached, form a C₃-C₆cycloalkyl ring;
  • R is halo, —S—C₁-C₆alkyl, or —O—C₁-C₆alkyl;
    • n=1 or 2;
  • R¹ is halo, —CH₂—CN, —C₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —C₁-C₆alk-OH, —C₁-C₆alk-O—C₁-C₆alkyl, —O—C₁-C₆alk-O—C₁-C₆alkyl, —C₁-C₆alk-O—C₃-C₆cycloalkyl, —C₁-C₆alk-O—C₁-C₆haloalkyl, or

• • • m=1 or 2
  • L³ is absent, or is —NR⁶S(O)—, —S(═O)₂NR⁶—, —NR⁶S(O)₂—,
  • L⁴ is —(CR⁴R⁵)_p, (CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, (CR⁴R⁵)_pO(CR⁴R⁵)_q, (CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q, (CR⁴R⁵)_pS(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)₂(CR⁴R⁵)_q, (CR⁴R⁵)_pC(O)NR^6A(CR⁴R⁵)_q, (CR⁴R⁵)_pNR^6AC(O)(CR⁴R⁵)_q, or —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • wherein each occurrence of p or q is independently p=0-2 and q=1-5;
  • L⁵ is absent,
  • L⁶ is absent, or is (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, or (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t;
  • wherein each occurrence of s or t is independently s=0-2 and t=0-2;
  • each R⁴ and each R⁷ is independently selected from H, OH, C₁-C₆alkyl, C₁-C₆haloalkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, —OC₃-C₇cycloalkyl, —CH₂—CN, —CN, —N(CH₃)₂,

• • each R⁵ and each R⁸ is independently selected from H, OH, —CH₂OH, C₁-C₆alkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, and —OC₃-C₇cycloalkyl;
  • wherein one R⁴ and R⁵ together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,

• • each R⁹ is independently H or —C₁-C₆alkyl.
  • and each R^4A and each R^4B is independently selected from H, Me, CF₃, and F.

In some aspects, the disclosure is directed to compounds of Formula IIB-1:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—;
  • R² and R^2A are each independently H, halo, C₁-C₆alkyl,
    • or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C₃-C₆spirocycloalkyl ring;
  • R^2B and R^2C are each independently H or C₁-C₆alkyl,
    • or R^2B and R^2C may, together with the carbon atom to which they are both attached, form a C₃-C₆spirocycloalkyl ring;
  • R is halo, —S—C₁-C₆alkyl, or —O—C₁-C₆alkyl;
    • n=1 or 2;
  • R¹ is halo, —CH₂—CN, —C₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —C₁-C₆alk-OH, —C₁-C₆alk-O—C₁-C₆alkyl, —O—C₁-C₆alk-O—C₁-C₆alkyl, —C₁-C₆alk-O—C₃-C₆cycloalkyl, —C₁-C₆alk-O—C₁-C₆haloalkyl, or

• • • m=1 or 2
  • L³ is absent, or is —NR⁶S(O)—, —S(═O)₂NR⁶—, —NR⁶S(O)₂—,
  • L⁴ is —(CR⁴R⁵)_p, (CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, (CR⁴R⁵)_pO(CR⁴R⁵)_q, (CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q, (CR⁴R⁵)_pS(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)₂(CR⁴R⁵)_q, (CR⁴R⁵)_pC(O)NR^6A(CR⁴R⁵)_q, (CR⁴R⁵)_pNR^6AC(O)(CR⁴R⁵)_q, or —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • wherein each occurrence of p or q is independently p=0-2 and q=1-5;
  • L⁵ is absent,
  • L⁶ is absent, or is (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, or (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t;
  • wherein each occurrence of s or t is independently s=0-2 and t=0-2;
  • each R⁴ and each R⁷ is independently selected from H, OH, C₁-C₆alkyl, C₁-C₆haloalkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, —OC₃-C₇cycloalkyl, —CH₂—CN, —CN, —N(CH₃)₂,

• • each R⁵ and each R⁸ is independently selected from H, OH, —CH₂OH, C₁-C₆alkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, and —OC₃-C₇cycloalkyl;
  • wherein one R⁴ and R⁵ together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,

• • each R⁹ is independently H or —C₁-C₆alkyl.
  • and each R^4A and each R^4B is independently selected from H, Me, CF₃, or F.

In some aspects, the disclosure is directed to compounds of Formula IIB-2:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • R is halo, —S—C₁-C₆alkyl, or —O—C₁-C₆alkyl;
    • n=1 or 2;
  • R¹ is halo, —CH₂—CN, —C₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —C₁-C₆alk-OH, —C₁-C₆alk-O—C₁-C₆alkyl, —O—C₁-C₆alk-O—C₁-C₆alkyl, —C₁-C₆alk-O—C₃-C₆cycloalkyl, —C₁-C₆alk-O—C₁-C₆haloalkyl, or

• • • m=1 or 2
  • L³ is absent, or is —NR⁶S(O)—, —S(═O)₂NR⁶—, —NR⁶S(O)₂—,
  • L⁴ is —(CR⁴R⁵)_p, (CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, (CR⁴R⁵)_pO(CR⁴R⁵)_q, (CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q, (CR⁴R⁵)_pS(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)₂(CR⁴R⁵)_q, (CR⁴R⁵)_pC(O)NR^6A(CR⁴R⁵)_q, (CR⁴R⁵)_pNR^6AC(O)(CR⁴R⁵)_q, or —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • wherein each occurrence of p or q is independently p=0-2 and q=1-5;
  • L⁵ is absent,
  • L⁶ is absent, or is (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, or (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t;
  • wherein each occurrence of s or t is independently s=0-2 and t=0-2;
  • each R⁴ and each R⁷ is independently selected from H, OH, C₁-C₆alkyl, C₁-C₆haloalkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, —OC₃-C₇cycloalkyl, —CH₂—CN, —CN, —N(CH₃)₂,

• • each R⁵ and each R⁸ is independently selected from H, OH, —CH₂OH, C₁-C₆alkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, —OC₃-C₇cycloalkyl;
  • wherein one R⁴ and R⁵ together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,

• • each R⁹ is independently H or —C₁-C₆alkyl.
  • and each R^4A and each R^4B is independently selected from H, Me, CF₃, or F.

In some aspects, the disclosure is directed to compounds of Formula IIB-3:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L³ is absent, or is —NR⁶S(O)—, —S(═O)₂NR⁶—, —NR⁶S(O)₂—,
  • L⁴ is —(CR⁴R⁵)_p, (CR⁴R⁵)_p—CR^4B═CR^4B—(CR⁴R⁵)_q, (CR⁴R⁵)_pO(CR⁴R⁵)_q, (CR⁴R⁵)_p—S(═O)₂NR^6A—(CR⁴R⁵)_q, (CR⁴R⁵)_pS(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)(CR⁴R⁵)_q, (CR⁴R⁵)_pS(O)₂(CR⁴R⁵)_q, (CR⁴R⁵)_pC(O)NR^6A(CR⁴R⁵)_q, (CR⁴R⁵)_pNR^6AC(O)(CR⁴R⁵)_q, or —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • wherein each occurrence of p or q is independently p=0-2 and q=1-5;
  • L⁵ is absent,
  • L⁶ is absent, or is (CR⁷R⁸)_sO(CR⁷R⁸)_t, (CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t, (CR⁷R⁸)_sS(CR⁷R⁸)_t, (CR⁷R⁸)_sS(O)(CR⁷R⁸)_t, or (CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t;
  • wherein each occurrence of s or t is independently s=0-2 and t=0-2;
  • each R⁴ and each R⁷ is independently selected from H, OH, C₁-C₆alkyl, C₁-C₆haloalkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, and —OC₃-C₇cycloalkyl;
  • each R⁵ and each R⁸ is independently selected from H, OH, —CH₂OH, C₁-C₆alkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, and —OC₃-C₇cycloalkyl;
  • wherein one R⁴ and R⁵ together with the C atom to which they are both attached may form a 3, 4, 5, or 6-membered cycloalkyl ring; and
  • each R^4A and each R^4B is independently selected from H, Me, CF₃ and F; and
  • each R⁹ is independently H or —C₁-C₆alkyl.

In some aspects, the disclosure is directed to compounds of Formula IIB-4:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L⁴ is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q—;
  • p=1 and q=1-4.
  • each R⁴ is independently selected from H, OH, C₁-C₆alkyl, C₁-C₆haloalkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, —OC₃-C₇cycloalkyl, —CH₂—CN, —CN, —N(CH₃)₂,

• • each R⁵ is independently selected from H, OH, —CH₂OH, C₁-C₆alkyl, —OC₁-C₆alkyl, —C₃-C₇cycloalkyl, and —OC₃-C₇cycloalkyl;
  • and each R^4A and each R^4B is independently selected from H, Me, and F.

In some aspects, the disclosure is directed to compounds of Formula IIB-5:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L⁴ is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q—;
  • p=1 and q=1-4;
  • R⁴ is independently H, or —C₁-C₆alkyl;
  • R⁵ is independently H, or C₁-C₆alkyl;
    • wherein one R⁴ and one R⁵, together with the carbon atom to which they are both attached, are

• • and each R^4A and each R^4B is independently selected from H, Me, or F.

In some aspects, the disclosure is directed to compounds of Formula IIB-6:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • R¹ is halo, —CH₂—CN, —C₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —OC₁-C₆haloalkyl, —C₁-C₆alk-OH, —C₁-C₆alk-O—C₁-C₆alkyl, —O—C₁-C₆alk-O—C₁-C₆alkyl, —C₁-C₆alk-O—C₃-C₆cycloalkyl, —C₁-C₆alk-O—C₁-C₆haloalkyl, or

• • • m=1 or 2;
  • L⁴ is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q—;
    • p=1 and q=1-4;
  • R⁴ is independently H, —OC₁-C₆alkyl, or —C₁-C₆alkyl;
  • R⁵ is independently H, —OC₁-C₆alkyl, or —C₁-C₆alkyl;
  • R^4A and R^4B are H.

In some aspects, the disclosure is directed to compounds of Formula IIB-7:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • R is halo, —S—C₁-C₆alkyl, or —O—C₁-C₆alkyl;
    • n=1 or 2;
  • L⁴ is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q—;
    • p=1 and q=1-4;
  • R⁴ is independently H, —OC₁-C₆alkyl, or —C₁-C₆alkyl;
  • R⁵ is independently H, —OC₁-C₆alkyl, or —C₁-C₆alkyl;
  • R^4A and R^4B are H.

The disclosure is directed to compounds of Formula IIC:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • Q is —O—, or —S—;
  • R is halo; n=1;
  • the moiety —W¹—W²—W³ is —CH₂—CH₂—CH₂—, —O—CH₂—CH₂—, or —CH₂—CH₂—O—;
  • R³ is H, or C₁-C₆alkyl;
  • L¹ is —C₁-C₆alkylene-;
  • L² is C₃-C₇cycloalkyl, or C₄-C₇heterocycloalkylene;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —S(O)₂—, —C(═O)—, —NR⁶—;
  • L⁴ is absent or is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, —(CR⁴R⁵)_pO(CR⁴R⁵)_q—;
  • L⁵ is a 6-membered arylene, 5-membered heteroarylene, 7- to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered monocyclic cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered monocyclic heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
  • L⁶ is absent, or is —(CR⁷R⁸)_s, (CR⁷R⁸)_sO(CR⁷R⁸)_t, —(CR⁷R⁸)_a—CR^4A═CR^4B—(CR⁷R⁸)_c, (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—NR⁶—;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
    • or R⁴ and R⁵ together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl,
  • each R⁷ is H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl,
  • each R⁸ is H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
    • or R⁷ and R⁸ together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
  • each R^4A and each R^4B is independently H, or —OC₁-C₆alkyl;
  • a=0-1; c=0-3; p=0-3; s=0-2, t=0-5; and q=0-2;

In some aspects, the disclosure is directed to compounds of Formula IIC-1:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L² is C₃-C₆cycloalkylene, or heterocycloalkylene;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —S(O)₂—, —C(═O)—, —NR⁶—;
  • L⁴ is absent or is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, —(CR⁴R⁵)_pO(CR⁴R⁵)_q—;
  • L⁵ is a 6-membered arylene, or 5-membered heteroarylene, 7- to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
  • L⁶ is absent, —(CR⁷R⁸)_s, (CR⁷R⁸)_sO(CR⁷R⁸)_t, —(CR⁷R⁸)_a—CR^4A═CR^4B—(CR⁷R⁸)_c, (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—NR⁶—;
  • a=0-1; c=0-3; p=0-3; s=0-2, t=0-5; and q=0-2;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • or R⁴ and R⁵ together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
  • each R^4A and each R^4B is independently H, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl;
  • each R⁷ is H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • each R⁸ is H, OH, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
    • or R⁷ and R⁸ together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring.

In some aspects, the disclosure is directed to compounds of Formula IIC-2:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —S(O)₂—, —C(═O)—, —NR⁶—;
  • L⁴ is absent or is —(CR⁴R⁵)_p—CR^4A═CR^4B—(CR⁴R⁵)_q, —(CR⁴R⁵)_pO(CR⁴R⁵)_q—,
  • L⁵ is a 7- to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, (CR⁷R⁸)_sO(CR⁷R⁸)_t, or (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t;
  • a=0-1; c=0-3; n=1; p=0-1; s=0-2; t=0-2; and q=0-2;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R^4A and each R^4B is independently H, or —OC₁-C₆alkyl;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl,
  • each R⁷ is independently H, —C₁-C₆alkyl, or —OC₁-C₆alkyl; and
  • each R⁸ is independently H, —C₁-C₆alkyl, or —OC₁-C₆alkyl.

In some aspects, the disclosure is directed to compounds of Formula IIC-3:

or a pharmaceutically acceptable salt or solvate thereof;

wherein

• • L⁶ is —(CR⁷R⁸)_a—CR^4A═CR^4B—(CR⁷R⁸)_c, (CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—NR⁶—;
  • a=0-1; c=1-3; n=1; s=0-2, t=0-5;
  • each R⁴ is independently H, OH, or —OC₁-C₆alkyl;
  • each R^4A and each R^4B is H;
  • each R⁵ is independently selected from is H, OH, or —OC₁-C₆alkyl;
  • each R⁶ is independently selected from is H or —C₁-C₆alkyl,
  • each R⁷ is independently H, —C₁-C₆alkyl, or —OC₁-C₆alkyl,
  • each R⁸ is independently H, —C₁-C₆alkyl, or —OC₁-C₆alkyl;
  • or R⁷ and R⁸, together with the carbon atom to which they are attached, for a C₃-C₆ cycloalyl ring.

It will be apparent that the compounds of Formula I and Formula II, including all subgenera described herein, have multiple stereogenic centers. As a result, there exist multiple stereoisomers (enantiomers and diastereomers) of the compounds of Formula I and Formula II (subgenera described herein). The present disclosure contemplates and encompasses each stereoisomer of any compound of Formula I and Formula II (and subgenera described herein), as well as mixtures of said stereoisomers.

Pharmaceutically acceptable salts and solvates of the compounds of Formula I and Formula II (including all subgenera described herein) are also within the scope of the disclosure.

Isotopic variants of the compounds of Formula I and Formula II (including all subgenera described herein) are also contemplated by the present disclosure.

Pharmaceutical Compositions and Methods of Administration

The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.

In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v or v/v.

In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v, or v/v.

In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.

In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.

In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above).

In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above).

In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

A pharmaceutical composition of the invention typically contains an active ingredient (i.e., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

Described below are non-limiting exemplary pharmaceutical compositions and methods for preparing the same.

Pharmaceutical Compositions for Oral Administration.

In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.

In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent.

In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.

Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

Other hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-lOoleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.

The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%, 50%), 100%, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.

The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.

Pharmaceutical Compositions for Injection.

In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.

The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Pharmaceutical Compositions for Topical (e.g. Transdermal) Delivery.

In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.

Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration-enhancing molecules known to those trained in the art of topical formulation.

Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.

The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Pharmaceutical Compositions for Inhalation.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

Other Pharmaceutical Compositions.

Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, N.Y., 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

In some embodiments, the compounds or pharmaceutical composition of the present invention are administered by intravenous injection.

The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.

In some embodiments, a compound of the invention is administered in a single dose.

Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition.

In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.

Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent. Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. A covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.

A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. Nos. 5,451,233; 5,040,548; 5,061,273; 5,496,346; 5,292,331; 5,674,278; 3,657,744; 4,739,762; 5,195,984; 5,292,331; U.S. Pat. Nos. 5,674,278; 5,879,382; 6,344,053.

The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.

When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half-life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.

The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

Methods of Use

The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

As used herein, the term “IC₅₀” refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50). EC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.

In some embodiments, the subject methods utilize a MCL-1 inhibitor with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay. In some embodiments, the MCL-1 inhibitor inhibits MCL-1 a with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less, 425 nM or less, 450 nM or less, 475 nM or less, 500 nM or less, 550 nM or less, 600 nM or less, 650 nM or less, 700 nM or less, 750 nM or less, 800 nM or less, 850 nM or less, 900 nM or less, 950 nM or less, 1 μM or less, 1.1 μM or less, 1.2 μM or less, 1.3 μM or less, 1.4 μM or less, 1.5 μM or less, 1.6 μM or less, 1.7 μM or less, 1.8 μM or less, 1.9 μM or less, 2 μM or less, 5 μM or less, 10 μM or less, 15 μM or less, 20 μM or less, 25 μM or less, 30 μM or less, 40 μM or less, 50 μM, 60 μM, 70 μM, 80 aM, 90 μM, 100 μM, 200 μM, 300 μM, 400 μM, or 500 μM, or less, (or a number in the range defined by and including any two numbers above).

In some embodiments, the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two, or three other MCL-1s.

In some embodiments, the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is less than about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, 950 nM, 1 μM, 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM, 1.9 μM, 2 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM, 200 μM, 300 μM, 400 μM, or 500 μM (or in the range defined by and including any two numbers above), and said IC50 value is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two or three other MCL-1s.

The subject methods are useful for treating a disease condition associated with MCL-1. Any disease condition that results directly or indirectly from an abnormal activity or expression level of MCL-1 can be an intended disease condition.

Different disease conditions associated with MCL-1 have been reported. MCL-1 has been implicated, for example, auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer such as, for example, colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.

Non-limiting examples of such conditions include but are not limited to Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblasts leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute myelogenous leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic Myeloproliferative Disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epidermoid cancer, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Kaposi Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, MALT lymphoma, Mantle cell lymphoma, Mast cell leukemia, Mastocytosis, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloblastoma, Medulloepithelioma, Melanoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Monocytic leukemia, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma, Multiple myeloma, Mycosis Fungoides, Mycosis fungoides, Myelodysplasia Disease, Myelodysplasia Syndromes, Myeloid leukemia, Myeloid sarcoma, Myeloproliferative Disease, Myxoma, Nasal Cavity Cancer, Nasopharyngeal Cancer, Nasopharyngeal carcinoma, Neoplasm, Neurinoma, Neuroblastoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Non-Hodgkin Lymphoma, Non-Hodgkin lymphoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oral cancer, Oropharyngeal Cancer, Osteosarcoma, Osteosarcoma, Ovarian Cancer, Ovarian cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Pancreatic cancer, Papillary thyroid cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene onChromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small cell lymphoma, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, Teratoma, Terminal lymphatic cancer, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, or any combination thereof.

In some embodiments, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

In other embodiments, said method is for treating a disease selected from breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, or cervical cancer.

In other embodiments, said method is for treating a disease selected from leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS) or epidermoid cancer.

Compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).

In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.

In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents.

In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.

In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an anti-proliferative agent.

Combination Therapies

For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. The compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all-trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinstat and zoledronate.

In some embodiments, the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferase inhibitors, histone arginine methyl transferase inhibitors, histone demethylase inhibitors, histone deacetylase inhibitors, histone acetylase inhibitors, and DNA methyltransferase inhibitors. Histone deacetylase inhibitors include, e.g., vorinostat. Histone arginine methyl transferase inhibitors include inhibitors of protein arginine methyltransferases (PRMTs) such as PRMT5, PRMT1 and PRMT4. DNA methyltransferase inhibitors include inhibitors of DNMT1 and DNMT3.

For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with targeted therapies, including JAK kinase inhibitors (e.g. Ruxolitinib), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors, MEK inhibitors, Cyclin Dependent kinase inhibitors, including CDK4/6 inhibitors and CDK9 inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (e.g. Bortezomib, Carfilzomib), HDAC inhibitors (e.g. panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family member (BET) inhibitors, BTK inhibitors (e.g. ibrutinib, acalabrutinib), BCL2 inhibitors (e.g. venetoclax), dual BCL2 family inhibitors (e.g. BCL2/BCLxL), PARP inhibitors, FLT3 inhibitors, or LSD1 inhibitors.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), or PDR001. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is atezolizumab, durvalumab, or BMS-935559. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab.

In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.

For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).

Compounds of the disclosure also include, for example, the compounds and genera identified in Tables A, B, and C.

TABLE A

TABLE B

TABLE C

Compounds of the disclosure also include, for example, the compounds described as Examples below.

Synthesis

Compounds of the invention can be prepared according to numerous preparatory routes known in the literature. The Schemes below provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.

A series of 1,3-diol derivatives of formula 4 (n=0, 1, 2) can be prepared by the methods outlined in Scheme 1. Johnson-Corey-Chaykovsky reaction of the substituted ketone 1 with sulfur ylide can form the corresponding epoxide 2 which can be converted to the aldehyde 3 under Lewis acid (e.g., boron trifluoride diethyl etherate or TiCl₄). The aldehyde 3 can be transformed to the 1,3-diol derivative 4 by treatment with formaldehyde under basic conditions (e.g., KOH).

A series of 1,3-diol derivatives of formula 12 (n=0, 1, 2) can be prepared by the methods outlined in Scheme 2. Compound 7 can be obtained by protecting the alcohol group (e.g., TBS or other silyl group) in 6 obtained from the reduction of the acid 5 using a suitable reductive reagent including, (e.g., BH₃, NaBH₄, LiBH₄, LiAlH₄). Lithiation of compound 7 with a suitable agent (e.g., BuLi or another lithium reagent) at low temperature and subsequent reaction of the intermediate with the ketone 8 can afford the alcohol derivative 9. Removal of the protecting group (e.g., TBAF removal of TBS group) followed by intra-molecular Mitsunobo reaction (e.g., DEAD and triphenylphospine) can yield the cyclic ether 11. Removal of the protecting group by treatment of 11 with acid (e.g. pTSA or HCl) can provide the 1,3-diol derivative 12.

A series of spiro-sulfonamide derivatives of formula 22 (X=CH₂, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 3. Mono-protection of the hydroxyl group 13 can be achieved by reaction of 4 or 12 with substituted benzoyl chloride in the presence of a base (e.g., TEA, DIEA, or NaOH). Oxidation of the hydroxyl group of 13 using a suitable oxidant (e.g., Dess-Martin or Swern oxidation conditions) can afford the corresponding aldehyde 14 which can be transformed into compound 15 by reaction with trimethyl orthoformate in the presence of p-toluenesulfonic acid (p-TsOH). Reaction of compound 15 with 4-fluoro-3-nitrobenzenesulfonamide 16 in the presence of base (e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS) can afford the corresponding compound 17. De-protection of the acetal group in 17 to the aldehyde 18 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA). Reduction of the nitro group in 18 using a suitable reducing agent (e.g., iron in acetic acid, iron and NH₄Cl in ethanol) can yield the imine intermediate 19 which can be further reduced to the amine derivative 20 by using suitable reductive reagent (e.g., NaBH₄ or NaBH(OAc)₃). Alternatively, the amine derivative 20 can be obtained by direct hydrogenation of the nitro compound 18 in the presence of a palladium catalyst (e.g., Pd/C or Pd(OH)₂/C in an appropriate solvent such as methanol or ethanol). Reductive amination of the amine derivative 20 can afford the corresponding derivative 21 which can be transformed into the desired product 22 by reaction with the suitable acid using standard amide coupling conditions (e.g., EDCI, CDI, BOP, HATU or HBTU in the presence of a suitable base, TEA or DIEA).

Alternatively, a series of sulfonamide derivatives of formula 21 (X=CH₂, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 4. Reaction of the sulfonyl chloride 23 with bis-(4-mothoxybenzyl)-amine (PMB)₂NH 24 can form the corresponding sulfonamide 25 which can be transformed into the derivative 30 in a similar manner as described for compound 15 to compound 21 in the scheme 3. The removal of the PMB protecting groups in 30 to afford the sulfonamide derivative 21 can be achieved by using acid (e.g., TFA in DCM) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H₂).

A series of macro-cyclic sulfonamide derivatives of formula 36 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 5. The sulfonamide 33 can be obtained by the removal of the protecting groups (e.g. PMB) in 32 under acid conditions (e.g. TFA, HCl) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H₂) following the reductive amination of the sulfonamide 29 with the appropriate aldehyde or ketone 31 (R^os=optional substituent) under suitable conditions (e.g. imine formation followed by treatment with a suitable reducing agent, such as NaBH₃(CN) or NaBH(OAc)₃). The amide coupling of the sulfonamide 33 with the suitable acid 34 using a coupling agent (e.g. EDC, DCC, or HATU) in the presence of a suitable base (e.g. TEA or DIEA) can yield the macrocyclic precursor 35 which can be then be converted to the corresponding macrocyclic-sulfonamide derivative 36 using a suitable ring closing metathesis (RCM) catalyst (e.g. Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B) under standard reaction conditions.

Similarly, a series of macrocyclic sulfonamide derivatives of formula 39 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 6. The amide coupling of the sulfonamide 33 with the appropriate acid 37 using a coupling agent (e.g. EDC, DCC, or HATU) in the presence of a suitable base (e.g. TEA or DIEA) can provide the sulfonamide derivative 38 which can be then converted to the corresponding macrocyclic sulfonamide derivative 39 in the presence of an RCM catalyst as described in Scheme 4.

A series of macrocyclic sulfonyl carbamate derivatives of formula 42 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared similar methods outlined in Scheme 7. The sulfonamide 33 can react with the appropriate chloroformate derivative 40 in the presence of a suitable base (e.g. DIEA, TEA, or NaOH) to produce the corresponding sulfonyl carbamate 41 which can be transformed into the desired macrocycle of formula 42 in the presence of an RCM catalyst as described in Scheme 4.

Alternatively, the macrocyclic sulfonamide derivatives of formula 36 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 8. Intermolecular olefin metathesis reaction of compound 33 with the vinyl derivative 43 in the presence of suitable olefin metathesis catalyst, (e.g., Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B under suitable reaction conditions) can provide the corresponding olefin compound 44 which can be then hydrolyzed under basic conditions (e.g., LiOH or NaOH) to provide the corresponding acid 45. Intra-molecular amide formation of 45 can afford compound 36 using a suitable amide coupling reagent (e.g., EDCI, CDI, BOP, HATU, or HBTU) and base (e.g., DMAP, Et₃N, or Hunig's base).

In a similar manner, a series of macrocyclic sulfonyl urea derivatives of formula 49 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 9. Grubbs metathesis reaction of compound 33 with the vinyl derivative 46 can provide the corresponding olefin compound 47. Removal the protecting Boc-group in 47 by using acid (e.g., TFA in DCM, HCl in dioxane) can afford the corresponding amine 48. Treatment of 48 with a suitable reagent such as CDI, phosgene or triphosgene and a base (e.g., DMAP, Et₃N, or Hunig's base) can provide the macrocyclic sulfonyl urea derivative 49.

Alternatively, a series of macro-cyclic sulfonyl urea derivatives of formula 49 (X=CH₂, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 10. The sulfonyl urea derivatives 49 can be obtained by treatment of the sulfonamide 33 with diphenyl carbonate or 4-nitrophenyl chloroformate in the presence of DMAP and triethylamine or Hunig's base, follow by the addition of the appropriate amine 50. Alternatively, treatment of the amine 50 with phosgene, or triphosgene to form the corresponding carbamoyl chloride which can react with the sulfonamide 33 to afford the sulfonyl urea derivatives 51. RCM reaction of 51 using methods described above can afford macrocycles of formula 49.

A series of macrocyclic sulfonamide derivatives of formula 59 (X=CH₂, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 10. The alcohol derivative 54 can be obtained by hydrolysis of the acetate ester 53 which can be produced by the reductive amination of 29 with the aldehyde 52. Mitsunobo reaction (e.g., DEAD and triphenylphospine) of compound 54 with ester 55 (R^os=optional substituent) can yield the ether derivative 56. Removal of the PMB groups in 56 under acid conditions (e.g. TFA, HCl) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H₂) can give 57, and hydrolysis of the ester group in 57 under basic conditions (e.g., LiOH or NaOH in water/THF) can afford the sulfonamide-acid derivative 58. Intra-molecular amide formation of 58 can form the macro-cyclic sulfonamide derivative 59 by methods provided above.

A series of spiro-cyclic sulfonamide derivatives of formula 60 can be prepared by the methods outlined in Scheme 12. Alkylation of phenol compound 61 with a bromide 62 can give the corresponding ether 63 in the presence of a base (e.g., NaH or NaOH) which can react with diethyl malonate 64 or other dialkyl malonate in the presence of a suitable palladium catalyst (e.g., Pd(PtButyl)₃ or other Pd catalyst) to afford the malonate derivative 65. 1,3-diol derivative 67 can be obtained by reduction (e.g., DIBAL, LAH, or NaBH₄) of the diethyl ester 66 provided by treatment of the malonate derivative 65 with 4-nitrobenzenesulfonyl fluoride in the presence of a base (e.g., DBU or DIEA). Asymmetric mono-protecting of the OH-group 68 can be achieved by reaction of 67 with substituted benzoyl chloride in the presence of a suitable chiral catalyst, such as (R,R)-Kang Catalyst. Dess-Martin oxidation or Swern oxidation of the hydroxyl group of 68 can afford the corresponding aldehyde 69 which can be transformed to compound 70 by reaction with trimethyl orthoformate in the presence of acid (e.g., p-TsOH in methanol). Hydrolysis of compound 70 can yield the alcohol 71 which can be transformed into the spiro-cyclic sulfonamide derivatives 60 in a similar manner as the those described above for compound 15 to compound 20 in Scheme 3. Reaction of the alcohol 71 with 4-fluoro-3-nitrobenzenesulfonamide 25 in the presence of base (e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS) can afford the corresponding compound 72. De-protection of the acetal group in 72 to the aldehyde 73 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA). Reduction of the nitro group in 73 by using a suitable reducing agent (e.g., iron in acetic acid, iron or zinc and NH₄Cl in ethanol) followed by further reduction of the imine formed in situ with suitable reductive reagent (e.g., NaBH₄ or NaBH(OAc)) can afford the spiro-cyclic sulfonamide derivatives of formula 60.

A series of allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 13. Reductive amination of the spiro-sulfonamide 74 with aldehyde 75 using reductive agent (e.g., NaBH₄, NaBH(OAc)₃, or NaBCNH₃) can afford the corresponding product 76 which can be transformed into the alcohol 77 under saponification conditions (e.g. acid or base). Swern oxidation or Dess-Martin oxidation of the alcohol 77 can afford the aldehyde 78. Alkylation of 78 with a suitable reagent (e.g., vinylmagnesium bromide or vinyllithium) can yield a mixture of the allyl alcohol 79 and 80. The diastereomers can be separated by chromatography (e.g., silica gel column, or preparative HPLC on a C18 column, or by SFC using a suitable column) using suitable conditions. Removal of the protecting group PMB in 79 or 80 under acid conditions (e.g., TFA in DCM or HCl in dioxane or phosphoric acid in water) can produce the 81 or 82, respectively.

Alternatively, the allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 14 via reductive amination of the spiro-sulfonamide 74 with the aldehyde 85 or 86 by methods described in Scheme 13.

The aldehyde 85 or 86 can be prepared by the methods outlined in Scheme 15. Alkylation of 75 with a suitable agent (e.g., vinylmagnesium bromide or vinyllithium) can produce a mixture of the allyl alcohol 83 or 84 that can be separated by chromatographic methods as described above. Oxidation of 83 or 84 under suitable conditions (e.g., Dess-Martin or Swern conditions) can afford the 85 or 86, respectively.

A series of carbamate derivatives of formula 92 can be prepared by the methods outlined in Scheme 16. Reaction of the allyl alcohol 81 or 82 with acid 87 can yield the amide 88 under amide coupling conditions (e.g., BOP, HATU, HBTU, or EDCI, and an organic base such as DMAP, Et₃N, or Hunig's base). Hydrolysis under basic conditions (e.g., LiOH or NaOH) of 88 can give the alcohol 89. Macrocyclic alcohol 90 can be obtained by a RCM reaction of 89 using RCM reaction conditions described above. Macrocyclic alcohol 90 can be transformed into the desired carbamate derivative 92 by reaction with a suitable dialkylcarbamoyl chloride 93, or by reaction with diphenyl carbonate or CDI followed by treatment with suitable amine R^cR^dNH.

Alternative, a series of carbamate derivatives of formula 98 can be prepared by the methods outlined in Scheme 17. Reaction of the allyl alcohol 81 or 82 with 3-allyl-oxazolidine-2,5-dione 94 in the presence of a suitable base (e.g., DBU or DIEA) can afford the amide 95 which can undergo a RCM reaction to yield the corresponding macrocycles 96. Reductive amination of 96 with an aldehyde RCHO with a suitable reducing agent (e.g., NaBH₃(CN) or NaBH(OAc)₃) can afford 97 which can be transformed into the desired carbamate derivative 98 by methods similar to those shown for conversion of 90 to 92 as described in Scheme 16.

A series of 2-aminoethylene ether of formula 102 can be prepared by the methods outlined in Scheme 18. Epoxide opening of compound 99 (R^os=optional substituent) with macrocyclic alcohol 90 can give the corresponding alcohol 100 which can be transformed into the ether 102 by a two-step process of activation of the alcohol (e.g., mesylation or tosylation) to yield 101 with a leaving group (Lg) and then displacement of the Lg with an amine R^cR^dNH to afford 102.

In a similar manner, a series of aminoalkylene ether of formula 105 can be prepared by the methods outlined in Scheme 19. Reaction of the macrocyclic alcohol 90 with bromoalkyl trifluoromethanesulfonate 103 (R^os=optional substituent, n=1-5) can give the bromide 104 which can be converted to the aminoalkylene ether 105 by reaction with a suitable amine R^cR^dNH.

A series of 2-aminoethylene ether of formula 110 and amide derivative of formula 111 can be prepared by the methods outlined in Scheme 20. Reaction of the macrocyclic alcohol 90 with substituted 2-bromoacetic acid 106 (R^os=optional substituent) using a suitable base (e.g. NaH or DBU) can give the acid 107 which can be converted to the isobutyl carbonic anhydride 108 by treatment with isobutyl chloroformate. Reduction of the anhydride 108 with a suitable reducing agent (e.g., DIBAL or NaBH₄) at low temperature can provide the aldehyde 109 which can be transformed into the 2-aminoethylene ether 110 by reductive amination with R^cR^dNH using reductive agent (e.g., NaBH₄, NaBH(OAc)₃, or NaBCNH₃). Alternatively, reaction of the anhydride 108 with amine R^cR^dNH can yield the corresponding amide 111.

Intermediate 1

6′-Chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

Step 1: 6′-chlorospiro[oxirane-2,1′-tetralin]

To a solution of 6-chlorotetralin-1-one (10.0 g, 55.3 mmol) in DMSO (100 mL) was added trimethylsulfonium iodide (12.4 g, 60.9 mmol) and hydroxypotassium (6.21 g, 110 mmol), the mixture was stirred at 25° C. for 24 hours. The mixture was added to ice water (500 mL), extracted with MTBE (400 mL×3), combined the organic phases, washed with brine (500 mL×2), dried over Na₂SO₄, filtered and concentrated in vacuum to give 6′-chlorospiro[oxirane-2,1′-tetralin] (10.0 g, 51.3 mmol, 92% yield).

Step 2: 6-chlorotetralin-1-carbaldehyde

To a solution of 6′-chlorospiro[oxirane-2,1′-tetralin] (10.0 g, 51.3 mmol) in THF (160 mL) was added Boron trifluoride etherate (364 mg, 2.57 mmol) at −8° C., the solution was stirred at −8° C. for 10 mins. The reaction was quenched with sat. NaHCO₃ (200 mL) at −8° C., extracted the aqueous with MTBE (400 mL×2), combined the organic phases, washed with brine (400 mL), dried over Na₂SO₄, filtered and concentrated in vacuum to give 6-chlorotetralin-1-carbaldehyde (11.40 g, 70% purity, 40.995 mmol, 79% yield).

Step 3: [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methanol

To a solution of 6-chlorotetralin-1-carbaldehyde (11.4 g, 70% purity, 41 mmol) in 2-(2-hydroxyethoxy)ethanol (80 mL, 41 mmol) was added paraformaldehyde (56 mL, 41 mmol), then potassium hydroxide (56 mL, 41 mmol) was added to the mixture at 5° C. The reaction mixture was stirred at 45° C. for 1 h. The reaction mixture was added brine (250 mL), extracted with DCM (300 mL×3), combined the organic phases, dried over Na₂SO₄, filtered and concentrated in vacuum, the residue was purified by silica gel column chromatography (PE:EA=1.5:1) to give [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methanol (11.2 g, 75% purity, 90% yield). H NMR (400 MHz, CDCl₃): δ 7.31-7.34 (m, 2H), 7.11-7.14 (m, 2H), 3.87-3.91 (m, 2H), 3.72-3.76 (m, 2H), 2.73-2.76 (m, 2H), 2.11-2.15 (m, 2H), 1.89-1.92 (m, 2H), 1.79-1.83 (m, 2H).

Step 4: 6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate

To a solution of [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methanol (11.2 g, 37 mmol) in DCM (150 mL) was added benzoyl chloride (6.26 g, 44 mmol) at 0° C., following by drop-wise addition of DIPEA (7.4 mL, 44 mmol). The mixture stirred at 25° C. 16 h. Added DCM (150 mL) to the mixture, washed with sat. NH₄Cl (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered and concentrated in vacuum, the residue was purified by silica gel column chromatography (PE:EA=9:1) to give 11.65 g of racemic product. ¹H NMR (400 MHz, CDCl₃): δ 8.00-8.02 (m, 2H), 7.57-7.61 (m, 1H), 7.44-7.48 (m, 3H), 7.14-7.16 (m, 2H), 4.48 (s, 2H), 3.74-3.82 (m, 2H), 2.78-2.81 (m, 2H), 1.83-1.95 (m, 4H).

Step 5. (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate

To a solution of [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (1.48 g, 4.47 mmol) in DCM (25 mL) was added Dess-Martin periodinane (2.84 g, 6.7 mmol) at 0° C., then the mixture was stirred at 25° C. for 1 h. To the reaction mixture was added a 1:1 mixture of 10% Na₂S₂O₃/sat. NaHCO₃ solution (100 mL). The mixture was extracted with DCM (100 mL×2). The combined organic phases were washed with brine (15 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by FC on a silica gel column to give (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (1.24 g, 84% yield). ¹H NMR (400 MHz, CDCl₃): δ 9.61 (s, 1H), 7.94-7.96 (m, 2H), 7.54-7.58 (m, 1H), 7.41-7.45 (m, 2H), 7.15-7.21 (m, 3H), 4.75 (d, J=11.6 Hz, 1H), 4.55 (d, J=11.6 Hz, 1H), 2.81-2.85 (m, 2H), 2.19-2.23 (m, 1H), 2.00-2.06 (m, 1H), 1.89-1.95 (m, 2H).

Step 6. [6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol

To a solution of (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (1.24 g, 3.77 mmol) in methanol (25 mL) were added p-TsOH H₂O (35 mg, 0.19 mmol) and trimethyl orthoformate (1.2 g, 11.3 mmol). The mixture was stirred at 70° C. for 4 h., then concentrated to 50% volume. The residue was diluted with THF (25 mL) and 1 N NaOH (25 mL) was added. The resulting reaction mixture was stirred at 40° C. 4 h. The solvent was removed. The residue was extracted with EA (20 mL×3). The combined organic layers were washed with 1 N NaOH (50 mL) and brine (100 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by FC on a silica gel column (PE:EA=9:1) to give [6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (0.98 g, 96% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.35 (d, J=8.4 Hz, 1H), 7.10-7.13 (m, 2H), 4.49 (s, 1H), 3.90 (dd, J=3.8, 11.2 Hz, 1H), 3.53 (dd, J=8.4, 11.2 Hz, 1H), 3.46 (s, 3H), 3.33 (s, 3H), 2.68-2.76 (m, 2H), 1.99-2.06 (m, 1H), 1.89-1.96 (m, 1H), 1.70-1.86 (m, 2H).

Step 7: 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide

A 100 mL flask with septum containing a mixture of [6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (818 mg, 3.02 mmol) and potassium t-butoxide (779 mg, 6.94 mmol) under N₂ was charged with THF (22 mL) giving a tan solution. The solution was stirred for 5 min at 0° C., followed by addition at 0° C. of a solution of 4-Fluoro-3-nitrobenzenesulfonamide (731 mg, 3.32 mmol) in THF (4 mL) over 8 min. The reaction was stirred at 0° C. for 20 min. The reaction mixture was quenched with sat. NH₄Cl (10 mL).The reaction mixture was diluted with water (80 mL) and sat. NH₄Cl (10 mL), and extracted with EtOAc (100 mL). The organic layer was washed with water (70 mL) and sat. NH₄Cl (10 mL), and brine (50 mL). The aqueous layers were combined, and back-extracted with EtOAc (60 mL), washed with water (60 mL), and brine (30 mL). The organic layers were combined, dried over Na₂SO₄, and filtered and concentrated under reduced pressure to afford 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide as a yellow foam (1.52 g) and was used directly in the next reaction without further purification. R_f=0.36 (1:1 hexanes:EtOAc); ¹H NMR (500 MHz, DMSO-d₆) δ 8.28 (d, J=2.3 Hz, 1H), 8.01 (dd, J=2.4, 8.9 Hz, 1H), 7.60 (dd, J=8.7, 16.3 Hz, 2H), 7.50 (s, 2H), 7.19-7.11 (m, 2H), 4.63 (s, 1H), 4.38-4.26 (m, 2H), 3.38 (s, 3H), 3.29 (s, 3H), 2.70 (d, J=6.2 Hz, 2H), 2.04-1.94 (m, 1H), 1.90-1.79 (m, 2H), 1.77-1.67 (m, 1H).

Step 8: 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide

The Amberlyst 16 wet catalyst was rinsed with acetone and dried under high vacuum before use. A 500 mL RBF with septum containing crude 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide (1.42 g, 3.02 mmol) and pre-treated Amberlyst 16 wet (1 g, ˜7.44 mmol) under N₂ was charged with acetone (30 mL). The reaction mixture was heated at 50° C. for 2 h., filtered through cotton and rinsed with DCM. The filtrate was concentrated under reduced pressure to afford 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide as an orange/brown oil (1.7 g) which was used directly in the next reaction without further purification. R_f=0.31 (1:1 hexanes:EtOAc); ¹H NMR (500 MHz, DMSO-d₆) δ 9.65 (s, 1H), 8.27 (d, J=2.4 Hz, 1H), 8.03 (dd, J=2.4, 8.9 Hz, 1H), 7.63 (d, J=9.0 Hz, 1H), 7.50 (s, 2H), 7.35-7.29 (m, 2H), 7.26 (dd, J=2.4, 8.4 Hz, 1H), 4.77 (d, J=9.6 Hz, 1H), 4.47 (d, J=9.6 Hz, 1H), 2.78 (t, J=6.3 Hz, 2H), 2.19 (ddd, J=3.0, 8.9, 13.2 Hz, 1H), 1.99 (ddd, J=2.8, 8.1, 13.5 Hz, 1H), 1.89-1.80 (m, 1H), 1.80-1.70 (m, 1H).

Step 9: 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

A solution of crude 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide (assumed 3.02 mmol) in acetic acid (50 mL) was charged with iron powder (1.69 g, 30.2 mmol). The mixture was heated at 70° C. for 3 h. The mixture was charged with Celite, diluted with DCM (50 mL), filtered through a Celite plug, and rinsed with DCM to yield crude 6′-chlorospiro[2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. R_f=0.24 (1:1 EtOAc/hexanes); LCMS calculated for C₁₈H₁₈ClN₂O₃S (M+H)⁺: m/z=377.07/379.07; found: 377.0/379.0.

The filtrate was concentrated under reduced pressure, dissolved in DCM (30 mL), cooled to 0° C., and charged with sodium triacetoxyborohydride (1.99 g, 9.44 mmol) over 1 min. The reaction mixture was stirred at 0° C. for 1 min, then stirred at RT for 80 min. The reaction mixture was quenched with 10% citric acid (30 mL), diluted with water (30 mL), and extracted with EtOAc (125 mL). The organic layer was washed with 10% citric acid (10 mL) and water (40 mL), washed with brine (2×40 mL), dried over Na₂SO₄, and filtered. The filtrate was concentrated under reduced pressure to yield 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.24 g, 2.61 mmol, 86% yield) as a light tan foam. R_f=0.45 (1:1 EtOAc/hexanes). LCMS calculated for C₁₈H₂₀ClN₂O₃S (M+H)⁺: m/z=379.09/379.08; found: 379.0/381.0; ¹H NMR (500 MHz, DMSO-d₆) δ 7.81 (d, J=8.5 Hz, 1H), 7.26 (dd, J=2.4, 8.5 Hz, 1H), 7.18 (dd, J=2.3, 15.2 Hz, 2H), 7.13 (s, 2H), 7.02 (dd, J=2.3, 8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 6.20 (t, J=4.1 Hz, 1H), 4.08 (q, J=12.2 Hz, 2H), 3.23 (dd, J=4.7, 13.7 Hz, 1H), 2.77-2.65 (m, 2H), 1.87-1.66 (m, 3H), 1.55 (ddd, J=2.9, 9.7, 12.7 Hz, 1H).

Intermediate 2

(3S)-6′-Chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

Step 1: 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide

To a cooled (−35° C.) solution of 4-Fluoro-3-nitrobenzenesulfonyl chloride (4.89 g, 20.42 mmol) in THF (50 mL) was added Triethylamine (3.13 mL, 22.46 mmol), followed by addition of Bis-(4-methoxybenzyl)amine (4.97 mL, 20.7 mmol) in THF (50 mL) solution over 30 min. while the temperature was kept at −35° C. After completion of the addition, the temperature was allowed slowly to warm to 0° C. over 1 h., and the mixture was stirred at 0° C. for an additional hour. The mixture was neutralized with 1 N HCl to pH about 4-5 and diluted with EtOAc (100 mL). The organic layer was separated, washed with 1 N HCl (10 mL), 7.5% NaHCO₃ aqueous solution (20 mL), and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was treated with DCM (30 mL), and hexane was added to the suspension until it became cloudy. The resulting suspension was sonicated for 2 min. and left at r.t. for 1 h. The mixture was filtered. and washed with hexane to afford the desired title product (6.85 g) without further purification. The mother liquid was concentrated under reduced pressure. The residue was treated with DCM (5 mL) and hexane was added as the procedures mentioned above to afford the additional 0.51 g of the title product. Total product 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide obtained is 7.36 g (78%). ¹H NMR (400 MHz, DMSO-d₆): δ 8.18-8.23 (m, 2H), 7.75-7.79 (q, 1H), 7.08 (d, 4H), 6.81 (d, 4H), 4.31 (s, 4H), 3.71 (s, 6H). ¹⁹F NMR (376 MHz, DMSO-d₆): δ −112.54 (s, 1F). LCMS calculated for C₂₂H₂₂FN₂O₆S (M+H)⁺: m/z=461.11; found: 461.1.

Step 2: [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate and [(1R)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate

Racemic product 6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (intermediate 1, Step 4) was separated by Waters-SFC80 instrument under the separation conditions: Column: AD-H (2.5*25 cm, 10 um); Mobile phase A: Supercritical CO₂, Mobile phase B: EtOH, A:B=80/20 at 60 mL/min; Circle Time: 15 min; Sample preparation: Ethanol; Injection Volume: 0.8 mL; Detector Wavelength: 214 nm; Column temperature: 25° C.; Back pressure: 100 bar. The separated products were determined by chiral HPLC. Chiral HPLC conditions: Chiral Column: AD-H, 5 um, 4.6 mm×250 mm (Daicel); Mobile phase: Supercritical CO₂/EtOH/DEA 70/30/0.06; Flow rate: 2.0 mL/min and Run time: 12 min. to afford [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (P1, Retention time=4.952 min.) and [(1R)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (P2, Retention time=6.410 min.). ¹H NMR (400 MHz, CDCl₃): δ 8.00-8.02 (m, 2H), 7.57-7.61 (m, 1H), 7.44-7.48 (m, 3H), 7.14-7.16 (m, 2H), 4.48 (s, 2H), 3.74-3.82 (m, 2H), 2.78-2.81 (m, 2H), 1.83-1.95 (m, 4H).

Step 3: [(1R)-6-chloro-1-formyl-tetralin-1-yl]methyl benzoate

This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (Step 2, P1) to replace the racemic [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate in Step 5. ¹H NMR (400 MHz, CDCl₃): δ 9.61 (s, 1H), 7.94-7.96 (m, 2H), 7.55-7.58 (m, 1H), 7.41-7.45 (m, 2H), 7.15-7.20 (m, 3H), 4.73-4.76 (d, 1H), 4.53-4.56 (d, 1H), 2.82-2.85 (m, 2H), 2.20-2.26 (m, 1H), 2.01-2.07 (m, 1H), 1.90-1.96 (m, 2H).

Step 4. [(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol

Method A: This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1R)-6-chloro-1-formyl-tetralin-1-yl]methyl benzoate to replace the racemic (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate in Step 6. ¹H NMR (400 MHz, CDCl₃+D₂O): δ 7.34-7.36 (m, 1H), 7.10-7.12 (m, 2H), 4.49 (s, 1H), 3.89-3.91 (d, 1H), 3.50-3.53 (m, 1H), 3.46 (s, 3H), 3.33 (s, 3H), 2.68-2.76 (m, 2H), 1.99-2.06 (m, 1H), 1.89-1.96 (m, 1H), 1.70-1.86 (m, 2H).

Method B: The racemic (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (Intermediate 1 Step 6) was separated by chiral column on Berger MG2 Preparative SFC instrument under the separation conditions: Column: ChiralPak IC (2×25 cm); Mobile phase A: i-PrOH, Mobile phase B: Supercritical CO₂, A:B=1/3 at 60 mL/min; Circle Time (Run Time): 5 min injection intervals; Sample preparation: 20 mg/mL iPrOH/DCM; Injection Volume: 0.5 mL; Detector Wavelength: 220 nm; Column temperature: 30° C.; Back pressure: 100 bar. The separated products were determined by chiral HPLC on Berger Analytical SFC. Chiral HPLC conditions: Chiral Column: ChiralPak IC, 5 um, 4.6 mm×250 mm (Daicel); Mobile phase: i-PrOH/Supercritical CO₂/EtOH 1/3; Flow rate: 3.0 mL/min and Run time: 7 min.; Detector Wavelength (UV length): 220 nm, 254 nm, and 280 nm; Column temperature: 30° C.; Back pressure: 120 bar. to afford [(1S)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (P1, Retention time=1.96 min.) and [(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (P2, Retention time=2.69 min.)

Step 5: N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)-tetralin-1-yl]methoxy]benzenesulfonamide

To a solution of [(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (2.96 g, 10.93 mmol, P2) in THF (50 mL) was drop-wised add LiHMDS (11.5 mL, 11.4 mmol) under N₂ atmosphere at −40° C., the solution was stirred at −40° C. for 5 mins, then dropwise added 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (7.55 g, 16.4 mmol) (Step 1) in THF (30 mL). The solution was stirred for 5 min. under −40° C., then the mixture was stirred at r.t. for 1 h. The reaction was cooled with ice-water bath, and quenched with sat. NH₄Cl aqueous solution (100 mL). The mixture was extracted with EtOAc (100 mL×3). The combined organic layers were washed with sat. NH₄Cl solution and brine, dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash chromatography on a silica gel column eluting with ethyl acetate (EA) and petroleum ether (PE) to give N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]benzenesulfonamide (6.41 g, 82% yield). ¹H NMR (400 MHz, DMSO-d₆): δ 8.06-8.07 (m, 1H), 7.97-8.00 (m, 1H), 7.60-7.62 (m, 1H), 7.49-7.51 (m, 1H), 7.14-7.17 (m, 2H), 6.99-7.07 (m, 4H), 6.77-6.79 (m, 4H), 4.62 (s, 1H), 4.27-4.36 (m, 2H), 4.24 (s, 4H), 3.70 (s, 6H), 3.39 (s, 3H), 3.30 (s, 3H), 2.68-2.71 (m, 2H), 1.98-2.00 (m, 1H), 1.81-1.85 (m, 2H), 1.71-1.73 (m, 1H).

Step 6: N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide

To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 8.59 mmol) in THF (80 mL) and water (20 mL) was added p-TsOH—H₂O (3.27 g, 17.18 mmol), the mixture was stirred at 70° C. for 16 h. The mixture was cooled to 0° C., and sat. NaHCO₃ aqueous (100 mL) was added. The mixture was extracted with EA (100 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EA and to give N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 85% purity, 91% yield).

Step 7: (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide

To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 7.81 mmol) in ethanol (40 mL) and water (20 mL) was added iron powder (2.18 g, 39 mmol) and NH₄Cl (827 mg, 15.6 mmol), the mixture was stirred at 100° C. for 3 h. LCMS showed the reaction completed. The mixture was filtered. The filtrate was added H₂O (20 mL), extracted with EA (30 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide (6.11 g, 70% purity, 86% yield) which was directly used in next step reaction without further purification. LCMS calculated for C₃₄H₃₄ClN₂O₅S (M+H)⁺: m/z=617.18; found: 617.3.

Step 8: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide (6.11 g, 6.73 mmol) (crude product from Step 7, 70% purity) in DCM (80 mL) was portion-wise added NaBH(OAc)₃ (7.14 g, 33.67 mmol). The mixture was stirred at 25° C. for 16 h. LCMS showed the reaction worked well. The reaction was added sat. NaHCO₃ aqueous (80 mL), extracted with DCM (100 mL×3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EA and PE to give (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (2.30 g, 53% yield). LCMS calculated for C₃₄H₃₆ClN₂O₅S (M+H)⁺: m/z=619.2; found: 619.3. ¹H NMR (400 MHz, DMSO-d₆): δ 7.81-7.83 (m, 1H), 7.24-7.28 (m, 2H), 7.17-7.18 (m, 1H), 6.95-7.06 (m, 6H), 6.78-6.80 (m, 4H), 6.20 (s, 1H), 4.15 (m, 4H), 4.08-4.14 (m, 2H), 3.68 (s, 6H), 3.30-3.36 (m, 1H), 3.23-3.27 (m, 1H), 2.71-2.75 (m, 2H), 1.76-1.86 (m, 3H), 1.56-1.61 (m, 1H).

Intermediate 3

(3S)-6′-Chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and

Intermediate 4

(3S)-6′-Chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

Step 1: [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate

2,2,2-trifluoroacetic acid (7.0 mL, 92 mmol) was dropwise added to a stirred solution of sodium borohydride (3.48 g, 92.0 mmol) in DCM (200 mL) at 0° C. The resulting mixture was stirred at 0° C. for 10 min. A solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (28.5 g, 46.03 mmol) and [(1R,2R)-2-formylcyclobutyl]methyl acetate (8.63 g, 55.24 mmol) in 200 mL DCM was then dropwise added at 0° C. The resulting mixture was stirred at room temperature for overnight. The reaction was monitored by LC-MS. Another 2 equivalents of sodium borohydride (3.48 g, 92.06 mmol) and 2,2,2-trifluoroacetic acid (7.04 mL, 92.06 mmol) were added to the mixture, followed by the stirring for 3 h. The reaction was quenched by addition of methanol (30 mL), and followed by addition of saturated NaHCO₃ solution (300 mL) slowly. The resulting mixture was extracted with DCM (300 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-40%) to afford the desired product [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (34.5 g, 45.4 mmol, 98% yield) as a white solid. LC-MS calc. for C₄₀H₄₃ClN₂O₆S [M+H]⁺: m/z=759.28/760.28; Found 759.67/760.64.

Step 2: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (54.0 g, 71.1 mmol) in THF (500 mL), methanol (500 mL) and water (500 mL) was added lithium hydroxide monohydrate (14.9 g, 355 mmol). The mixture was stirred at r.t. overnight. The solvent was removed, and the aqueous layer was extracted with DCM (100 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (52 g, 101% yield) as white solid which was directly used for the next step without further purification. LC-MS calc. for C₄₀H₄₅ClN₂O₆S [M+H]⁺: m/z=717.27/718.27; Found 717.6/718.6.

Step 3: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

DMSO (20.5 mL, 289 mmol) was slowly added to a cooled (−78° C.) solution of oxalyl chloride (12.4 mL, 144.9 mmol) in DCM (1000 mL). Gas was produced during this addition. The mixture was stirred at −78° C. for 30 min. Then a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (52.0 g, 72.4 mmol) in DCM (50 mL) was added over 5 min. The resulting mixture was stirred at −78° C. for 40 min. Then triethylamine (101 mL, 724 mmol) was added. The solution was stirred at −78° C. for additional 10 min, and allowed to warm slowly to 0° C. After the starting material was consumed, water (150 mL) was added. The organic layer were separated. The aqueous layer was extracted with DCM (300 mL×3). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-50%) to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (43 g, 83% yield) as a white solid. LC-MS calc. for C₄₀H₄₃ClN₂O₆S [M+H]⁺: m/z=715.25/716.26; Found 715.7/716.7.

Step 4: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

Vinylmagnesium bromide (1.0 M solution in THF, 300 mL, 300 mmol) was diluted with THF (200 mL) in a 3 necked round bottom flack under nitrogen. (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (43.0 g, 60.1 mmol) dissolved in THF (400 mL) was introduced dropwise through a dropping funnel over 2 hours at room temperature. The reaction was monitored by LC-MS. After the starting material was consumed, the reaction was then quenched by addition of sat. aqueous solution NH₄Cl (300 mL) at 0° C. The organic layer was then separated, and the aqueous layer was extracted with ethyl acetate (300 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-40%) to afford two products: P1 (the earlier eluted product: 24.3 g, 40%) and P2 (the latter eluted product: 20 g, 33%).

P1 was assigned as (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Rt=4.43 min from LC-MS). LC-MS calc. for C₄₂H₄₈ClN₂O₆S [M+H]⁺: m/z=743.28/744.29; Found 743.76/744.78. ¹H NMR (300 MHz, CDCl₃) δ 7.76 (t, J=7.2 Hz, 1H), 7.53 (d, J=1.9 Hz, 1H), 7.24-7.14 (m, 2H), 7.12 (d, J=2.0 Hz, 1H), 7.03-6.97 (m, 5H), 6.79 (t, J=5.7 Hz, 4H), 5.84-5.69 (m, 1H), 5.16 (d, J=17.2 Hz, 1H), 5.05 (d, J=10.4 Hz, 1H), 4.26 (t, J=5.6 Hz, 4H), 4.13 (s, 2H), 3.97 (d, J=4.4 Hz, 1H), 3.80 (d, J=1.8 Hz, 6H), 3.74 (d, J=6.2 Hz, 1H), 3.26 (d, J=14.2 Hz, 1H), 3.09 (dd, J=15.0, 9.3 Hz, 1H), 2.93 (d, J=4.2 Hz, 1H), 2.83-2.75 (m, 2H), 2.48-2.35 (m, 1H), 2.10-1.92 (m, 4H), 1.82 (m, 3H), 1.50 (m, 2H).

And P2 was assigned as (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Rt=4.13 min from LC-MS). LC-MS calc. for C₄₂H₄₈ClN₂O₆S [M+H]⁺: m/z=743.28/745.29; Found 743.8/745.8. ¹H NMR (300 MHz, CDCl₃) δ 7.75-7.68 (m, 1H), 7.24-7.14 (m, 3H), 7.12 (d, J=2.0 Hz, 1H), 7.01 (t, J=8.3 Hz, 5H), 6.79 (d, J=8.7 Hz, 4H), 5.85 (ddd, J=17.0, 10.4, 6.4 Hz, 1H), 5.29 (dd, J=17.2, 1.2 Hz, 1H), 5.17-5.08 (m, 1H), 4.26 (d, J=8.4 Hz, 4H), 4.14 (d, J=8.0 Hz, 3H), 3.81 (s, 6H), 3.69 (d, J=14.3 Hz, 1H), 3.59 (d, J=12.9 Hz, 1H), 3.31 (d, J=14.3 Hz, 1H), 3.15 (dd, J=14.9, 9.0 Hz, 1H), 2.84-2.76 (m, 2H), 2.67-2.56 (m, 1H), 2.23-2.09 (m, 2H), 2.03 (m, 2H), 1.86-1.73 (m, 3H), 1.59-1.46 (m, 2H).

Step 5: (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3)

To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (24.3 g, 32.6 mmol, P1, Step 4) and anisole (23.7 mL, 218 mmol) in DCM (240 mL) was added 2,2,2-trifluoroacetic acid (243 mL). The mixture was stirred overnight. The reaction was monitored by LC-MS. Solvents were removed under reduced pressure. The residue was diluted with DCM (200 mL). The mixture was washed with saturated aqueous NaHCO₃ solution (200 mL×3) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EA/heptane (5%-70%) to afford (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15.7 g, 31.2 mmol, 95% yield) as a pale white solid. LC-MS calc. for C₂₆H₃₂ClN₂O₄S [M+H]⁺: m/z=503.17/505.17; Found 503.5/505.5; ¹H NMR (300 MHz, CDCl₃) δ 7.74 (d, J=8.5 Hz, 1H), 7.55 (d, J=1.8 Hz, 1H), 7.21 (dd, J=11.4, 4.2 Hz, 2H), 7.12-7.08 (m, 2H), 6.97-6.94 (m, 1H), 6.85 (d, J=8.6 Hz, 1H), 5.90-5.76 (m, 1H), 5.25 (d, J=17.2 Hz, 1H), 5.16-5.08 (m, 1H), 4.11 (s, 2H), 3.88 (d, J=5.1 Hz, 1H), 3.81 (s, 2H), 3.27 (d, J=14.3 Hz, 1H), 3.14 (m, 1H), 2.84-2.75 (m, 2H), 2.51 (dd, J=16.9, 8.5 Hz, 1H), 2.08 (m, 3H), 1.90 (dd, J=15.8, 5.6 Hz, 2H), 1.63 (m, 3H), 1.45 (t, J=12.1 Hz, 1H).

Step 6: (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4)

This compound was prepared using procedures analogous to those described for step 5 using P2 Step 4. LC-MS calc. for C₂₆H₃₂ClN₂O₄S [M+H]⁺: m/z=503.17/505.17; Found 503.5/505.5; ¹H NMR (300 MHz, CDCl₃) δ 7.72 (d, J=8.5 Hz, 1H), 7.27-7.16 (m, 3H), 7.12 (s, 1H), 6.99-6.94 (m, 1H), 5.94-5.79 (m, 1H), 5.31 (d, J=17.2 Hz, 1H), 5.19 (d, J=10.5 Hz, 1H), 4.34-4.26 (m, 1H), 4.15-4.08 (m, 2H), 3.70 (d, J=14.5 Hz, 2H), 3.28 (d, J=14.2 Hz, 1H), 3.16 (dd, J=15.1, 9.0 Hz, 1H), 2.79 (dd, J=9.3, 5.0 Hz, 2H), 2.75-2.65 (m, 1H), 2.31-2.21 (m, 1H), 2.05-1.88 (m, 3H), 1.80-1.71 (m, 2H), 1.71-1.59 (m, 2H), 1.50 (t, J=11.4 Hz, 1H).

Intermediate 5

[(1S)-1-[(1R,2R)-2-[[(3S)-6′-Chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate

Step 1: [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.20 g, 1.61 mmol, Intermediate 3 and 4, Step 4, P1) in DCM (40 mL) was added DMAP (39 mg, 0.32 mmol), triethylamine (0.27 mL, 2.1 mmol) and Ac20 (0.18 mL, 1.8 mmol).The reaction mixture was then stirred at r.t. for 6 h. The reaction was diluted with DCM (40 mL), washed with water (30 mL) and brine. The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to afford the desired product (1.26 g) as a light orange colored solid. LC-MS calc. for C₄₄H₅₀ClN₂O₇S [M+H]⁺: m/z=785.29/787.29. Found: 785.2/787.4.

Step 2: [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate

To a stirred solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (1.26 g, 1.6 mmol) in DCM (20 mL) was added TFA (20 mL, 137 mmol) dropwise. The reaction was stirred at 40° C. overnight. LC-MS showed the starting material was consumed. The reaction was cooled to r.t. and slowly poured into a 120 mL of saturated K₂CO₃ solution under an ice bath. The mixture was extracted with DCM (30 mL×3). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Hetpanes (2% to 50%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (680 mg, 77% yield). LC-MS calc. for C₂₈H₃₄ClN₂O₅S [M+H]⁺: mz=545.18/547.18. Found: 544.8/546.4.

Intermediate 6

[(1R)-1-[(1R,2R)-2-[[(3S)-6′-Chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate

This compound was prepared using procedures analogous to those described for Intermediate 5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4, P2) in Step 1. LC-MS calc. for C₂₈H₃₄ClN₂O₅S [M+H]⁺: m/z=545.18/547.18. Found: 544.8/546.6.

Intermediate 7

(3R)-6′-Chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

Step 1: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a cooled (ice-water bath) solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.2 g, 4.3 mmol, Intermediate 3 and 4, Step 4, P1) in THF (70 mL) was added sodium hydride (0.52 g, 12.9 mmol). The mixture was stirred for 5 min., then iodomethane (0.8 mL, 12.9 mmol) was added. The mixture was stirred at 50° C. overnight. The reaction was quenched by addition of saturated aqueous ammonium chloride (70 mL) and water (70 mL). The mixture was extracted with EA (70 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.1 g, 95% yield) which was directly used in next step directly without further purification. LC-MS calc. for C₄₃H₅₀ClN₂O₆S [M+H]⁺: m/z=757.3/759.3. Found: 757.0/759.4.

Step 2: (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LC-MS calc. for C₂₇H₃₄ClN₂O₄S [M+H]⁺: m/z=517.2/519.2. Found: 516.8/518.7.

Intermediate 8

(3S)-6′-Chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 7 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4, P2) in Step 1. LC-MS calc. for C₂₇H₃₅ClN₂O₄S [M+H]⁺: m/z=517.2/519.2. Found: 516.8/518.5.

Intermediate 9

[(1S)-1-[(1R,2R)-2-[[(3S)-6′-Chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

Step 1: [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

To a stirred solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (0.8 g, 1.08 mmol, Intermediate 3 and 4, Step 4, P1) in THF (10 mL)/Toluene (10 mL) was added N,N-dimethylcarbamoyl chloride (1.16 g, 10.7 mmol). The resulting mixture was cooled to −78° C. and KHMDS (8.15 mL, 0.5 M in Toluene) was added dropwise over 10 min. The reaction was stirred at −78° C. for 10 min. Then the solution was slowly warmed up to r.t. and stirred for 1 h. LC-MS showed the consumption of starting material and the formation of desired product. The reaction was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EtOAc/Heptanes (10% to 60%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (0.69 g, 78% yield) as a white solid. LC-MS calc. for C₄₅H₅₃ClN₃O₇S [M+H]⁺: m/z=814.3/816.3; Found: 814.8/816.9.

Step 2. [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2. LC-MS calc. for C₂₉H₃₇ClN₃O₅S [M+H]⁺: m/z=574.2/576.2; Found: 574.6/576.5.

Intermediate 10

[(1R)-1-[(1R,2R)-2-[[(3S)-6′-Chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

Step 1: [(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Intermediate 9 Step 1 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4 P2) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₄₅H₅₃ClN₃O₇S [M+H]⁺: m/z=814.3/816.3; Found: 814.7/816.1.

Step 2: [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2. LC-MS calc. for C₂₉H₃₇ClN₃O₅S [M+H]⁺: m/z=574.2/576.2; Found: 574.8/576.7.

Intermediate 11

(S)-7′-Chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chromane]-7-sulfonamide

Step 1: (2-(2-bromo-5-chlorophenoxy)ethoxy) (tert-butyl)dimethylsilane

To a solution of 2-bromo-5-chlorophenol (20.0 g, 96.4 mmol) in NMP (100 mL) was added K₂CO₃ (26.6 g, 192 mmol) and 2-bromoethoxy-tert-butyldimethylsilane (22.7 mL, 106 mmol). The resulting suspension was stirred at 90° C. for 5 h. After cooling to r.t., the suspension was diluted with water (150 mL), and extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with water (150 mL), brine (150 mL) and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with PE/EA (5%) to afford 2-(2-bromo-5-chloro-phenoxy)ethoxy-tert-butyl-dimethyl-silane (32 g, 90% yield) as light yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.58 (d, J=8.4 Hz, 1H), 7.24 (d, J=2.4 Hz, 1H), 6.95 (dd, J=8.4, 2.4 Hz, 1H), 4.18-4.16 (m, 2H), 3.94-3.93 (m, 2H), 0.86 (s, 9H), 0.06 (s, 6H).

Step 2: diethyl 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-chlorophenyl)malonate

To a suspension of K₃PO₄ (21.35 g, 100.6 mmol) and bis(tri-tert-butylphosphine)palladium(0) (1.70 g, 3.34 mmol) in toluene (100 mL), was added 2-(2-bromo-5-chloro-phenoxy)ethoxy-tert-butyl-dimethyl-silane (12.2 g, 33.3 mmol), followed by the addition of diethyl malonate (10.68 g, 66.7 mmol). The resulting suspension was heated at 85° C. for 6 h. under an atmosphere of argon, and then cooled to r.t. The mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-10%) to afford diethyl 2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chloro-phenyl]propanedioate (7.3 g, 49.2% yield) as a clear oil. ¹H NMR: (400 MHz, CDCl₃) δ 7.30 (d, J=8.2 Hz, 1H), 6.96 (dd, J=8.3, 2.0 Hz, 1H), 6.92 (d, J=2.0 Hz, 1H), 5.11 (s, 1H), 4.27-4.15 (m, 4H), 4.04 (t, J=5.0 Hz, 2H), 3.94 (t, J=5.1 Hz, 2H), 1.26 (t, J=7.2 Hz, 6H), 0.91 (s, 9H), 0.09 (s, 6H).

Step 3: diethyl 7-chlorochromane-4,4-dicarboxylate

To a solution of diethyl 2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chloro-phenyl]propanedioate (9.53 g, 21.4 mmol) and DBU (6.52 g, 42.8 mmol) in MeCN (200 mL) under N₂ atmosphere was added 4-nitrobenzenesulfonyl fluoride (8.79 g, 42.8 mmol). The resulting solution was stirred at 70° C. for 24 h. After cooling, the solution was concentrated at 35° C. under reduced pressure to remove MeCN. The residue was diluted with water (120 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with water (100 mL), 1 N HCl (100 mL), followed by NaHCO₃ (500 mL) solution and brine (100 mL). The organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-10%) (R_f=0.4 in 10% ethyl acetate in hexane) to afford diethyl 7-chlorochromane-4,4-dicarboxylate (7.400 g, 110.5% yield). ¹H NMR: (400 MHz, CDCl₃) δ 7.36 (d, J=8.4 Hz, 1H), 6.90 (dd, J=2.0 Hz, 8.4 Hz, 1H), 6.86 (d, J=2.4 Hz, 1H), 4.28-4.19 (m, 6H), 2.54-2.51 (m, 2H), 1.27 (t, J=7.2 Hz, 6H).

Step 4: [7-chloro-4-(hydroxymethyl)chroman-4-yl]methanol

To a solution of diethyl 7-chlorochromane-4,4-dicarboxylate (6.30 g, 20.1 mmol) in THF (25 mL) was added diisobutylaluminum hydride (201.4 mL, 201 mmol, 1 M in THF) dropwise at 0° C. The reaction mixture was stirred at r.t. for 18 h. Then it was quenched by the addition of saturated solution of NH₄Cl (200 mL) and extracted with ethyl acetate (3×280 mL). The combined organic layers were concentrated under reduced pressure. The crude material was dissolved in THF (100 mL) and water (200 mL), and sodium borohydride (4.4 g, 114.8 mmol) was added. The reaction was stirred at r.t. for 3 h., and then quenched with saturated NH₄Cl solution (75 mL). The mixture was extracted with ethyl acetate (2×60 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-70%) to afford [7-chloro-4-(hydroxymethyl)chroman-4-yl]methanol (2.80 g, 61% yield). ¹H NMR: (400 MHz, CDCl₃) δ 7.23 (d, J=9.2 Hz, 1H), 6.87-6.85 (m, 2H), 4.21 (t, J=5.2 Hz, 2H), 3.97 (d, J=10.8 Hz, 2H), 3.78 (d, J=10.8 Hz, 2H), 2.09 (t, J=5.2 Hz, 2H).

Step 5: (S)-(7-chloro-4-(hydroxymethyl)chroman-4-yl)methyl 4-bromobenzoate

To a solution of 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (934 mg, 1.57 mmol) in dry DCM (3 mL) was added CuC12 (211 mg, 1.57 mmol) and the resulting green solution was stirred at r.t. for 3 h. This solution was added to a solution of [7-chloro-4-(hydroxymethyl)chroman-4-yl]methanol (3.60 g, 15.74 mmol) in dry DCM (60 mL). The resulting solution was cooled to −78° C. A solution of 4-bromobenzoyl chloride (4.15 g, 18.8 mmol) in DCM (5 mL) was then added slowly, followed by the dropwise addition of DIPEA (3.29 mL, 18.8 mmol). The resulting reaction mixture was stirred at −78° C. for 2 h. and then quenched with KH₂PO₄/H₃PO₄ buffer solution (70 mL, pH˜3). The reaction was diluted with ethyl acetate (150 mL) and the layers were separated. The organic phase was washed with pH˜3 buffer (1×50 mL), saturated NaHCO₃ (2×50 mL) and brine (1×50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column eiuting with 100% DCM to afford [(4S)-7-chloro-4-(hydroxymethyl)chroman-4-yl]methyl 4-bromobenzoate (4.10 g, 63% yield) (e.r.=92:8). The chiral HPLC: Chiral Column: AD, 2.5 um, 3.0 mm×150 mm; Mobile phase A: Supercritical CO₂, Mobile phase B: MeOH (with 0.1% DEA), A:B=50:50; Run time: 20 min.; Detector Wavelength: 254 nm, Instrument: Waters Acouity UPC². ¹H NMR: (400 MHz, CDCl₃) δ 7.86 (d, J=8.0 Hz, 1H), 7.84 (s, 1H), 7.60 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.0 Hz, 1H), 6.88 (d, J=8.4 Hz, 2H), 4.53 (d, J=6.0 Hz, 2H), 4.23 (d, J=6.0 Hz, 2H), 3.80 (s, 2H), 2.16-2.09 (m, 1H), 2.02-1.97 (m, 1H).

Step 6: (R)-(7-chloro-4-formylchroman-4-yl)methyl 4-bromobenzoate (GXL002-55-1)

Dess-Martin periodinane (5.07 g, 11.95 mmol) was added to a stirring solution of [(4S)-7-chloro-4-(hydroxymethyl)chroman-4-yl]methyl 4-bromobenzoate (4.10 g, 9.96 mmol) in DCM (130 mL) at 10° C. After addition, the cooling bath was removed and the reaction mixture was stirred for 30 min. at ambient temperature. Water (17 ml) was then added slowly and the reaction mixture was stirred further at ambient temperature for 30 min. The reaction was cooled to 0° C., quenched with a 1:1 mixture of 10% Na₂S₂O₃ and saturated NaHCO₃ (20 mL) solution and stirred further at r.t. for 1 h. The solution was then diluted with ethyl acetate (700 mL) and the aqueous phase was separated. The organic phase was washed with 1:1 mixture of 10% Na₂S₂O₃/saturated NaHCO₃ solution (200 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column with eluting with ethylacetate in hexanes (10%) to afford [(4R)-7-chloro-4-formyl-chroman-4-yl]methyl 4-bromobenzoate (3.0 g, 73% yield). ¹H NMR: (400 MHz, CDCl₃) δ 9.60 (s, 1H), 77.81 (d, J=6.8 Hz, 2H) 7.58 (d, J=8.4 Hz, 2H), 7.13 (dd, J=1.2 Hz, 7.6 Hz, 1H), 6.94 (d, J=8.4 Hz, 2H), 4.84 (d, J=11.2 Hz, 1H), 4.54 (d, J=11.2 Hz, 1H), 4.27-4.24 (m, 2H), 2.52-2.46 (m, 1H), 2.12-2.06 (m, 1H).

Step 7: (R)-(7-chloro-4-(dimethoxymethyl)chroman-4-yl)methyl 4-bromobenzoate

To a mixture of [(4R)-7-chloro-4-formyl-chroman-4-yl]methyl 4-bromobenzoate (3.0 g, 7.3 mmol) and trimethyl orthoformate (2.33 g, 21.9 mmol) in anhydrous MeOH (10 mL) was added p-toluenesulfonic acid (63 mg, 0.37 mmol). The reaction was refluxed for 6 h., and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with eluting with ethyl acetate/hexane (10%) to afford [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methyl 4-bromobenzoate (2.5 g, 74% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J=8.4 Hz, 1H), 7.74 (s, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 1H), 6.87-6.83 (m, 1H), 6.51 (d, J=4.4 Hz, 1H), 4.53-4.49 (m, 2H), 4.32-4.29 (m, 1H), 4.20-4.18 (m, 1H), 3.45 (s, 3H), 3.30 (s, 3H), 2.34-2.29 (m, 1H), 2.02-1.97 (m, 1H).

Step 8: (R)-(7-chloro-4-(dimethoxymethyl)chroman-4-yl)methanol

To a mixture of [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methyl 4-bromobenzoate (2.50 g, 5.49 mmol) in water (17 mL) and THF (34 mL) was added NaOH (658 mg, 16.4 mmol). The resulting mixture was stirred at r.t. overnight, and then concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and washed with water (10 mL), 1 N NaOH (10 mL), water (10 mL) and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methanol (1.50 g, 100% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.28-7.26 (m, 1H), 6.86-6.84 (m, 2H), 4.48 (s, 1H), 4.29-4.23 (m, 1H), 4.66-4.11 (m, 1H), 3.98 (d, J=11.2 Hz, 1H), 3.56 (d, J=11.2 Hz, 1H), 3.48 (s, 3H), 3.36 (s, 3H), 2.26-2.20 (m, 1H), 2.08-1.97 (m, 1H).

Step 9: N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfinamide

To a solution of [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methanol (1.50 g, 5.5 mmol) in anhydrous THF (50 mL) was added KOBu-t (1.23 g, 11 mmol). After stirring for 5 min at r.t., a solution of 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (3.04 g, 6.6 mmol, Intermediate 2 Step 1) in THF (30 mL) was added dropwise and the resulting mixture was stirred at r.t. for 3 h. The reaction was quenched with saturated NH₄Cl solution (50 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with NH₄Cl (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with ethyl acetate/hexane (20%) to afford N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfonamide (3.35 g, 85% yield) as a yellow semi-solid. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J=2.4 Hz, 1H), 7.78 (dd, J=2.4, 8.8 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.00-6.97 (m, 5H), 6.82-6.79 (m, 2H), 6.73-6.70 (m, 4H), 4.68 (s, 1H), 4.28-4.21 (m, 8H), 3.72 (s, 6H), 3.42 (s, 3H), 3.25 (s, 3H), 2.31-2.25 (m, 1H), 1.97-1.84 (m, 1H).

Step 10: (R)-4-((7-chloro-4-formylchroman-4-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide

To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfonamide (3.35 g, 4.7 mmol) in 1,4-Dioxane (50 mL) and water (17 mL) was added TsOH (1.79 g, 9.39 mmol). The resulting solution was stirred at 105° C. overnight. The reaction was diluted with ethyl acetate (50 mL) and washed with sat. NaHCO₃ solution (15 mL), water (15 mL) and brine (15 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-formyl-chroman-4-yl]methoxy]benzenesulfonamide (2.50 g, 79% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 9.51 (s, 1H), 8.09 (d, J=2.4 Hz, 1H), 6.89-7.86 (m, 1H), 7.12 (d, J=9.2 Hz, 1H), 7.08-7.03 (m, 5H), 6.99-6.93 (m, 2H), 6.81-6.78 (m, 4H), 4.71 (d, J=9.2 Hz, 1H), 4.37-4.35 (m, 1H), 4.30-4.23 (m, 6H), 3.79 (s, 6H), 2.54-2.47 (m, 1H), 2.42-2.36 (m, 1H).

Step 11: (S)-7′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chromane]-7-sulfonamide

To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-formyl-chroman-4-yl]methoxy]benzenesulfonamide (2.50 g, 3.75 mmol) and NH₄Cl (1.99 g, 37.4 mmol) in ethanol (30 mL) was added zinc (2.45 g, 37.4 mmol) and the resulting solution was stirred at 80° C. under N₂ atmosphere overnight. After cooling, the mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (1.44 g, 58% yield) as a white solid. LC-MS calc. for C₃₃H₃₄ClN₂O₆S [M+H]⁺: m/z=621.17/623.17; Found: 621.2/623.2. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=8.4 Hz, 1H), 7.21-7.18 (m, 1H), 7.04-6.93 (m, 6H), 6.91 (m, 1H), 6.85 (d, J=2.4 Hz, 1H), 6.78-6.75 (m, 4H), 4.23-4.10 (m, 8H), 3.78 (s, 6H), 3.53 (d, J=12.8 Hz, 1H), 3.40 (d, J=12.8 Hz, 1H), 2.05-2.00 (m, 1H), 1.96-1.92 (m, 1H).

Intermediate 12

(3S)-7′-Chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide and

Intermediate 13

(3S)-7′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide

Step 1: (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 1-3 using (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 11) and [(1R,2R)-2-formylcyclobutyl]methyl acetate in Step 1. LC-MS: calc. for C₃₉H₄₂ClN₂O₇S [M+H]⁺: m/z=717.3/719.3; Found: 717.4/719.2.

Step 2. (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide and (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH₄Cl solution (300 mL) and extracted with (EA 300 mL×3). The organic layer was concentrated and purified by flash chromatography on a silica gel column eluting with EA/Hep (20% to 50%) to afford the two products: P1 (the earlier eluted product) which was assigned to (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide. LC-MS calc. for C₄₁H₄₆ClN₂O₇S [M+H]⁺: m/z=745.3/747.3; Found: 745.5/747.4.

And P2 (the latter eluted product) was assigned to (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide. LC-MS calc. for C₄₁H₄₆ClN₂O₇S [M+H]⁺: m/z=745.3/747.3; Found: 745.5/747.4.

Step 3. (3S)-7′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 12)

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (P1 Step 2). LC-MS: calcd. for C₂₅H₃₀ClN₂O₅S [M+H]⁺: m/z=505.0/507.0; Found: 505.1/507.0.

Step 4. (3S)-7′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 13)

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (P2 Step 2). LC-MS: calc. for C₂₅H₃₀ClN₂O₅S [M+H]⁺: m/z=505.0/507.0; Found: 505.1/507.0.

Intermediate 14

(R)-6′-Chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide

Step 1: 2-(2-bromo-5-chlorophenyl)ethanol (LGY001-54-1)

To a suspension of 2-(2-bromo-5-chloro-phenyl)acetic acid (60.0 g, 240 mmol) in THF (300 mL) was added BH₃-THF (760 mL, 760 mmol) at 0° C. The reaction mixture was stirred at 25° C. for 4 h., and then quenched by MeOH (300 mL) under N₂ at 0° C. The mixture was concentrated to give crude product which was diluted with DCM (100 mL) and washed with 1 M HCl and brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduce pressure to afforded 2-(2-bromo-5-chloro-phenyl)ethanol (60 g, 84% yield) as a colorless oil which was used for the next step directly. ¹H NMR: (400 MHz, CDCl₃) δ 7.46 (d, J=8.4 Hz, 1H), 7.27 (d, J=2.8 Hz, 1H), 7.07 (dd, J=2.8 Hz, 8.8 Hz, 1H), 3.86 (t, J=6.4 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 1.88 (s, 1H).

Step 2. (2-bromo-5-chlorophenethoxy)(tert-butyl)dimethylsilane

tert-Butylchlorodimethylsilane (25.34 g, 168 mmol) was slowly added to a solution of imidazole (17.34 g, 254 mmol) and 2-(2-bromo-5-chloro-phenyl)ethanol (60.0 g, 254 mmol) in dry DCM (400 mL) at 0° C. over 30 min. After addition, the reaction mixture was stirred at r.t. for 18 h., and treated with 5% of NaHCO₃ aqueous. The mixture was extracted with EA (200 mL×3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE:EA (0-10%) to give 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (61 g, 68% yield) as an colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, J=8.4 Hz, 1H), 7.30 (d, J=2.8 Hz, 1H), 7.09 (dd, J=8.4, 2.8 Hz, 1H), 3.85 (t, J=6.4 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 0.90 (s, 9H), 0.00 (s, 6H).

Step 3: 5-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-chlorophenyl)-2,2-dimethyl-1,3-dioxan-5-ol

To a solution of 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (40.0 g, 114 mmol) in THF (400 mL) was added n-BuLi (54.8 mL, 137 mmol) (2.5 M in hexane) at −78° C. dropwised, and stirred at this temperature for 30 min. To the reaction mixture was added 2,2-dimethyl-1,3-dioxan-5-one (20.8 g, 160 mmol) in THF (15 mL), stirred at −78° C. to −15 OC for 4 h. The mixture was quenched by sat. NH₄Cl (150 mL), and extracted with EA (150 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with PE/EA (2-10%) to give 5-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (30 g, 65% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=8.4 Hz, 1H), 7.33-7.18 (m, 2H), 4.84 (s, 1H), 4.18 (d, J=11.6 Hz, 2H), 4.03 (d, J=11.6 Hz, 2H), 3.97 (t, J=6.0 Hz, 2H), 3.24 (t, J=6.0 Hz, 2H), 1.62 (s, 3H), 1.52 (s, 3H), 0.88 (s, 9H), 0.01 (s, 6H).

Step 4: 5-(4-chloro-2-(2-hydroxyethyl)phenyl)-2,2-dimethyl-1,3-dioxan-5-ol (LGY001-75-1)

To a solution of 5-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (30.0 g, 74.8 mmol) in THF (150 mL) was slowly added TBAF (97 mL, 97 mmol) (1 M in THF) at 0° C. After addition, the mixture was stirred at 25° C. for 1 h., and diluted with EtOAc (150 mL). The mixture was washed with brine (50 mL) and H₂O (50 mL×3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA (10-50%) to give 5-(4-chloro-2-(2-hydroxyethyl)phenyl)-2,2-dimethyl-1,3-dioxan-5-ol (21 g, 97% yield) as a colorless oil. TLC (PE/EA=2/1, R_f=0.2). ¹H NMR (400 MHz, DMSO-d₆) δ 7.61 (d, J=8.4 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H), 7.22 (dd, J=8.4, 2.4 Hz, 1H), 5.44 (s, 1H), 4.75 (t, J=5.0 Hz, 1H), 4.03 (d, J=11.6 Hz, 2H), 3.84 (d, J=11.6 Hz, 2H), 3.62 (dd, J=12.0, 6.8 Hz, 2H), 3.04 (t, J=6.8 Hz, 2H), 1.44 (s, 3H), 1.28 (s, 3H).

Step 5: 6′-chloro-2,2-dimethylspiro[[1,3]dioxane-5,1′-isochroman] (LGY001-80-1)

To a solution of 5-[4-chloro-2-(2-hydroxyethyl)phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (42.0 g, 146 mmol) in THF (150 mL) was added Ph₃P (69.15 g, 263 mmol), and followed by DIAD (52.27 mL, 263.64 mmol) at 0° C. dropwise. The mixture was stirred at 0° C. for 1 h. and 25° C. for 2 h. The reaction was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA (5%) to give (27 g, 68.6% yield) as colorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.53 (d, J=8.4 Hz, 1H), 7.29-7.25 (m, 2H), 3.92 (d, J=12.4 Hz, 2H), 3.84 (t, J=5.6 Hz, 2H), 3.77 (d, J=12.4 Hz, 2H), 2.75 (t, J=5.6 Hz, 2H), 1.51 (s, 3H), 1.35 (s, 3H).

Step 6: (6-chloroisochroman-1,1-diyl)dimethanol (LGY001-82-1)

To a solution of 6′-chloro-2,2-dimethyl-spiro[1,3-dioxane-5,1′-isochromane] (17.0 g, 63.2 mmol) in methanol (25 mL) was added TsOH (0.6 g, 3.16 mmol) and stirred at 25° C. for 18 h. The mixture was quenched by NaHCO₃ aqueous (20 mL), and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine and water, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give (6-chloroisochroman-1,1-diyl)dimethanol (7.6 g, 52.5% yield) as a white solid which was used for next step directly. TLC (silica gel, PE/EA=1/1, R.f.=0.4). ¹H NMR (400 MHz, CDCl₃) δ 7.20 (dd, J=8.4, 2.4 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 4.01 (t, J=5.6 Hz, 1H), 3.91-3.83 (m, 4H), 2.84 (t, J=5.6 Hz, 1H), 2.20 (s, 2H).

Step 7: (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (LGY001-98-1)

To a solution of R,R-Kang catalyst (2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine) (908.93 mg, 1.53 mmol) in dry DCM (25 mL) was added Copper(II) chloride (205.79 mg, 1.53 mmol). The resulting green solution was stirred at ambient temperature for 3 h. This solution was transferred via cannula to a solution of 4-bromobenzoyl chloride (5.76 g, 26.2 mmol) in dry DCM (25 mL). The resulting solution was cooled to −78° C. and light green colored precipitation was observed in the reaction after some time. A solution of [6-chloro-1-(hydroxymethyl)isochroman-1-yl]methanol (5.0 g, 21.87 mmol)) in DCM (25 mL) was then added slowly (over 10 min.), followed by the dropwise addition of DIPEA (3.81 mL, 21.8 mmol). The resulting mixture was stirred at −78° C. for 2 h., and quenched by KH₂PO₄ sat. aqueous solution (100 mL) and allowed to warm to ambient temperature with vigorous stirring. The reaction was diluted with ethyl acetate (400 mL) and the layers were separated. The organic phase was washed with pH˜3 buffer (1×50 mL), saturated NaHCO₃ (2×100 mL), and brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The crude material was purified by flash chromatography on a silica gel column eluting with EA/PE (5-10%) to give (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (5.1 g, 56% yield). The chiral HPLC showed (e.e=93%): Chiral Column: AD, 2.5 um, 3.0 mm×150 mm; Mobile phase A: Supercritical CO₂, Mobile phase B: MeOH (with 0.1% DEA), A:B=50:50; Run time: 18 min.; Detector Wavelength: 254 nm, Instrument: Waters Acouity UPC². ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.26-7.16 (m, 3H), 4.72 (d, J=12.0 Hz, 1H), 4.56 (d, J=12.0 Hz, 1H), 4.13-3.96 (m, 2H), 3.98-3.84 (m, 2H), 2.88-2.78 (m, 2H).

Step 8: (S)-(6-chloro-1-formylisochroman-1-yl)methyl 4-bromobenzoate (LGY001-100-1)

To a solution of (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (2.6 g, 6.32 mmol) in DCM (35 mL) was added Dess-Martin periodinane (3.48 g, 8.21 mmol) at 10° C. After addition, the cooling bath was removed. The reaction mixture was stirred for 2 h. at ambient temperature. The reaction was then cooled to 0° C., and diluted with ethyl acetate (100 mL), quenched with a 1:1 mixture of 10% Na₂S₂O₃ and saturated NaHCO₃ (100 mL) solution and stirred at r.t. for an additional 0.5 h. The aqueous phase was separated. The organic phase was washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eluting with ethyl acetate in hexanes (10%) to afforded [(S)-6-chloro-1-formyl-isochroman-1-yl]methyl 4-bromobenzoate (2.00 g, 77% yield) as light yellow oil. R_f=0.5 in 10% ethyl acetate in hexane. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (s, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.26 (m, 2H), 7.21 (s, 1H), 4.85 (d, J=11.6 Hz, 1H), 4.67 (d, J=11.6 Hz, 1H), 4.26-4.12 (m, 1H), 4.09 (m, 1H), 2.98-2.78 (m, 2H).

Step 9: (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (LGY001-91-1)

To a solution of (S)-(6-chloro-1-formylisochroman-1-yl)methyl 4-bromobenzoate (700.0 mg, 1.71 mmol) in anhydrous methanol (15 mL), TsOH (16.25 mg, 0.09 mmol) and trimethyl orthoformate (217 mg, 2.05 mmol) were added and the reaction mixture was refluxed for 4 h. The reaction mixture was then concentrated to 50% volume, diluted with THF (12 mL) and added NaOH (273 mg, 6.83 mmol) in water (2 mL). The resulting mixture was stirred at r.t. overnight, concentrated under reduced pressure. The residue was diluted with diethyl ether (50 mL). The aqueous layer was separated, and the organic layer was washed with 1 N NaOH (10 mL). The combined aqueous layers were extracted with diethyl ether (20 mL). The combined organic layers were washed with 1 N NaOH (10 mL) and brine, dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eluting with ethyl acetate/hexane (20%) to afford (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (320 mg, 68% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, J=8.5 Hz, 1H), 7.18-7.03 (m, 2H), 4.16-4.13 (m, 1H), 3.96-3.93 (m, 2H), 3.70 (d, J=11.6 Hz, 1H), 3.54 (s, 3H), 3.48 (s, 3H), 2.90-2.69 (m, 2H).

Step 10: (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide

To a solution of tert-butoxypotassium (987.47 mg, 8.8 mmol) in anhydrous THF (3 mL) was cooled to 0° C. and a solution of (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (2.0 g, 7.33 mmol) in THF (5 mL) was added dropwise. After 5 min., 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (4390 mg, 9.53 mmol) (1 M in THF) was added dropwise via syringe and the resulting mixture was warmed to r.t. After 1 h the reaction was cooled to 0° C., quenched with saturated NH₄Cl solution (10 mL) and extracted with ethyl acetate (50 mL). The combined organic layers were washed with NH₄Cl (10 mL), brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eluting with ethyl acetate/PE (25%) (TLC R_f=0.5 in 30% ethyl acetate in hexane) to afford (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (4.2007 g, 80% yield) as a yellow semi-solid. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.4 Hz, 1H), 7.50 (d, J=8.6 Hz, 1H), 7.21-7.16 (m, 2H), 7.09-7.04 (m, 5H), 6.82-6.76 (m, 4H), 4.71 (s, 1H), 4.38 (s, 2H), 4.27 (s, 4H), 4.18-4.13 (m, 1H), 4.02-3.92 (m, 1H), 3.79 (s, 6H), 3.54 (d, J=2.0 Hz, 3H), 3.50 (s, 3H), 2.83 (m, 2H).

Step 11: (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide

To a solution (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (3.5 g, 4.91 mmol) in 1,4-dioxane (30 mL) was added TsOH (2.53 g, 14.72 mmol) and the suspension was heated to 110° C. for 18 h. Upon completion, the mixture was cooled to r.t., and concentrated under reduced pressure. The residue was dissolved in EtOAc (100 mL) and washed by NaHCO₃ (100 mL). The organic layer was concentrated to give (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (3.2 g, 78.2% yield) which was used directly in next step. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (s, 1H), 8.06 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.4 Hz, 1H), 7.26-7.45 (m, 3H), 7.10-7.03 (m, 5H), 6.81-6.77 (m, 4H), 4.59-4.48 (m, 2H), 4.26 (s, 4H), 4.16-4.07 (m, 2H), 3.79 (s, 6H), 3.02-2.85 (m, 2H).

Step 12: (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide

To a solution (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (500 mg, 0.75 mmol) in acetic acid (8 mL) was added iron powder (3382 mg, 14.9 mmol) and the suspension was heated to 40° C. for 12 h. Upon completion, the suspension was cooled to r.t. The solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was diluted with DCE (10 mL). To the solution was added NaHB(OAc)₃ (795 mg, 3.75 mmol). The reaction mixture was stirred at r.t. for 3 h., and MeOH (10 mL) was added. The resulting mixture was stirred for 1 h., and then concentrated under reduced pressure. The residue was purified by flash chromatograph on a silica gel column to afford (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide (70 mg, 14% yield). LC-MS calc. for C₃₃H₃₄ClN₂O₆S [M+H]⁺: m/z=621.18/623.18; Found: 621.1/623.0. ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J=8.4 Hz, 1H), 7.25-7.21 (m, 2H), 7.20 (d, J=2.0 Hz, 1H), 7.08 (d, J=2.4 Hz, 1H), 7.02-6.99 (m, 5H), 6.80-6.76 (m, 4H), 4.38 (dd, J=41.2, 12.6 Hz, 2H), 4.24 (s, 4H), 3.99 (t, J=5.6 Hz, 2H), 3.78-3.75 (m, 7H), 3.51 (d, J=14.0 Hz, 1H), 2.85 (t, J=5.2 Hz, 2H).

Intermediate 15

(3R)-6′-Chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide and

Intermediate 16

(3R)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide

Step 1: (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 1-3 using (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide (Intermediate 14) and [(1R,2R)-2-formylcyclobutyl]methyl acetate in Step 1. LC-MS: calc. for C₃₉H₄₂ClN₂O₇S [M+H]⁺: m/z=717.3/719.3; Found: 717.3/719.3.

Step 2. (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide and (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH₄Cl solution (300 mL) and extracted with (EA 300 mL×3). The organic layer was concentrated and purified by flash chromatography on a silica gel column eluting with EA/Hep (20% to 50%) to afford the two products: P1 (the earlier eluted product) which was assigned to (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide. LC-MS calc. for C₄₁H₄₆ClN₂O₇S [M+H]⁺: m/z=745.3/747.3; Found: 745.5/747.4.

And P2 (the latter eluted product) was assigned to (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide. LC-MS calc. for C₄₁H₄₆ClN₂O₇S [M+H]⁺: m/z=745.3/747.3; Found: 745.5/747.4.

Step 3: (3R)-6′-chloro-5-[[(1R,2R)-2-[(S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 15)

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (P1 Step 2). LC-MS: calcd. for C₂₅H₃₀ClN₂O₅S [M+H]⁺: m/z=505.0/507.0; Found: 505.1/507.0.

Step 4. (3R)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 16)

This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (P2 Step 2). LC-MS: calc. for C₂₅H₃₀ClN₂O₅S [M+H]⁺: m/z=505.0/507.0; Found: 505.1/507.0.

Example 1

N-[6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

Step 1: 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

A 20 mL vial with septum under N₂ containing a solution of ˜80% pure 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 1, 400 mg, 0.84 mmol) in DCM (9 mL) and 2,2,2-trifluoroacetic acid (TFA) (1.5 mL, 19.6 mmol) was charged with cyclobutanecarboxaldehyde (very impure, 262 μL, 3.36 mmol). The solution was stirred at RT for 30 min. The reaction vessel was then placed at 0° C. in an ice-water bath, and charged with sodium borohydride (100 mg, 2.64 mmol) in small portions over 2 min. The reaction was stirred at 0° C. for 1 h. The reaction was quenched by dumping it into sat.NaHCO₃ (20 mL, caution: gas evolution), diluting with water (30 mL) and extracting with EtOAc (60 mL). The organic layer was washed with water (20 mL) and sat. NaHCO₃ (20 mL), brine (30 mL), dried over Na₂SO₄, and filtered. The filtrate was concentrated to afford a yellow gum, then turned into a yellow/white solid by repeated concentration after dissolving in DCM and triturating with hexanes. Solids were mostly dissolved in hot DCM (˜10 mL), then charged with hexanes until a cloudy color appeared. The resulting suspension was let cool to RT, then cooled to 0° C. After 2 h, a white/grey precipitate formed. The supernatant was decanted, and the precipitate was washed twice more with DCM/hexanes (2×2 mL, 2:1 ratio). The precipitate was dried under reduced pressure to yield 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (105 mg, 27.9% yield) as a grey solid.

The remaining filtrates were combined, dry loaded on Celite, and purified by FCC (40 g SiO₂, 0-50% EtOAc in hexanes). Fractions containing pure desired product by TLC were combined and concentrated under reduced pressure and heat (˜50° C.) to yield 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (93.8 mg, 24.8% yield) as a white solid. Combined yield of 52.7%. R_f=0.28 (2:1 hexanes:EtOAc); LCMS calculated for C₂₃H₂₈ClN₂O₃S (M+H)⁺: m/z=447.15/449.15; found: 447.0/449.0; ¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.24 (dd, J=2.2, 8.3 Hz, 1H), 7.19-7.14 (m, 2H), 7.09 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 4.74 (s, 2H), 4.11 (ABq, 2H), 3.60 (dd, J=1.2, 14.4 Hz, 1H), 3.40-3.26 (m, 3H), 2.84-2.74 (m, 2H), 2.74-2.64 (m, 1H), 2.14-2.04 (m, 2H), 1.97-1.76 (m, 7H), 1.61-1.53 (m, 1H).

Step 2: N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

A 2 mL microwave vial with septum containing a mixture of solid 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (18 mg, 0.04 mmol), 4-(dimethylamino)pyridine (0.74 mg, 0.01 mmol), and DCM (1 mL) under N₂ was charged with acetyl chloride (5.75 uL, 0.08 mmol), followed by N,N-Diisopropylethylamine (17.54 uL, 0.10 mmol) at r.t. (white vapors appeared). The mixture was shaken then stirred vigorously at 45° C. for 30 min, and shaken occasionally until all solids were dissolved. The reaction solution was quenched by addition of sat. NH₄Cl (3 mL). The mixture was extracted with DCM (3 mL), washed with water (2 mL) and sat. NH₄Cl (2 mL), brine (4 mL), dried over Na₂SO₄, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by FCC (12 g SiO₂, 0→35% EtOAc in hexanes, wet-loaded in DCM). Fractions containing pure product were combined, and concentrated under reduced pressure and heat (˜75° C.) to yield 98% pure N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide (14.2 mg, 70.6% yield) as a white solid after scratching. LCMS calculated for C₂₅H₃₀ClN₄O₄S (M+H)⁺: m/z=489.15/491.15; found: 489.0/491.0. ¹H NMR (500 MHz, CDCl₃) δ 7.88 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.32 (dd, J=2.2, 8.3 Hz, 1H), 7.29 (d, J=2.3 Hz, 1H), 7.17 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 4.13 (s, 2H), 3.60 (d, J=14.7 Hz, 1H), 3.39-3.29 (m, 3H), 2.82-2.74 (m, 2H), 2.70 (dt, J=7.3, 14.0 Hz, 1H), 2.17-2.06 (m, 5H), 1.96-1.71 (m, 8H).

Example 2

N-[6′-Chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

Step 1: 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 1, 60 mg, 0.16 mmol) in TFA (0.18 mL, 2.38 mmol) and DCM (1 mL) was added cyclopropylcarboxaldehyde (16.65 mg, 0.24 mmol). The mixture was stirred at r.t. for 15 min., then the mixture was cooled by ice-water bath, and sodium borohydride (15 mg, 0.40 mmol) was added slowly (over 15 min). The mixture was stirred at 0° C. for 1 h., then the volatiles were removed under reduced pressure. The residue was diluted with AcOEt (5 mL), and washed with sat. NaHCO₃ solution (2 mL×2), and brine. The organics was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (49 mg, 71%) was directly used in next step reaction without further purification. LCMS calculated for C₂₂H₂₆ClN₂O₃S (M+H)⁺: m/z=433.13/435.12; found: 433.0/435.0.

Step 2: N-[6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

To a mixture of 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (21 mg, 0.05 mmol), acetic acid (0.01 mL, 0.10 mmol) and 4-(dimethylamino)pyridine (12.2 mg, 0.10 mmol) in DCM (2 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (19.1 mg, 0.10 mmol) at r.t. The mixture was stirred at r.t. overnight. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-60%) (both contains 0.3% AcOH) to afford the desired product as white solid. LCMS calculated for C₂₄H₂₈ClN₂O₄S (M+H)⁺: m/z=475.14/476.14; found: 475.0/477.0. ¹H NMR (500 MHz, DMSO-d₆) δ 11.90 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.37 (d, J=2.2 Hz, 1H), 7.24 (dd, J=2.4, 8.5 Hz, 1H), 7.19 (dd, J=2.2, 8.3 Hz, 1H), 7.17 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 4.09 (s, 2H), 3.56 (d, J=14.4 Hz, 1H), 3.45 (d, J=14.4 Hz, 1H), 3.28 (s, 1H), 3.21 (dd, J=5.9, 14.8 Hz, 1H), 3.09 (dd, J=6.7, 14.8 Hz, 1H), 2.79-2.64 (m, 2H), 2.04-1.91 (m, 1H), 1.90 (s, 3H), 1.76 (d, J=14.5 Hz, 2H), 1.48 (m, 1H), 1.09-0.99 (m, 1H), 0.51 (dq, J=2.1, 8.2 Hz, 2H), 0.33-0.28 (m, 1H), 0.27-0.21 (m, 1H).

Example 3

N-[6′-Chloro-5-(cyclohexylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

This compound was prepared using procedures analogous to those described for Example 2 using cyclohexanecarboxaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C₂₇H₃₄ClN₂O₄S (M+H)⁺: m/z=517.18/519.18; found: 517.1/519.1. ¹H NMR (500 MHz, DMSO-d₆) δ 11.92 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.23 (dt, J=2.6, 5.8 Hz, 2H), 7.19-7.13 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.08 (q, J=12.2 Hz, 2H), 3.61 (d, J=14.4 Hz, 1H), 3.34 (d, J=14.2 Hz, 1H), 3.18 (dd, J=6.4, 14.8 Hz, 1H), 3.07 (dd, J=7.4, 14.8 Hz, 1H), 2.81-2.64 (m, 2H), 1.99-1.92 (m, 1H), 1.91 (s, 3H), 1.79 (m, 3H), 1.75-1.63 (m, 4H), 1.63-1.56 (m, 1H), 1.52 (m, 1H), 1.13 (m, 3H), 0.96 (m, 2H).

Example 4

N-(5-Benzyl-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl)sulfonylacetamide

This compound was prepared using procedures analogous to those described for Example 2 using benzaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C₂₇H₂₈ClN₂O₄S (M+H)⁺: m/z=511.14/513.14; found: 511.0/513.0. ¹H NMR (500 MHz, DMSO-d₆) δ 11.77 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.31 (dd, J=6.8, 8.5 Hz, 2H), 7.27-7.17 (m, 5H), 7.14 (d, J=2.3 Hz, 1H), 7.09-7.01 (m, 2H), 4.64-4.53 (m, 2H), 4.26-4.14 (m, 2H), 3.75 (d, J=14.5 Hz, 1H), 3.41 (d, J=14.4 Hz, 1H), 2.72-2.64 (m, 2H), 1.95 (m, 1H), 1.77 (s, 3H), 1.66 (m, 2H), 1.51 (t, J=12.3 Hz, 1H), 1.22 (m, 2H).

Example 5

N-[6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-phenyl-acetamide

A 4 mL vial with septum containing a suspension of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1 Step 1, 40 mg, 0.09 mmol) and 4-(dimethylamino)pyridine (1.5 mg, 0.01 mmol) in DCM (2 mL) and N,N-diisopropylethylamine (40 μL, 0.23 mmol) under N₂ was charged with phenylacetyl chloride (18 μL, 0.14 mmol). The vial was heated at 40° C. for 30 min. The reaction mixture was charged with additional phenylacetyl chloride (23 μL, 0.17 mmol) and N,N-diisopropylethylamine (60 uL, 0.34 mmol), and heated at 40° C. for 1 h. The reaction mixture was diluted with EtOAc (40 mL), washed with sat. NH₄Cl (20 mL), water (20 mL) and sat. NH₄Cl (20 mL), and brine (30 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure, and purified by FCC (30 g C18, 10→100% MeCN in water, wet-loaded in DMSO). The fraction containing pure desired product was lyophilized, then further dried under reduced pressure and heat (60° C.) to yield N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-phenyl-acetamide (21.5 mg, 97% purity, 41% yield) as a white solid. LCMS calculated for C₃₁H₃₄ClN₂O₄S (M+H)⁺: m/z=565.19/567.19; found: 565.2/567.1. ¹H NMR (500 MHz, CDCl₃) δ 7.76 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.41-7.30 (m, 3H), 7.30-7.26 (m, 2H), 7.20-7.14 (m, 3H), 7.09 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.8 Hz, 1H), 4.13 (s, 2H), 3.63 (s, 2H), 3.59 (d, J=14.3 Hz, 1H), 3.38-3.26 (m, 3H), 2.83-2.71 (m, 2H), 2.68 (p, J=7.2 Hz, 1H), 2.13-2.04 (m, 2H), 1.97-1.71 (m, 8H).

Example 6

N-[6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide

This compound was prepared using procedures analogous to those described for Example 5 using isobutyryl chloride to replace phenylacetyl chloride. The product was purified by FCC (12 g SiO₂, 0→20% EtOAc in hexanes with 0.3% AcOH, wet-loaded in DCM to afford N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide as a white solid. R_f=0.40 (2:1 hexanes:EtOAc). LCMS calculated for C₂₇H₃₄ClN₂O₄S (M+H)⁺: m/z=517.19/517.19; found: 517.1/519.1. ¹H NMR (500 MHz, CDCl₃) δ 7.91 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.33 (dq, J=2.2, 4.4 Hz, 2H), 7.17 (dd, J=2.4, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98-6.95 (m, 1H), 4.13 (s, 2H), 3.60 (d, J=14.3 Hz, 1H), 3.39-3.29 (m, 3H), 2.82-2.66 (m, 3H), 2.43 (hept, J=6.9 Hz, 1H), 2.16-2.06 (m, 2H), 1.97-1.73 (m, 8H), 1.16 (d, J=6.9 Hz, 6H).

Example 7

4-Chloro-N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-benzamide

This compound was prepared using procedures analogous to those described for Example 5 using 4-chlorobenzoyl chloride to replace phenylacetyl chloride. The product was purified by FCC (12 g SiO₂, 0→20% EtOAc in hexanes with 0.3% AcOH, wet-loaded in DCM to afford 4-chloro-N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-benzamide as a white solid. R_f=0.25 (2:1 hexanes:EtOAc); LCMS calculated for C₃₀H₃₁C₁₂N₂O₄S (M+H)⁺: m/z=585.14/587.13; found: 585.1/587.1; ¹H NMR (500 MHz, CDCl₃) δ 8.72 (s, 1H), 7.74 (dt, J=2.0, 2.4, 8.6 Hz, 2H), 7.66 (d, J=8.5 Hz, 1H), 7.48-7.39 (m, 4H), 7.16 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.01-6.96 (m, 1H), 4.13 (s, 2H), 3.60 (d, J=14.4 Hz, 1H), 3.42-3.29 (m, 3H), 2.74 (dq, J=5.5, 6.1, 17.8 Hz, 3H), 2.16-2.06 (m, 2H), 1.98-1.70 (m, 8H).

Example 8

N-[6′-Chloro-5-[[rac-(2S,6R)-2,6-dimethyltetrahydropyran-4-yl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

This compound was prepared using procedures analogous to those described for Example 2 using (2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-carbaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C₂₈H₃₆ClN₂O₅S (M+H)⁺: m/z=547.2/549.19; found: 547.2/549.1. ¹H NMR (500 MHz, DMSO-d₆) δ 11.91 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.24 (dd, J=2.2, 9.9 Hz, 2H), 7.17 (d, J=2.4 Hz, 1H), 7.15 (dd, J=2.1, 8.3 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 4.12-4.04 (m, 2H), 3.64 (d, J=14.4 Hz, 1H), 3.30 (m, 2H) overlap with water signal, 3.16 (qd, J=6.8, 14.8 Hz, 2H), 2.81-2.65 (m, 2H), 2.13 (s, 1H), 2.02-1.92 (m, 2H), 1.90 (s, 3H), 1.85-1.73 (m, 2H), 1.62 (t, J=10.6 Hz, 2H), 1.54-1.40 (m, 2H), 1.05 (dd, J=4.4, 6.2 Hz, 6H), 0.90-0.77 (m, 3H).

Example 9

N-[6′-Chloro-5-[(1-methylpyrazol-4-yl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

This compound was prepared using procedures analogous to those described for Example 2 using 1-methyl-1H-pyrazole-4carboxaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C₂₅H₂₈ClN₄O₄S (M+H)⁺: m/z=515.14/517.14; found: 515.2.0/517.1. ¹H NMR (500 MHz, DMSO-d₆) δ 11.90 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.65 (s, 1H), 7.38 (s, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.23 (dd, J=2.4, 8.6 Hz, 1H), 7.20-7.14 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.32 (s, 2H), 4.13 (s, 2H), 3.74 (s, 3H), 3.49 (d, J=14.1 Hz, 1H), 3.35 (d, J=14.2 Hz, 1H), 2.69 (d, J=16.0 Hz, 2H), 2.04-1.94 (m, 2H), 1.87 (s, 3H), 1.48 (m, 2H).

Example 10

N-[5-[(1-Allylpyrazol-4-yl)methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylhex-5-enamide

Step 1: 5-[(1-allylpyrazol-4-yl)methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Example 2 using 1-allylpyrazole-4-carbaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C₂₅H₂₈ClN₄O₃S (M+H)⁺: m/z=499.15/501.15; found: 499.1/501.0. ¹H NMR (500 MHz, DMSO-d₆) δ 7.66 (t, J=4.3 Hz, 2H), 7.42 (s, 1H), 7.34 (d, J=2.1 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.19-7.14 (m, 3H), 7.11 (dd, J=2.1, 8.3 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 5.94 (ddt, J=5.7, 10.1, 17.2 Hz, 1H), 5.16-5.02 (m, 2H), 4.66 (dt, J=1.6, 5.7 Hz, 2H), 4.39-4.28 (m, 2H), 4.08 (s, 2H), 3.47 (d, J=14.2 Hz, 1H), 3.34 (d, J=15.4 Hz, 1H), 2.69 (dt, J=5.7, 10.1 Hz, 2H), 2.02-1.94 (m, 2H), 1.92-1.84 (m, 1H), 1.67 (d, J=29.4 Hz, 2H), 1.52-1.40 (m, 2H), 1.27 (d, J=13.9 Hz, 2H), 1.16 (t, J=7.3 Hz, 1H), 0.84 (t, J=6.8 Hz, 1H).

Step 2: N-[5-[(1-allylpyrazol-4-yl)methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylhex-5-enamide

This compound was prepared using procedures analogous to those described for Example 2 using 5-hexenoic acid to replace acetic acid in Step 2. LCMS calculated for C₃₁H₃₆ClN₄O₄S (M+H)⁺: m/z=595.21/597.20; found: 595.3/597.2. ¹H NMR (500 MHz, DMSO-d₆) δ 11.87 (s, 1H), 7.69 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.43 (s, 1H), 7.35 (d, J=2.2 Hz, 1H), 7.23 (dd, J=2.3, 8.5 Hz, 1H), 7.18 (dd, J=2.2, 8.2 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 5.94 (ddt, J=5.7, 10.2, 17.1 Hz, 1H), 5.71 (ddt, J=6.5, 10.1, 16.9 Hz, 1H), 5.12 (dq, J=1.5, 10.2 Hz, 1H), 5.05 (dq, J=1.6, 17.0 Hz, 1H), 4.97-4.88 (m, 2H), 4.65 (dt, J=1.6, 5.8 Hz, 2H), 4.33 (s, 2H), 4.12 (s, 2H), 3.49 (d, J=14.3 Hz, 1H), 3.35 (d, J=14.3 Hz, 1H), 2.69 (m, 2H), 2.17 (t, J=7.4 Hz, 2H), 2.03-1.94 (m, 2H), 1.94-1.83 (m, 2H), 1.50 (p, J=7.4 Hz, 4H).

Example 11

(4′Z,5′E)-6-Chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-13-thia-12-aza-1(5,7)-benzo[b][1,4]oxazepina-3(4,1)-pyrazolacyclotridecaphanen]-5′-en-11′-one 13′,13′-dioxide and (4′Z,5′Z)-6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-13-thia-12-aza-1(5,7)-benzo[b][1,4]oxazepina-3(4,1)-pyrazolacyclotridecaphanen]-5′-en-11′-one 13′,13′-dioxide

A solution of N-[5-[(1-allylpyrazol-4-yl)methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylhex-5-enamide (Example 10, Step 2, 42 mg, 0.07 mmol) in toluene (50 mL) was evacuated and re-charged with nitrogen for three cycles. To the solution was added (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Hoveyda-Grubbs II, 8.84 mg, 0.01 mmol) in toluene (5 mL). The mixture was then heated at 105° C. for 2 h. Additional Hoveyda-Grubbs II (8.84 mg, 0.01 mmol) was added. The system was evacuated and re-charged with nitrogen for three cycles. The mixture was heated at 105° C. overnight. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-60%) (both contains 0.1% AcOH). The desired fractions were collected and concentrated under reduced pressure. The residue was further purified by RP FC on C₁₈ eluting with MeCN/water (10-80%) (both contains 0.2% AcOH) to afford the desired product as slight brown solid which contained 1 eq. AcOH. Based on 1H NMR spectrum, the ratio of the cis- and trans-isomers is about 1:4. Some signals from the cis-isomer could not be distinguished and overlaps with those for the trans-isomer. LCMS calculated for C₂₉H₃₂ClN₄O₄S (M+H)⁺: m/z=567.18/569.17; found: 567.1/569.1. ¹H NMR (500 MHz, Methanol-d₄) δ 7.78 (d, J=8.6 Hz, 1H), 7.46 (d, J=13.9 Hz, 2H), 7.32 (dd, J=2.2, 8.3 Hz, 1H), 7.18 (dd, J=2.4, 8.5 Hz, 1H), 7.11 (dd, J=2.3, 5.0 Hz, 2H), 6.98 (d, J=8.4 Hz, 1H), 5.51 (dt, J=6.2, 14.9 Hz, 0.81H for the 1H in trans-isomer), 5.42 (dt, J=6.9, 14.9 Hz, 0.81H for the 1H in trans-isomer), 5.35 (tt, J=5.0, 1.5 Hz, 0.48H for the 2H in cis-isomer) 4.62-4.56 (m, 2H from trans and 4H from cis), 4.51 (d, J=4.7 Hz, 2H), 4.23 (d, J=4.2 Hz, 2H), 3.79-3.70 (m, 1H), 3.46 (d, J=14.6 Hz, 1H), 2.78 (d, J=5.8 Hz, 2H, overlaps with 2H for cis-isomer), 2.21-2.16 (m, 2H, overlaps with 2H for cis-isomer), 2.03 (m, 2H, overlaps with 2H for cis-isomer), 1.97 (s, 2H, AcOH signal), 1.91-1.85 (m, 2H), 1.68-1.57 (m, 4H).

Example 12

N-[(3S)-6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

Step 1: (3S)-6′-chloro-5-(cyclobutylmethyl)-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of rac-(3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 2, 46 mg, 0.07 mmol) in TFA (0.06 mL, 0.74 mmol) and DCM (2 mL) was added cyclobutanecarboxaldehyde (12.5 mg, 0.15 mmol) The mixture was stirred at r.t. for 15 min., then the mixture was cooled by ice-water bath, and sodium borohydride (8.43 mg, 0.22 mmol) was added slowly (over 15 min). The mixture was stirred at 0° C. for 1 h., then the volatile was removed under reduced pressure. The residue was diluted with AcOEt (5 mL) and washed with sat. NaHCO₃ solution (2 mL×2), and brine. The organics was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by FC on a silica gel column with EtOAc in hexane (0-50%) to afford the desired product (3S)-6′-chloro-5-(cyclobutylmethyl)-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LCMS calculated for C₃₉H₄₄ClN₂O₅S (M+H)⁺: m/z=687.26/689.26; found: 688.7.2/689.2.

Step 2: (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of (3S)-6′-chloro-5-(cyclobutylmethyl)-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (48 mg, 0.07 mmol) in DCM (1 mL) was added TFA (0.8 mL, 10.4 mmol). The mixture was stirred at r.t. overnight. and diluted with DCM (5 mL) and carefully neutralized with 7.5% NaHCO₃ solution to about pH 8. The organic layer was separated. The aqueous layer was extracted with DCM (3 mL). The combined organic layers were washed with 7.5% NaHCO₃ solution (2 mL), and water (2 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide which was directly used in next step reaction without further purification. LCMS calculated for C₂₃H₂₈ClN₂O₃S (M+H)⁺: m/z=447.14/449.14; found: 447.0/449.0.

Step 3: N-[(3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide

To a mixture of (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15 mg, 0.03 mmol), acetic acid (0.5 mL, 0.07 mmol) and 4-(dimethylamino)pyridine (8.2 mg, 0.07 mmol) in DCM (1 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (12.8 mg, 0.07 mmol) at r.t. The mixture was stirred at r.t. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water, and was lyophilized to afford the desired product as white solid. LCMS calculated for C₂₅H₃₀ClN₄O₄S (M+H)⁺: m/z=489.15/491.15; found: 489.1/491.1. ¹H NMR (500 MHz, DMSO-d₆) δ 11.90 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.20-7.15 (m, 3H), 7.03-6.98 (m, 1H), 4.07 (s, 2H), 3.52 (d, J=14.3 Hz, 1H), 3.23-3.36 (m, 3H, overlap with water), 2.80-2.58 (m, 3H), 2.08-1.95 (m, 2H), 1.92 (s, 3H), 1.91-1.84 (m, 1H), 1.77 (m, 6H), 1.51 m, 1H).

Example 13

N-[(3S)-6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcyclopentanecarboxamide

To a mixture of (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15 mg, 0.03 mmol), 4-(dimethylamino)pyridine (8.2 mg, 0.07 mmol) and N,N-Diisopropylethylamine (0.01 mL, 0.07 mmol) in DCM (1 mL) was added cyclopentanecarbonyl chloride (6.67 mg, 0.05 mmol) at r.t. The mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by FCC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water and was lyophilized to afford the desired product as white solid. LCMS calculated for C₂₉H₃₆ClN₄O₃S (M+H)⁺: m/z=543.2/545.2; found: 543.1/545.1. ¹H NMR (500 MHz, DMSO-d₆) δ 11.87 (s, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.19-7.13 (m, 3H), 6.98 (d, J=8.7 Hz, 1H), 4.06 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.29-3.21 (m, 3H), 2.81-2.57 (m, 4H), 2.00 (d, J=6.9 Hz, 2H), 1.90 (d, J=13.9 Hz, 1H), 1.84-1.68 (m, 8H), 1.50 (d, J=29.6 Hz, 7H).

Example 14

Benzyl N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamate

To a mixture of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15.0 mg, 0.03 mmol), Benzyl chloroformate (8.2 mg, 0.07 mmol) and N,N-Diisopropylethylamine (0.01 mL, 0.07 mmol) in DCM (1 mL) was added Benzyl chloroformate (6.67 mg, 0.04 mmol) at r.t. The mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water, and was lyophilized to afford the desired product as white solid. LCMS calculated for C₃₁H₃₄ClN₂O₅S (M+H)⁺: m/z=581.18/583.18; found: 581.3/583.3. ¹H NMR (500 MHz, Acetonitrile-d₃) δ 9.05 (sbr, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.41-7.32 (m, 3H), 7.32-7.27 (m, 2H), 7.27-7.16 (m, 4H), 6.98 (d, J=8.3 Hz, 1H), 5.12 (s, 2H), 4.14 (s, 2H), 3.64-3.56 (m, 1H), 3.39-3.32 (m, 2H), 3.28 (dd, J=6.1, 14.9 Hz, 1H), 2.86-2.73 (m, 2H), 2.66 (p, J=7.3 Hz, 1H), 2.09-2.02 (m, 3H), 1.92-1.75 (m, 6H), 1.58 m, 1H).

Example 15

2-(1,5-Dimethylpyrazol-3-yl)-N-[(3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-acetamide

This compound was prepared using procedures analogous to those described for Example 12 using 2-(1,5-dimethylpyrazol-3-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C₃₀H₃₆ClN₄O₄S (M+H)⁺: m/z=583.21/585.21; found: 583.2/585.2. ¹H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J=8.5 Hz, 1H), 7.38-7.32 (m, 2H), 7.17 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.9 Hz, 1H), 5.95 (s, 1H), 4.12 (s, 2H), 3.81 (d, J=8.3 Hz, 3H), 3.61 (s, 2H), 3.38-3.30 (m, 2H), 2.80-2.65 (m, 2H), 2.33-2.20 (m, 5H), 2.16-2.05 (m, 3H), 1.99-1.71 (m, 8H).

Example 16

N-[(3S)-6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-thiazol-2-yl-acetamide

This compound was prepared using procedures analogous to those described for Example 12 using 2-(4-thiazolyl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C₂₈H₃₁ClN₃O₄S₂ (M+H)⁺: m/z=571.14/573.14; found: 571.2/573.2. ¹H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 9.00 (d, J=2.0 Hz, 1H), 7.68-7.61 (m, 2H), 7.50-7.39 (m, 2H), 7.24 (dd, J=2.4, 8.5 Hz, 1H), 7.21-7.14 (m, 2H), 6.98 (d, J=8.8 Hz, 1H), 4.06 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 2.82-2.58 (m, 4H), 2.06-1.67 (m, 12H), 1.52 (dd, J=7.0, 14.2 Hz, 1H).

Example 17

2-(6-Methyl-3-pyridyl)-N-[(3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-acetamide

This compound was prepared using procedures analogous to those described for Example 12 using 2-(6-methylpyridin-3-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C₃₁H₃₅ClN₃O₄S (M+H)⁺: m/z=580.2/582.20; found: 580.3/582.3. ¹H NMR (500 MHz, DMSO-d₆) δ 12.33 (s, 1H), 8.51 (s, 1H), 8.00 (s, 1H), 7.63 (d, J=8.5 Hz, 2H), 7.29-7.15 (m, 4H), 7.01 (d, J=8.2 Hz, 1H), 4.11-4.03 (m, 2H), 3.77 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.35-3.20 (m, 3H), 2.82-2.67 (m, 2H), 2.58 (s, 3H), 2.04-1.66 (m, 11H), 1.50 (dd, J=5.5, 12.2 Hz, 1H).

Example 18

(3R,6R,24S)-6′-Chloro-17,17-dioxo-spiro[8,22-dioxa-17λ{circumflex over ( )}6-thia-1,16-diazapentacyclo[16.7.2.1{circumflex over ( )}9,13.0{circumflex over ( )}3,6.0{circumflex over ( )}21,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

Step 1: [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate

To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 2, 1.20 g, 1.94 mmol) and [(1R,2R)-2-formylcyclobutyl]methyl acetate (0.333 g, 2.13 mmol) in DCM (25 mL) was added 2,2,2-trifluoroacetic acid; TFA (1.2 mL, 15.68 mmol, 8 eq.). The mixture was stirred for 5 min., and then cooled with ice-water bath. To the cooled solution was added sodium borohydride (146.64 mg, 3.88 mmol) in small portion-wise over 15 min. The mixture was stirred at 0° C. for 1.5 h. and was quenched by addition of methanol (1 mL). The reaction mixture was then carefully neutralized with 7.5% NaHCO₃ aq. solution to about pH 8. The organic layer was separated and washed with water, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the desired crude product (1.63 g, 90% purity) without further purification. LCMS: m/z=781.3 (M+Na)⁺.

Step 2: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (1635.0 mg, 1.94 mmol, 90% pure) in methanol (5 mL) and THF (5 mL) was added a solution of lithium hydroxide (100 mg, 4.0 mmol) in water (5 mL). The mixture was stirred at r.t overnight. The volatiles were removed under reduced pressure. The residue was neutralized with 1 N HCl aqueous solution to about pH 7. The mixture was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with ethyl acetate in hexane (0-50%) to afford the desired product (1.21 g, 87%).

Step 3: methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate

A 4 mL vial with septum containing triphenylphosphine (36.0 mg, 0.14 mmol) and vacuum-dried (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (60.9 mg, 0.08 mmol) was charged with 3-hydroxyphenylacetic acid methyl ester (13.5 uL, 0.09 mmol) followed by diisopropyl azodicarboxylate (24.0 μL, 0.12 mmol) dropwise over 1 min at r.t. The reaction mixture was stirred at r.t. for 2 h. The vial was then charged with additional triphenylphosphine (16.5 mg, 0.06 mmol), diisopropyl azodicarboxylate (15.0 μL, 0.08 mmol), and 3-hydroxyphenylacetic acid methyl ester (6.0 μL, 0.04 mmol). The solution was stirred at r.t. for an additional 1 h., then quenched with 2 drops water. The solution was dried under reduced pressure and purified by FCC (12 g SiO₂, 0→35% EtOAc in hexanes, wet-loaded in DCM). Fractions containing desired product were combined and concentrated under reduced pressure and heat (˜100 OC) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (53.6 mg, 0.0619 mmol, 72.9% yield) as a slightly white/hazy clear glass. R_f=0.30 (2:1 hexanes:EtOAc); LCMS calcd for C₄₉H₅₄ClN₂O₈S (M+H)⁺: m/z=865.33; found: 865.2.

Step 4: methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate

A 4 mL vial with septum containing methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (50.0 mg, 0.06 mmol) under N₂ was charged with DCM (1 mL) followed by TFA (1.0 mL, 0.06 mmol) and stirred at r.t. overnight. The purple reaction mixture was concentrated under reduced pressure, neutralized with sat. sodium bicarbonate (10 mL), diluted with water (30 mL) and extracted with EtOAc (40 mL). The organic layer was washed with water (40 mL), brine (20 mL), and dried over Na₂SO₄. The organic layer was filtered, concentrated under reduced pressure, and heat (˜50° C.) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (44.1 mg) as a yellow gum. LCMS calculated for C₃₃H₃₈ClN₂O₆S (M+H)⁺: m/z=625.21; found: 625.4.

Step 5: 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetic acid

A 20 mL vial containing methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (40 mg, 0.06 mmol) and lithium hydroxide (8.2 mg, 0.33 mmol) was charged with THF (900 μL) and water (300 μL). The vial was purged with N₂ and stirred at r.t. for 2 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with 0.1 M HCl (5 mL) and brine (20 mL), and washed with brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure and heat (˜60° C.) to yield crude 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetic acid (37 mg, 0.061 mmol, 95% yield) as an off-white glass. LCMS calculated for C₃₂H₃₆ClN₂O₅S (M+H)⁺: m/z=611.20; found: 611.3.

Step 6: (3R,6R, 24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17λ{circumflex over ( )}6-thia-1,16-diazapentacyclo[16.7.2.1{circumflex over ( )}9,13.0{circumflex over ( )}3,6.0{circumflex over ( )}21,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

A 20 mL vial with septum containing 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetic acid (26 mg, 0.04 mmol) in DCM (3 mL) was charged with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (25 mg, 0.13 mmol) and 4-(dimethylamino)pyridine (25 mg, 0.20 mmol) in one portion. The reaction mixture was stirred at r.t. for 2 h. The reaction mixture was quenched with 2 drops of water. The reaction mixture was then diluted with EtOAc (30 mL), washed twice with 0.1 M HCl (3 mL) and water (20 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure, and purified by FCC (12 g SiO₂, 0→40% EtOAc in hexanes, wet-loaded in DCM+hexanes). Fractions containing mostly product were combined and re-purified by FCC (15.5 g C18, 40→95% MeCN in H₂O, wet-loaded in DMSO). Fraction of high purity were combined, and concentrated under reduced pressure and heat (˜60° C.) to yield 96.3% pure (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17λ{circumflex over ( )}6-thia-1,16-diazapentacyclo[16.7.2.1{circumflex over ( )}9,13.0{circumflex over ( )}3,6.0{circumflex over ( )}21,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (8.1 mg, 0.013 mmol, 30% yield) as an off-white solid. R_f=0.54 (1:2 hexanes:EtOAc). LCMS calculated for C₃₂H₃₄ClN₂O₅S (M+H)⁺: m/z=593.19; found: 593.1; ¹H NMR (500 MHz, Acetonitrile-d₃) δ 9.40 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.20 (dd, J=2.4, 8.5 Hz, 1H), 7.16 (d, J=2.3 Hz, 1H), 7.13 (dd, J=2.2, 8.3 Hz, 1H), 7.09 (t, J=7.9 Hz, 1H), 6.92 (d, J=2.2 Hz, 1H), 6.83 (t, J=2.1 Hz, 1H), 6.78-6.71 (m, 2H), 6.67 (d, J=7.4 Hz, 1H), 4.13-4.02 (m, 4H), 3.46 (d, J=14.5 Hz, 1H), 3.41 (s, 2H), 3.32 (dd, J=5.4, 14.7 Hz, 2H), 3.19 (dd, J=9.5, 14.7 Hz, 1H), 2.84-2.70 (m, 2H), 2.64 (h, J=7.5, 8.5 Hz, 1H), 2.60-2.51 (m, 1H), 2.03-1.95 (m, 3H), 1.88-1.78 (m, 3H), 1.65-1.55 (m, 2H).

Example 19

2-Pyridin-4-yl-N-[(3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-acetamide

This compound was prepared using procedures analogous to those described for Example 12 using 2-(pyridin-4-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C₃₀H₃₃ClN₃O₄S (M+H)⁺: m/z=566.18; found: 566.1. ¹H NMR (500 MHz, DMSO-d₆) δ 12.20 (s, 1H), 8.55 (d, J=5.2 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 7.35 (s, 1H), 7.27-7.13 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.06 (s, 1H), 3.71 (s, 1H), 2.82-2.65 (m, 1H), 2.02-1.86 (m, 2H), 1.84-1.68 (m, 4H), 1.50 (d, J=6.8 Hz, 1H).

Example 20

3-Pyridin-4-yl-N-[rac-(3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide

This compound was prepared using procedures analogous to those described for Example 12 using 2-(pyridin-4-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C₃₁H₃₅ClN₃O₄S (M+H)⁺: m/z=580.2; found: 580.2. ¹H NMR (500 MHz, DMSO-d₆) δ 12.33 (s, 1H), 8.51 (s, 1H), 8.00 (s, 1H), 7.63 (d, J=8.5 Hz, 2H), 7.29-7.15 (m, 5H), 7.01 (d, J=8.2 Hz, 1H), 4.11-4.03 (m, 2H), 3.77 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.35-3.20 (m, 3H), 2.82-2.67 (m, 2H), 2.58 (s, 4H), 2.04-1.66 (m, 10H), 1.50 (dd, J=5.5, 12.2 Hz, 1H).

Example 21

tert-Butyl 4-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]piperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 2 using N-Boc-isonipecotic acid to replace acetic acid in Step 2. LCMS calculated for C₃₄H₄₅ClN₃O₆S (M+H)⁺: m/z=658.26; found: 657.9.

Example 22

tert-Butyl 4-[2-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]piperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 2 using 2-(1-tert-butoxycarbonyl-4-piperidyl)acetic acid to replace acetic acid in Step 2. LCMS calculated for C₃₅H₄₇ClN₃O₆S (M+H)⁺: m/z=672.28; found: 671.9.

Example 23

tert-Butyl (3S)-3-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyloxy]piperidine-1-carboxylate

Step 1: tert-butyl (3S)-3-chlorocarbonyloxypiperidine-1-carboxylate

A solution of tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate (2.01 g, 9.99 mmol) in DCM (20 mL) was cooled to 0° C. and a freshly prepared solution of triphosgene (1.48 g, 4.99 mmol) in 5 mL of DCM was added dropwise over 5 minutes. The mixture was stirred at this temperature for 30 min., then pyridine (0.81 mL, 9.9 mmol) was added dropwise. The mixture was kept stirring at 0° C. for 1 h. Water (30 mL) was added to the mixture and the layers were separated. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to afford the crude product tert-butyl (3S)-3-chlorocarbonyloxypiperidine-1-carboxylate (1.8 g, 68% yield) which was used in next step without further purification.

Step 2: tert-Butyl (3S)-3-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyloxy]piperidine-1-carboxylate

A solution of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1, Step 1, 15 mg, 0.03 mmol) and potassium carbonate (13.8 mg, 0.10 mmol) in acetone (2 mL) was stirred for 5 min in a sealed tube. Then a solution of tert-butyl (3S)-3-chlorocarbonyloxypiperidine-1-carboxylate (13.3 mg, 0.05 mmol) in acetone was added. The resulting mixture was stirred at 60° C. overnight, and poured into water (5 mL) and extracted with DCM (5 mL×3). The combined organic layer were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by prep-HPLC on C18 column to afford desired product tert-butyl (3S)-3-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyloxy]piperidine-1-carboxylate (12.1 mg, 53% yield) as a white solid. LCMS calculated for C₃₄H₄₅ClN₃O₇S (M+H)⁺: m/z=674.26; found: 673.9.

Example 24

N-[6′-Chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpyrrolidine-1-carboxamide

To a solution of pyrrolidine (23.8 mg, 0.34 mmol) in THF (2 mL) was added triphosgene (49.7 mg, 0.17 mmol). The mixture was kept stirring at r.t. for 2 hrs. Then pyridine was added to the solution. The mixture was further kept stirring at r.t. for 1 h. Then the whole solution was transferred to a solution of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1, Step 1, 15.0 mg, 0.03 mmol) and potassium carbonate (4.64 mg, 0.03 mmol) in acetone. The mixture was kept stirring at reflux overnight. The mixture was poured into water (5 mL) and the pH of aqueous was adjusted to 7-8 by adding saturated potassium bicarbonate solution. The aqueous layer was extracted with DCM (5 mL×3). The combined organic layer was dried over sodium sulfate and concentrated. The crude product was further purified prep HPLC on C18 column to afford N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpyrrolidine-1-carboxamide (9 mg, 47% yield) as a yellow solid. LCMS calculated for C₂₈H₃₅ClN₃O₄S (M+H)⁺: m/z=544.20; found: 543.8.

Example 25

(1S,1′R,2′R)-6-Chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-5,10-dithia-9-aza-1(5,7)-benzo[b][1,4]oxazepina-6(1,3)-benzena-3(1,2)-cyclobutanacyclodecaphan]-8′-one 10′,10′-dioxide

Step 1: [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl 4-methylbenzenesulfonate

To a mixture of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 18, Step 2, 44.0 mg, 0.06 mmol), tosyl chloride (16.2 mg, 0.08 mmol) in DCM (0.5 mL) was added TEA (22 uL, 0.16 mmol) at r.t. The reaction mixture was stirred at r.t. for 22 h. The additional tosyl chloride (21.2 mg, 0.11 mmol) and TEA (70 μL, 0.50 mmol) were added, and the reaction mixture was stirred for an additional 3 d at r.t. The reaction mixture was diluted with EtOAc (30 mL), washed with sat. NH₄Cl (15 mL) and water (15 mL), 0.05N HCl (30 mL), sat. NaHCO₃ (2×20 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure to yield crude [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl 4-methylbenzenesulfonate (65.8 mg) which was directly used in next step reaction without further purification.

Step 2: methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate

A mixture of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl 4-methylbenzenesulfonate (65.8 mg), methyl 2-(3-sulfanylphenyl)acetate (26.3 mg, 0.12 mmol), and potassium carbonate (21.5 mg, 0.15 mmol) was purged with N₂, and charged with DMF (400 μL). The mixture was stirred at r.t. overnight. LCMS analysis to form two major products. The reaction mixture was diluted with EtOAc (30 mL), washed with 0.1 N HCl (3 mL) and water (30 mL), sat. NaHCO₃ (30 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure to yield crude methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (74 mg) as a brown solid. R_f=0.34 (2:1 hexanes:EtOAc)

Step 3: methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate

A solution of methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (74 mg) in DCM (1.3 mL) and TFA (1.3 mL) was stirred at r.t. for 18 h. The volatiles were removed under reduced pressure. The residue was co-evaporated with DCM twice under reduced pressure, and purified by FCC (12 g SiO₂, 10→35% EtOAc in hexanes, wet-loaded in DCM) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (19.3 mg with -80% pure) as a white solid. R_f=0.18 (2:1 hexanes:EtOAc); LCMS m/z calcd for C₃₃H₃₈ClN₂O₅S₂ (M+H)⁺: m/z=641.19/643.19; found: 641.2/643.1.

Step 4: 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetic acid

Methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl sulfanyl]phenyl]acetate (19.0 mg, 0.02 mmol) in THF (400 uL) was treated with lithium hydroxide (6.0 mg, 0.24 mmol) in water (130 μL) at r.t. The reaction mixture was stirred at r.t. for 4 h. The mixture was diluted with EtOAc (20 mL), washed with water (5 mL), 0.1 N HCl (4 mL), and brine (15 mL). The aqueous layer was separated and extracted again with EtOAc (20 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure to yield 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetic acid (29 mg) as an opaque yellow gum. LCMS m/z calcd for C₃₂H₃₆ClN₂O₅S₂ (M+H)⁺: m/z=627.17/629.17; found: 627.1/629.1.

Step 5: (1S,1′R, 2′R)-6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-5,10-dithia-9-aza-1(5,7)-benzo[b][1,4]oxazepina-6(1,3)-benzena-3(1,2)-cyclobutanacyclodecaphan]-8′-one 10′,10′-dioxide

A solution of 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl sulfanyl]phenyl]acetic acid (29 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (26.0 mg, 0.14 mmol) in DCM (1.5 mL) was charged with 4-(dimethylamino)pyridine (27.0 mg, 0.22 mmol). The mixture was purged with N₂ and stirred at r.t. for 20 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with 1 N HCl (3 mL) and brine (20 mL). The aqueous layers were combined and back-extracted with DCM (3×20 mL). The organic combined layers were dried over Na₂SO₄, and filtered, and concentrated under reduced pressure. The residue was purified by FCC (15.5 g C18, 20→100% MeCN in H₂O, wet-loaded in DMSO). Fractions containing clean desired product were combined and concentrated under reduced pressure to yield (1S,1′R,2′R)-6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-5,10-dithia-9-aza-1(5,7)-benzo[b][1,4]oxazepina-6(1,3)-benzena-3(1,2)-cyclobutanacyclodecaphan]-8′-one 10′,10′-dioxide (5.5 mg) as a white solid. LCMS m/z calcd for C₃₂H₃₄ClN₂O₄S₂ (M+H)⁺: m/z=609.16/611.16; found: 609.0/611.0. ¹H NMR (500 MHz, Chloroform-d) δ 7.88 (s, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.45 (dd, J=2.1, 8.4 Hz, 1H), 7.28 (d, J=4.2 Hz, 2H), 7.21 (dd, J=2.3, 8.5 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.07 (s, 1H), 7.03 (t, J=4.7 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 4.23 (d, J=12.1 Hz, 1H), 4.08 (d, J=12.0 Hz, 1H), 3.61 (ABq, 2H, J_AB=14.8 Hz, Δδ_AB=0.017 Hz), 3.46 (d, J=14.4 Hz, 1H), 3.38-3.27 (m, 2H), 3.07 (dt, J=6.8, 13.6 Hz, 2H), 2.84-2.73 (m, 3H), 2.26 (ddd, J=7.7, 15.0, 31.3 Hz, 2H), 2.06 (dtd, J=2.6, 8.0, 10.9 Hz, 1H), 1.98-1.75 (m, 3H), 1.66 (p, J=9.0 Hz, 2H), 1.61-1.48 (m, 2H).

Example 26

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

Step 1: 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid

To a suspension of 1-(aminomethyl)cyclobutanecarboxylic acid hydrochloride salt (500 mg, 3.02 mmol) and sodium bicarbonate (1014 mg, 12.0 mmol) in THF (5 mL) and water (5 mL) was added di-tert-butyl dicarbonate (790 mg, 3.62 mmol). The resulting mixture was heated at 40° C. for 3 h. The reaction was acidified with 0.5 N HCl (to pH 4-5) and extracted with MTBE. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (15% to 40%) to afford 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid (520 mg, 75% yield). LCMS: calc. for C₁₁H₁₈NO₄ (M−H)⁻: m/z=228.12; Found: 228.17.

Step 2: 1-[[allyl(tert-butoxycarbonyl)amino]methyl]cyclobutanecarboxylic acid

To a solution of 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid (520 mg, 2.27 mmol) in THF (10 mL) was slowly added sodium hydride (272 mg, 6.8 mmol) at r.t. After 20 min, allyl bromide (411 mg, 3.4 mmol) was added in one portion. The resulting slurry was heated to a gentle reflux for 48 h. The reaction was cool to r.t., concentrated under reduced pressure, charged with EtOAc, and acidified with 0.5 N HCl (to pH 4-5). The layers were separated, and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (10% to 30%) to afford 1-[[allyl(tert-butoxycarbonyl)amino]methyl]cyclobutanecarboxylic acid (203 mg, 33% yield) as a yellow oil. LCMS: calc. for C₁₄H₂₂NO₄ (M−H)⁻: m/z=268.16, Found: 268.13.

Step 3: tert-butyl N-allyl-N-[[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]methyl]carbamate

A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (120.0 mg, 0.23 mmol, Intermediate 8), 1-[[allyl(tert-butoxycarbonyl)amino]methyl]cyclobutanecarboxylic acid (125 mg, 0.46 mmol), DMAP (170 mg, 1.39 mmol) and EDCI (0.27 mL, 1.39 mmol) was stirred at r.t. for 4 h. The reaction was diluted with CH₂Cl₂ and washed with 0.5 N HCl. The organic phase was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (5% to 50%) to afford tert-butyl N-allyl-N-[[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]methyl]carbamate (180 mg) as a colorless oil. LCMS: calc. for C₄₁H₅₅ClN₃O₇S [M+H]⁺: m/z=768.34/770.34; Found: 768.14/770.47.

Step 4: (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-(tert-butoxycarbonyl)-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

A solution of tert-butyl N-allyl-N-[[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]methyl]carbamate (180 mg, 0.23 mmol) in DCE (90 mL) was bubbled with N₂ for 10 min. (1,3-Dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride; Hoveyda-Grubbs II (29.3 mg, 0.05 mmol) was added and the resulting greenish solution was further bubbled with N₂ for 5 min, and was heated to reflux under N₂ for 16 h. LC-MS analysis indicated the completion of reaction. The reaction was allowed to cool to r.t. while being exposed to air. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Hetpanes (5% to 60%) to afford (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-(tert-butoxycarbonyl)-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (140 mg, 80% yield). LC-MS: [M+H]⁺ calc. for C₃₉H₅₁ClN₃O₇S: 740.31/742.31; Found: 739.96/742.29.

Step 5: (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-11-(tert-butoxycarbonyl)-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (140.0 mg, 0.19 mmol) in 2 N HCl in EtOAc (3 mL) was stirred at r.t. overnight. The reaction was diluted with EtOAc, washed with saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product (120 mg). 40 mg of the crude product was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H₂O to afford the desired (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (19 mg) as a white solid. LCMS: calc. for C₃₄H₄₃ClN₃O₅S [M+H]⁺: m/z=640.26/642.26; Found: 639.96/642.23. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.27 (d, 1H, overlapped with CDCl₃), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.90 (app s, 1H), 5.62 (dd, J=15.6, 8.0 Hz, 1H), 4.07 (t, J=9.3 Hz, 2H), 3.74 (d, J=14.4 Hz, 1H), 3.54 (app s, 1H), 3.41 (app s, 1H), 3.28 (d, J=14.6 Hz, 1H), 3.25 (s, 3H), 3.18-3.10 (m, 1H), 3.02 (d, J=13.4 Hz, 1H), 2.89-2.71 (m, 2H), 2.63-2.42 (m, 2H), 2.26 (app s, 1H), 2.09-1.77 (m, 8H), 1.62-1.50 (m, 9H).

Example 27

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-11-methyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

To a solution of (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (40.0 mg, 0.06 mmol, Example 26) in DCM (5 mL) was added acetic acid (0.02 mL, 0.31 mmol) and formaldehyde solution (37% wt %, 51 mg, 0.625 mmol HCHO). After 2 h, the reaction mixture was cooled at 0° C. and sodium borohydride (47.2 mg, 1.25 mmol) was added in portions. The reaction was stirred at r.t. for 3 h, and diluted with DCM and water, filtered through a pad of Celite. The organic layer was washed with saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H₂O to afford (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-methyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (20 mg, 48.9% yield). LCMS: calc. for C₃₅H₄₅ClN₃O₅S [M+H]⁺: m/z=654.28/656.27; Found: 654.02/656.36. ¹H NMR (600 MHz, CDCl₃) δ 13.75 (br s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.95 (br s, 1H), 6.12-6.03 (m, 1H), 5.53 (dd, J=15.8, 8.8 Hz, 1H), 4.06 (s, 2H), 3.72 (d, J=14.6 Hz, 1H), 3.60 (t, J=8.5 Hz, 1H), 3.52 (q, J=12.8, 11.3 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.28 (s, 3H), 3.19 (q, J=13.4, 9.2 Hz, 1H), 3.09 (t, J=11.4 Hz, 1H), 2.96 (dd, J=15.1, 11.2 Hz, 1H), 2.87 (d, J=13.8 Hz, 1H), 2.83-2.66 (m, 3H), 2.60-2.52 (m, 1H), 2.45 (app s, 5H), 2.15-1.58 (m, 13H).

Example 28

(3R,6R,7S,8E,22S)-6′-Chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[[11,20]dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: methyl 1-(allyloxy)cyclopropane-1-carboxylate

NaH (1.03 g, 25.84 mmol) washed by ether (30 mL) was added in one portion to a solution of methyl 1-hydroxycyclopropanecarboxylate (2.0 g, 17.22 mmol) in THF (20 mL). The reaction mixture was stirred at r.t. for 1 h. Allyl bromide (2.08 g, 17.2 mmol) was added, and the reaction mixture was stirred at r.t. for 14 h., then quenched with saturated aqueous NH₄Cl (20 mL). The resulting mixture was extracted with ether (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentrated by decompression distillation at 0° C. to give methyl 1-(allyloxy)cyclopropane-1-carboxylate (1.2 g, 44% yield) as colorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 5.91-5.83 (m, 1H), 5.24-5.19 (m, 1H), 5.12-5.09 (m, 1H), 4.096-4.06 (m, 2H), 3.65 (s, 3H), 1.19-1.17 (m, 4H).

Step 2: 1-(allyloxy)cyclopropane-1-carboxylic acid

NaOH (1.5 g, 37.5 mmol) was added to a solution of methyl 1-allyloxycyclopropanecarboxylate (1.2 g, 7.68 mmol) in methanol (5 mL) and water (5 mL). The reaction mixture was stirred at r.t. for 14 h. To the reaction mixture was added 20 mL of water. The resulting mixture was extracted with DCM (3×20 mL), then adjusted with HCl (3 M) to pH 2-3, extracted with DCM (5 mL×3). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated to give the crude product 1-allyloxycyclopropanecarboxylic acid (369 mg, 34% yield) which was used directly in next step reaction without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 12.54 (br s, 1H), 5.92-5.82 (m, 1H), 5.20 (ddd, J=17.3, 3.8, 1.8 Hz, 1H), 5.09 (ddd, J=10.5, 3.4, 1.5 Hz, 1H), 4.07 (dt, J=5.4, 1.6 Hz, 2H), 1.15-1.14 (m, 2H), 1.11-1.09 (m, 1H).

Step 3: (3R,6R,7S,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[[11,20]dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),7,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C₃₂H₃₈ClN₂O₆S [M+H]⁺: m/z=613.2/615.2. Found: 612.8/615.1. ¹H NMR (600 MHz, DMSO-d₆) δ 11.73 (s, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.33 (d, J=15.7 Hz, 1H), 7.27-7.19 (m, 3H), 7.08 (d, J=14.5 Hz, 1H), 5.66-5.57 (m, 1H), 5.09-5.01 (m, 1H), 4.14 (d, J=11.9 Hz, 1H), 4.09-4.03 (m, 1H), 4.00 (d, J=12.0 Hz, 1H), 3.93 (dd, J=12.7, 9.3 Hz, 1H), 3.52 (d, J=14.2 Hz, 1H), 3.33-3.28 (m, 2H), 3.16-3.05 (m, 2H), 3.02 (s, 3H), 2.84-2.71 (m, 2H), 2.11-2.05 (m, 1H), 2.06-1.97 (m, 1H), 1.88-1.80 (m, 3H), 1.78-1.72 (m, 3H), 1.56 (q, J=9.3 Hz, 1H), 1.40-1.37 (m, 1H), 1.27-1.23 (m, 2H), 1.07-1.05 (m, 2H).

Example 29

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[[11,20]dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C₃₂H₃₈ClN₂O₆S [M+H]⁺: m/z=613.2/615.2. Found: 613.2/615.1. ¹H NMR (600 MHz, DMSO-d₆) 11.79 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.30 (dd, J=8.5, 2.3 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.21-7.20 (m, 2H), 7.05 (d, J=8.2 Hz, 1H), 5.67-5.63 (m, 1H), 5.40 (dd, J=15.4, 8.5 Hz, 1H), 4.16-4.05 (m, 3H), 3.80 (dd, J=13.1, 7.2 Hz, 1H), 3.63-3.57 (m, 2H), 3.09-3.05 (m, 4H), 2.83-2.80 (m, 1H), 2.75-2.69 (m, 1H), 2.64-2.59 (m, 1H), 2.29-2.27 (m, 1H), 2.00 (d, J=13.7 Hz, 1H), 1.88-1.82 (m, 3H), 1.76-1.61 (m, 3H), 1.44-1.41 (m, 1H), 1.26-1.14 (m, 3H), 1.06-1.04 (m, 1H).

Example 30

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[[11,20]dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: 2-allyloxy-2-methyl-propanoic acid

This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl 2-hydroxy-2-methyl-propanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1.

Step 2: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₆S [M+H]⁺: m/z=615.22/617.22. Found: 614.8/617.1. ¹H-NMR (600 MHz, CDCl₃) δ 9.07 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.51 (d, J=8.2 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H), 6.99 (dd, J=8.7, 5.1 Hz, 2H), 5.83 (d, J=15.4 Hz, 1H), 5.53 (dd, J=15.6, 8.5 Hz, 1H), 4.11 (dt, J=21.2, 7.1 Hz, 3H), 3.77 (d, J=12.2 Hz, 1H), 3.72 (d, J=14.7 Hz, 1H), 3.59-3.44 (m, 2H), 3.33 (d, J=14.7 Hz, 1H), 3.27 (s, 3H), 3.07 (dd, J=15.0, 9.9 Hz, 1H), 2.84-2.67 (m, 2H), 2.58-2.44 (m, 1H), 2.25-2.13 (m, 1H), 2.04-1.89 (m, 4H), 1.87-1.77 (m, 1H), 1.65-1.52 (m, 3H), 1.42 (s, 3H), 1.38 (s, 3H).

Example 31

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: ethyl 1-hydroxycyclobutanecarboxylate

To a solution of ethyl 1-aminocyclobutanecarboxylate hydrochloride (501.2 mg, 2.79 mmol) in aqueous sulfuric acid (11.2 mL, 5.6 mmol) at 0° C. was dropwise added a solution of sodium nitrite (980 mg, 14 mmol) in water (3 mL). The reaction was stirred at 0° C. for 1 h and allowed to warm to r.t. After 24 h., the reaction was extracted with MTBE. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo to give ethyl 1-hydroxycyclobutane-1-carboxylate as colorless oil (240 mg). The crude product was used in next step without further purification. TLC: R_f=0.38 (3:7 EtOAc/Hept).

Step 2: 1-allyloxycyclobutanecarboxylic acid

This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl 1-hydroxycyclobutane-1-carboxylate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. LC-MS calc. for C₈H₁₁O₃ [M−H]⁻: m/z=155.1; Found: 155.1.

Step 3: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25), 17, 19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-allyloxycyclobutanecarboxylic acid in Step 3. LC-MS calc. for C₃₃H₄₀ClN₂O₆S [M+H]⁺: m/z=627.23/629.23. Found: 626.9/629.0. ¹H-NMR (400 MHz, CDCl₃) δ 10.13 (s, 1H), 7.73 (d, J=8.5 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 7.23 (s, 1H), 7.20 (d, J=10.1 Hz, 1H), 7.10 (s, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.90-5.79 (m, 2H), 4.29-3.63 (m, 8H), 3.33 (s, 3H), 3.27 (d, J=14.5 Hz, 1H), 3.00 (dd, J=15.2, 10.5 Hz, 1H), 2.84-2.72 (m, 2H), 2.70-2.59 (m, 1H), 2.37 (s, 2H), 2.10-1.16 (m, 12H).

Example 32

(3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and

Example 33

(3R,6R,7S,8Z,22S)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-allyloxy-2-methyl-propanoate

A solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (200.0 mg, 0.40 mmol, Intermediate 3), 2-allyloxy-2-methyl-propanoic acid (171.96 mg, 1.19 mmol, Example 30, Step 1), EDCI (0.47 mL, 2.39 mmol), and DMAP (291.43 mg, 2.39 mmol) in DCM (4 mL) was stirred at r.t. for 16 h. LC-MS indicated the completion of reaction. The reaction was diluted with DCM and washed with 0.5 N HCl. The organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (10% to 20%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-allyloxy-2-methyl-propanoate (300 mg, 99.9% yield). LC-MS: calc. for C₄₀H₅₂ClN₂O₈S [M+H]⁺: m/z=755.31/757.31; Found: 755.1/757.4.

Step 2: 2-allyloxy-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide

A solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-allyloxy-2-methyl-propanoate (300 mg, 0.40 mmol) and lithium hydroxide monohydrate (83.3 mg, 1.99 mmol) in THF/MeOH/H₂O (0.3 mL each) was heated at 45° C. for 4 h. LC-MS indicated the completion of reaction. The reaction was adjusted with 1 N HCl to pH 3-4 and extracted with DCM. The combined organic layers were washed with saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-allyloxy-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (175 mg, 70% yield), which was used without further purifications. LCMS: calc. for C₃₃H₄₂ClN₂O₆S [M+H]⁺: m/z=629.24/631.24; Found: 628.9/631.2.

Step 3. (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

A solution of 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (1.40 g, 2.23 mmol) in DCE (1230 mL) was bubbled with N₂ for 10 min. 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethyl aminosulfonyl)phenyl]methyleneruthenium(II) dichloride (Zhan Catalyst 1B) (326 mg, 0.45 mmol) was added and the resulting greenish solution was further bubbled with N₂ for 5 min., and was heated at 40° C. under N₂ for 2 h. The reaction was concentrated under reduced pressure, and the residue purified by flash column chromatography on a silica gel column with EtOAc/Hept (10% to 70%) to afford two products: P1 (the earlier eluted product, 160 mg, 11% yield) and P2 (the latter eluted product, 647 mg, 47% yield).

P2 was assigned to (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32). HPLC: major product, C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 90% MeCN/H₂O (with 0.1% HCO₂H) 10 min λ=220 nm. tR=3.2 min. LC-MS calc. for C₃₁H₃₈ClN₂O₆S [M+H]⁺: m/z=601.21/603.21; Found 601.6/603.6; ¹H NMR (300 MHz, CDCl₃) δ 9.15 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.6, 2.2 Hz, 1H), 7.12 (s, 1H), 7.06 (d, J=1.8 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 5.84-5.72 (m, 2H), 4.24 (d, J=3.3 Hz, 1H), 4.13 (t, J=7.2 Hz, 2H), 4.00 (dd, J=13.2, 4.5 Hz, 1H), 3.88 (d, J=12.5 Hz, 1H), 3.72 (d, J=14.6 Hz, 1H), 3.40-3.24 (m, 3H), 2.84-2.71 (m, 3H), 2.43-2.33 (m, 1H), 2.01 (d, J=15.5 Hz, 2H), 1.94-1.81 (m, 4H), 1.75-1.58 (m, 2H), 1.54 (d, J=14.5 Hz, 1H), 1.45 (s, 3H), 1.41 (s, 3H).

And P1 to (3R,6R,7S,8Z,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 33). P1: minor product, C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 90% MeCN/H₂O (with 0.1% HCO₂H) 10 min λ=220 nm. tR=4.3 min. LC-MS calc. for C₃₁H₃₈ClN₂O₆S [M+H]⁺: m/z=601.21/603.21; Found 601.6/603.6; ¹H NMR (300 MHz, CDCl₃) δ 9.22 (s, 1H), 7.68 (t, J=8.3 Hz, 1H), 7.55 (dd, J=8.4, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.1 Hz, 1H), 7.13 (dd, J=9.6, 2.0 Hz, 2H), 7.03 (d, J=8.4 Hz, 1H), 5.92-5.75 (m, 2H), 4.22-4.14 (m, 1H), 4.00 (dd, J=13.4, 4.9 Hz, 1H), 3.89 (dd, J=13.3, 2.9 Hz, 1H), 3.81-3.61 (m, 4H), 3.33 (d, J=14.5 Hz, 1H), 3.15 (dd, J=15.1, 9.2 Hz, 1H), 2.79 (d, J=9.2 Hz, 2H), 2.53 (d, J=5.2 Hz, 1H), 2.33-2.22 (m, 1H), 2.08-1.92 (m, 4H), 1.81 (dd, J=35.4, 6.4 Hz, 2H), 1.71-1.57 (m, 2H), 1.45 (s, 3H), 1.42 (s, 3H).

Example 34

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-3,5,5-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (13.0 mg, 0.02 mmol, Example 32) in THF (0.5 mL) was added sodium hydride (4.3 mg, 0.11 mmol) at r.t. After 10 min, N,N-dimethylcarbamoyl chloride (4.6 mg, 0.04 mmol) was added, and followed by DMAP (5.3 mg, 0.04 mmol). The mixture was stirred at r.t. for 6 h., and diluted with DCM and acidified with 0.5 N HCl to pH 5-6. The organic phase was separated, washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H₂O to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (6 mg, 38% yield) as a white solid. LCMS: calc. for C₃₄H₄₃ClN₃O₇S [M+H]⁺: m/z=672.25/674.25; Found: 672.45/674.37. ¹H NMR (600 MHz, CDCl₃) δ 9.08 (br s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 7.04-6.95 (m, 2H), 5.86-5.78 (m, 1H), 5.74-5.67 (m, 1H), 5.30 (t, J=4.5 Hz, 1H), 4.15 (d, J=12.2 Hz, 1H), 4.12-4.05 (m, 2H), 3.76-3.72 (m, 1H), 3.70 (d, J=14.8 Hz, 1H), 3.43 (dd, J=15.1, 4.7 Hz, 1H), 3.37 (d, J=14.7 Hz, 1H), 3.21 (dd, J=15.1, 9.3 Hz, 1H), 2.95 (d, J=14.6 Hz, 6H), 2.83-2.73 (m, 3H), 2.37 (dtd, J=15.2, 10.2, 9.7, 5.5 Hz, 1H), 2.06-1.90 (m, 3H), 1.88-1.77 (m, 3H), 1.67-1.60 (m, 2H), 1.56 (s, 2H), 1.43 (s, 6H).

Example 35

[(3R,6R,7S,8Z,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8Z,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 33) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₄H₄₃ClN₃O₇S [M+H]⁺: m/z=672.24/674.24; Found: 672.6/674.6.

Example 36

(3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) to replace (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) in Step 2. LC-MS calc. for C₃₁H₃₈ClN₂O₆S [M+H]⁺: m/z=601.21/603.21; Found: 600.9/602.8. ¹H NMR (600 MHz, DMSO-d₆) δ 11.87 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=14.2, 5.6 Hz, 2H), 7.18 (d, J=1.9 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 6.89 (s, 1H), 5.83 (d, J=12.7 Hz, 1H), 5.49 (dd, J=15.6, 7.9 Hz, 1H), 4.85 (d, J=4.0 Hz, 1H), 4.09 (dd, J=29.6, 12.2 Hz, 2H), 3.99 (dd, J=13.4, 7.4 Hz, 1H), 3.74 (dd, J=11.8, 8.0 Hz, 1H), 3.60 (d, J=14.6 Hz, 1H), 3.45 (d, J=12.5 Hz, 1H), 3.38 (dd, J=21.8, 9.7 Hz, 2H), 3.08 (dd, J=14.8, 10.0 Hz, 1H), 2.81 (d, J=16.9 Hz, 1H), 2.75-2.67 (m, 1H), 2.37-2.30 (m, 1H), 2.03-1.77 (m, 6H), 1.63 (ddd, J=30.2, 19.2, 10.3 Hz, 2H), 1.44 (dd, J=19.1, 9.3 Hz, 1H), 1.34 (s, 3H), 1.21 (s, 3H) ppm.

Example 37

[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₄H₄₃ClN₃O₇S [M+H]⁺: m/z=672.24/674.24; Found: 672.0/674.2. ¹H NMR (600 MHz, CDCl₃) δ 9.27 (br s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.04 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.85 (dt, J=15.6, 4.2 Hz, 1H), 5.80-5.73 (m, 1H), 5.08 (dd, J=7.9, 5.0 Hz, 1H), 4.11 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 4.05-3.96 (m, 2H), 3.79 (d, J=14.5 Hz, 1H), 3.73 (dd, J=15.2, 3.8 Hz, 1H), 3.27 (d, J=14.5 Hz, 1H), 3.08 (dd, J=15.3, 9.8 Hz, 1H), 2.96 (s, 3H), 2.92 (s, 3H), 2.77 (dddd, J=22.3, 16.7, 11.4, 4.6 Hz, 3H), 2.54 (td, J=13.0, 11.6, 6.5 Hz, 1H), 2.41 (qd, J=9.4, 4.9 Hz, 1H), 2.05-1.78 (m, 6H), 1.66 (tq, J=14.6, 7.5, 6.4 Hz, 2H), 1.55 (qd, J=10.4, 8.5 Hz, 1H), 1.40 (s, 3H), 1.36 (s, 3H).

Example 38

(3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4) and 1-allyloxycyclopropanecarboxylic acid (Example 28, Step 2) in Step 1. LCMS: calc. for C₃₁H₃₆ClN₂O₆S [M+H]⁺: m/z=599.20/601.19; Found: 599.4/601.5. ¹H NMR (600 MHz, DMSO-d₆) δ 11.68 (br, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.29 (dd, J=8.5, 2.3 Hz, 1H), 7.27-7.15 (m, 3H), 7.01 (dd, J=12.3, 5.6 Hz, 1H), 5.58-5.47 (m, 2H), 4.76 (d, J=4.5 Hz, 1H), 4.10 (d, J=12.0 Hz, 1H), 4.04-3.95 (m, 2H), 3.84-3.76 (m, 1H), 3.69-3.57 (m, 2H), 3.03 (d, J=14.5 Hz, 1H), 2.86-2.77 (m, 1H), 2.70 (dt, J=16.9, 8.6 Hz, 1H), 2.05-1.95 (m, 2H), 1.87-1.78 (m, 3H), 1.74-1.68 (m, 2H), 1.62-1.58 (m, 1H), 1.49-1.45 (m, 1H), 1.41 (td, J=15.3, 8.3 Hz, 1H), 1.32-1.10 (m, 6H).

Example 39

[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 38) and N,N-dimethylcarbamoyl chloride. LCMS: calc. for C₃₄H₄₁ClN₃O₇S [M+H]⁺: m/z=670.24/672.23; Found: 670.84/672.86. ¹H NMR (600 MHz, CDCl₃) δ 9.04 (s, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.29 (d, J=2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 5.71 (app q, J=2.6 Hz, 2H), 4.88 (d, J=3.0 Hz, 1H), 4.13 (d, J=12.1 Hz, 1H), 4.05-3.99 (m, 2H), 3.96-3.91 (m, 1H), 3.85 (d, J=14.4 Hz, 1H), 3.82-3.76 (m, 1H), 3.18 (d, J=14.5 Hz, 1H), 3.06 (dd, J=15.3, 5.7 Hz, 1H), 2.91 (s, 3H), 2.84 (s, 3H), 2.76 (dt, J=11.0, 5.4 Hz, 2H), 2.56 (tt, J=10.7, 5.2 Hz, 2H), 2.03-1.85 (m, 4H), 1.83-1.63 (m, 2H), 1.72-1.64 (m, 1H), 1.44 (td, J=13.6, 13.1, 2.6 Hz, 1H), 1.38 (q, J=3.2 Hz, 2H), 1.24-1.19 (m, 1H), 1.18-1.11 (m, 1H).

Example 40

(3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) and 1-allyloxycyclopropanecarboxylic acid (Example 28, Step 2) in Step 1. LCMS: calc. for C₃₁H₃₆ClN₂O₆S [M+H]⁺: m/z=599.20/601.19; Found: 599.7/601.6. ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 7.31 (s, 1H), 7.18 (d, J=8.6 Hz, 1H), 7.10 (d, J=1.9 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 5.86 (dd, J=15.5, 4.2 Hz, 1H), 5.69-5.51 (m, 1H), 4.19-4.02 (m, 3H), 3.96 (dd, J=12.0, 6.7 Hz, 2H), 3.74 (d, J=14.5 Hz, 1H), 3.54 (dd, J=15.0, 8.1 Hz, 1H), 3.33 (dd, J=17.5, 7.5 Hz, 2H), 2.79 (dd, J=9.1, 5.2 Hz, 2H), 2.64 (dd, J=14.6, 8.3 Hz, 1H), 2.55-2.41 (m, 1H), 2.10-1.77 (m, 3H), 1.65 (ddd, J=35.5, 23.7, 11.9 Hz, 3H), 1.51-1.41 (m, 2H), 1.41-1.31 (m, 2H), 1.23 (ddd, J=17.1, 9.8, 5.4 Hz, 3H).

Example 41

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 40) and N,N-dimethylcarbamoyl chloride. LCMS: calc. for C₃₄H₄₁ClN₃O₇S [M+H]⁺: m/z=670.24/672.23; Found: 670.84/672.73. ¹H NMR (600 MHz, CDCl₃) δ 9.16 (s, 1H), 7.65 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.2 Hz, 1H), 7.25 (d, J=2.3 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.79-5.65 (m, 2H), 5.21-5.17 (m, 1H), 4.15 (d, J=12.2 Hz, 1H), 4.10 (d, J=12.1 Hz, 1H), 4.06-3.98 (m, 2H), 3.63 (d, J=14.7 Hz, 1H), 3.54 (dd, J=15.3, 7.6 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.22 (dd, J=15.2, 6.5 Hz, 1H), 2.85 (s, 3H), 2.82-2.71 (m, 3H), 2.63 (s, 3H), 2.55 (qd, J=8.8, 6.2 Hz, 1H), 2.09-1.87 (m, 4H), 1.78 (tdd, J=20.5, 10.8, 6.3 Hz, 2H), 1.63 (p, J=9.8 Hz, 1H), 1.50-1.42 (m, 1H), 1.41-1.33 (m, 2H), 1.30-1.23 (m, 1H), 1.20-1.12 (m, 1H).

Example 42

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: 2-[allyl(tert-butoxycarbonyl)amino]-2-methyl-propanoic acid

To a stirred solution of 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (2.0 g, 9.84 mmol) in THF (40 mL) was added sodium hydride (0.98 g, 24.6 mmol) in portions under an ice bath. The resulting solution was stirred at r.t. for 10 minutes. Then Allyl bromide (2.13 mL, 24.6 mmol) was added. The reaction was stirred at 50° C. for 24 h. The reaction was quenched with saturated NH₄Cl solution (40 mL). The mixture was extracted with EtOAc (40 mL×3). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (40 g) with EtOAc/Heptanes (5% to 80%) to afford 2-[allyl(tert-butoxycarbonyl)amino]-2-methyl-propanoic acid (1.6 g, 66% yield) as a white solid. LC-MS calc. for C₁₂H₂₀NO₄ [M−H]⁻: m/z=242.1; Found: 242.1.

Step 2: tert-butyl N-[1,1-dimethyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate

To a stirred solution of 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (176.87 mg, 0.87 mmol) in DCM (5 mL) was added DMAP (212 mg, 1.74 mmol) followed by EDCI (135 mg, 0.87 mmol). The resulting mixture was stirred at r.t. for 10 min. Then (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (150.0 mg, 0.29 mmol, Intermediate 8) was added. The reaction was stirred at 40° C. for 8 h. LC-MS showed full conversion of starting material. The reaction was quenched by HCl (1 M, 10 mL), and was extracted with DCM (10 mL×2). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (10% to 80%) to afford tert-butyl N-[1,1-dimethyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (159 mg, 78% yield) as a yellow liquid. LC-MS calc. for C₃₆H₄₉ClN₃O₇S [M+H]⁺: m/z=702.3/704.3; Found: 702.0/704.3.

Step 3: 2-amino-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide

tert-Butyl N-[1,1-dimethyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (230 mg, 0.33 mmol) was treated with 2M HCl in EA (10.0 mL, 0.33 mmol) at r.t. for 2 h. The solvent was evaporated under reduced pressure to afford the crude product as HCl salt which was used in next step without further purification. LC-MS calc. for C₃₁H₄₁ClN₃O₅S [M+H]⁺: m/z=602.2/604.2; Found: 602.0/604.2.

Step 4: 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide

To a stirred solution of 2-amino-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide hydrochloride (180 mg, 0.28 mmol) in DMF (5 mL) was added sodium hydride (45 mg, 1.13 mmol). The resulting mixture was stirred at r.t. for 5 min. Then allyl bromide (0.02 mL, 0.28 mmol) was added. The reaction was stirred at r.t. for 48 h. LC-MS showed unreacted starting material (˜15%), desired product (˜60%) and dialkylation product (25%). The reaction was quenched by adding water (20 mL). EtOAc (20 mL) was added and the layers were separated. The organic layer was washed with water (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (30% to 100%) to afford 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (57.5 mg, 31.7% yield) as a white solid. LC-MS calc. for C₃₄H₄₅ClN₃O₅S [M+H]⁺: 642.3/644.3; Found: 642.5/644.2.

Step 5: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide. LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: 614.2/616.2; Found: 614.3/616.3.

Step 6: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.3/630.3; Found: 628.0/630.2. ¹H NMR (600 MHz, DMSO-d₆) δ 9.13 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.2 Hz, 1H), 6.83 (d, J=8.2 Hz, 1H), 6.74-6.70 (m, 1H), 6.27 (dd, J=12.4, 6.4 Hz, 1H), 5.62-5.57 (m, 1H), 4.04-3.95 (m, 2H), 3.56 (d, J=14.5 Hz, 1H), 3.53-3.37 (m, 2H), 3.21 (s, 3H), 3.01 (dd, J=15.2, 11.0 Hz, 1H), 2.80 (dt, J=17.0, 4.3 Hz, 1H), 2.71 (ddd, J=16.8, 10.4, 6.5 Hz, 1H), 2.65-2.55 (m, 2H), 2.49-2.25 (m, 3H), 2.03-1.90 (m, 3H), 1.87-1.81 (m, 1H), 1.77-1.70 (m, 2H), 1.54-1.31 (m, 4H), 1.31-1.04 (m, 6H).

Example 43

(3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione

To a solution of 2-[allyl(tert-butoxycarbonyl)amino]-2-methyl-propanoic acid (4.79 g, 19.6 mmol, Example 83 Step 1) in ethyl acetate (25 mL) was added t-butylchlorodiphenylsilane (3.26 g, 21.6 mmol) at 0° C. followed by addition of triethylamine (TEA) (2.74 mL, 19.6 mmol). White precipitate was formed immediately. The reaction was stirred at 0° C. for 30 min. The white solid was filtered off and rinsed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was dissolved in DCM (25 mL) and followed by addition of oxalyl chloride (2.1 mL, 24 mmol) and DMF (10 drops). Gas was evolved and the reaction was stirred at r.t. overnight. TLC showed a new spot (R_f=0.6, EA:Heptane=1:1) formed. The reaction was concentrated and co-evaporated THF 3 times to remove excess oxalyl chloride. The residue was treated with THF (30 mL) and filtered to provide a stock solution of the desired product (about 0.66 M with 98.6% purity showed by GC at 8.93 min.) which was directly used in next step reaction without further purification.

Step 2: 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide

To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (500.0 mg, 0.99 mmol, Intermediate 3) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (3.01 mL, 1.99 mmol) in THF (5 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (298 μL, 1.99 mmol). The resulting mixture was heated to 65° C. for 2 h. The reaction was cooled to r.t. Methanol (8 mL) and water (8 mL) were added, followed by addition of lithium hydroxide monohydrate (500 mg, 11.9 mmol). The reaction was heated to 45° C. for 3 h. THF was removed under reduced pressure. The residue was re-dissolved in DCM, and was quenched with sat. NH₄Cl aq. (5 mL). The mixture was extracted with DCM (5 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (20% to 100%) then MeOH/EtOAc (0% to 50%) to afford 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (490 mg, 78.5% yield). LC-MS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.3/630.3; Found: 628.8/630.8.

Step 3: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide. LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.2/602.2; Found: 600.7/602.7.

Step 4: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution. LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: m/z=614.24/616.24; Found: 614.8/616.8. ¹H NMR (600 MHz, DMSO-d₆) δ 7.63 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.14-7.10 (m, 1H), 7.08 (br, 1H), 6.86-6.84 (m, 2H), 5.79-5.73 (m, 1H), 5.37-5.31 (m, 1H), 4.09 (d, J=19.1 Hz, 1H), 3.51 (d, J=14.6 Hz, 1H), 3.07 (t, J=12.7 Hz, 1H), 2.84-2.76 (m, 1H), 2.71 (ddd, J=16.8, 10.8, 6.1 Hz, 1H), 2.64-2.60 (m, 1H), 2.17 (d, J=11.4 Hz, 1H), 2.04-2.00 (m, 2H), 1.89-1.82 (m, 3H), 1.67-1.61 (m, 2H), 1.47-1.41 (m, 3H), 1.35-1.33 (m, 2H), 1.27-1.22 (m, 10H), 0.89-0.81 (m, 2H).

Example 44

[(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₅H₄₆ClN₄O₆S [M+H]⁺: m/z=685.3/687.3; Found: 685.3/687.3. ¹H NMR (400 MHz, DMSO-d₆) δ 9.02 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.10 (dd, J=8.1, 1.9 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.77-6.73 (m, 1H), 6.62-6.59 (m, 1H), 6.29-6.26 (m, 1H), 5.91-5.83 (m, 1H), 4.15-3.92 (m, 3H), 3.56 (d, J=14.6 Hz, 1H), 3.29 (d, J=14.4 Hz, 2H), 3.02 (s, 3H), 2.86 (s, 3H), 2.75-2.65 (m, 2H), 2.57-2.51 (m, 4H), 2.43-2.26 (m, 3H), 2.08-1.79 (m, 4H), 1.68 (dt, J=17.5, 8.3 Hz, 2H), 1.57 (t, J=9.0 Hz, 2H), 1.36 (s, 3H), 1.18 (s, 3H).

Example 45

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (425 mg, 0.71 mmol, Example 43) in DCE (10 mL) was added formaldehyde-d2 solution (˜20 wt. % in D₂O) (113 mg, 3.54 mmol). The mixture was stirred at 20° C. for 2 h. LC-MS analysis indicated the starting material was consumed and the iminium intermediate was formed. Sodium cyanoborodeuteride (233 mg, 3.54 mmol) was then added the reaction was stirred for 4 h. LC-MS analysis indicated the reaction was complete. The reaction was quenched with 1M HCl aq. solution (20 mL), and extracted with DCM (20 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (393 mg, 89.9% yield) as a light brown colored solid. LC-MS: calc. for C₃₂H₃₈D₃ClN₃O₅S [M+H]⁺: m/z=617.26/619.26; Found: 617.3/619.1.

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₅H₄₃ClD₃N₃O₆S [M+H]⁺: m/z=688.29/690.29; Found 688.5/690.3. ¹H NMR (499 MHz, DMSO-d₆) δ 7.62 (d, J=8.6 Hz, 1H), 7.23 (dd, J=8.5, 2.4 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.09 (dd, J=8.1, 1.9 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 6.75 (s, 1H), 6.23 (s, 1H), 5.82 (d, J=15.8 Hz, 1H), 5.22 (s, 1H), 3.98 (q, J=12.2 Hz, 2H), 3.54 (d, J=14.5 Hz, 2H), 3.40 (t, J=11.6 Hz, 3H), 3.06 (dd, J=15.1, 10.8 Hz, 1H), 3.00 (s, 3H), 2.84 (s, 3H), 2.78 (dt, J=16.8, 4.5 Hz, 1H), 2.69 (ddd, J=16.4, 10.6, 5.9 Hz, 2H), 2.39-2.28 (m, 1H), 2.02-1.93 (m, 1H), 1.93-1.76 (m, 3H), 1.68 (dt, J=17.7, 8.4 Hz, 2H), 1.63-1.52 (m, 1H), 1.47-1.36 (m, 1H), 1.34 (s, 3H), 1.16 (s, 3H).

Example 46

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)piperazine-1-carboxylate

Step 1: phenyl [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo-[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]carbonate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 g, 4.66 mmol, Example 32) and phenyl chloroformate (3.64 g, 23.2 mmol) in ACN (60 mL) was added pyridine (3.77 mL, 46.5 mmol). The mixture was stirred at r.t. for 1 h. The reaction was monitored by LC-MS. The mixture was carefully neutralized with 0.5 N HCl (80 mL), and extracted with ethyl acetate (40 mL×2). The organic layer was washed with saturated NaHCO₃ (80 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/10% DCM in Heptanes (5-65%) to afford the desired product phenyl [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] carbonate (1.24 g, 36.9% yield). LC-MS calc. for C₃₈H₄₂ClN₂O₈S [M+H]⁺: m/z=721.23.21/723.23; Found 721.8/723.8.

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)piperazine-1-carboxylate

To a solution of phenyl [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] carbonate (20.0 mg, 0.03 mmol) in MeCN (0.50 mL) was added 1-(2-methoxyethyl)piperazine (12.0 mg, 0.08 mmol). The reaction was heated to 80° C. for 2 h. The reaction was cooled to r.t. and concentrated under reduced pressure. The residue was re-dissolved in DCM (2 mL) and washed with 0.5 N HCl aq. (2 mL). Aqueous layer was extracted with DCM (2 mL) one more time. The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (21.2×150 mm, 5 m) using MeCN/H₂O (20% to 100% over 18 min) to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)piperazine-1-carboxylate (10.6 mg, 48.7% yield). LC-MS calc. for C₃₉H₅₂ClN₄O₈S [M+H]⁺: m/z=771.32/773.32; Found: 771.8/773.8. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.02-6.95 (m, 2H), 5.88-5.75 (m, 1H), 5.70 (dd, J=15.7, 4.9 Hz, 1H), 5.34 (s, 1H), 4.11 (dt, J=11.6, 9.0 Hz, 3H), 3.81-3.65 (m, 3H), 3.62-3.43 (m, 5H), 3.43-3.31 (m, 4H), 3.22 (dd, J=15.1, 9.1 Hz, 1H), 2.85-2.67 (m, 2H), 2.60 (t, J=5.5 Hz, 3H), 2.38 (d, J=3.8 Hz, 2H), 2.08-1.89 (m, 5H), 1.89-1.71 (m, 4H), 1.63 (t, J=9.4 Hz, 2H), 1.50 (d, J=12.5 Hz, 2H), 1.44 (s, 3H), 1.37 (s, 3H).

Example 47

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate

To a solution of DIPEA (232 mg, 1.8 mmol) in MeCN (3 mL) was added 1,1,1-trideuterio-N-(trideuteriomethyl)methanamine hydrochloride (0.3 mL, 1.8 mmol). The resulting mixture was stirred for 5 min at r.t. [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (260 mg, 0.36 mmol, Example 46 Step 1) was then added to the reaction mixture and the resulting solution was stirred at 65° C. for 4 h. LCMS analysis indicated the reaction was complete. The reaction mixture was concentrated under reduced pressure and the residue was purified by prep-HPLC. The desired fractions were collected and concentrated under reduced pressure to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate (202 mg, 82.6% yield) as a white solid. LC-MS: calc. for C₃₄H₃₆D₆ClN₃O₇S [M+H]⁺: m/z=678.3/680.3; Found 678.4/680.4. ¹H NMR (300 MHz, CDCl₃) δ 9.14 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.02-6.94 (m, 2H), 5.97-5.58 (m, 2H), 5.30 (d, J=5.0 Hz, 1H), 4.17-4.04 (m, 3H), 3.79-3.63 (m, 3H), 3.50-3.32 (m, 2H), 3.19 (dd, J=14.5, 4.9 Hz, 1H), 2.78 (t, J=5.5 Hz, 3H), 2.38 (qd, J=9.0, 3.6 Hz, 1H), 2.06-1.90 (m, 3H), 1.83 (q, J=8.9 Hz, 3H), 1.64 (p, J=9.7 Hz, 1H), 1.45 (s, 3H), 1.37 (s, 3H).

Example 48

[(3R,6R,7R,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: (3S)-6′-chloro-5-[[(1R,2R)-2-[(S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 0.60 mmol) in DMF (3 mL) was added TBSCl (269 mg, 1.79 mmol) followed by imidazole (243 mg, 3.58 mmol). The resulting mixture was stirred at r.t. for 4 h. HCl (aq, 0.5 M, 10 mL) was added followed by 10 mL of EtOAc. The layers were separated, and the organic layer was washed with 10 mL of HCl (0.5 M). The organic layer was dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) using 2% to 35% EtOAc/Heptanes. The desired fractions were collected to afford (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (260 mg, 70% yield) as a white solid. LC-MS calc. for C₃₂H₄₆ClN₂O₄SiS[M+H]⁺: m/z=617.3/619.3; Found: 617.8/619.4.

Step 2: tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (260 mg, 0.42 mmol) in DCM (10 mL) was added 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (322 mg, 1.26 mmol), 4-(dimethylamino)pyridine (308 mg, 2.53 mmol) and EDCI (0.25 mL, 1.26 mmol) successively. The resulting mixture was stirred at r.t. for 48 hours. HCl (1 M, 30 mL) was added followed by 30 mL of DCM. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (5% to 80%). The desired fractions were collected to afford tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (190 mg, 53% yield) as a white solid. LC-MS calc. for C₄₅H₆₅ClN₃O₇SiS [M+H]⁺: m/z=854.4/856.4; Found: 855.0/857.1.

Step 3: tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate

A solution of tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (190 mg, 0.22 mmol) in THF (3 mL) and tetrabutylammonium fluoride solution (3.0 mL, 0.22 mmol, 1 M in THF) was stirred at r.t. overnight. The reaction was quenched by adding 10 mL of saturated NH₄Cl solution followed by 10 mL of EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (20 g) using 10% to 100% EtOAc/Heptanes then 0% to 50% MeOH/EtOAc. The desired fractions were collected to afford tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (101 mg, 61% yield) as a white solid. LC-MS: calcd. For C₃₉H₅₁ClN₃O₇S [M+H]⁺: m/z=740.3/742.3; Found: 740.8/743.0.

Step 4: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

To a stirred solution of tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (60 mg, 0.08 mmol) in DCE (80 mL) was bubbled with nitrogen for 20 minutes. Then 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethyl aminosulfonyl)phenyl]methyleneruthenium(II) dichloride (resin supported) Zhan Catalyst II (11.8 mg, 0.02 mmol) was added under nitrogen. The resulting mixture was further bubbled with nitrogen for 20 minutes. Then the reaction was stirred at 60° C. under nitrogen for 3 hours. LC-MS showed the consumption of the starting material and the formation of desired product. The reaction was cooled to r.t. and stirred under air for 30 minutes to deactivate the catalyst. The solution was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using 20% to 100% EtOAc/Heptanes. The desired fractions were collected to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (54 mg, 93% yield) as a white solid. LC-MS calc. for C₃₇H₄₇ClN₃O₇S [M+H]⁺: m/z=712.3/714.3; Found: 712.9/714.6.

Step 5. (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

To a stirred solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (45.0 mg, 0.06 mmol) in DCM (3 mL) was added phosphoric acid (3.0 mL, 43.8 mmol). The resulting mixture was stirred at r.t. for 48 h. The solution was slowly poured into saturated NaHCO₃ solution (20 mL) under an ice bath. The mixture was extracted with DCM (10 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure The crude product (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (37 mg, quantitative yield) was used in next step without further purification. LC-MS calc. for C₃₂H₃₉ClN₃O₅S [M+H]: m/z=612.2/614.2; Found: 612.8/614.6.

Step 6. (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C₃₃H₄₁ClN₃O₅S [M+H]⁺: m/z=626.2/628.2; Found: 626.9/628.8. ¹H NMR (499 MHz, DMSO-d₆) δ 7.61 (d, J=8.5 Hz, 1H), 7.23 (dd, J=8.5, 2.4 Hz, 1H), 7.20 (dd, J=8.2, 2.0 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 6.99-6.95 (m, 1H), 6.88 (d, J=8.2 Hz, 1H), 5.64-5.56 (m, 1H), 4.84-4.77 (m, 1H), 4.06 (d, J=12.1 Hz, 1H), 4.00-3.84 (m, 2H), 3.49 (d, J=14.3 Hz, 1H), 2.89-2.57 (m, 6H), 2.39-2.21 (m, 4H), 2.07-1.96 (m, 2H), 1.86-1.77 (m, 6H), 1.70-1.64 (m, 1H), 1.61-1.54 (m, 2H), 1.47 (q, J=7.2 Hz, 1H), 1.30-1.23 (m, 5H), 0.89-0.84 (m, 1H).

Step 7: [(3R,6R,7R,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₆H₄₆ClN₄O₆S [M+H]⁺: m/z=697.3/699.3; Found: 697.9/699.7. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.85 (d, J=2.3 Hz, 1H), 5.79-5.59 (m, 2H), 5.28 (s, 1H), 4.29-3.97 (m, 2H), 3.70 (d, J=14.7 Hz, 1H), 3.53-3.26 (m, 2H), 3.04 (s, 3H), 2.95 (s, 3H), 2.89-2.57 (m, 6H), 2.40 (s, 3H), 2.27 (ddt, J=11.9, 8.2, 3.2 Hz, 2H), 2.19-1.90 (m, 7H), 1.87-1.73 (m, 3H), 1.73-1.55 (m, 3H), 1.41 (t, J=11.8 Hz, 1H).

Example 49

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3,3-difluoroazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 3,3-difluoroazetidine hydrochloride and N,N-diisopropylethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₅H₄₁C₁F₂N₃O₇S [M+H]⁺: m/z=720.22/722.22; Found 720.8/722.89. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.05-6.94 (m, 2H), 5.82 (m, 1H), 5.71 (m, 1H), 5.28 (s, 1H), 4.32 (m, 2H), 4.18-4.05 (m, 3H), 3.81-3.68 (m, 2H), 3.47-3.32 (m, 2H), 3.23 (m, 1H), 2.85-2.69 (m, 3H), 2.46-2.35 (m, 1H), 2.01 (m, 3H), 1.90-1.76 (m, 4H), 1.71-1.58 (m, 3H), 1.46-1.58 (m, 1H), 1.45 (s, 3H), 1.37 (s, 3H).

Example 50

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using methylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₃H₄₁ClN₃O₇S [M+H]⁺: m/z=658.23/660.23; Found 658.7/660.7. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.08-7.02 (m, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.88-5.65 (m, 2H), 5.24 (s, 1H), 4.86 (s, 1H), 4.20-4.05 (m, 3H), 3.74 (m, 2H), 3.47 (dd, J=15.1, 4.8 Hz, 1H), 3.34 (d, J=14.6 Hz, 1H), 3.17 (m, 1H), 2.80 (m, 6H), 2.42-2.32 (m, 1H), 1.98 (m, 4H), 1.81 (m, 3H), 1.64 (m, 2H), 1.44 (s, 3H), 1.38 (s, 3H).

Example 51

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 4-methoxypiperidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.29; Found: 742.7/744.8. ¹H NMR (300 MHz, CDCl₃) δ 9.08 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 6.99 (d, J=8.2 Hz, 2H), 5.73 (t, J=20.2 Hz, 2H), 5.32 (d, J=3.8 Hz, 1H), 4.22-3.98 (m, 3H), 3.92-3.64 (m, 5H), 3.51-3.29 (m, 6H), 3.22 (dd, J=14.5, 8.9 Hz, 4H), 2.79 (d, J=4.1 Hz, 3H), 2.39 (d, J=6.8 Hz, 1H), 2.10-1.46 (m, 10H), 1.44 (s, 3H), 1.37 (s, 3H).

Example 52

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethylazetidin-3-amine dihydrochloride salt and Hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.3/729.3; Found: 727.6/729.6. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51-7.40 (m, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.81-5.59 (m, 1H), 5.15 (s, 1H), 4.29 (s, 1H), 4.11 (q, J=11.4, 10.7 Hz, 4H), 3.85 (dd, J=9.1, 4.9 Hz, 2H), 3.71 (d, J=14.6 Hz, 2H), 3.40 (t, J=17.2 Hz, 2H), 2.97 (s, 5H), 2.80 (s, 3H), 2.21 (s, 6H), 1.99 (d, J=16.0 Hz, 3H), 1.90-1.73 (m, 3H), 1.73-1.58 (m, 2H), 1.46 (s, 3H), 1.34 (s, 3H).

Example 53

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(dimethylamino)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3R)-N,N-dimethylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.3/743.3; Found: 741.4/743.2. ¹H NMR (499 MHz, DMSO-d₆) δ 7.67 (d, J=8.5 Hz, 1H), 7.27 (dd, J=8.4, 2.3 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.11 (dd, J=8.1, 1.9 Hz, 1H), 6.92-6.80 (m, 2H), 6.23 (dd, J=16.5, 7.7 Hz, 1H), 5.54 (dd, J=16.0, 4.1 Hz, 1H), 5.10 (d, J=40.1 Hz, 1H), 4.02 (d, J=7.7 Hz, 3H), 3.88 (dd, J=13.5, 8.0 Hz, 1H), 3.57 (dt, J=12.3, 4.5 Hz, 4H), 3.34-3.26 (m, 4H), 3.08 (td, J=15.2, 9.8 Hz, 2H), 2.75 (dddd, J=33.6, 16.8, 11.5, 5.3 Hz, 3H), 2.39 (d, J=23.1 Hz, 6H), 2.16-1.76 (m, 6H), 1.74-1.56 (m, 3H), 1.49-1.36 (m, 1H), 1.23 (d, J=2.4 Hz, 3H), 1.12 (s, 3H).

Example 54

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methyl-1,4-diazepane-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 1-methyl-1,4-diazepane to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.3/743.3; Found: 741.4/743.2. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (dd, J=8.5, 3.6 Hz, 1H), 7.54-7.37 (m, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.02-6.84 (m, 2H), 6.26-5.60 (m, 1H), 5.28 (s, 1H), 4.31 (d, J=12.4 Hz, 1H), 4.21-3.96 (m, 4H), 3.72 (d, J=14.5 Hz, 2H), 3.52-3.01 (m, 10H), 2.92-2.48 (m, 8H), 2.43 (s, 1H), 2.24 (t, J=9.9 Hz, 1H), 2.06-1.75 (m, 7H), 1.42 (s, 3H), 1.34 (s, 3H).

Example 55

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 46 using N,N,N′-trimethylethylenediamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₇H₅₀ClN₄O₇S [M+H]⁺: m/z=729.31/731.31; Found: 729.5/731.5. ¹H NMR (500 MHz, DMSO-d₆) δ 11.62 (s, 1H), 9.39 (s, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.19 (d, J=2.2 Hz, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.94 (s, 1H), 6.59 (d, J=61.5 Hz, 1H), 5.71 (s, 2H), 5.24 (d, J=88.7 Hz, 1H), 4.34-3.89 (m, 3H), 3.56 (d, J=14.4 Hz, 2H), 3.02-2.62 (m, 13H), 2.12-1.44 (m, 10H), 1.39 (s, 3H), 1.24 (s, 6H).

Example 56

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 3-methoxyazetidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₆H₄₅ClN₃O₈S [M+H]⁺: m/z=714.25/716.25; Found: 714.5/716.5. ¹H NMR (499 MHz, DMSO-d₆) δ 7.71 (d, J=8.5 Hz, 1H), 7.30 (dd, J=8.5, 2.5 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.12 (dd, J=8.2, 1.9 Hz, 1H), 6.94-6.80 (m, 2H), 6.30 (d, J=12.0 Hz, 1H), 5.51 (ddd, J=16.0, 3.7, 1.7 Hz, 1H), 5.05 (s, 1H), 4.25 (s, 1H), 4.17-4.10 (m, 1H), 4.08-3.99 (m, 2H), 3.87 (dd, J=13.5, 7.8 Hz, 1H), 3.78 (d, J=7.9 Hz, 1H), 3.65-3.53 (m, 2H), 3.38 (s, 2H), 3.32 (d, J=14.3 Hz, 2H), 3.26 (s, 3H), 3.10 (dd, J=14.9, 10.1 Hz, 1H), 2.89-2.67 (m, 3H), 2.33 (td, J=8.8, 2.8 Hz, 1H), 2.06-1.97 (m, 1H), 1.92-1.83 (m, 3H), 1.69 (ddt, J=17.6, 12.7, 8.1 Hz, 3H), 1.47 (td, J=13.2, 12.1, 3.9 Hz, 1H), 1.30 (s, 1H), 1.24 (s, 3H), 1.13 (s, 3H).

Example 57

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-ethoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 3-ethoxyazetidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.27/730.27; Found: 728.5/730.5. ¹H NMR (499 MHz, DMSO-d₆) δ 7.66 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.06 (dd, J=8.1, 1.9 Hz, 1H), 6.85 (d, J=2.0 Hz, 1H), 6.79 (d, J=8.1 Hz, 1H), 6.24 (d, J=13.1 Hz, 1H), 5.46 (dt, J=16.1, 2.9 Hz, 1H), 5.00 (s, 1H), 4.28 (q, J=5.3 Hz, 1H), 4.09 (dd, J=9.3, 6.5 Hz, 2H), 4.03-3.93 (m, 2H), 3.85-3.64 (m, 3H), 3.60-3.47 (m, 2H), 3.39 (d, J=6.9 Hz, 1H), 3.26 (d, J=14.3 Hz, 2H), 3.04 (dd, J=14.8, 10.1 Hz, 1H), 2.86-2.60 (m, 3H), 2.28 (qd, J=9.2, 3.0 Hz, 1H), 2.03-1.91 (m, 1H), 1.88-1.75 (m, 3H), 1.71-1.56 (m, 3H), 1.41 (td, J=13.1, 12.2, 4.3 Hz, 1H), 1.30-1.21 (m, 1H), 1.18 (s, 3H), 1.13 (t, J=7.5 Hz, 3H), 1.08 (s, 3H).

Example 58

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3R)-3-methoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.27/730.27; Found: 728.5/730.5. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.37 (dd, J=8.3, 1.9 Hz, 1H), 7.13 (dd, J=8.4, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.96 (t, J=3.1 Hz, 1H), 6.87 (dd, J=8.3, 3.2 Hz, 1H), 6.08 (d, J=23.0 Hz, 1H), 5.69 (dt, J=15.3, 6.5 Hz, 1H), 5.19 (d, J=15.8 Hz, 1H), 4.08-3.92 (m, 3H), 3.82 (d, J=6.9 Hz, 1H), 3.69-3.58 (m, 2H), 3.48 (dt, J=19.4, 8.9 Hz, 3H), 3.35-3.24 (m, 4H), 3.17-3.05 (m, 2H), 2.75 (s, 3H), 2.56 (q, J=7.2 Hz, 1H), 2.31 (t, J=9.7 Hz, 1H), 2.01-1.89 (m, 3H), 1.78 (s, 3H), 1.60 (t, J=9.1 Hz, 1H), 1.39-1.30 (m, 10H).

Example 59

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3R)-3-ethoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.28; Found: 742.6/744.6. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.37-7.28 (m, 1H), 7.12 (dd, J=8.4, 2.3 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 7.00 (d, J=3.4 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.34-6.07 (m, 1H), 5.70 (dt, J=15.5, 8.1 Hz, 1H), 5.13 (s, 1H), 4.07-3.86 (m, 4H), 3.67-3.38 (m, 7H), 3.22 (d, J=14.4 Hz, 1H), 3.05 (p, J=8.8 Hz, 1H), 2.76-2.74 (m, 2H), 2.68-2.50 (m, 1H), 2.23-2.19 (m, 6H), 2.02-1.70 (m, 8H), 1.63-1.53 (m, 1H), 1.35-1.25 (m, 8H).

Example 60

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)-1,4-diazepane-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-methoxyethyl)-1,4-diazepane to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₄₀H₅₄ClN₄O₈S [M+H]⁺: m/z=785.33/787.32; Found: 785.5/787.4; ¹H NMR (300 MHz, CDCl₃) δ 9.29 (s, 1H, NH), 7.68 (dd, J=8.5, 5.1 Hz, 1H), 7.47 (dd, J=7.1, 5.2 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.87 (d, J=10.0 Hz, 1H), 5.90 (s, 2H), 5.27 (s, 1H), 4.13 (m, 4H), 3.75 (m, 9H), 3.47 (d, J=15.0 Hz, 2H), 3.35 (d, J=12.2 Hz, 6H), 3.25-3.16 (m, 2H), 2.79 (d, J=4.2 Hz, 4H), 2.36 (d, J=8.0 Hz, 2H), 1.98 (d, J=11.1 Hz, 2H), 1.91-1.76 (m, 4H), 1.76-1.63 (m, 2H), 1.46 (s, 3H), 1.36 (d, J=2.4 Hz, 3H).

Example 61

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using (3S)-tetrahydrofuran-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₆H₄₅ClN₃O₈S [M+H]⁺: m/z=714.2; Found: 714.4. ¹H NMR (300 MHz, CDCl₃) δ 9.85 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.4 Hz, 2H), 6.02 (m, 1H), 5.65 (m, 2H), 5.17 (s, 1H), 4.27 (m, 2H), 4.21-4.03 (m, 2H), 3.99 (d, J=9.7 Hz, 1H), 3.81-3.59 (m, 6H), 3.47-3.28 (m, 2H), 3.08 (dd, J=15.0, 10.2 Hz, 1H), 2.96-2.69 (m, 3H), 2.37-2.19 (m, 2H), 1.93 (m, 7H), 1.67-1.54 (m, 1H), 1.47 (s, 3H), 1.34 (s, 3H).

Example 62

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using (3R)-tetrahydrofuran-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₆H₄₅ClN₃O₈S [M+H]⁺: m/z=714.2; Found: 714.4. ¹H NMR (300 MHz, CDCl₃) δ 9.08 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.07-6.96 (m, 2H), 5.87-5.61 (m, 2H), 5.18 (s, 1H), 4.36-4.01 (m, 6H), 3.97 m, 1H), 3.91-3.66 (m, 5H), 3.47 (dd, J=15.3, 5.0 Hz, 1H), 3.33 (d, J=14.6 Hz, 1H), 3.18 (dd, J=15.2, 8.5 Hz, 1H), 2.78 (m, 3H), 2.48-2.34 (m, 1H), 2.32-2.19 (m, 1H), 2.09-1.70 (m, 7H), 1.63 (t, J=9.4 Hz, 1H), 1.44 (s, 3H), 1.38 (s, 3H).

Example 63

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate

Step 1: N-methoxy-N-methyl-carbamoyl chloride

To a solution of N,O-dimethylhydroxylamine hydrochloride (500 mg, 8.19 mmol) in DCM (10 mL) was added triphosgene (2429 mg, 8.19 mmol), followed by potassium carbonate (4525 mg, 32.7 mmol). The mixture was stirred at r.t. for 1 h. NMR showed that the starting material was consumed. The reaction was then added H₂O (15 mL) and extracted with DCM (10 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The resulting residue N-methoxy-N-methyl-carbamoyl chloride (600 mg, 59% yield) was directly used in the following step without further purification.

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (40.0 mg, 0.07 mmol, Example 32) and N-methoxy-N-methyl-carbamoyl chloride (41 mg, 0.33 mmol) in toluene (2 mL) was dropwise added KHMDS (0.8 mL, 3.53 mmol) at −30° C. The mixture was then warmed to r.t. and stirred for 4 h. LC-MS showed that most of the starting material was consumed. The mixture was then added 1 N HCl (5 mL) and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H₂O/ACN (20-100%) to afford the desired product [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate (19.7 mg, 43% yield). LC-MS calc. for C₃₄H₄₃ClN₃O₈S [M+H]⁺: m/z=688.24/690.24; Found: 688.4/690.5; ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H, NH), 7.69 (t, J=7.0 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.0 Hz, 1H), 7.10 (d, J=1.9 Hz, 1H), 7.01 (dd, J=8.7, 3.2 Hz, 2H), 5.90-5.79 (m, 1H), 5.70 (dd, J=15.6, 5.6 Hz, 1H), 5.32 (d, J=4.0 Hz, 1H), 4.14 (q, J=12.2 Hz, 2H), 4.04 (dd, J=13.9, 5.6 Hz, 1H), 3.77 (d, J=9.1 Hz, 1H), 3.72 (d, J=3.3 Hz, 4H), 3.44-3.34 (m, 2H), 3.28 (dd, J=13.8, 7.7 Hz, 1H), 3.19 (s, 3H), 2.79 (d, J=4.6 Hz, 3H), 2.49-2.39 (m, 1H), 2.00 (dd, J=11.5, 3.6 Hz, 2H), 1.84 (dd, J=16.9, 8.9 Hz, 3H), 1.66-1.60 (m, 3H), 1.45-1.41 (s, 3H), 1.37 (s, 3H).

Example 64

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LC-MS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.27/730.27; Found: 728.4/730.3. ¹H NMR (300 MHz, CDCl₃) δ 9.11 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H), 6.96 (d, J=2.3 Hz, 1H), 5.83 (d, J=4.3 Hz, 1H), 5.73 (dd, J=15.8, 5.3 Hz, 1H), 5.35 (d, J=5.7 Hz, 1H), 4.93 (s, 1H), 4.14 (d, J=6.5 Hz, 2H), 4.08 (d, J=5.4 Hz, 1H), 3.77 (d, J=5.1 Hz, 2H), 3.71 (s, 1H), 3.49-3.34 (m, 2H), 3.23 (dd, J=15.1, 9.4 Hz, 1H), 2.92 (s, 3H), 2.83-2.75 (m, 3H), 2.44-2.36 (m, 1H), 2.28-2.16 (m, 4H), 2.05-1.95 (m, 3H), 1.89-1.75 (m, 4H), 1.65 (t, J=9.4 Hz, 2H), 1.44 (d, J=4.2 Hz, 3H), 1.37 (s, 3H).

Example 65

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: ethyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate

To a cooled (ice-bath) solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (1.0 g, 1.66 mmol, Example 32) in THF (10 mL) was added sodium hydride (199 mg, 8.32 mmol). After stirring 10 mins at r.t., ethyl bromoacetate (1111 mg, 6.65 mmol) was added. The resulting mixture was stirred at r.t. overnight. The reaction was monitored by LC-MS and quenched with a mixture of cold 1 N HCl aq. (50 mL) and DCM (50 mL). The aqueous layer was extracted with DCM (50 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EA/Heptane (5%-80%) to afford the desired product ethyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (600 mg, 52.4% yield). LC-MS calc. for C₃₅H₄₄ClN₂O₈S [M+H]⁺: m/z=687.20; Found: 687.72.

Step 2: 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetic acid

To a solution of ethyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (600 mg, 0.87 mmol) in THF (10 mL) and water (10 mL) was added lithium hydroxide monohydrate (183.18 mg, 4.37 mmol). The mixture was stirred at r.t. for 1 h. The mixture was then was quenched with 1N HCl (50 mL), extracted with EA (50 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]oxyacetic acid (400 mg, 70% yield) which was directly used in next step without purification. LC-MS calc. for C₃₃H₄₀ClN₂O₆S [M+H]⁺: m/z=659.22; Found: 659.70. 1H NMR (300 MHz, CDCl₃) δ 9.24 (s, 1H, NH), 7.64 (t, J=6.0 Hz, 1H), 7.49 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.05 (d, J=2.0 Hz, 1H), 7.02-6.98 (m, 1H), 5.73-5.59 (m, 2H), 4.15-4.03 (m, 4H), 3.94-3.83 (m, 3H), 3.68 (d, J=14.7 Hz, 1H), 3.36 (dd, J=14.4, 8.5 Hz, 3H), 2.85-2.72 (m, 3H), 2.45-2.35 (m, 1H), 2.02 (t, J=7.9 Hz, 3H), 1.95-1.75 (m, 3H), 1.64 (t, J=8.8 Hz, 1H), 1.54 (d, J=11.7 Hz, 1H), 1.46-1.41 (m, 3H), 1.39 (s, 3H).

Step 3: isobutoxycarbonyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate

To a solution 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetic acid (400 mg, 0.60 mmol) in THF (16 mL) cooled with an ice-bath was added triethylamine (0.33 mL, 2.38 mmol) and isobutyl chloroformate (0.27 mL, 2.09 mmol). The reaction mixture was stirred at r.t. for 60 min. and monitored by LC-MS. When LC-MS shows complete reaction, the crude was directly used in further step without work-up and purification. LC-MS calc. for C₃₈H₄₈ClN₂O₁₀S [M+H]⁺: m/z=759.27; Found: 759.87.

Step 4:2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetaldehyde

To a solution of isobutoxycarbonyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (456.0 mg, 0.60 mmol) in THF (16 mL) at −78° C. was added diisobutylaluminum hydride (4.0 mL, 6.0 mmol, 1.5 M in toluene). The reaction was stirred for 30 mins at −78° C. The reaction mixture was quenched with 10% Rochelle's salt aqueous solution (40 mL) and the mixture was stirred at r.t. for 1 h. The layers were separated, and the aqueous layer was extracted with EA (2×50 mL). The combined organic layers were dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetaldehyde (400 mg, 60%) which was directly used in next step without purification. LC-MS calc. for C₃₃H₄₀ClN₂O₆S [M+H]⁺: m/z=643.22; Found: 643.5.

Step 5: (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetaldehyde (235 mg, 0.37 mmol, 60%) in DCE (5 mL) was added dimethylamine in THF (750.0 μL, 1.5 mmol, 2.0 M THF solution). The mixture was stirred at r.t. for 5 min., followed by adding of sodium triacetoxyborohydride (316 mg, 1.5 mmol). The mixture was then stirred at r.t. for additional 30 min. LC-MS showed that the starting material was consumed. The reaction was quenched by 1N HCl (10 mL) and extracted with DCM (2×10 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H₂O/ACN (20-100%) to afford the desired product (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (73 mg, 46% yield). LC-MS calc. for C₃₅H₄₇ClN₃O₆S [M+H]⁺: m/z=672.28; Found: 672.4. ¹H NMR (300 MHz, DMSO-d₆) δ 9.42 (s, 1H, NH), 7.61 (d, J=8.5 Hz, 1H), 7.33-7.16 (m, 3H), 7.03 (t, J=7.5 Hz, 2H), 5.59 (dd, J=15.6, 6.7 Hz, 1H), 5.43 (d, J=14.1 Hz, 1H), 4.08 (dd, J=19.7, 12.1 Hz, 2H), 3.91 (dd, J=14.3, 6.0 Hz, 1H), 3.67-3.60 (m, 2H), 3.32 (m, 5H), 3.15 (dd, J=14.5, 7.5 Hz, 2H), 2.79 (s, 9H), 2.43 (d, J=8.5 Hz, 2H), 1.97 (d, J=10.0 Hz, 1H), 1.86 (t, J=12.2 Hz, 4H), 1.71 (d, J=8.4 Hz, 1H), 1.58 (d, J=9.0 Hz, 2H), 1.43-1.31 (m, 3H), 1.24 (s, 3H).

Example 66

(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using pyrrolidine to replace dimethylamine in THF (2.0 M) in Step 5. LC-MS calc. for C₃₇H₄₉ClN₃O₆S [M+H]⁺: m/z=698.30/700.29; Found: 698.5/700.7; ¹H NMR (300 MHz, DMSO-d₆) δ 9.56 (s, 1H, NH), 7.66-7.56 (m, 1H), 7.25 (m, 3H), 7.03 (dd, J=9.5, 6.1 Hz, 2H), 5.58 (dd, J=15.5, 6.9 Hz, 1H), 5.40 (d, J=13.6 Hz, 1H), 4.08 (dd, J=19.3, 12.1 Hz, 2H), 3.88 (dd, J=14.4, 6.0 Hz, 1H), 3.66-3.58 (m, 2H), 3.32 (d, J=14.9 Hz, 8H), 3.15 (dd, J=14.5, 7.9 Hz, 2H), 3.04 (s, 3H), 2.79-2.62 (m, 3H), 1.97 (d, J=5.4 Hz, 3H), 1.87 (dd, J=18.6, 5.1 Hz, 6H), 1.72 (d, J=8.4 Hz, 1H), 1.63-1.52 (m, 2H), 1.43-1.30 (m, 3H), 1.24 (s, 3H).

Example 67

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-11-methoxycarbonyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

To a solution of (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (8.0 mg, 0.01 mmol, Example 26) and triethylamine (0.01 mL, 0.06 mmol) in DCM (1 mL) was added methyl carbonochloridate (4.72 mg, 0.05 mmol) in one portion at r.t. After 10 min, LC-MS indicated the completion of reaction. The reaction was diluted with DCM, washed with saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the desired product (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-methoxycarbonyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26), 18,20(25)]tetraene-23,1′-tetralin]-14-one (8 mg, 89.9% yield). LCMS: calc. for C₃₆H₄₅ClN₃O₇S [M+H]⁺: m/z=698.27/700.26; Found: 697.97/700.24. ¹H NMR (600 MHz, CDCl₃) δ 7.66 (d, J=8.5 Hz, 1H), 7.43 (d, J=5.8 Hz, 1H), 7.29 (dd, J=8.3, 2.1 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 5.40-5.32 (m, 1H), 5.12 (app s, 1H), 4.18 (d, J=12.0 Hz, 1H), 4.04 (d, J=11.9 Hz, 1H), 3.94-3.81 (m, 2H), 3.67 (app s, 6H), 3.58-3.49 (m, 2H), 3.43-3.21 (m, 4H), 3.15 (m, 1H), 2.84-2.68 (m, 3H), 2.54-2.30 (m, 3H), 2.12-1.77 (m, 9H), 1.63 (ddt, J=26.9, 18.3, 9.5 Hz, 2H), 1.47 (t, J=12.8 Hz, 1H). The sulfonamide NH was not observed due to solvent exchange.

Example 68

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-13,13-dimethyl-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one

This compound was prepared using procedures analogous to those described for Example 26 using 3-[(tert-butoxycarbonylamino)-2,2-dimethyl-propanoic acid to replace 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid in Step 2. LCMS: calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.25/630.25; Found: 628.0/630.2. ¹H NMR (300 MHz, CDCl₃) δ 8.07 (s, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.43 (dd, J=8.3, 1.7 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.08 (s, 2H), 6.94 (d, J=8.3 Hz, 1H), 5.99 (dt, J=15.6, 5.5 Hz, 1H), 5.64 (dd, J=15.6, 7.7 Hz, 1H), 4.12-3.99 (m, 2H), 3.81-3.61 (m, 3H), 3.57 (t, J=7.3 Hz, 1H), 3.46 (dd, J=14.8, 4.5 Hz, 1H), 3.27 (s, 3H), 3.01 (dd, J=15.0, 10.3 Hz, 1H), 2.81 (dd, J=24.0, 11.2 Hz, 3H), 2.72-2.52 (m, 2H), 2.32-2.15 (m, 1H), 1.90 (ddd, J=33.7, 25.8, 12.0 Hz, 5H), 1.77-1.54 (m, 4H), 1.40 (t, J=12.1 Hz, 1H), 1.16 (s, 3H), 1.11 (s, 3H).

Example 69

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[[20]oxa[15]thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one and

Example 70

(3R,6R,7R,8Z,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-but-3-enylcyclopropanecarboxylic acid in Step 3. The major product was assigned to Example 69 (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C₃₃H₄₀ClN₂O₅S [M+H]⁺: m/z=611.23/613.23; Found: 611.0/612.8. Analytic HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H₂O (with 0.1% HCO₂H) 1 min, 5% to 95% 7 min, 95% 5 min. λ=230 nm. t_R=4.6 min. ¹H NMR: (600 MHz, CDCl₃) δ 8.18 (br s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.41 (d, J=2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.30 (ddd, J=14.9, 9.9, 4.7 Hz, 1H), 5.08 (dd, J=15.2, 9.0 Hz, 1H), 4.18-4.07 (m, 2H), 3.68-3.56 (m, 2H), 3.32 (d, J=14.5 Hz, 1H), 3.15-3.11 (m, 1H), 3.09 (s, 3H), 2.97 (dd, J=8.8, 2.7 Hz, 1H), 2.82-2.69 (m, 3H), 2.46-2.36 (m, 1H), 2.24-2.14 (m, 1H), 2.09-1.98 (m, 2H), 1.93-1.53 (m, 9H), 1.43 (t, J=13.1 Hz, 1H), 1.39-1.19 (m, 3H).

And the minor peak was assigned to Example 70 (3R,6R,7R,8Z,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C₃₃H₄₀ClN₂O₅S [M+H]⁺: m/z=611.23/613.23; Found: 611.0/613.1. Analytic HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H₂O (with 0.1% HCO₂H) 1 min, 5% to 95% 7 min, 95% 5 min. λ=230 nm. t_R=4.1 min (minor product). ¹H NMR: (600 MHz, CDCl₃) δ 8.14 (br s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.47-7.45 (m, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 5.40 (td, J=10.7, 3.9 Hz, 1H), 5.07 (t, J=10.4 Hz, 1H), 4.15-4.05 (m, 2H), 3.74-3.58 (m, 3H), 3.40 (d, J=14.7 Hz, 1H), 3.28 (dd, J=14.8, 5.3 Hz, 1H), 3.15 (s, 3H), 2.77 (dddd, J=22.5, 16.6, 11.0, 4.9 Hz, 3H), 2.35 (t, J=7.5 Hz, 1H), 2.26-2.18 (m, 1H), 2.10-1.75 (m, 8H), 1.68-1.52 (m, 3H), 1.48 (t, J=12.8 Hz, 1H), 1.34 (dt, J=10.3, 5.7 Hz, 2H), 1.15 (ddd, J=9.7, 6.5, 4.3 Hz, 1H).

Example 71

(3R,6R,7R,8E,11S,22S)-6′-Chloro-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: (R,E)-3-(but-2-enoyl)-4-phenyloxazolidin-2-one

To a solution of (R)-(+)-4-Phenyl-1,3-oxazolidin-2-one (20.0 g, 122 mmol) in THF (400 mL) was added n-BuLi (53.9 mL, 134 mmol) slowly at −78° C. The reaction solution was stirred at −78° C. for 20 min. Then (E)-but-2-enoyl chloride (14.09 g, 134 mmol) was added slowly. The reaction solution was stirred at −78° C. for 0.5 h and then at 0° C. for 15 mins. The reaction was quenched with saturated NH₄Cl solution (20 mL), extracted with EA (200 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-phenyl-3-[(E)-but-2-enoyl]oxazolidin-2-one (33 g, 58% yield). LC-MS calc. for C₁₃H₁₄NO₃ [M+H]⁺ m/z=232.09; Found: 232.0. ¹H NMR: (400 MHz, CDCl₃) δ 7.43-7.28 (m, 6H), 7.16-7.07 (m, 1H), 5.51 (dd, J=8.8, 4.0 Hz, 1H), 4.72 (t, J=8.8 Hz, 1H), 4.30 (dd, J=8.8, 4.0, Hz, 1H), 1.96 (dd, J=6.8, 1.6 Hz, 3H).

Step 2: (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one

To a solution of (4R)-4-phenyl-3-[(E)-but-2-enoyl]oxazolidin-2-one (11.5 g, 49.73 mmol) in DCM (400 mL) was added TiCl₄ (28.3 g, 149.19 mmol) at −78° C. under N₂. The solution was stirred at −78° C. for 20 min. Then allyltrimethylsilane (17.0 g, 149 mmol) was added slowly at −78° C. After the addition the reaction solution was stirred at −78° C. for 4 h., and quenched with saturated sodium bicarbonate solution. The organic layer was separated, and the aqueous layer was extracted with EA (200 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (5.33 g, 39% yield). The product was purified by recrystallization (n-pentane/Et₂O=60/1 with trace CH₂Cl₂ at 0° C.) to give (R)-3-((S)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (3 g with dr=97/3). LC-MS calc. for C₁₆H₂₀NO₃ [M+H]⁺ m/z=2734.14; Found: 274.0. ¹H NMR: (400 MHz, CDCl₃) δ 7.41-7.27 (m, 5H), 5.79-5.69 (m, 1H), 5.43 (dd, J=8.4, 3.6 Hz, 1H), 5.01-4.95 (m, 2H), 4.71-4.66 (m, 1H), 4.29-4.25 (m, 1H), 3.03-2.68 (m, 2H), 2.15-1.91 (m, 3H), 0.92 (d, J=6.4 Hz, 3H).

Step 3: (S)-3-methylhex-5-enoic acid

To a solution of (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (1.6 g, 5.85 mmol) in THF (25 mL) and water (5 mL) was added hydrogen peroxide (2.35 mL, 23 mmol) and LiOH—H₂O (0.49 g, 11 mmol) at 0° C. Then the reaction solution was stirred at 0° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was extracted with DCM. The aqueous solution was adjusted pH to 1 with HCl (2 N) and extracted with DCM. The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give (3S)-3-methylhex-5-enoic acid (600 mg, 80.0% yield). [Ca]²⁰D=−4.5 (c=0.79, CHCl₃) {lit. [α]²²_D=−2.8 (c=1.00, CHCl₃), Ref: Angew. Chem., 2009, 48, 8780-8783}. ¹H NMR: (400 MHz, CDCl₃) δ 5.74-5.83 (m, 1H), 5.04-5.08 (m, 2H), 2.40-2.44 (m, 1H), 2.03-2.20 (m, 4H), 1.01 (d, J=6.4 Hz, 3H).

Step 4. (3R,6R,7R,8E,11S,22S)-6′-chloro-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (3S)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found 598.9/600.5. ¹H NMR (600 MHz, DMSO-d₆) 11.76 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.16 (dd, J=8.3, 2.1 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.11 (d, J=2.4 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.13-5.06 (m, 1H), 4.78 (dd, J=15.3, 9.0 Hz, 1H), 4.93-3.96 (m, 2H), 3.43 (d, J=14.3 Hz, 2H), 3.01 (dd, J=15.0, 5.3 Hz, 1H), 2.87 (s, 3H), 2.71-2.68 (m, 2H), 2.64-2.56 (m, 2H), 2.21-2.19 (m, 1H), 2.05-1.87 (m, 5H), 1.76-1.64 (m, 4H), 1.54-1.44 (m, 3H), 1.38-1.31 (m, 1H), 0.80 (d, J=6.3 Hz, 3H).

Example 72

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: hex-5-enoyl chloride

To the solution of hex-5-enoic acid (1.0 g, 8.76 mmol) in DCM (10 mL) was added oxalyl chloride (0.62 mL, 8.76 mmol) and DMF (0.10 mL) in one portion. The reaction mixture was stirred at r.t. for 1 h., and concentrated to give hex-5-enoyl chloride (1.16 g, 94.7% yield) which was directly used in next step reaction without further purification.

Step 2. (S)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-one

To a solution of (4R)-4-benzyloxazolidin-2-one (1.55 g, 8.75 mmol) in THF (10 mL) was added LiCl (370 mg, 8.75 mmol) and triethylamine (2.65 g, 26.25 mmol) slowly at 0° C. The reaction solution was stirred at 0° C. for 20 min. Then hex-5-enoyl chloride (1.16 g, 8.75 mmol) was added slowly, and stirred at r.t. overnight. The reaction solution was quenched with water (20 mL) and extracted with EA (40 mL). The organic layer was washed with saturated NaHCO₃ solution, dried over Na₂SO₄, filtered and concentrated to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one (500 mg, 21% yield) as a white oil. ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.27 (m, 3H), 7.24-7.17 (m, 2H), 5.83 (ddt, J=16.9, 10.2, 6.7 Hz, 1H), 5.13-4.95 (m, 2H), 4.68 (ddd, J=10.6, 6.9, 3.3 Hz, 1H), 4.27-4.07 (m, 2H), 3.30 (dd, J=13.4, 3.3 Hz, 1H), 3.07-2.85 (m, 2H), 2.76 (dt, J=18.7, 9.3 Hz, 1H), 2.16 (q, J=7.3 Hz, 2H), 1.89-1.74 (m, 2H).

Step 3: (R)-4-benzyl-3-((R)-2-methylhex-5-enoyl)oxazolidin-2-one

To a solution of (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one (500.0 mg, 1.83 mmol) in THF (5 mL) was added NaHMDS (2.5 mL, 1.0 M THF solution, 2.5 mmol) slowly at −78° C. After stirring at −78° C. for 1 h. Iodomethane (778 mg, 5.49 mmol) was added slowly. The mixture was stirred at −78° C. for additional 3 h. The mixture was quenched with CH₃COOH (0.1 mL) and warmed up to r.t. Then water (15 mL) was added and extracted with EA (2×20 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The resulting mixture was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-benzyl-3-[(2R)-2-methylhex-5-enoyl]oxazolidin-2-one (200 mg, 38% yield) as a white oil. ¹H NMR (400 MHz, CDCl₃) δ 7.36-7.27 (m, 3H), 7.23-7.20 (m, 2H), 5.84-5.74 (m, 1H), 4.70-4.64 (m, 1H), 4.22-4.13 (m, 2H), 3.76-3.71 (m, 1H), 3.26 (dd, J=13.4, 3.3 Hz, 1H), 2.77 (dd, J=13.3, 9.6 Hz, 1H), 2.12-2.06 (m, 2H), 1.93-1.84 (m, 1H), 1.55-1.48 (m, 1H), 1.24 (d, J=6.9 Hz, 3H).

Step 4: (R)-2-methylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 41 using (4R)-4-benzyl-3-[(2R)-2-methylhex-5-enoyl]oxazolidin-2-one to replace (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one in Step 3. [α]_D²⁰ −23.5 (c 0.79, CHCl₃) (lit. [α]_D²³ −25.0 (c 1.07, CHCl₃)). (Ref: Tetrahedron 2007 vol. 63#26 p. 5754-5767). ¹H NMR (400 MHz, CDCl₃) δ 5.79 (ddt, J=16.9, 10.2, 6.6 Hz, 1H), 5.14-4.86 (m, 2H), 2.58-2.44 (m, 1H), 2.16-2.02 (m, 2H), 1.89-1.71 (m, 1H), 1.53 (dt, J=13.9, 7.6 Hz, 1H), 1.25-1.12 (m, 3H). ¹³C NMR: (100 MHz, CDCl₃) δ 183.2, 137.7, 115.2, 38.7, 32.5, 31.2, 16.8.

Step 5: (3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and using (R)-2-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found: 599.0/600.9. ¹H NMR (600 MHz, DMSO-d₆) δ 11.82 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.31-7.23 (m, 3H), 7.20 (d, J=2.4 Hz, 1H), 7.04 (d, J=8.2 Hz, 1H), 5.26-5.11 (m, 1H), 5.01-4.91 (m, 1H), 4.16 (d, J=12.3 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.57-3.46 (m, 2H), 3.29 (d, J=14.3 Hz, 1H), 3.05-2.99 (m, 1H), 2.98 (s, 3H), 2.83-2.78 (m, 1H), 2.74-2.68 (m, 1H), 2.22-2.17 (m, 1H), 2.11-2.07 (m, 1H), 2.00 (dt, J=18.9, 6.8 Hz, 1H), 1.93 (d, J=14.0 Hz, 1H), 1.86-1.67 (m, 6H), 1.59-1.51 (m, 2H), 1.44 (td, J=14.9, 6.6 Hz, 2H), 1.34 (dd, J=7.9, 4.4 Hz, 2H), 1.00 (d, J=6.5 Hz, 3H).

Example 73

(3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-16,16-dioxo-spiro[21-oxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-8,17,19,25-tetraene-23,1′-tetralin]-14-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and hept-6-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.23/601.22; Found: 599.0/600.8. ¹H NMR (400 MHz, DMSO-d₆) δ 11.96 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.29-7.24 (m, 2H), 7.21 (d, J=2.4 Hz, 1H), 7.13 (d, J=2.3 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 5.60 (dt, J=15.6, 6.3 Hz, 1H), 5.09 (dd, J=15.6, 8.2 Hz, 1H), 4.21 (d, J=12.1 Hz, 1H), 4.12 (d, J=12.1 Hz, 1H), 3.34-3.30 (m, 1H), 3.27-3.18 (m, 2H), 3.08 (s, 3H), 2.81-2.66 (m, 3H), 2.41 (q, J=7.8 Hz, 1H), 2.29-2.08 (m, 4H), 2.03-1.91 (m, 3H), 1.88-1.92 (m, 4H), 1.61-1.45 (m, 4H), 1.45-1.37 (m, 1H), 1.25-1.20 (m, 3H), 1.15-1.06 (m, 1H).

Example 74

(3R,6R,7R,8E,21S)-6′-Chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and pent-4-enoic acid in Step 3. LC-MS calc. for C₃₀H₃₆ClN₂O₅S [M+H]⁺: m/z=571.20/573.19; Found: 570.9/572.7. ¹H NMR (600 MHz, MeOH-d₄) δ 7.63 (d, J=8.3 Hz, 1H), 7.27-7.21 (m, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.09-7.06 (m, 1H), 7.02 (d, J=2.5 Hz, 1H), 6.89 (d, J=8.3 Hz, 1H), 5.05 (s, 1H), 4.91 (dd, J=15.6, 8.2 Hz, 1H), 4.33-4.28 (m, 1H), 3.99-3.96 (m, 1H), 3.66-3.61 (m, 1H), 3.56-3.50 (m, 1H), 3.34-3.27 (m, 3H), 3.02 (s, 3H), 2.78-2.71 (m, 4H), 2.31-2.28 (m, 2H), 2.15-2.02 (m, 3H), 1.85-1.78 (m, 6H), 1.61 (dt, J=10.9, 9.0 Hz, 1H), 1.54-1.43 (m, 3H).

Example 75

(3R,6R,7S,8E,21S)-6′-Chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.0˜3,6.0˜18,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and pent-4-enoic acid in Step 3. LC-MS calc. for C₃₀H₃₆ClN₂O₅S [M+H]⁺: m/z=571.20/573.19; Found: 570.9/572.8. ¹H NMR (600 MHz, Methanol-d₄) δ 7.49 (d, J=8.4 Hz, 1H), 7.38 (dd, J=8.3, 2.2 Hz, 1H), 7.04 (ddd, J=12.3, 7.4, 2.3 Hz, 3H), 6.95 (d, J=8.3 Hz, 1H), 5.28 (dd, J=15.6, 8.6 Hz, 1H), 4.54 (t, J=11.8 Hz, 1H), 4.15 (d, J=11.9 Hz, 1H), 3.95 (d, J=11.9 Hz, 1H), 3.60 (dd, J=14.1, 3.3 Hz, 1H), 3.46 (d, J=14.2 Hz, 1H), 3.27 (dd, J=8.7, 2.5 Hz, 1H), 3.04 (s, 3H), 2.88 (dd, J=14.2, 11.1 Hz, 1H), 2.79-2.61 (m, 2H), 2.50 (qd, J=8.3, 4.0 Hz, 2H), 2.41 (dt, J=14.7, 4.4 Hz, 1H), 2.34-2.22 (m, 1H), 2.19-2.03 (m, 3H), 1.92-1.78 (m, 3H), 1.74-1.59 (m, 3H), 1.47 (dq, J=13.0, 9.9, 9.5 Hz, 1H), 1.25-1.17 (m, 1H).

Example 76

(3R,6R,7R,21S)-6′-Chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-15,17,23-triene-21,1′-tetralin]-12-one

To a stirred solution of (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one (Example 74, 7.9 mg, 0.01 mmol) was added platinum(IV) oxide anhydrous (0.63 mg). The reaction flask was charged with hydrogen and the reaction mixture was stirred at 20° C. with a hydrogen balloon. LC-MS showed full conversion of starting material after 3 h. The solution was filtered through a pad of Celite and concentrated under reduced pressure The crude product was further purified by Prep-HPLC to afford (3R,6R,7R,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-15,17,23-triene-21,1′-tetralin]-12-one (2.9 mg, 28.2% yield) as a white solid. LC-MS calc. for C₃₀H₃₈ClN₂O₅S [M+H]⁺: m/z=573.21/575.20; Found: 572.8/574.6.

Example 77

(3R,6R,7S,21S)-6′-Chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-15,17,23-triene-21,1′-tetralin]-12-one

This compound was prepared using procedures analogous to those described for Example 46 using (3R,6R,7S,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one (Example 51). LC-MS calc. for C₃₀H₃₈ClN₂O₅S [M+H]⁺: m/z=573.21/575.20; Found: 572.8/574.8.

Example 78

(3R,6R,7R,8E,1S,12R,22S)-6′-Chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (R)-3-((2R,3S)-2,3-dimethylhex-5-enoyl)-4-phenyloxazolidin-2-one

To a solution of LiHMDS, 1 M in THF (30.7 mL, 39.9 mmol) in THF (10 mL) was slowly added (R)-3-((S)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (5.46 g, 19.9 mmol, Example 71, Step 2) in THF (1 mL) at −78° C. The mixture was stirred at −78° C. for 1 h. Iodomethane (2.5 mL, 39 mmol) was added slowly. The mixture was stirred at −78° C. for 3 h. Then the mixture was stirred at −35° C. overnight. The mixture was quenched with saturated NH₄Cl solution. The organic layer was separated, and the aqueous layer was extracted with EA (3×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give crude solid. The crude solid was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (R)-3-((2R,3S)-2,3-dimethylhex-5-enoyl)-4-phenyloxazolidin-2-one (1.4 g, 24% yield) as a white solid. ¹H NMR: (400 MHz, CDCl₃) δ 7.40-7.27 (m, 1H), 5.82-5.75 (m, 1H), 5.41 (dd, J=3.6 Hz, 8.8 Hz, 1H), 5.02 (t, J=6.8 Hz, 2H), 4.66 (d, J=8.8 Hz, 1H), 4.24 (dd, J=3.6 Hz, 8.8 Hz, 1H), 3.74-3.69 (m, 1H), 2.14-2.09 (m, 1H), 2.01-1.95 (m, 2H), 1.03 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.4 Hz, 3H). ¹³C NMR: (100 MHz, CDCl₃) δ 176.3, 153.4, 139.4, 137.1, 129.2, 128.6, 125.7, 116.1, 69.7, 57.8, 41.9, 40.0, 34.5, 15.5, 13.3.

Step 2: (2R,3S)-2,3-dimethylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 71 using (R)-3-((2R,3S)-2,3-dimethylhex-5-enoyl)-4-phenyloxazolidin-2-one to replace (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one in Step 3. dr=97:3. [α]²²_D=−33.8 (c=0.94, CHCl₃). ¹H NMR: (400 MHz, CDCl₃) δ 11.2 (br s, 1H), 5.82-5.73 (m, 1H), 5.06-5.01 (m, 2H), 2.49-2.42 (m, 1H), 2.14-2.09 (m, 1H), 2.04-1.96 (m, 2H), 1.10 (d, J=6.8 Hz, 3H), 0.90 (d, J=6.4 Hz, 3H).

Step 3: (3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2,3-dimethylhex-5-enoic in Step 3. LC-MS calc. for C₃₃H₄₂ClN₂O₅S [M+H]⁺: m/z=613.25/615.25; Found: 612.9/615.0. ¹H NMR (400 MHz, DMSO-d₆) δ 11.78 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.5, 2.5 Hz, 1H), 7.27-7.18 (m, 2H), 7.16 (s, 1H), 7.03 (d, J=8.2 Hz, 1H), 5.60-5.51 (m, 1H), 5.08-4.97 (m, 1H), 4.20 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.6 Hz, 1H), 3.27 (d, J=14.0 Hz, 2H), 3.03 (s, 3H), 2.86-2.62 (m, 4H), 2.24-1.98 (m, 4H), 1.95-1.72 (m, 6H), 1.65-1.40 (m, 5H), 1.24 (d, J=3.0 Hz, 3H), 0.84 (d, J=4.2 Hz, 3H).

Example 79

(3R,6R,7S,8E,11S,12R,22S)-6′-Chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (2R,3S)-2,3-dimethylhex-5-enoic acid (Example 47 Step 2) in Step 3. LC-MS calc. for C₃₃H₄₂ClN₂O₅S [M+H]⁺: m/z=613.25/615.25; Found: 613.0/615.0. ¹H NMR (600 MHz, MeOH-d₄) δ 7.61 (d, J=8.6 Hz, 1H), 7.46-7.41 (m, 2H), 7.19-7.14 (m, 2H), 7.05 (d, J=8.3 Hz, 1H), 5.41-5.33 (m, 2H), 5.17 (s, 1H), 4.23 (d, J=11.8 Hz, 1H), 4.07 (d, J=12.0 Hz, 1H), 3.60 (d, J=12.2 Hz, 1H), 3.53 (d, J=14.3 Hz, 2H), 3.17 (s, 3H), 2.86-2.79 (m, 3H), 2.25-2.18 (m, 3H), 2.05 (d, J=7.0 Hz, 3H), 1.94 (d, J=7.5 Hz, 2H), 1.80 (d, J=15.9 Hz, 2H), 1.63 (d, J=6.0 Hz, 2H), 1.34-1.28 (m, 6H), 1.16 (d, J=6.9 Hz, 3H).

Example 80

(3R,6R,7S,8E,22S)-6′-Chloro-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and hex-5-enoic acid in Step 3. LC-MS calc. for C₃₁H₃₈ClN₂O₅S [M+H]⁺: m/z=585.21/587.21; Found: 585.0/586.9. ¹H NMR (600 MHz, DMSO-d₆) 11.76 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.16 (dd, J=8.3, 2.1 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.11 (d, J=2.4 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.13-5.06 (m, 1H), 4.78 (dd, J=15.3, 9.0 Hz, 1H), 4.93-3.96 (m, 2H), 3.43 (d, J=14.3 Hz, 2H), 3.01 (dd, J=15.0, 5.3 Hz, 1H), 2.87 (s, 3H), 2.71-2.68 (m, 2H), 2.64-2.56 (m, 2H), 2.21-2.19 (m, 1H), 2.05-1.87 (m, 5H), 1.76-1.64 (m, 4H), 1.54-1.44 (m, 3H), 1.38-1.31 (m, 1H), 0.80 (d, J=6.3 Hz, 3H).

Example 81

(3R,6R,7S,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (R)-2-methylhex-5-enoic acid (Example 72, Step 4) in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found: 599.4/601.5. ¹H NMR (600 MHz, MeOH-d₄) δ 7.58 (d, J=8.4 Hz, 1H), 7.51 (d, J=2.3 Hz, 1H), 7.44 (dd, J=8.4, 2.2 Hz, 1H), 7.20-7.13 (m, 2H), 7.08 (d, J=8.3 Hz, 1H), 5.12 (dd, J=15.4, 8.3 Hz, 1H), 4.99-4.89 (m, 1H), 4.25 (d, J=12.0 Hz, 1H), 4.04 (d, J=11.9 Hz, 1H), 3.68 (dd, J=14.6, 4.3 Hz, 1H), 3.53 (d, J=14.3 Hz, 1H), 3.29 (dd, J=8.9, 2.7 Hz, 1H), 3.13 (s, 3H), 2.88-2.80 (m, 3H), 2.57 (tt, J=9.0, 4.5 Hz, 1H), 2.35 (ddd, J=10.5, 6.7, 3.0 Hz, 1H), 2.21 (dt, J=9.6, 3.3 Hz, 1H), 2.09-1.98 (m, 2H), 1.99-1.90 (m, 2H), 1.88-1.73 (m, 5H), 1.64-1.53 (m, 3H), 1.17 (d, J=7.0 Hz, 3H).

Example 82

(3R,6R,7S,8E,11S,22S)-6′-Chloro-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (S)-3-methylhex-5-enoic acid (Example 71, Step 3) in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found: 599.3/601.1 ¹H NMR (600 MHz, MeOH-d₄) δ 7.59 (d, J=8.4 Hz, 1H), 7.48-7.41 (m, 2H), 7.18-7.14 (m, 2H), 7.08 (d, J=8.2 Hz, 1H), 5.17 (dd, J=15.4, 7.9 Hz, 1H), 5.09-5.02 (m, 1H), 4.27 (d, J=11.9 Hz, 1H), 4.03 (d, J=11.9 Hz, 1H), 3.74-3.67 (m, 1H), 3.36 (d, J=10.2 Hz, 1H), 3.14 (s, 3H), 3.06 (dd, J=14.1, 11.4 Hz, 1H), 2.87-2.74 (m, 3H), 2.63-2.58 (m, 1H), 2.39 (dd, J=14.7, 2.6 Hz, 1H), 2.25-2.19 (m, 1H), 2.13-1.92 (m, 7H), 1.87-1.67 (m, 5H), 1.62-1.57 (m, 2H), 1.01 (d, J=6.6 Hz, 3H).

Example 83

(3R,6R,7S,8E,23S)-6′-Chloro-7-methoxy-16,16-dioxo-spiro[21-oxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-8,17,19,25-tetraene-23,1′-tetralin]-14-one

This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and hept-6-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.23/601.23; Found: 598.8/601.1. ¹H NMR (400 MHz, DMSO-d₆) δ 12.00 (s, 1H), 7.59-7.54 (m, 1H), 7.36 (dd, J=8.4, 2.1 Hz, 1H), 7.27 (d, J=2.3 Hz, 1H), 7.24-7.20 (m, 2H), 7.11 (d, J=8.3 Hz, 1H), 5.13 (dd, J=15.6, 8.0 Hz, 1H), 4.85 (ddd, J=14.9, 8.2, 5.2 Hz, 1H), 4.20 (d, J=11.9 Hz, 1H), 3.99 (d, J=12.0 Hz, 1H), 3.61 (dd, J=8.0, 3.5 Hz, 1H), 3.55 (dd, J=14.0, 2.9 Hz, 1H), 3.34-3.24 (m, 2H), 3.10 (s, 3H), 3.04-2.98 (m, 1H), 2.79-2.72 (m, 2H), 2.45 (dt, J=8.6, 4.4 Hz, 1H), 2.40-2.33 (m, 1H), 2.26 (ddd, J=12.4, 8.0, 3.9 Hz, 1H), 2.11 (ddd, J=13.0, 6.3, 3.0 Hz, 1H), 2.06-1.98 (m, 1H), 1.94-1.91 (m, 1H), 1.88-1.70 (m, 5H), 1.70-1.62 (m, 2H), 1.58-1.47 (m, 3H), 1.39 (td, J=9.1, 4.8 Hz, 1H), 1.17-1.10 (m, 1H).

Example 84

(3R,6R,7S,8E,11R,22S)-6′-Chloro-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: (R)-3-methylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 71 Step 1-3 using (S)-(+)-4-Phenyl-1,3-oxazolidin-2-one to replace (R)-(+)-4-Phenyl-1,3-oxazolidin-2-one in Step 1. [α]²⁰D=+3.6 (c=0.74, CHCl₃). ¹H NMR: (400 MHz, CDCl₃) δ 5.83-5.74 (m, 1H), 5.10-5.04 (m, 2H), 2.44-2.40 (m, 1H), 2.23-2.03 (m, 4H), 1.01 (d, J=6.0 Hz, 3H).

Step 2: (3R,6R,7S,8E,11R,22S)-6′-chloro-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (R)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found: 599.0/601.0. ¹H NMR (600 MHz, DMSO-d₆) δ 11.94 (s, 1H), 7.61 (d, J=8.5 Hz, 1H), 7.27 (dd, J=8.3, 2.1 Hz, 1H), 7.23 (dd, J=8.4, 2.5 Hz, 1H), 7.21 (d, J=2.5 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 7.03 (d, J=2.2 Hz, 1H), 5.14-5.06 (m, 2H), 4.13 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.1 Hz, 1H), 3.52 (dd, J=14.5, 6.4 Hz, 2H), 3.43-3.37 (m, 1H), 3.22-3.13 (m, 1H), 3.07 (s, 3H), 2.80-2.71 (m, 3H), 2.45-2.41 (m, 1H), 2.21 (dd, J=16.7, 7.8 Hz, 1H), 2.18-2.12 (m, 2H), 2.02-1.94 (m, 4H), 1.89-1.82 (m, 3H), 1.78-1.71 (m, 2H), 1.66 (t, J=11.2 Hz, 1H), 1.55 (p, J=9.2 Hz, 1H), 0.89 (d, J=6.9 Hz, 3H).

Example 85

(3R,6R,7S,8E,12S,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: (2S)-2-methylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 72 Step 2-4 using (4S)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one to replace (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one in Step 2. ¹H NMR (400 MHz, CDCl₃) 5.76-5.86 (m, 1H), 4.99-5.09 (m, 2H), 2.50-2.55 (m, 1H), 2.11-2.16 (m, 2H), 1.79-1.88 (m, 1H), 1.51-1.59 (m, 1H), 1.22 (d, J=7.2 Hz, 3H).

Step 2: (3R,6R,7S,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (2S)-2-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.2/601.2; Found: 598.9/600.9. ¹H NMR (400 MHz, DMSO-d₆) δ 11.94 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 7.27-7.19 (m, 2H), 7.06 (d, J=8.3 Hz, 1H), 7.00 (d, J=2.1 Hz, 1H), 5.18-5.07 (m, 2H), 4.16 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.0 Hz, 1H), 3.54-3.43 (m, 3H), 3.07 (s, 3H), 2.82-2.74 (m, 2H), 2.01 (dd, J=14.4, 6.7 Hz, 2H), 1.93-1.79 (m, 5H), 1.73-1.65 (m, 4H), 1.54-1.45 (m, 3H), 1.33-1.17 (m, 4H), 0.96 (d, J=6.8 Hz, 3H).

Example 86

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[[20]oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: ethyl 1-but-3-enylcyclobutanecarboxylate

To a solution of diisopropylamine (4.86 g, 48. mmol) in THF (25 mL) was added n-butyllithium (18.3 mL, 45 mmol, 2.5 M in hexane) at −65° C. slowly. After addition, the reaction mixture was allowed to warm slowly to −10° C. and then cooled back to −65° C. Ethyl cyclobutanecarboxylate (5.6 g, 43 mmol) was added dropwise. The resulting mixture was stirred at −65° C. for 1 h., and then 4-bromobut-1-ene (7.08 g, 52 mmol) in N-[bis(dimethylamino)phosphoryl]-N-methyl-methanamine (10 mL, 43 mmol) was added. The reaction was stirred at ambient temperature overnight. The mixture was quenched with water at 0° C., and extracted with MTBE (2×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column to afford ethyl 1-but-3-enylcyclobutanecarboxylate (7.78 g, 97% yield).

Step 2: 1-(but-3-en-1-yl)cyclobutane-1-carboxylic acid

Ethyl 1-but-3-enylcyclobutanecarboxylate (240.0 mg, 1.32 mmol) in methanol (2 mL) and water (2 mL) was treated with lithium hydroxide monohydrate (226 mg, 5.2 mmol). The reaction was heated and stirred at 50° C. over weekend. After cooling, the reaction was adjusted with 1 N HCl to pH about 2. The mixture was extracted with EA (2×10 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column to afford pure 1-but-3-enylcyclobutanecarboxylic acid (128.7 mg, 63% yield). LC-MS calc. for C₈H₁₃O₂ [M−H]⁻: m/z=153.1; Found: 153.0.

Step 3: (3R,6R,7R,8E,22S)-6′-Chloro-7-m ethoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25), 17, 19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(but-3-en-1-yl)cyclobutane-1-carboxylic acid in Step 3. LC-MS calc. for C₃₄H₄₂ClN₂O₅S [M+H]⁺: m/z=625.24/627.24; Found: 625.0/627.3. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=8.5 Hz, 1H), 7.58 (dd, J=8.4, 2.1 Hz, 1H), 7.35 (d, J=1.7 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.11 (d, J=2.1 Hz, 1H), 7.04 (d, J=8.4 Hz, 1H), 5.27-5.15 (m, 1H), 4.86 (dd, J=15.1, 9.1 Hz, 1H), 4.26 (d, J=11.7 Hz, 1H), 4.15 (d, J=11.9 Hz, 1H), 3.58 (d, J=14.4 Hz, 2H), 3.31 (ddd, J=35.6, 22.1, 11.1 Hz, 3H), 3.11 (d, J=13.4 Hz, 2H), 3.01 (d, J=6.7 Hz, 2H), 2.84-2.70 (m, 2H), 2.63 (d, J=22.6 Hz, 1H), 2.51 (dt, J=16.4, 9.1 Hz, 2H), 2.41-2.29 (m, 2H), 2.13-1.74 (m, 10H), 1.56 (ddd, J=27.7, 19.1, 11.5 Hz, 5H).

Example 87

(3R,6R,7R,8E,11S,12S,22S)-6′-Chloro-7-methoxy-12-(methoxymethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (R)-3-((2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one

To a solution of LiHMDS, 1M in THF (179 mL, 179 mmol) was slowly added (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (27.3 g, 99 mmol, Example 41, Step 2) in THF (30 mL) at −78° C. After stirring at −78° C. for 2 h., bromo(methoxy)methane (11 mL, 179 mmol) was slowly added. The reaction mixture was stirred at −78° C. for additional 3 h., and then stirred at −30° C. overnight. The mixture was quenched with saturated NH₄Cl aqueous solution. The organic layer was separated and the aqueous layer was extracted with EA (50 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue solid was purified by silica gel with PE/EA=10/1 to give (R)-3-((2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (11.6 g, 36% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.27 (m, 5H), 5.80-5.70 (m, 1H), 5.48 (dd, J=8.8, 4.1 Hz, 1H), 5.04-4.99 (m, 2H), 4.65 (t, J=8.8 Hz, 1H), 4.22-4.15 (m, 2H), 3.60-3.50 (m, 2H), 3.16 (s, 3H), 2.20-2.12 (m, 1H), 2.05-1.95 (m, 2H), 0.92 (d, J=8.4 Hz, 3H).

Step 2: (2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 71, Step 3 using (4R)-4-phenyl-3-[(2S,3S)-2-(methoxymethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one. ¹H NMR (400 MHz, CDCl₃) 5.81-5.71 (m, 1H), 5.07-5.03 (m, 2H), 3.65 (t, J=9.2 Hz, 1H), 3.57-3.54 (m, 1H), 3.12 (s, 3H), 2.64-2.59 (m, 1H), 2.22-2.18 (m, 1H), 2.18-1.97 (m, 1H), 2.06-1.95 (m, 2H), 0.95 (d, J=6.6 Hz, 3H).

Step 3: (3R,6R,7R,8E,11S,12S,22S)-6′-Chloro-7-methoxy-12-(methoxymethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₄H₄₄ClN₂O₆S [M+H]⁺: m/z=643.25/645.25; Found: 642.9/645.2. ¹H NMR (400 MHz, DMSO-d₆) δ 11.89 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.5, 2.4 Hz, 1H), 7.22 (d, J=2.3 Hz, 2H), 7.14 (s, 1H), 7.03 (d, J=8.2 Hz, 1H), 5.60-5.52 (m, 1H), 5.08-4.99 (m, 1H), 4.19-4.12 (m, 4H), 3.45 (t, J=9.2 Hz, 2H), 3.33-3.25 (m, 2H), 3.19-3.11 (m, 3H), 3.04 (s, 3H), 2.86-2.65 (m, 4H), 2.55 (s, 3H), 2.09 (q, J=6.2, 5.2 Hz, 2H), 2.01 (q, J=6.8, 6.1 Hz, 1H), 1.88-1.80 (m, 5H), 1.64-1.36 (m, 5H).

Example 88

(3R,6R,7R,8E,11S,12S,22S)-6′-Chloro-7-hydroxy-12-(methoxymethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4) and (2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₃H₄₂ClN₂O₆S [M+H]⁺: m/z=629.2/631.2; Found: 628.9/631.1. ¹H NMR (600 MHz, DMSO-d₆) δ 11.69 (s, 1H), 7.65 (d, J=8.5 Hz, 2H), 7.32-7.19 (m, 4H), 7.15 (s, 1H), 7.00 (d, J=7.7 Hz, 1H), 5.52 (s, 1H), 5.27 (s, 1H), 4.53 (d, J=3.4 Hz, 1H), 4.27-3.93 (m, 3H), 3.55 (s, 2H), 3.43 (t, J=9.2 Hz, 2H), 3.34 (s, 12H), 3.21 (dd, J=32.9, 8.9 Hz, 5H), 2.94 (d, J=11.3 Hz, 1H), 2.85-2.68 (m, 3H), 2.11-1.97 (m, 3H), 1.90 (d, J=13.2 Hz, 2H), 1.79 (d, J=19.7 Hz, 5H), 1.66-1.36 (m, 5H), 0.60 (s, 4H).

Example 89

(3R,6R,7R,8E,11S,12R,22S)-6′-Chloro-7-methoxy-12-(2-methoxyethyl)-1-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: tert-butyl (3R,4S)-4-methyl-3-((R)-2-oxo-4-phenyloxazolidine-3-carbonyl)hept-6-enoate

To a mixture of (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 71 Step 2, 20.0 g, 73.2 mmol) in THF (150 mL) at −78° C. was added the solution of NaHMDS (2 M in THF) (54.8 mL, 109 mmol) dropwise. The mixture was stirred at −78° C. for 3.5 h. Then t-butyl bromoacetate (21.4 g, 109 nmmol) was added dropwise. The mixture was stirred at −78° C. for 30 min., and then allowed to warm to −40° C. and stirred at −40° C. for 1 h. The mixture was quenched with 50 mL of saturated NH₄Cl aqueous solution, extracted with ethyl acetate (3×200 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=10:1 to get tert-butyl-(3R,4S)-4-methyl-3-[-(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoate (8 g, 27.2% yield) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.27 (m, 5H), 5.89-5.70 (m, 1H), 5.45-5.35 (m, 1H), 5.09-4.96 (m, 2H), 4.75-4.61 (m, 1H), 4.29-4.20 (m, 2H), 2.67 (dd, J=16.9, 11.7 Hz, 1H), 2.30 (dd, J=16.9, 3.4 Hz, 1H), 2.18 (dd, J=15.5, 8.6 Hz, 1H), 2.08-1.93 (m, 2H), 1.32-1.19 (m, 9H), 0.87 (dd, J=19.0, 6.6 Hz, 3H).

Step 2: (3R,4S)-4-methyl-3-((4R)-2-oxo-4-phenyloxazolidine-3-carbonyl)hept-6-enoic acid

To a mixture of tert-butyl-(3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoate (9.6 g, 24.7 mmol) in 50 mL of DCM was added trifluoroacetic acid (73 mL, 991 mmol). The mixture was stirred at r.t. for 12 h. LC-MS showed the reaction was complete. The mixture was concentrated under reduced pressure. To the residue was added water (60 mL). The mixture was adjusted to pH ˜7 with saturated NaHCO₃ aqueous solution (100 mL), and extracted with ethyl acetate (100 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=2:1 to afford (3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoic acid (6.6 g, 79% yield) as a pale yellow solid. LC-MS calc. for C₁₈H₂₂N₀₅ [M+H]⁺: m/z=332.14; Found: 332.2. ¹H NMR (400 MHz, DMSO-d₆) δ 12.17 (s, 1H), 7.26-7.36 (m, 5H), 5.74-5.84 (m, 1H), 5.49 (dd, J=2.8, 8.4 Hz, 1H), 5.01-5.08 (m, 2H), 4.76 (t, J=8.4 Hz, 1H), 4.17 (dt, J=3.2, 11.6 Hz, 1H), 4.10 (dd, J=2.8, 8.8 Hz, 1H), 2.54 (dd, J=12.0, 17.2 Hz, 1H), 2.34 (dd, J=3.2, 17.2 Hz, 1H), 1.99-2.13 (m, 3H), 0.76 (d, J=6.4 Hz, 3H).

Step 3: (4R)-4-phenyl-3-[(2R,3S)-2-(2-hydroxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one

To a mixture of (3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoic acid (3.0 g, 9.05 mmol) and triethylamine (3.7 g, 36 mmol) in 100 mL of dry THF at −40° C. was added isobutyl chloroformate (2.47 g, 18.11 mmol). The mixture was stirred at −40° C. for 1 h. Then sodium borohydride (1.37 g, 36.21 mmol) in 30 mL of water was added. The mixture was stirred at −40° C. for 2 h. The reaction mixture was treated with 3 N HCl (80 mL) and allowed to warm to r.t. The organic solvent was removed under reduced pressure, and the aqueous solution was extracted with DCM (100 mL). The organic layer was dried and concentrated to afford the crude product (4R)-4-phenyl-3-[(2R,3S)-2-(2-hydroxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (5.6 g) which was directly used in next step reaction without further purification. LC-MS calc. for C₁₈H₂₄NO₄ [M+H]⁺: m/z=318.16; Found: 318.2.

Step 4: (4R)-4-phenyl-3-[(2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one

To a mixture of (4R)-4-phenyl-3-[(2R,3S)-2-(2-hydroxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (600 mg, 1.89 mmol) in 20 mL of dry DCM was added trimethyloxonium tetrafluoroborate (279 mg, 1.89 mmol) and proton sponge (1,8-bis(dimethylamino)naphthalene) (405 mg, 1.89 mmol). The mixture was stirred at r.t. for 2 d. The mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (50 mL). The mixture was washed with 3 M HCl (30 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column with PE/EA=10:1 to afford (4R)-4-phenyl-3-[(2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (320 mg, 50% yield) as a colorless oil. LC-MS calc. for C₁₉H₂₆NO₄ [M+H]⁺: m/z=332.18; Found: 332.2.

Step 5: (2R,3S)-2-(2-methoxyethyl)-3-methylhex-5-enoic acid (HHC001-80-1)

To a mixture of (4R)-4-phenyl-3-[(2R,3 S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (320 mg, 0.97 mmol) in 15 mL of THF and 3 mL of water at 0° C. was added hydrogen peroxide (30% in water) (0.39 mL, 3.8 mmol) and lithium hydroxide (46 mg, 1.9 mmol). The mixture was stirred at 0° C. for 1 h and then allowed to warm to r.t. and stirred at r.t. for 12 h. The organic solvent was removed and the aqueous solution was added 10 mL of water, adjusted to pH 3.0 with con. HCl, extracted with ethyl acetate (30 mL). The organic layer was dried and concentrated to get (2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoic acid (90 mg, 47% yield) as a colorless oil. LC-MS calc. for C₁₀H₁₉O₃ [M+H]⁺: m/z=187.13; Found: 169.2 ([M−H₂O+H]⁺). ¹H NMR (400 MHz, CDCl₃) δ 0.94 (d, J=6.4 Hz, 3H), 1.71-1.79 (m, 1H), 1.85-1.92 (m, 1H), 1.93-2.01 (m, 2H), 2.13-2.21 (m, 1H), 2.44-2.49 (m, 1H), 3.33 (s, 3H), 3.37-3.47 (m, 2H), 5.02 (s, 1H), 5.05-5.06 (m, 1H), 5.71-5.82 (m, 1H).

Step 6: (3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-12-(2-methoxyethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoic acid in Step 3. LC-MS calc. for C₃₅H₄₆ClN₂O₆S [M+H]⁺: m/z=657.28/659.28; Found: 657.1/658.8.

Example 90

(3R,6R,7R,8E,11S,12R,22S)-6′-Chloro-12-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (2R,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-methylhex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 71 Step 3 using tert-butyl (3R,4S)-4-methyl-3-((R)-2-oxo-4-phenyloxazolidine-3-carbonyl)hept-6-enoate (Example 89 Step 1). ¹H NMR (400 MHz, CDCl₃) δ 0.91 (d, J=6.4 Hz, 3H), 1.44 (s, 9H), 1.94-2.08 (m, 2H), 2.10-2.16 (m, 1H), 2.31 (dd, J=4.0 Hz, 16.8 Hz, 1H), 2.61 (m, J=11.2 Hz, 16.8 Hz, 1H), 2.88 (m, J=4.0 Hz, 11.2 Hz, 1H), 5.02-5.03 (m, 1H), 5.06 (m, J=1.2 Hz, 1H), 5.71-5.81 (m, 1H).

Step 2: tert-butyl 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14 diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetate

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C₃₅H₅₀ClN₂O₇S [M+H]⁺: m/z=713.3/715.3; Found: 712.9/715.2.

Step 3: 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetic acid

A solution of tert-butyl 2-[(3R,6R,7R,8E,11 S, 12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetate (25.0 mg, 0.04 mmol) in CH₂Cl₂ (1 mL) at 0° C. was treated with 2,2,2-trifluoroacetic acid (TFA) (0.5 mL) drop-wise. The reaction was stirred at at r.t. overnight. The volatile components are removed under vacuum to afford the crude product 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetic acid (21 mg) which was directly used in next step without further purification. LC-MS: calc. for C₃₄H₄₂ClN₂O₇S [M+H]⁺: m/z=657.2/659.2; Found: 657.0/659.3.

Step 4: (3R,6R,7R,8E,11S,12R,22S)-6′-chloro-12-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

A mixture of 2-[(3R,6R,7R,8E,11S, 12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetic acid (20.0 mg, 0.03 mmol), 3,3-difluoroazetidine hydrochloride (7.94 mg, 0.06 mmol), and HATU (34.71 mg, 0.09 mmol) in DCM (1 mL) was stirred at 0° C. for 1 h., and then diisopropylethylamine (11.78 mg, 0.09 mmol) was added. The mixture was stirred at r.t. overnight. LC-MS analysis indicated complete conversion. The reaction was quenched with 0.5M HCl (1.0 mL) and volatile components were removed under reduced pressure. The residue was purified by prep-HPLC on a C18 column with ACN and water to afforded (3R,6R,7R,8E,11S,12R,22S)-6′-chloro-12-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2 mg, 9.0% yield). LC-MS calc. for C₃₇H₄₅ClF₂N₃O₆S [M+H]⁺: m/z=732.2/734.2; Found: 732.0/734.3.

Example 91

2-[(3R,6R,7R,8E,11S,12R,22S)-6′-Chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]-N,N-dimethyl-acetamide

This compound was prepared using procedures analogous to those described for Example 149 Step 4 using dimethylamine HCl salt. LC-MS: calc. for C₃₆H₄₇ClN₃O₆S [M+H]⁺=684.2/686.2; Found: 684.0/686.3.

Example 92

(3R,6R,7R,8E,11S,12R,22S)-6′-Chloro-7-methoxy-11-methyl-12-(2-morpholino-2-oxo-ethyl)-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 149 Step 4 using morpholine. LC-MS: calc. for C₃₈H₄₉ClN₃O₇S [M+H]⁺=726.3/728.3; Found: 726.7/728.1.

Example 93

(3R,6R,7R,8E,11S,12S,22S)-6′-chloro-7-methoxy-12-(2-methoxyethoxymethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (2S,3S)-2-(2-methoxyethoxymethyl)-3-methyl-hex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 86 Step 2) and 1-(chloromethoxy)-2-methoxy-ethane in Step 1. ¹H NMR (400 MHz, CDCl₃) δ 5.81-5.72 (m, 1H), 5.06-5.03 (m, 2H), 3.74 (t, J=9.2 Hz 1H), 3.67-3.60 (m, 3H), 3.56-3.52 (m, 2H), 3.38 (s, 3H), 2.67-2.65 (m, 1H), 2.21-2.19 (m, 1H), 2.03-1.96 (m, 2H), 0.96 (d, J=6.4 Hz, 3H).

Step 2: (3R,6R,7R,8E,11S,12S,22S)-6′-chloro-7-methoxy-12-(2-methoxyethoxymethyl)-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-2-(2-methoxyethoxymethyl)-3-methyl-hex-5-enoic acid in Step 3. LC-MS calc. for C₃₆H₄₇ClN₂O₇S [M+H]⁺: m/z=687.28/689.28; Found:

Example 94

(3R,6R,7R,8E,11S,12S,22S)-6′-Chloro-12-(hydroxymethyl)-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (2S,3S)-3-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 86 Step 2) and (2-(chloromethoxy)ethyl)trimethylsilane in Step 1. ¹H NMR (400 MHz, CDCl₃) δ 5.78-5.71 (m, 1H), 5.06-5.02 (m, 2H), 3.66-3.51 (m, 4H), 2.60-2.57 (m, 1H), 2.30-2.11 (m, 1H), 2.03-1.96 (m, 2H), 1.01-0.85 (m, 5H), 0.01 (s, 9H).

Step 2: (3R,6R,7R,8E,11S,12S,22S)-6′-chloro-7-methoxy-11-methyl-15,15-dioxo-12-(2-trimethylsilylethoxymethyl)spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-3-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid in Step 3. LC-MS calc. for C₃₈H₅₄ClN₂O₆SiS [M+H]⁺: m/z=729.31; Found: 729.7.

Step 3: (3R,6R,7R,8E,11S,12S,22S)-6′-chloro-12-(hydroxymethyl)-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,7R,8E,11S,12S,22S)-6′-chloro-7-methoxy-11-methyl-15,15-dioxo-12-(2-trimethylsilylethoxymethyl)spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (10 mg) in DCM (1 mL) was added 50% TFA (1 mL). The resulting mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified on C18 column with MeCN/H₂O (30-100%) to afford the desired product (5 mg). LC-MS calc. for C₃₃H₄₂ClN₂O₆S [M+H]⁺: m/z=629.24; Found: 629.0.

Example 95

(3R,6R,7R,8E,12S,22S)-6′-Chloro-12-(hydroxymethyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one

To a solution of (R)-(−)-phenyl-2-oxazolidinone (15.0 g, 93 mmol) in THF (500 mL) was added n-BuLi (80.9 mL, 202 mmol) slowly at −78° C. The reaction solution was stirred at −78° C. for 20 min. Then hex-5-enoyl chloride (26.8 g, 202 mmol) was added slowly. The reaction was stirred at −78° C. for 0.5 h and allowed to warm to ambient temperature overnight. The reaction was quenched with saturated NH₄Cl solution (100 mL), and extracted with EA (100 mL×2). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA (10/1) to give (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one (15 g, 31% yield). ¹H NMR: (400 MHz, CDCl₃) 7.29-7.43 (m, 5H), 5.73-5.83 (m, 1H), 5.43-5.46 (m, 1H), 4.96-5.04 (m, 2H), 4.71 (t, J=8.8 Hz, 1H), 4.28-4.31 (m, 1H), 2.95-2.99 (m, 2H), 2.06-2.12 (m, 2H), 1.70-1.77 (m, 2H).

Step 2: (S)-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and (2-(chloromethoxy)ethyl)trimethylsilane in Step 1. ¹H NMR (400 MHz, CDCl₃) δ 5.78 (ddt, J=16.9, 10.2, 6.6 Hz, 1H), 5.09-4.88 (m, 2H), 3.58-3.39 (m, 4H), 2.67 (ddd, J=15.5, 7.8, 5.6 Hz, 1H), 2.23-2.07 (m, 2H), 1.81 (ddd, J=21.5, 11.5, 5.8 Hz, 1H), 1.68-1.52 (m, 1H), 0.99-0.81 (m, 2H), 0.04-−0.01 (m, 9H).

Step 3: (3R,6R,7R,8E,12S,22S)-6′-chloro-12-(hydroxymethyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 94 Step 2-3 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid. LC-MS calc. for C₃₂H₄₀ClN₂O₆S [M+H]⁺: m/z=615.22; Found: 615.0.

Example 96

(3R,6R,7R,8E,12S,22S)-6′-Chloro-12-(methoxymethyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (S)-2-(methoxymethyl)hex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and bromo(methoxy)methane in Step 1. ¹H NMR (400 MHz, CDCl₃) δ 5.84-5.74 (m, 1H), 5.08-4.98 (m, 2H), 3.59 (dd, J=9.2, 8.0 Hz, 1H), 3.52 (dd, J=9.2, 5.2 Hz, 1H), 3.37 (s, 3H), 2.74-2.67 (m, 2H), 2.17-2.10 (m, 2H), 1.85-1.74 (m, 1H), 1.66-1.57 (m, 1H).

Step 2: (3R,6R,7R,8E,12S,22S)-6′-chloro-12-(methoxymethyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(methoxymethyl)hex-5-enoic acid in Step 3. LC-MS calc. for C₃₃H₄₂ClN₂O₆S [M+H]⁺: m/z=629.24/631.24; Found:

Example 97

(3R,6R,7R,8E,12S,22S)-6′-Chloro-12-((2-methoxyethoxy)methyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (S)-2-((2-methoxyethoxy)methyl)hex-5-enoic acid

This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and 1-(chloromethoxy)-2-methoxyethane in Step 1. ¹H NMR (400 MHz, CDCl₃) δ 5.85-5.75 (m, 1H), 5.09-4.98 (m, 2H), 3.72-3.69 (m, 1H), 3.67-3.60 (m, 3H), 3.56-3.52 (m, 2H), 3.36 (s, 3H), 2.78-2.71 (m, 1H), 2.19-2.09 (m, 2H), 1.81-1.71 (m, 1H), 1.69-1.59 (m, 1H).

Step 2: (3R,6R,7R,8E,12S,22S)-6′-chloro-12-((2-methoxyethoxy)methyl)-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-((2-methoxyethoxy)methyl)hex-5-enoic acid in Step 3. LC-MS calc. for C₃₅H₄₆ClN₂O₇S [M+H]⁺: m/z=673.26/675.26; Found:

Example 98

(3R,6R,24S)-6′-Chloro-8,8,17,17-tetraoxo-spiro[22-oxa-8,17-dithia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

To a solution of (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[22-oxa-8,17-dithia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28), 10,12,18(27), 19,21(26)-hexaene-24,1′-tetralin]-15-one (3.5 mg, Example 25) in DCM (0.50 mL) was added m-CPBA (77 wt %) (2.0 mg, 0.01 mmol) under N₂, and stirred at r.t. for 18 h. The reaction mixture was concentrated under reduced pressure. The residue (white solid) was purified by FCC (15.5 g C18, 20→100% MeCN in H₂O, wet-loaded in DMSO). Fractions containing pure product were combined and concentrated under reduced pressure to afford (3R,6R,24S)-6′-chloro-8,8,17,17-tetraoxo-spiro[22-oxa-8,17-dithia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (1.66 mg) as a white solid. LCMS m/z calc. for C₃₂H₃₄ClN₂O₆S₂ [M+H]⁺: m/z=641.15/643.15; Found: 641.1/643.1.

Example 99

(3R,6R,10E,23S)-6′-Chloro-16,16-dioxo-spiro[8,21-dioxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-10,17(26),18,20(25)-tetraene-23,1′-tetralin]-14-one

Step 1: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

A solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (56.8 mg, 0.08 mmol, Example 18 Step 2) in DMF (0.5 mL) was charged with sodium hydride (60% dispersion in mineral oil, 14 mg, 0.36 mmol) (caution: evolves H₂) at r.t. and was purged with N₂. After 1 min., the mixture was charged with allyl bromide (27 uL, 0.32 mmol) and stirred at r.t. for 22 h. The reaction mixture was quenched with water (1 mL) (caution: evolves H₂), diluted with sat. NH₄Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer was separated, washed with water (2×20 mL) and brine (2×20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure to yield (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (67 mg) without further purification.

Step 2: (3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

The crude (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (67 mg) was dissolved in DCM (800 μL). The flask was purged with N₂, then charged with TFA (800 μL), and stirred at r.t. for 22 h. The reaction mixture was co-evaporated with DCM twice under reduced pressure, and diluted with EtOAc (30 mL), washed with sat. NaHCO₃ (20 mL), water (20 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated under reduced pressure to yield (3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (62.1 mg) as a yellow/white solid. LCMS m/z calc. for C₂₇H₃₄ClN₂O₄S [M+H]⁺: m/z=517.19/519.19; Found: 517.1/519.2.

Step 3: N-[(3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpent-4-enamide

A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (40.95 mg, 0.08 mmol), 4-(dimethylamino)pyridine (DMAP) (48.38 mg, 0.40 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (53.14 mg, 0.28 mmol) under N₂ was dissolved in DCM (1 mL). To the solution was added 4-pentenoic acid (24 uL, 0.24 mmol). The mixture was stirred at r.t. for 2.5 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with brine (20 mL) and 0.1 N HCl (5 mL), and washed with brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to yield N-[(3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpent-4-enamide (36 mg, 76% yield) as a clear yellow glass (36 mg). R_f=0.44 (2:1 hexanes:EtOAc); LCMS m/z calc. for C₃₂H₄₀ClN₂O₅S [M+H]⁺: m/z=599.23/601.23; Found: 599.3/601.2.

Step 4: (3R,6R,10E,23S)-6′-chloro-16,16-dioxo-spiro[8,21-dioxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-10,17(26),18,20(25)-tetraene-23,1′-tetralin]-14-one

A solution of N-[(3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpent-4-enamide (28.0 mg, 0.05 mmol) in DCM (2 mL) was purged with N₂ and was charged with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Hoveyda-Grubbs II) (2.9 mg) in DCM (1 mL). The reaction mixture was stirred at r.t. for 1 d. The reaction mixture was charged with 3 drops DMSO, concentrated under reduced pressure, and purified by FCC (15.5 g C18, 40→100% MeCN in H₂O, wet-loaded in DMSO). Fractions containing pure product were combined and concentrated under reduced pressure and heat (˜50° C.) to yield the desired (3R,6R,10E,23S)-6′-chloro-16,16-dioxo-spiro[8,21-dioxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-10,17(26),18,20(25)-tetraene-23,1′-tetralin]-14-one (14.4 mg, 51% yield) as a white solid. LCMS m/z calc. for C₃₀H₃₅ClN₂O₅S [M+H]⁺: m/z=571.20/573.20; Found: 571.1/573.0; ¹H NMR (500 MHz, MeCN-d₃) δ 9.31 (s, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.36 (dd, J=2.2, 8.4 Hz, 1H), 7.20 (d, J=2.2 Hz, 1H), 7.19-7.13 (m, 2H), 6.98 (d, J=8.4 Hz, 1H), 5.48-5.38 (m, 1H), 4.95 (dt, J=5.5, 15.8 Hz, 1H), 4.35 (d, J=11.9 Hz, 1H), 4.02 (d, J=11.9 Hz, 1H), 3.64 (dd, J=5.9, 13.0 Hz, 1H), 3.59 (dd, J=4.6, 14.4 Hz, 1H), 3.54 (dt, J=1.5, 5.0, 12.7 Hz, 1H), 3.50 (d, J=14.6 Hz, 1H), 3.35 (d, J=14.4 Hz, 1H), 3.29 (dd, J=6.3, 9.8 Hz, 1H), 3.19 (dd, J=4.1, 9.8 Hz, 1H), 3.08 (dd, J=10.5, 14.5 Hz, 1H), 2.85 (td, J=4.3, 9.4 Hz, 1H), 2.77 (q, J=6.6, 7.8 Hz, 2H), 2.46-2.40 (m, 1H), 2.40-2.34 (m, 1H), 2.27-2.18 (m, 3H), 2.08-2.04 (m, 1H), 2.01-1.96 (m, 1H), 1.88-1.82 (m, 3H), 1.71-1.52 (m, 3H).

Example 100

(3R,6R,7S,8E,15S,24S)-6′-Chloro-7-methoxy-17,17-dioxo-spiro[22-oxa-17-thia-1,11-diazapentacyclo[16.7.2.03,6.011,15.021,26]heptacosa-8,18,20,26-tetraene-24,1′-tetralin]-16-one

Step 1: Methyl allyl-L-prolinate

To a solution of L-proline methyl ester hydrochloride (6.64 g, 40.0 mmol) in DMF (80 mL) was added Et₃N (223 mL, 160 mmol) and Allyl bromide (9.7 g, 80 mmol) at 0° C. The mixture was stirred at ambient temperature for 12 h. The reaction mixture was poured into water, and extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (EtOAc/hexane=1:3) to give methyl (2S)-1-allylpyrrolidine-2-carboxylate (5.4 g, 79% yield) as a colorless liquid. ¹H NMR (400 MHz, CDCl₃) δ 6.04-5.94 (m, 1H), 5.20 (dd, J=16.8, 1.6 Hz, 1H), 5.16 (d, J=10.0 Hz, 1H), 3.71 (s, 3H), 3.33-3.28 (m, 1H), 3.16-3.11 (m, 3H), 2.39-2.37 (m, 1H), 2.17-2.04 (m, 1H), 1.95-1.90 (m, 2H), 1.82-1.79 (m, 1H).

Step 2: (2S)-1-allylpyrrolidine-2-carboxylic acid HCl salt

To a solution of methyl (2S)-1-allylpyrrolidine-2-carboxylate (2.0 g, 11 mmol) in THF (10 mL) and water (5 mL) was added NaOH (945 mg, 23 mmol). After stirring for 18 h at rt., the reaction mixture was added water (10 mL) and washed with ethyl acetate (2×20 mL). The aqueous layer was acidified with 1 N HCl (10 mL) and washed with ethyl acetate (10 mL). The aqueous layer was concentrated under reduced pressure. The residue was dissolved in DCM/MeOH (1:1, 20 mL). The salt was removed by filtration and the filtrate was evaporated under reduced pressure to afford (2S)-1-allylpyrrolidine-2-carboxylic acid HCl salt (1.9 g, 84% yield) as a white solid. [α]_D²⁰=−74.0 (c=1.0, MeOH). ¹H NMR (400 MHz, MeOH-d₄) δ 5.98-5.94 (m, 1H), 5.60 (dd, J=17.2, 1.2 Hz, 1H), 5.51 (d, J=10.0 Hz, 1H), 4.09-4.05 (m, 1H), 3.95-3.90 (m, 1H), 3.86-3.81 (m, 1H), 3.74-3.68 (m, 1H), 3.23-3.18 (m, 1H), 2.54-2.48 (m, 1H), 2.20-2.11 (m, 2H), 2.03-1.96 (m, 1H).

Step 3: (3R,6R,7S,8E,15S,24S)-6′-Chloro-7-methoxy-17,17-dioxo-spiro[22-oxa-17-thia-1,11-diazapentacyclo[16.7.2.03,6.011,15.021,26]heptacosa-8,18,20,26-tetraene-24,1′-tetralin]-16-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and allylpyrrolidine-2-carboxylic acid in Step 3. LC-MS calc. for C₃₃H₄₁ClN₃O₅S [M+H]⁺: m/z=626.24/628.24; Found: 626.0/628.0. ¹H NMR (600 MHz, DMSO-d₆) δ 8.85 (s, 1H), 7.61 (d, J=8.5 Hz, 1H), 7.27 (d, J=2.0 Hz, 1H), 7.24 (dd, J=8.5, 2.4 Hz, 1H), 7.19 (d, J=2.4 Hz, 1H), 7.12 (dd, J=8.2, 1.9 Hz, 1H), 6.86 (d, J=8.2 Hz, 1H), 5.71 (dd, J=15.4, 6.5 Hz, 1H), 5.14-5.00 (m, 1H), 4.02 (d, J=12.0 Hz, 1H), 3.97 (d, J=12.1 Hz, 1H), 3.77 (d, J=8.7 Hz, 2H), 3.59 (d, J=18.3 Hz, 2H), 3.54 (d, J=14.2 Hz, 1H), 3.39 (dd, J=14.4, 5.4 Hz, 1H), 3.26 (d, J=14.4 Hz, 2H), 3.03 (s, 3H), 2.86-2.78 (m, 1H), 2.77-2.70 (m, 2H), 2.45-2.38 (m, 1H), 2.34-2.30 (m, 1H), 2.08-1.93 (m, 5H), 1.88-1.80 (m, 3H), 1.79-1.71 (m, 2H), 1.63-1.44 (m, 3H).

Example 101

(3R,6R,11R,24S)-6′-Chloro-10-methyl-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,10,14,16-tetrazapentacyclo[16.7.2.111,14.03,6.021,26]octacosa-18(27),19,21(26)-triene-24,1′-tetralin]-9,15-dione

Step 1: [(JR, 2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl carbonochloridate

To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.42 mmol, Intermediate 3 Step 2) in DCM (5 mL) was added triphosgene (62 mg, 0.21 mmol) and pyridine (0.03 mL, 0.42 mmol) at r.t. The reaction was stirred for 1 h. Water was added and extracted with DCM. The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was used directly without further purification.

Step 2: tert-butyl (3R)-3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxycarbonylamino]pyrrolidine-1-carboxylate

To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl carbonochloridate (161 mg, 0.21 mmol) in MeCN (2 mL) was added potassium carbonate (285 mg, 2.07 mmol) and tert-butyl (3R)-3-(methylamino)pyrrolidine-1-carboxylate (124 mg, 0.62 mmol). The reaction mixture was stirred at r.t. for 2 d. After the reaction was completed, Water was added and extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc in Hexane (0-50%) to afford tert-butyl (3R)-3-[[(1R,2R)-2-[[rac-(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxycarbonylamino]pyrrolidine-1-carboxylate (105 mg, 54% yield)

Step 3: [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate

To a solution of tert-butyl (3R)-3-[methyl-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxycarbonyl]amino]pyrrolidine-1-carboxylate (105.0 mg, 0.11 mmol) in DCM (0.50 mL) was added 2,2,2-trifluoroacetic acid (1.0 mL, 13.07 mmol). The reaction mixture was stirred at r.t. overnight. The mixture was neutralized by sat. NaHCO₃ aq. and extracted with DCM. The combined organic layers were dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by prep-HPLC with MeCN/H₂O to afford [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate (47.5 mg, 70.78% yield).

Step 4: [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-1-(pyrrole-1-carbonyl)pyrrolidin-3-yl]carbamate

To a solution of [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate (47.4 mg, 0.08 mmol) in THF (0.50 mL) was added 1,1′-carbonyldiimidazole (14.0 mg, 0.09 mmol). The reaction was heated to 55° C. for 30 min. The resulting mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and evaporated under reduced pressure to afford the crude product which was used directly in next step without further purification.

Step 5: (3R,6R,11R,24S)-6′-chloro-10-methyl-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,10,14,16-tetrazapentacyclo[16.7.2.111,14.03,6.021,26]octacosa-18(27),19,21(26)-triene-24,1′-tetralin]-9,15-dione

To a solution of [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-1-(pyrrole-1-carbonyl)pyrrolidin-3-yl]carbamate (52.2 mg, 0.07 mmol) in MeCN (0.50 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (34.24 mg, 0.22 mmol). The reaction was heated to 85° C. overnight. The reaction was quenched with water (2 mL) and the mixture was extracted with DCM (2×2 mL). The combined organic layers were dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 μm) using MeCN/H₂O (20% to 100%) to afford (3R,6R,11R,24S)-6′-chloro-10-methyl-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,10,14,16-tetrazapentacyclo[16.7.2.111,14.03,6.021,26]octacosa-18(27),19,21(26)-triene-24,1′-tetralin]-9,15-dione (7 mg, 14% yield). LC-MS: calc. for C₃₁H₃₈ClN₄O₆S [M+H]⁺: m/z=629.21/631.21; Found: 628.9/631.1. ¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J=8.4 Hz, 1H), 7.30-7.21 (m, 1H), 7.19 (d, J=2.1 Hz, 1H), 7.11 (d, J=18.0 Hz, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.57 (s, 1H), 4.21-3.90 (m, 4H), 3.88-3.29 (m, 10H), 3.23 (dd, J=25.3, 21.5 Hz, 3H), 2.87-2.56 (m, 4H), 2.40-1.74 (m, 6H), 1.58 (d, J=47.6 Hz, 3H).

Example 102

(3R,6R,11R,24S)-6′-Chloro-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,10,14,16-tetrazapentacyclo[16.7.2.111,14.03,6.021,26]octacosa-18(27),19,21(26)-triene-24,1′-tetralin]-9,15-dione

This compound was prepared using procedures analogous to those described for Example 101 Step 2-5 using tert-butyl (3R)-3-aminopyrrolidine-1-carboxylate to replace (3R)-3-(methylamino)pyrrolidine-1-carboxylate in Step 2. LC-MS calc. for C₃₀H₃₆ClN₄O₆S [M+H]⁺: 615.22/617.22; Found: 614.9/616.7. ¹H NMR (400 MHz, DMSO-d₆) δ 7.65 (d, J=8.1 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 7.20 (s, 1H), 7.12 (s, 1H), 6.97 (dd, J=16.3, 8.5 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.57 (s, 1H), 4.22 (s, 1H), 4.05 (s, 1H), 3.80 (d, J=16.1 Hz, 1H), 3.71 (d, J=2.6 Hz, 1H), 3.12 (s, 2H), 2.84-2.62 (m, 2H), 2.37-2.27 (m, 1H), 1.68 (ddd, J=134.6, 64.0, 36.5 Hz, 10H).

Example 103

(3R,6R,11S,24S)-6′-Chloro-10-methyl-17,17-dioxo-spiro[8,22-dioxa-17λ{circumflex over ( )}6-thia-1,10,14,16-tetrazapentacyclo[16.7.2.1{circumflex over ( )}11,14.0{circumflex over (°)}3,6.0{circumflex over ( )}21,26]octacosa-18,20,26-triene-24,1′-tetralin]-9,15-dione

This compound was prepared using procedures analogous to those described for Example 101 Step 2-5 using (3S)-3-(methylamino)pyrrolidine-1-carboxylate to replace (3R)-3-(methylamino)pyrrolidine-1-carboxylate in Step 2. LC-MS: calc. for C₃₁H₃₈ClN₄O₆S [M+H]⁺: m/z=629.2/631.2; Found: 628.9/631.1. ¹H NMR (600 MHz, MeOH-d₄) δ 7.72 (d, J=8.5 Hz, 1H), 7.32 (d, J=6.4 Hz, 1H), 7.21-7.18 (m, 1H), 7.17 (s, 1H), 7.14 (s, 1H), 6.96 (d, J=8.0 Hz, 1H), 4.24-4.03 (m, 6H), 3.71 (s, 2H), 3.62-3.36 (m, 3H), 2.94 (s, 2H), 2.81 (dt, J=16.9, 13.1 Hz, 3H), 2.70 (s, 1H), 2.46 (s, 1H), 2.22-2.09 (m, 3H), 2.00 (s, 2H), 1.91 (d, J=6.6 Hz, 3H), 1.67 (d, J=28.3 Hz, 3H), 1.33 (d, J=27.8 Hz, 2H).

Example 104

(3R,6R,24S)-6′-Chloro-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,11,16-triazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (PRT1001203)

Step 1: (3S)-5-[[2-(bromomethyl)cyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of CBr₄ (388.35 mg, 1.17 mmol) in DCM (25 mL) under an atmosphere of nitrogen was added triphenylphosphine (307 mg, 1.17 mmol) and stirred for 30 mins. To this was added the (3S)-6′-chloro-5-[[2-(hydroxymethyl)cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 18, Step 2, 420 mg, 0.59 mmol). The reaction was stirred at r.t. for 14 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using 0-30% EtOAc in hexane to give (3S)-5-[[2-(bromomethyl)cyclobutyl]methyl]-6′-chloro-N,N-bi s[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 65% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.24-7.08 (m, 3H), 7.06-6.96 (m, 6H), 6.84-6.75 (m, 4H), 4.29 (d, J=5.7 Hz, 4H), 4.11 (d, J=1.7 Hz, 2H), 3.79 (d, J=7.5 Hz, 8H), 3.70-3.55 (m, 2H), 3.40-3.19 (m, 4H), 2.78 (d, J=12.2 Hz, 2H), 2.46-2.29 (m, 2H), 2.05-1.80 (m, 4H), 1.70-1.48 (m, 2H).

Step 2: Methyl 2-[5-[[(JR, 2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate

To (3S)-5-[[2-(bromomethyl)cyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.38 mmol) in MeCN (20 mL) was added the potassium carbonate (215 mg, 1.54 mmol), and methyl 2-(5-hydroxy-3-pyridyl)acetate (128 mg, 0.77 mmol). The reaction was heated at 80° C. overnight, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using 0-40% EtOAc in hexane to give methyl 2-[5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (170 mg, 51% yield). LC-MS calc. for C₄₈H₅₃ClN₃O₈S [M+H]⁺: m/z=866.3; found 866.5. ¹H NMR (500 MHz, CDCl₃) δ 8.13 (s, 2H), 7.68 (d, J=8.4 Hz, 1H), 7.47 (s, 1H), 7.19 (dd, J=2.3, 8.5 Hz, 1H), 7.15-7.10 (m, 2H), 7.05 (d, J=2.1 Hz, 1H), 6.98 (d, J=8.2 Hz, 1H), 6.93 (d, J=8.7 Hz, 4H), 6.76 (d, J=8.6 Hz, 4H), 4.13 (d, J=15.2 Hz, 8H), 3.99-3.90 (m, 2H), 3.78 (s, 7H), 3.71 (s, 4H), 3.64 (s, 4H), 3.34-3.19 (m, 2H), 2.79 (s, 2H), 2.49 (s, 2H).

Step 3: Methyl 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate

To methyl 2-[5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (170 mg, 0.20 mmol) in DCM (3 mL) was added the 2,2,2-trifluoroacetic acid (TFA) (1.5 mL). The reaction stirred at r.t. for 16 h. The reaction was concentrated under vacuum, extracted with DCM, the organic layer was washed with water, saturated sodium bicarbonate, and dried over sodium sulfate. The DCM layer was filtered, concentrated under reduced pressure, and purified by flash chromatography on a silica gel column using 0-10% methanol in DCM to give methyl 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (99 mg, 80.6% yield).

Step 4: 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetic acid

To methyl 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (99.0 mg, 0.16 mmol) in THF (3 mL) and water (3 mL) was added the lithium hydroxide (18.0 mg, 0.72 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated and the residue neutralized with 0.25 N HCl, extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate, filtered and concentrated to give 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetic acid (92 mg, 80% yield). LC-MS calc. for C₃₃H₃₅ClF₃N₃O₈S [M+H]⁺: m/z=612.2; found 612.4.

Step 5: (3R,6R, 24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,11,16-triazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28), 10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

To 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetic acid (72.0 mg, 0.12 mmol) in DCM (9 mL) and DMF (1 mL) was added the EDCI (67 mg, 0.35 mmol) and DMAP (67 mg, 0.55 mmol) and stirred at r.t. for 16 h. The reaction was diluted with water, extracted with ethyl acetate. The ethyl acetate layer was washed with water brine, dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using 0-15% MeOH in DCM to give (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,11,16-triazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28), 10,12,18(27), 19,21(26)-hexaene-24,1′-tetralin]-15-one (20 mg, 28% yield). LC-MS calc. for C₃₁H₃₃ClN₃O₅S [M+H]⁺: m/z=594.2; Found 594.3. ¹H NMR (500 MHz, MeCN-d₃) δ 8.04 (d, J=2.6 Hz, 1H), 7.90 (d, J=1.7 Hz, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.30 (t, J=2.2 Hz, 1H), 7.23-7.07 (m, 3H), 6.98 (d, J=2.2 Hz, 1H), 6.75 (d, J=8.3 Hz, 1H), 4.17-3.98 (m, 4H), 3.53 (d, J=14.5 Hz, 1H), 3.45-3.20 (m, 7H), 2.84-2.69 (m, 3H), 2.55 (d, J=12.0 Hz, 3H), 1.90-1.47 (m, 5H).

Example 105

(3R,6R,24S)-6′-Chloro-11-(2-morpholinoethoxy)-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

Step 1: methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-hydroxy-phenyl]acetate

This compound was prepared using procedure analogous to that described for Example 18 Step 3 using methyl 2-(3,5-dihydroxyphenyl)acetate to replace methyl 3-hydroxyphenylacetate. R_f=0.73 (1:1 hexanes:EtOAc).

Step 2: methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-(2-morpholinoethoxy)phenyl]acetate

A mixture of methyl 2-[3-hydroxy-5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (72 mg, 0.08 mmol), and triphenylphosphine (37.0 mg, 0.14 mmol) were evacuated and recharged with N₂ (×2). Then N-(2-hydroxyethyl)morpholine (15.0 μL, 0.12 mmol) in DCM (3 mL) was added. To the mixture was added a solution of di-tert-butyl azodicarboxylate (25.0 mg, 0.11 mmol) in DCM (850 μL) dropwise over 2 min at r.t. The reaction mixture was stirred at r.t. overnight. An additional triphenylphosphine (9.0 mg, 0.03 mmol) was added, followed by diisopropyl azodicarboxylate (9.0 μL, 0.05 mmol). The mixture was stirred at r.t. for 1 h., concentrated under reduced pressure and purified by flash chromatography on a silica gel column with EtOAc in hexanes (10-100%) and then MeOH in DCM (2%) (with 0.2% NH₄OH) to afford methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-(2-morpholinoethoxy)phenyl]acetate (44 mg, 54% yield). LCMS m/z calc. for C₅₅H₆₅ClN₃O₁₀S [M+H]⁺: m/z=994.41; Found: 994.5.

Step 3: (3R,6R, 24S)-6′-chloro-11-(2-morpholinoethoxy)-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,16-diazapentacyclo[16.7.2.19,13.03, 6.021, 26]octacosa-9(28), 10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one

This compound was prepared as TFA salt using procedures analogous to those described for Example 18 Step 4-6 using methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-(2-morpholinoethoxy)phenyl]acetate. LCMS m/z calc. for C₃₈H₄₅ClN₃O₇S [M+H]⁺: m/z=722.27; found: 722.5. ¹H NMR (500 MHz, DMSO-d₆) δ 12.05 (s, 1H), 9.94 (s, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.27 (dd, J=2.4, 8.5 Hz, 1H), 7.21 (d, J=2.3 Hz, 1H), 7.07 (dd, J=2.1, 8.3 Hz, 1H), 6.92-6.86 (m, 1H), 6.82 (d, J=8.3 Hz, 1H), 6.64 (s, 1H), 6.51 (bs, 2H), 6.35 (d, J=2.2 Hz, 1H), 6.28 (s, 1H), 4.21 (q, J=5.0, 6.2 Hz, 2H), 4.11-4.03 (m, 2H), 4.03-3.95 (m, 4H), 3.74-3.65 (m, 2H), 3.48 (d, J=7.8 Hz, 1H), 3.41 (t, J=13.7 Hz, 1H), 3.39-3.25 (m, 4H), 3.20 (q, J=11.5, 14.9 Hz, 3H), 2.83-2.69 (m, 2H), 2.63 (s, 1H), 2.01-1.86 (m, 3H), 1.83-1.73 (m, 3H), 1.60 (q, J=10.4 Hz, 1H), 1.56-1.49 (m, 1H).

Example 106

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,12,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: 1-but-3-enyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (100 mg, 0.19 mmol, Intermediate 8) in MeCN (3 mL) was added TEA (0.1 mL, 0.58 mmol) and phenyl chloroformate (0.07 mL, 0.58 mmol). The resulting mixture was stirred at r.t. for 10 min. LCMS indicated the starting material was consumed. But-3-en-1-amine (16.5 mg, 0.23 mmol) was then added to the reaction mixture and the resulting solution was stirred overnight. The reaction was quenched by water (5 mL), extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (2% to 60%) to afford 1-but-3-enyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (91 mg, 76% yield) as a white solid. LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: m/z=614.25/616.25. Found: 613.9/615.4.

Step 2: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,12,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

A solution of 1-but-3-enyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (91.0 mg, 0.15 mmol) in DCE (100 mL) was bubbled with N₂ for 30 min. Hoveyda-Grubbs II (18.5 mg, 0.03 mmol) was added and the reaction mixture was further bubbled with N₂ for 30 min., and was stirred at 80° C. under N₂ overnight. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Hetpanes (2% to 60%). The desired fractions were collected, concentrated under reduced pressure, and further purified by Prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% CH₃CN/H₂O (t_R=23 min) to afford (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,12,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (38 mg, 43% yield) as a white solid. LC-MS calc. for C₃₀H₃₇ClN₃O₅S [M+H]⁺: m/z=586.21/588.21; Found 586.1/587.9. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.18 (dt, J=8.7, 2.4 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 7.02 (s, 1H), 6.99 (s, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.88 (dt, J=14.2, 6.5 Hz, 1H), 5.48 (dd, J=15.7, 8.3 Hz, 1H), 4.09 (s, 2H), 3.80 (d, J=14.6 Hz, 1H), 3.67 (d, J=15.0 Hz, 1H), 3.49 (t, J=8.2 Hz, 2H), 3.42-3.30 (m, 2H), 3.26 (s, 3H), 3.02 (dd, J=15.1, 10.7 Hz, 1H), 2.89-2.67 (m, 2H), 2.57 (d, J=10.2 Hz, 1H), 2.38 (s, 2H), 2.29-2.12 (m, 1H), 2.10-1.91 (m, 3H), 1.84 (d, J=12.9 Hz, 1H), 1.67 (p, J=9.5 Hz, 3H), 1.42 (t, J=13.1 Hz, 1H), 1.39-1.21 (m, 2H).

Example 107

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,12,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 106 using N-methylbut-3-en-1-amine hydrochloride to replace but-3-en-1-amine in Step 1. LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found 600.1/602.0. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.52-7.30 (m, 2H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (t, J=1.6 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.53-5.11 (m, 2H), 4.13 (d, J=12.2 Hz, 1H), 4.03 (d, J=12.1 Hz, 1H), 3.76-3.58 (m, 3H), 3.31 (d, J=14.6 Hz, 1H), 3.17-3.00 (m, 5H), 2.85 (s, 3H), 2.82-2.68 (m, 3H), 2.43-2.15 (m, 3H), 2.02-1.94 (m, 1H), 1.91-1.69 (m, 5H), 1.43 (q, J=16.1, 11.8 Hz, 2H), 1.36-1.18 (m, 1H).

Example 108

(3R,6R,7R,8E,21S)-6′-Chloro-7-methoxy-11-methyl-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[3.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one

This compound was prepared using procedures analogous to those described for Example 106 using N-methylprop-2-en-1-amine hydrochloride to replace but-3-en-1-amine in Step 1. LC-MS: calc. for C₃₀H₃₇ClN₃O₅S [M+H]⁺: m/z=586.2/588.2; Found: 586.0/587.8. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.48-7.32 (m, 1H), 7.22-7.13 (m, 1H), 7.07 (d, J=2.2 Hz, 1H), 7.01 (s, 1H), 6.93 (s, 1H), 5.85 (d, J=16.0 Hz, 1H), 5.69 (s, 1H), 4.25 (d, J=18.4 Hz, 1H), 4.07 (s, 2H), 3.76 (d, J=14.4 Hz, 3H), 3.61 (t, J=7.0 Hz, 1H), 3.32-3.22 (m, 4H), 3.13-2.95 (m, 3H), 2.85-2.67 (m, 2H), 2.52 (t, J=8.9 Hz, 1H), 2.09-1.97 (m, 2H), 1.91 (s, 2H), 1.87-1.76 (m, 1H), 1.66 (p, J=9.4 Hz, 2H), 1.57-1.46 (m, 1H), 1.40 (t, J=13.0 Hz, 1H), 1.28-1.22 (m, 1H).

Example 109

(3R,6R,8E,22S)-6′-Chloro-7-hydroxy-7-[(4-isopropylpiperazin-1-yl)methyl]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (3R,6R,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7,13-dione

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (175 mg, 0.29 mmol, Example 32) in DCM (17 mL) was added Dess-Martin periodinane (144 mg, 0.34 mmol) at 0° C. (ice-water bath). The mixture was stirred at r.t. for 30 min., and then quenched with 10% sodium thiosulfate (5 mL) and stirred for additional 30 min. The resulting mixture was extracted with DCM (10 mL×2). The combined organic layers were washed with saturated NaHCO₃ (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-90%) to afford the desired product (3R,6R,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7,13-dione (100 mg, 57% yield). LC-MS calc. for C₃₁H₃₆ClN₂O₆S [M+H]⁺: m/z=599.19/601.19; Found 599.5/601.5.

Step 2: (3R,6R,8E,22S)-6′-chloro-7,7-(1-oxa-ethylene)-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7,13-dione (100 mg, 0.17 mmol) in DMSO (8 mL) and THF (2 mL) was added trimethylsulfonium iodide (51 mg, 0.25 mmol), followed by potassium t-butoxide (1.0M in THF) (46 mg, 0.42 mmol) at 0° C. in ice-water bath. The mixture was then stirred at r.t. for 3 h. The reaction was monitored by LC-MS. The reaction was quenched with 1 drop acetic acid and stirred for 1 min. The mixture was poured into ethyl acetate (20 mL) and washed with water (20 mL). The aqueous layer was extracted with EA (20 mL×2). The combined organic layers were washed with water (50 mL), brine (50 mL) and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-90%) to afford the desired product (3R,6R,8E,22S)-6′-chloro-7,7-(1-oxa-ethylene)-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (50 mg, 48% yield). LC-MS calc. for C₃₂H₃₈ClN₂O₆S [M+H]⁺: m/z=613.21/615.20; Found 613.7/615.7.

Step 3: (3R,6R,8E,22S)-6′-chloro-7-hydroxy-7-[(4-isopropylpiperazin-1-yl)methyl]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,8E,22S)-6′-chloro-7,7-(1-oxa-ethylene)-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (10.0 mg, 0.02 mmol) and 1-isopropylpiperazine (3.1 mg, 0.02 mmol) in THF (2 mL) was added potassium t-butoxide (1.0 M in THF) (3.6 mg, 0.03 mmol). The mixture was stirred at 65° C. for 3 d. and monitored by LC-MS. The reaction mixture was neutralized with 1-2 drops of 2 N HCl in ethyl acetate. The solvent was then removed and the residue was purified through Prep-HPLC on C18 column to afford (3R,6R,8E,22S)-6′-chloro-7-hydroxy-7-[(4-isopropylpiperazin-1-yl)methyl]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 mg, 23% yield) as a white solid. LC-MS calc. for C₃₉H₅₄ClN₄O₆S [M+H]⁺: m/z=741.34/743.33; Found 741.8/743.8.

Example 110

(3R,6R,22S)-6′-Chloro-8,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-thia-1,8,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16(25),17,19(24)-triene-22,1′-tetralin]-7,13-dione

Step 1: 2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoic acid

To a stirred solution of 2-bromo-2-methyl-propanoic acid (500 mg, 2.99 mmol) in MeCN (3 mL) was added tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (786 mg, 4.49 mmol) and DIPEA (1.15 mL, 6.59 mmol) at 40° C. The resulting solution was stirred at 40° C. for 3 h. LC-MS analysis indicated the reaction was complete. The reaction mixture was adjusted with 1 N HCl to pH 1-2, and then extracted with EtOAc (2×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoic acid (160 mg, 20% yield) as a colorless oil. LC-MS calc. for C₁₂H₂₂NO₅ [M−H]⁻: m/z=260.3; Found: 260.2.

Step 2: (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid

To a suspension of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1450.0 mg, 2.03 mmol, Intermediate 3 Step 3) in 1-butanol (5 mL) and 2-methylbut-2-ene (5.0 mL, 47.2 mmol) was added sodium chlorite (458 mg, 4.05 mmol) and the solution of sodium phosphate monobasic monohydrate (559 mg, 4.05 mmol) in water (5 mL). The reaction was stirred at r.t. for 3 h. LC-MS showed reaction was completed. The reaction was quenched with 10% Na₂S₂O₃ aq. (5 mL) and the mixture was extracted with EtOAc (2×2 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product (500 mg) which was used directly in next step reaction without further purification.

Step 3: methyl (1R,2R)-2-[[rac-(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate

To a solution of (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (500 mg, 0.68 mmol) in DMF (5 mL) was added iodomethane (116 mg, 0.82 mmol) and potassium carbonate (141 mg, 1.03 mmol). The reaction was stirred overnight and then quenched with water (20 mL), and extracted with MTBE (2×10 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product which was used without further purification.

Step 4: methyl (1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate

To a solution of methyl (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (850 mg, 1.14 mmol) in DCM (2 mL) was added anisole (0.5 mL, 4.6 mmol) and 2,2,2-trifluoroacetic acid (TFA) (2.0 mL, 26.14 mmol). The reaction was stirred at r.t. overnight. Upon completion of the reaction, the mixture was concentrated under reduced pressure. The residue was re-dissolved in DCM and washed with sat. Na₂CO₃ aq. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product which was used without further purification.

Step 5: methyl (1R,2R)-2-[[(3S)-7-[[2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate

To a stirred solution of methyl (1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl] (50 mg, 0.10 mmol) in DCM (1 mL) was added DMAP (48 mg, 0.40 mmol) and EDCI (38 mg, 0.20 mmol) at 20° C. The resulting solution was stirred at 20° C. for 3 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 N HCl solution and extracted with EtOAc (5 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-90%) to afford methyl (1R,2R)-2-[[(3S)-7-[[2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (37 mg, 50% yield) as a light orange solid. LC-MS calc. for C₃₇H₅₁ClN₃O₉S [M+H]⁺: m/z=748.3/750.3; Found: 748.5/750.3.

Step 6: methyl (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate

To a solution of methyl (1R,2R)-2-[[(3S)-7-[[2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (40 mg, 0.05 mmol) in DCM (0.50 mL) was added phosphoric acid (0.67 mL, 11 mmol). The resulting solution was vigorously stirred at 40° C. for 3 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 M NaOH aqueous solution to pH 8 and extracted with 2×4 mL DCM. The combined organic layers were concentrated under reduced pressure to afford methyl (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (19 mg, 55% yield) as a white solid. LC-MS calc. for C₃₂H₄₃ClN₃O₇S [M+H]⁺: m/z=648.2/650.2; Found: 648.3/650.3 Step 7: (JR, 2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid

To a solution of methyl (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (19.0 mg, 0.03 mmol) in methanol (0.50 mL) and THF (0.50 mL) was added lithium hydroxide monohydrate (3.7 mg, 0.09 mmol) in water (0.50 mL). The resulting solution was stirred at 40° C. for 2 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 M HCl aqueous solution to pH 5-6 and extracted with EtOAc (2×10 mL). The combined organic layers were concentrated under reduced pressure to afford (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (16 mg, 86% yield) as a white solid. LC-MS calc. for C₃₁H₄₁ClN₃O₇S [M+H]⁺: m/z=634.2/636.2; Found: 634.6/636.7.

Step 8: (3R,6R,22S)-6′-chloro-8,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-thia-1,8,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16(25),17,19(24)-triene-22,1′-tetralin]-7,13-dione

To a solution of (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (16 mg, 0.03 mmol) in DMF (5 mL) was added HATU (2.1 mg, 0.05 mmol) and DIPEA (0.01 mL, 0.05 mmol). The resulting solution was stirred at 20° C. for 1 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with water and extracted with EtOAc (2×10 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by prep-HPLC on C18 column (30×250 mm, 10 μm) using MeCN/H₂O (20 to 100%) to afford (3R,6R,22S)-6′-chloro-8,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-thia-1,8,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16(25),17,19(24)-triene-22,1′-tetralin]-7,13-dione (4 mg, 25% yield) as a white solid. LC-MS calc. for C₃₁H₃₉ClN₃O₆S [M+H]⁺: m/z=616.2/618.2; Found 616.6/618.6. ¹H NMR (300 MHz, CDCl₃) δ 7.74 (d, J=8.5 Hz, 1H), 7.51-7.31 (m, 2H), 7.22-7.04 (m, 2H), 6.94 (d, J=8.4 Hz, 1H), 4.10 (s, 2H), 4.03-3.89 (m, 1H), 3.89-3.77 (m, 1H), 3.73-3.63 (m, 1H), 3.56 (t, J=6.5 Hz, 1H), 3.29 (d, J=14.5 Hz, 2H), 3.11 (s, 5H), 2.77 (q, J=5.5, 5.0 Hz, 2H), 2.30-2.15 (m, 1H), 2.06-1.67 (m, 9H), 1.41 (s, 3H), 1.34 (s, 3H).

Example 111

(3R,6R,7S,8E,22S)-6′-Chloro-7-methoxy-15,15-dioxo-spiro[[11,20]dioxa[15]thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 2-(allyloxy)acetic acid in Step 3. LC-MS calc. for C₃₀H₃₆ClN₂O₆S [M+H]⁺: m/z=587.19/589.19; Found: 586.8/588.9. ¹H NMR (600 MHz, DMSO-d₆) δ 12.01 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.29 (dd, J=8.3, 2.1 Hz, 1H), 7.24 (dd, J=8.5, 2.4 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H), 5.43 (ddt, J=15.6, 7.6, 1.4 Hz, 1H), 5.20-5.09 (m, 1H), 4.13 (d, J=12.0 Hz, 1H), 4.06 (d, J=12.0 Hz, 1H), 4.01-3.90 (m, 4H), 3.55-3.47 (m, 2H), 3.39 (dd, J=7.5, 3.1 Hz, 1H), 3.20-3.12 (m, 1H), 3.05 (s, 3H), 2.80-2.73 (m, 2H), 2.02 (ddd, J=14.2, 6.4, 2.8 Hz, 1H), 1.91 (ddt, J=11.2, 7.6, 3.8 Hz, 1H), 1.89-1.80 (m, 2H), 1.79-1.71 (m, 2H), 1.66 (ddd, J=13.8, 10.3, 3.2 Hz, 1H), 1.58-1.50 (m, 1H), 1.30-1.20 (m, 3H).

Example 112

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-15,15-dioxo-spiro[[11,20]dioxa[15]thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 2-(allyloxy)acetic acid in Step 3. LC-MS calc. for C₃₀H₃₆ClN₂O₆S [M+H]⁺: m/z=587.19/589.19; Found: 586.8/589.0. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.26-7.21 (m, 1H), 7.13 (d, J=8.3 Hz, 1H), 7.07 (s, 1H), 6.83 (d, J=63.8 Hz, 1H), 6.05 (s, 1H), 5.34 (qd, J=11.1, 6.0 Hz, 1H), 5.17 (dd, J=99.9, 13.5 Hz, 1H), 4.52 (s, 1H), 4.19-3.88 (m, 4H), 3.78 (dt, J=31.6, 15.8 Hz, 2H), 3.34 (s, 3H), 3.28 (d, J=14.7 Hz, 1H), 3.00 (dd, J=29.7, 15.2 Hz, 1H), 2.83-2.68 (m, 2H), 2.64 (s, 1H), 2.33 (d, J=31.7 Hz, 2H), 2.08-1.95 (m, 3H), 1.74-1.54 (m, 3H), 1.34 (dd, J=28.1, 12.4 Hz, 3H).

Example 113

[(3R,6R,7S,8E,12S,22S)-6′-Chloro-12-methyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] acetate

Step 1: (2S)-2-allyloxypropanoic acid

This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl (2S)-2-hydroxypropanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. TLC R_f=0.25 (EA:Hep=2:1).

Step 2. [(3R,6R,7S,8E,12S,22S)-6′-chloro-12-methyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] acetate

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (Intermediate 5) and (2S)-2-allyloxypropanoic acid in Step 3. LC-MS calc. for C₃₂H₃₈ClN₂O₇S [M+H]⁺: m/z=629.20/631.20; Found: 629.0/630.8. ¹H NMR (600 MHz, CDCl₃) δ 8.95 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.55-7.48 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 5.59 (q, J=3.7 Hz, 2H), 5.41-5.28 (m, 1H), 5.21 (t, J=4.3 Hz, 1H), 4.39-4.29 (m, 1H), 4.24 (d, J=12.2 Hz, 1H), 4.13 (d, J=12.2 Hz, 1H), 3.83-3.70 (m, 2H), 3.66 (d, J=14.6 Hz, 1H), 3.48-3.31 (m, 2H), 3.23 (dd, J=15.0, 8.1 Hz, 1H), 2.87-2.72 (m, 3H), 2.53 (dt, J=13.7, 8.8 Hz, 1H), 2.07 (s, 3H), 2.07-1.72 (m, 5H), 1.60 (td, J=18.9, 17.8, 11.1 Hz, 2H), 1.41 (d, J=6.8 Hz, 3H).

Example 114

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S)-2-allyloxypropanoic acid (Example 113 Step 1) in Step 3. LC-MS calc. for C₃₃H₃₈ClN₂O₆S [M+H]⁺: m/z=601.2/603.2; Found: 601.0/602.8. ¹H NMR (400 MHz, DMSO-d₆) δ 12.00 (s, 1H), 7.63 (dd, J=30.8, 26.0 Hz, 1H), 7.29 (dd, J=8.5, 2.2 Hz, 1H), 7.26-7.21 (m, 3H), 7.05 (d, J=7.4 Hz, 1H), 5.38-5.20 (m, 1H), 4.21 (d, J=12.9 Hz, 1H), 4.11 (d, J=12.2 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.80-3.52 (m, 4H), 3.07-2.94 (m, 3H), 2.87-2.65 (m, 3H), 2.33 (dd, J=11.1, 9.2 Hz, 1H), 2.05-1.92 (m, 1H), 1.88-1.54 (m, 6H), 1.42 (dd, J=22.3, 11.3 Hz, 1H), 1.30-1.21 (m, 5H) ppm.

Example 115

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (2R)-2-allyloxypropanoic acid

This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl (2R)-2-hydroxypropanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. TLC R_f=0.3 (50% EA in Hep).

Step 2: (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R)-2-allyloxypropanoic acid in Step 3. LC-MS calc. for C₃₃H₃₈ClN₂O₆S [M+H]⁺: m/z=601.2/603.2; Found: 600.8/603.0. ¹H NMR (400 MHz, DMSO-d₆) δ 12.09 (s, 1H), 7.67 (d, J=8.6 Hz, 1H), 7.30-7.23 (m, 2H), 7.19 (d, J=2.2 Hz, 1H), 7.02 (d, J=8.3 Hz, 2H), 5.70-5.61 (m, 1H), 5.13 (dd, J=15.6, 8.0 Hz, 1H), 4.25 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 3.97 (dd, J=12.8, 6.2 Hz, 2H), 3.78 (dd, J=14.4, 6.8 Hz, 1H), 3.52 (d, J=14.4 Hz, 1H), 3.39 (t, J=6.5 Hz, 2H), 3.30 (d, J=7.3 Hz, 2H), 3.09 (s, 2H), 2.84-2.65 (m, 3H), 2.30 (dd, J=16.0, 10.6 Hz, 2H), 2.06-1.96 (m, 2H), 1.95-1.76 (m, 4H), 1.62-1.42 (m, 4H), 1.24 (d, J=6.6 Hz, 3H).

Example 116

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[[20]oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate

To a solution of ethyl 1-aminocyclobutanecarboxylate hydrochloride (1.00 g, 5.57 mmol) and sodium bicarbonate (1.43 g, 16.7 mmol) in THF (5 mL) and water (5 mL) was added di-tert butyl dicarbonate (1.46 g, 6.68 mmol). The resulting mixture was stirred at r.t. for 10 min. and briefly heated in a hot water bath at 50° C. for 10 min. diluted with water, and extracted with MTBE. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product which was used without further purifications. LC-MS calc. for C₁₂H₂₂N₀₄ [M+H]⁺: m/z=244.15; Found 244.0.

Step 2: ethyl 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylate

To a suspension of sodium hydride (60%, 446 mg, 11.5 mmol) in DMF (15 mL) was added ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate (1.35 g, 5.57 mmol) in DMF (5 mL) at 0° C. After 20 min., allyl bromide (1.01 g, 8.36 mmol) was added in one portion. The reaction was stirred at ambient temperature overnight, quenched with saturated aqueous NH₄Cl and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (3% to 8% EtOAc/Hept) to afford ethyl 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylate (1.42 g, 90% yield) as a colorless oil. TLC (10% EtOAc/Hept) R_f=0.48.

Step 3: 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid

A solution of ethyl 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylate (1.40 g, 4.94 mmol) and lithium hydroxide monohydrate (1.03 g, 24.7 mmol) in MeOH/THF/H₂O (5 mL, 5 mL, 8 mL) was heated at 45° C. overnight. The reaction was cooled to 0° C., acidified with 2 N HCl, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (10% to 30% EtOAc/Hept) to afford 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (0.790 g, 62.6% yield). LC-MS calc. for C₁₃H₂₀NO₄ [M−H]⁻: m/z=254.14; Found 254.1.

Step 4. (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid in Step 3. LC-MS calc. for C₃₃H₄₁ClN₃O₅S [M+H]⁺: m/z=626.24/628.24; Found: 626.0/628.2. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.42 (dd, J=8.6, 2.1 Hz, 1H), 7.26 (app s, 1H, overlapped with CHCl₃), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.37-5.24 (m, 2H), 4.11 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.2 Hz, 1H), 3.70 (d, J=14.6 Hz, 1H), 3.65 (dd, J=14.4, 7.0 Hz, 1H), 3.40 (dd, J=14.7, 4.3 Hz, 1H), 3.31 (d, J=14.6 Hz, 1H), 3.13 (s, 3H), 3.09 (d, J=5.6 Hz, 1H), 3.02 (dd, J=15.1, 7.1 Hz, 1H), 2.94 (d, J=13.1 Hz, 1H), 2.82-2.71 (m, 2H), 2.59 (dqd, J=16.2, 8.8, 8.2, 2.6 Hz, 2H), 2.45 (tt, J=8.4, 3.3 Hz, 1H), 2.28 (d, J=8.1 Hz, 1H), 2.08-1.77 (m, 10H), 1.76-1.69 (m, 1H), 1.68-1.60 (m, 1H), 1.44-1.37 (m, 1H).

Example 117

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: (2S)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid

This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2S)-2-(tert-butoxycarbonylamino)propanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.

Step 2: tert-butyl N-allyl-N-[(1S)-1-methyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(JR)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 26 Step 3 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid.

Step 3: tert-butyl (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-11-carboxylate and

tert-butyl (3R,6R,7R,8Z,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,1′-tetralin]-11-carboxylate

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using tert-butyl N-allyl-N-[(1S)-1-methyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (81.3 mg, 0.11 mmol) in DCE (110 mL) at 80° C. overnight and purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford two products: P1 (the earlier eluted product, 29.8 mg, 38.1% yield) and P2 (the latter eluted product, 21.7 mg, 27% yield).

P1 was assigned to tert-butyl (3R,6R,7R,8Z,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate, and P2 was assigned to tert-butyl (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17, 19(24)-tetraene-22,1′-tetralin]-11-carboxylate.

Step 5: (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

tert-butyl (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (21.7 mg, 0.03 mmol, P2 Step 4) was treated with 2 N HCl in EA (0.5 mL). The reaction mixture was stirred at r.t. overnight and quenched with sat. NaHCO₃ aq. solution. The mixture was extracted with DCM (2 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) using MeCN/H₂O (20% to 100%) to afford (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17, 19(24)-tetraene-22,1′-tetralin]-13-one (9.4 mg, 48.7% yield). LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found=599.9/601.7. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=8.5 Hz, 1H), 7.32 (s, 1H), 7.15 (s, 1H), 7.10 (d, J=1.8 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 5.45 (dd, J=15.3, 8.8 Hz, 2H), 5.39-5.24 (m, 2H), 4.13 (d, J=12.0 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.87-3.65 (m, 2H), 3.65-3.48 (m, 2H), 3.48-3.38 (m, 1H), 3.32 (d, J=14.6 Hz, 2H), 3.23 (s, 1H), 3.13 (d, J=8.2 Hz, 1H), 3.03 (dd, J=15.2, 6.0 Hz, 2H), 2.87-2.68 (m, 1H), 2.64 (s, 4H), 2.31 (d, J=3.4 Hz, 2H), 2.02 (d, J=13.6 Hz, 2H), 1.97-1.53 (m, 3H), 1.53-1.22 (m, 2H), 1.16 (dd, J=6.0, 3.4 Hz, 2H).

Example 118

(3R,6R,7R,8Z,12S,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 117 using tert-butyl (3R,6R,7R,8Z,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-1-carboxylate (P1, Example 117, step 4) in Step 5. LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found: 600.9/602.1. ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.41 (dd, J=8.3, 1.7 Hz, 1H), 7.18 (dd, J=8.8, 2.4 Hz, 2H), 7.08 (d, J=2.1 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.58 (d, J=5.1 Hz, 2H), 4.08 (s, 2H), 3.78-3.55 (m, 3H), 3.48-3.25 (m, 4H), 3.22 (s, 2H), 3.07 (dd, J=15.2, 8.0 Hz, 1H), 2.85-2.65 (m, 2H), 2.65-2.50 (m, 5H), 2.40-2.30 (m, 1H), 2.01 (d, J=14.6 Hz, 1H), 1.87 (ddd, J=32.6, 16.9, 6.0 Hz, 4H), 1.65-1.49 (m, 2H), 1.49-1.34 (m, 3H).

Example 119

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: 1-(allyl(tert-butoxycarbonyl)amino)cyclopropane-1-carboxylic acid

This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using ethyl 1-(tert-butoxycarbonylamino)cyclopropanecarboxylate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.

Step 2. (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyl(tert-butoxycarbonyl)amino)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C₃₂H₃₉ClN₃O₅S [M+H]⁺: m/z=612.22/614.22; Found: 611.9/614.2. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 7.31 (s, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 5.40 (d, J=4.0 Hz, 2H), 4.08 (dd, J=37.7, 12.1 Hz, 2H), 3.79-3.67 (m, 2H), 3.29 (dd, J=34.7, 13.2 Hz, 2H), 3.20-3.07 (m, 5H), 3.04 (dd, J=15.2, 6.4 Hz, 1H), 2.84-2.63 (m, 3H), 2.37 (s, 1H), 2.00 (d, J=13.3 Hz, 1H), 1.95-1.72 (m, 4H), 1.69-1.49 (m, 4H), 1.44-1.35 (m, 2H), 1.17-1.11 (m, 1H), 1.08 (dd, J=12.8, 8.7 Hz, 1H), 0.95 (tdd, J=15.5, 9.4, 6.0 Hz, 1H).

Example 120

(3R,6R,7R,8E,22S)-6′-Chloro-7-methoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 116) and formaldehyde aqueous solution (37%). LC-MS calc. for C₃₄H₄₃ClN₃O₅S [M+H]⁺: m/z=640.25/642.25; Found: 640.0/642.2. ¹H NMR (600 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.45 (d, J=16.9 Hz, 1H), 7.16 (d, J=7.7 Hz, 1H), 7.08 (t, J=4.6 Hz, 1H), 6.90 (s, 2H), 5.41 (dd, J=14.8, 9.0 Hz, 1H), 4.07 (dd, J=33.9, 11.7 Hz, 2H), 3.71 (d, J=14.7 Hz, 1H), 3.48 (s, 1H), 3.34 (d, J=15.0 Hz, 1H), 3.26 (s, 3H), 2.97 (dd, J=34.6, 21.1 Hz, 1H), 2.85-2.66 (m, 2H), 2.49 (s, 1H), 2.42 (s, 3H), 2.29 (s, 1H), 2.17 (s, 1H), 2.11-1.88 (m, 6H), 1.83 (d, J=8.0 Hz, 1H), 1.65 (s, 9H), 1.40 (t, J=12.9 Hz, 1H), 0.95-0.73 (m, 1H).

Example 121

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: (2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid

This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2R)-2-(tert-butoxycarbonylamino)propanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.

Step 2: tert-butyl (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-11-carboxylate and tert-butyl (3R,6R,7R,8Z,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-11-carboxylate

These two compounds were prepared using procedures analogous to those described for Example 117 Step 2-3 using (2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid to replace (2S)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid in Step 2. P1 (the earlier eluted product) was assigned to the cis-isomer and P2 (the earlier eluted product) was assigned to the trans-isomer.

Step 3: (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 117 Step 5 using tert-butyl (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (P2). LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found: 599.9/602.0. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.34 (d, J=8.3 Hz, 1H), 7.30 (s, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.08 (s, 1H), 6.95 (d, J=8.3 Hz, 1H), 5.42-5.26 (m, 2H), 4.12 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.1 Hz, 1H), 3.77-3.63 (m, 3H), 3.31 (d, J=14.5 Hz, 1H), 3.16 (d, J=6.9 Hz, 1H), 3.12 (s, 3H), 3.03 (dd, J=15.1, 6.4 Hz, 3H), 2.85-2.71 (m, 2H), 2.71-2.59 (m, 1H), 2.28 (td, J=14.0, 9.1 Hz, 1H), 2.00 (t, J=6.8 Hz, 2H), 1.94-1.69 (m, 7H), 1.64 (dd, J=19.0, 9.5 Hz, 2H), 1.40 (d, J=7.0 Hz, 2H).

Example 122

(3R,6R,7R,8Z,12R,22S)-6′-Chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 117 Step 5 using tert-butyl (3R,6R,7R,8Z,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]-pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (P1, Example 121 Step 2). LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found: 599.9/602.0. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.17 (d, J=6.6 Hz, 2H), 7.08 (d, J=1.7 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 5.53 (s, 2H), 4.11-4.03 (m, 2H), 3.75 (d, J=9.6 Hz, 1H), 3.69 (d, J=14.5 Hz, 1H), 3.53 (d, J=14.6 Hz, 1H), 3.33 (dd, J=42.0, 19.1 Hz, 4H), 3.21 (s, 3H), 3.06 (dd, J=14.8, 7.7 Hz, 1H), 2.82-2.69 (m, 2H), 2.60-2.51 (m, 1H), 2.40-2.32 (m, 1H), 2.01 (dd, J=15.3, 8.8 Hz, 1H), 1.86 (ddd, J=42.9, 24.7, 5.6 Hz, 5H), 1.65-1.53 (m, 2H), 1.41 (t, J=9.9 Hz, 4H), 1.27 (d, J=18.2 Hz, 1H).

Example 123

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121). LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: m/z=614.24/616.24; Found: 614.0/615.8. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.4, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.1 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.97 (d, J=8.4 Hz, 2H), 5.74-5.67 (m, 1H), 5.44 (dd, J=15.7, 8.7 Hz, 1H), 4.09 (dd, J=24.3, 12.1 Hz, 2H), 3.71 (d, J=14.6 Hz, 1H), 3.50 (d, J=8.8 Hz, 1H), 3.44-3.37 (m, 1H), 3.35 (d, J=14.7 Hz, 1H), 3.23 (d, J=15.4 Hz, 2H), 3.09-3.02 (m, 2H), 2.97 (dd, J=14.9, 7.3 Hz, 1H), 2.87 (dd, J=14.9, 4.3 Hz, 1H), 2.81 (s, 1H), 2.80-2.72 (m, 2H), 2.55-2.46 (m, 2H), 2.37 (d, J=10.0 Hz, 2H), 2.15 (dd, J=15.0, 7.4 Hz, 1H), 2.06-1.89 (m, 4H), 1.83 (d, J=7.6 Hz, 2H), 1.72-1.36 (m, 2H), 1.35-1.19 (m, 2H), 0.97-0.76 (m, 2H).

Example 124

(3R,6R,7R,8Z,12R,22S)-6′-Chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8Z,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 122). LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: m/z=614.24/616.24; Found: 614.0/615.8. ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, J=7.9 Hz, 1H), 7.70 (d, J=8.7 Hz, 2H), 7.45 (dd, J=15.8, 7.4 Hz, 2H), 7.35 (d, J=8.5 Hz, 1H), 7.18 (dd, J=27.6, 9.5 Hz, 3H), 7.06 (dd, J=16.6, 8.7 Hz, 3H), 6.97 (s, 2H), 6.77 (dd, J=28.8, 20.2 Hz, 4H), 6.61 (s, 1H), 6.05 (s, 1H), 5.80-5.61 (m, 3H), 5.46 (s, 1H), 5.31 (dd, J=15.4, 8.3 Hz, 1H), 5.19 (s, 1H), 5.07 (s, 2H), 4.29 (d, J=11.2 Hz, 2H), 4.06 (d, J=10.7 Hz, 3H), 3.85-3.71 (m, 3H), 3.71-3.18 (m, 20H), 2.87 (ddt, J=92.3, 76.4, 36.2 Hz, 20H), 2.47 (d, J=30.6 Hz, 4H), 2.23 (t, J=38.8 Hz, 10H), 2.11-1.74 (m, 20H), 1.74-1.45 (m, 10H), 1.45-1.18 (m, 12H), 1.18-0.95 (m, 10H), 0.89 (ddd, J=29.8, 15.5, 8.0 Hz, 4H).

Example 125

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-12-(methoxymethyl)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

Step 1: methyl (2S)-2-hydroxy-3-methoxy-propanoate

Mg(ClO₄)₂ (819 mg, 3.67 mmol) was added to methyl (2S)-oxirane-2-carboxylate (1.5 g, 14.69 mmol) in methanol (2 mL) under stirring vigorously. The reaction mixture was heated to 80° C. for 20 h. After the reaction was completed (monitored by GC, GC:SM Rt=4.68 min, product Rt=6.0 min), the mixture was cooled to r.t., filtered and concentrated under reduced pressure. The residue was re-dissolved in heptane, filtered again and concentrated to remove MeOH completely. The residue (1.97 g) was used for next step directly.

Step 2: methyl (2S)-2-allyloxy-3-methoxy-propanoate

Allyl bromide (3.55 g, 29 mmol) was added to methyl (2S)-2-hydroxy-3-methoxy-propanoate (1.97 g, 14 mmol) in tert-butyl methyl ether (40 mL) and followed by addition of silver(I) oxide (6.8 g, 29 mmol) for 3 d. The reaction was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EtOAc/Heptanes (2% to 30%) to afford methyl (2S)-2-allyloxy-3-methoxy-propanoate (810.9 mg, 31.7% yield).

Step 3. (2S)-2-allyloxy-3-methoxy-propanoic acid

This compound was prepared using procedures analogous to those described for Example 86 Step 2 using methyl (2S)-2-allyloxy-3-methoxy-propanoat and LiOH.

Step 3. (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-(methoxymethyl)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and (2S)-2-allyloxy-3-methoxy-propanoic acid. LC-MS calc. for C₃₂H₄₀ClN₂O₇S [M+H]⁺: m/z=631.22/633.21; Found: 631.0/632.8. ¹H NMR (600 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.24 (s, 1H), 7.18 (d, J=8.2 Hz, 1H), 7.09 (d, J=1.8 Hz, 1H), 6.99 (d, J=8.2 Hz, 1H), 5.46 (d, J=15.6 Hz, 1H), 5.39 (dd, J=15.6, 8.3 Hz, 1H), 4.51-4.43 (m, 1H), 4.12 (dd, J=23.8, 11.9 Hz, 2H), 3.84-3.75 (m, 2H), 3.69 (d, J=13.8 Hz, 2H), 3.60 (dd, J=10.3, 5.6 Hz, 1H), 3.56-3.46 (m, 1H), 3.40 (s, 3H), 3.35 (d, J=14.6 Hz, 1H), 3.23-3.13 (m, 2H), 3.11 (s, 3H), 2.83-2.63 (m, 3H), 2.35-2.25 (m, 1H), 2.06-1.97 (m, 1H), 1.97-1.77 (m, 4H), 1.77-1.66 (m, 1H), 1.63 (dt, J=18.8, 9.5 Hz, 2H), 1.45 (t, J=12.5 Hz, 1H).

Example 126

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-12-cyclopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (S)-2-(allyl(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid

To a suspension of (2S)-2-(tert-butoxycarbonylamino)-2-cyclopropyl-acetic acid (1500 mg, 6.97 mmol) in THF (20 mL) was added sodium hydride (60% in oil) (351 mg, 14.6 mmol) and the reaction mixture was stirred at r.t. for 20 min. Allyl bromide (927 mg, 7.67 mmol) was added drop-wise. After addition, the reaction was stirred at 50° C. overnight. The reaction was quenched with 10 mL saturated aqueous NH₄Cl and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (3% to 8%) to afford (2S)-2-[allyl(tert-butoxycarbonyl)amino]-2-cyclopropyl-acetic acid (840 mg, 47% yield) as a colorless oil.

Step 2: (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-cyclopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(allyl(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid in Step 3. LC-MS calc. for C₃₃H₄₁ClN₃O₅S [M+H]⁺: m/z=626.24/628.23; Found: 626.0/628.2. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.37 (dd, J=8.3, 2.1 Hz, 1H), 7.32 (s, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.11-7.06 (m, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.39-5.32 (m, 1H), 5.28 (d, J=5.6 Hz, 1H), 4.14-4.01 (m, 2H), 3.71 (d, J=14.6 Hz, 1H), 3.69-3.59 (m, 2H), 3.31 (d, J=14.6 Hz, 1H), 3.12 (s, 3H), 3.02 (dd, J=14.9, 6.7 Hz, 2H), 2.88 (d, J=13.5 Hz, 1H), 2.83-2.70 (m, 2H), 2.65 (q, J=8.3 Hz, 1H), 2.32-2.18 (m, 2H), 2.00 (d, J=13.5 Hz, 2H), 1.94-1.78 (m, 4H), 1.80-1.69 (m, 2H), 1.64 (p, J=11.1, 10.4 Hz, 2H), 1.46-1.37 (m, 1H), 1.02 (d, J=7.2 Hz, 1H), 0.73-0.54 (m, 3H).

Example 127

(3R,6R,7R,8E,12S,22S)-6′-Chloro-12-cyclopropyl-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12S,22S)-6′-chloro-12-cyclopropyl-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 126). LC-MS calc. for C₃₄H₄₂ClN₃O₅S [M+H]⁺: m/z=640.3/642.3; Found: 640.0/642.2. ¹H NMR (600 MHz, DMSO-d₆) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.13 (dd, J=8.2, 1.9 Hz, 1H), 6.85 (d, J=8.1 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.08 (dd, J=13.4, 6.9 Hz, 1H), 5.70-5.58 (m, 1H), 4.00 (s, 2H), 3.55 (t, J=12.7 Hz, 2H), 3.33 (s, 6H), 3.19 (s, 3H), 3.04 (dd, J=15.2, 10.0 Hz, 1H), 2.78 (s, 4H), 2.13-2.04 (m, 1H), 2.04-1.94 (m, 2H), 1.94-1.87 (m, 2H), 1.84 (dq, J=10.2, 5.5, 4.7 Hz, 2H), 1.69 (p, J=10.2 Hz, 2H), 1.39 (q, J=6.9 Hz, 1H), 1.04 (ddt, J=13.4, 9.2, 4.5 Hz, 1H), 0.89-0.83 (m, 1H), 0.70 (td, J=8.6, 7.5, 4.0 Hz, 1H), 0.60 (tt, J=8.8, 3.4 Hz, 1H), 0.56-0.47 (m, 2H).

Example 128

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-12-isopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (S)-2-(allyl(tert-butoxycarbonyl)amino)-3-methyl-butanoic acid

This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.

Step 2: (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-isopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(allyl(tert-butoxycarbonyl)amino)butanoic acid in Step 3. LC-MS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.25/630.25; Found: 628.1/629.8. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (dd, J=8.6, 3.9 Hz, 1H), 7.38 (s, 1H), 7.26 (s, 1H), 7.16 (d, J=9.6 Hz, 1H), 7.11-7.01 (m, 1H), 6.91 (s, 1H), 5.58-5.17 (m, 2H), 4.19-3.92 (m, 2H), 3.77-3.60 (m, 2H), 3.32 (d, J=14.6 Hz, 1H), 3.15 (d, J=25.0 Hz, 3H), 3.02 (dd, J=15.0, 6.7 Hz, 1H), 2.94 (s, 1H), 2.86-2.69 (m, 2H), 2.65 (s, 1H), 2.23 (dd, J=18.4, 10.8 Hz, 1H), 2.11-1.95 (m, 2H), 1.95-1.69 (m, 4H), 1.62 (dq, J=28.8, 9.6 Hz, 2H), 1.45-1.35 (m, 1H), 1.35-1.21 (m, 3H), 1.09-0.97 (m, 4H), 0.94 (d, J=6.9 Hz, 1H), 0.88 (t, J=6.9 Hz, 1H).

Example 129

(3R,6R,7R,8E,12S,22S)-6′-Chloro-7-methoxy-11-methyl-12-isopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12 S,22S)-6′-chloro-7-methoxy-12-isopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 128). LC-MS calc. for C₃₄H₄₅ClN₃O₅S [M+H]⁺: m/z=642.27/644.27; Found: 642.0/643.8. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.28 (s, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.05-6.93 (m, 1H), 6.07-5.16 (m, 2H), 4.28-3.97 (m, 2H), 3.82-3.68 (m, 1H), 3.53-3.26 (m, 4H), 3.20-2.91 (m, 2H), 2.91-2.66 (m, 3H), 2.58-2.14 (m, 4H), 2.14-1.90 (m, 5H), 1.91-1.54 (m, 5H), 1.54-1.37 (m, 3H), 1.32-1.20 (m, 6H).

Example 130

(3R,6R,7R,8Z,21S)-6′-Chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one and Example 131 (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one

Step 1: 1-allyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (120.0 mg, 0.23 mmol, Intermediate 8) in MeCN (5 mL) was added triethylamine (0.19 mL, 1.39 mmol) followed by phenyl chloroformate (0.09 mL, 0.70 mmol). The resulting mixture was stirred at r.t. for 20 min. LC-MS showed the consumption of starting material. Allylamine (0.35 mL, 4.6 mmol) was added and the reaction was stirred at r.t. overnight. Water (10 mL) was added, and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford 1-allyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (127 mg, 91% yield) as a white solid. LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.2/602.2; Found: 599.9/602.0.

Step 2: (3R,6R,7R,8Z,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one and (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one

To a stirred solution of 1-allyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (108.0 mg, 0.18 mmol) in DCE (180 mL) was bubbled with nitrogen for 20 min. Then Hoveyda-Grubbs II (22.5 mg, 0.04 mmol) was added under nitrogen. The reaction was further bubbled with nitrogen for 10 min. The reaction was stirred at 80° C. under nitrogen overnight. The reaction was cooled to r.t. and bubbled with air for 30 min. to deactivate the catalyst. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (20% to 100%). The desired fractions were collected, concentrated and re-purified by prep-HPLC on C18 column (30×250 mm, 10 m) using MeCN/H₂O (20% to 100%) to afford two products: P1 as a white solid (the earlier eluted product, 7.4 mg, 7.2%) and P2 as a white solid (the latter eluted product, 32.4 mg, 31% yield).

P1 was assigned to the cis-isomer Example 130 (3R,6R,7R,8Z,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one. LC-MS calc. for C₂₉H₃₅ClN₃O₅S [M+H]⁺: m/z=572.2/574.2; Found: 572.0/573.8. HPLC (cis isomer): C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: 60% MeCN/H₂O (with 0.1% TFA) 1 min, 60% to 95% 7 min, 95% 7 min; λ=220 nm. tR=6.7 min. ¹H NMR (600 MHz, DMSO-d₆) δ 10.58 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.29-7.24 (m, 1H), 7.19 (dd, J=8.5, 2.7 Hz, 1H), 7.12-7.05 (m, 1H), 7.02-6.94 (m, 2H), 5.76-5.71 (m, 1H), 5.42 (dd, J=15.9, 7.8 Hz, 1H), 4.22 (q, J=11.5, 11.0 Hz, 1H), 4.14-3.96 (m, 3H), 3.67 (d, J=14.5 Hz, 1H), 3.54-3.47 (m, 1H), 3.47-3.39 (m, 2H), 3.11 (s, 3H), 2.80 (dq, J=16.4, 6.6, 5.5 Hz, 1H), 2.72 (ddt, J=16.6, 10.9, 4.9 Hz, 2H), 2.07-1.95 (m, 3H), 1.95-1.82 (m, 4H), 1.73-1.59 (m, 2H), 1.46 (t, J=12.1 Hz, 2H).

P2 was assigned to the trans-isomer Example 131 and (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one. LC-MS calc. for C₂₉H₃₅ClN₃O₅S [M+H]⁺: m/z=572.2/574.2; Found: 571.9/573.7. HPLC (trans isomer): C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: 60% MeCN/H₂O (with 0.1% TFA) 1 min, 60% to 95% 7 min, 95% 7 min; λ=220 nm. tR=9.6 min. ¹H NMR (600 MHz, DMSO-d₆) δ 10.54 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.27 (dd, J=8.5, 2.4 Hz, 1H), 7.21-7.11 (m, 3H), 7.05 (d, J=8.3 Hz, 1H), 6.99 (d, J=2.2 Hz, 1H), 5.66 (dt, J=15.8, 3.9 Hz, 1H), 5.40 (ddt, J=15.7, 7.5, 1.9 Hz, 1H), 4.20 (d, J=12.2 Hz, 1H), 4.07 (d, J=12.1 Hz, 1H), 3.88-3.73 (m, 2H), 3.63 (d, J=14.5 Hz, 1H), 3.52 (dd, J=7.4, 5.1 Hz, 1H), 3.42-3.30 (m, 3H), 3.25 (dd, J=14.9, 9.2 Hz, 1H), 3.11 (s, 3H), 2.85-2.77 (m, 1H), 2.73 (q, J=8.3 Hz, 1H), 2.22 (dq, J=8.8, 3.6 Hz, 1H), 2.03 (dt, J=13.5, 4.2 Hz, 1H), 1.92-1.83 (m, 4H), 1.71-1.60 (m, 1H), 1.56-1.42 (m, 2H).

Example 132

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-11-ethyl-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and acetaldehyde. LC-MS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.25/630.25; Found: 628.0/630.2. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.4, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.03 (s, 1H), 6.99 (d, J=8.4 Hz, 1H), 5.84-5.68 (m, 1H), 5.48 (dd, J=15.4, 8.5 Hz, 1H), 4.10 (s, 2H), 3.81-3.67 (m, 1H), 3.59 (d, J=14.6 Hz, 2H), 3.48-3.37 (m, 1H), 3.37-3.28 (m, 2H), 3.26 (s, 3H), 3.23-3.13 (m, 1H), 3.05 (dd, J=15.2, 9.3 Hz, 1H), 2.88 (d, J=5.5 Hz, 1H), 2.85-2.64 (m, 4H), 2.51 (d, J=4.0 Hz, 1H), 2.30-2.14 (m, 1H), 1.90 (ddd, J=16.7, 13.7, 6.3 Hz, 4H), 1.74-1.53 (m, 2H), 1.48-1.36 (m, 1H), 1.28 (d, J=7.0 Hz, 4H), 1.10 (t, J=7.1 Hz, 3H).

Example 133

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-11-acetyl-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 87) (32.4 mg, 0.04 mmol) in DCM (0.50 mL) was added acetyl chloride (10.0 μL, 0.14 mmol) at r.t. The mixture was stirred for 10 min. and LC-MS indicated the reaction was completed. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with MeCN/H₂O (20% to 100%) (w/ 0.1% TFA) to afford the title product (9.9 mg, 35% yield). LC-MS calc. for C₃₃H₄₁ClN₃O₆S [M+H]: m/z=642.23/644.23; Found: 642.0/644.2. ¹H NMR (300 MHz, CDCl₃) δ 9.62 (d, J=13.2 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.37 (d, J=1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.44 (dd, J=15.3, 7.2 Hz, 1H), 5.20 (d, J=4.2 Hz, 1H), 5.00 (s, 1H), 4.14 (d, J=9.1 Hz, 2H), 3.84 (ddd, J=23.1, 15.6, 9.4 Hz, 3H), 3.66 (t, J=14.1 Hz, 2H), 3.40-3.19 (m, 3H), 3.19-3.04 (m, 4H), 2.89-2.50 (m, 4H), 2.36 (d, J=5.5 Hz, 1H), 2.15 (d, J=20.1 Hz, 3H), 2.08-1.54 (m, 4H), 1.45 (t, J=11.1 Hz, 4H).

Example 134

Methyl (3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate

This compound was prepared using procedures analogous to those described for Example 133 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and methyl chloroformate. LC-MS calc. for C₃₃H₄₁ClN₃O₇S [M+H]⁺: m/z=658.23/660.23; Found: 658.4/660.3. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.49 (s, 1H), 7.29 (d, J=15.1 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 7.08 (d, J=1.9 Hz, 1H), 6.99 (s, 1H), 5.48 (s, 1H), 4.57 (s, 1H), 4.09 (dd, J=30.4, 11.9 Hz, 2H), 3.90-3.80 (m, 1H), 3.80-3.60 (m, 6H), 3.25 (dd, J=27.0, 13.3 Hz, 2H), 3.19-3.09 (m, 2H), 3.07 (s, 1H), 2.84-2.69 (m, 2H), 2.65 (s, 1H), 2.35 (d, J=21.3 Hz, 1H), 1.99 (d, J=11.0 Hz, 1H), 1.97-1.86 (m, 2H), 1.80 (ddd, J=19.4, 16.4, 9.7 Hz, 2H), 1.64 (ddd, J=36.5, 19.0, 9.2 Hz, 5H), 1.45-1.36 (m, 3H), 1.35-1.28 (m, 1H).

Example 135

(3R,6R,7R,8E,12R,22S)-6′-Chloro-7-methoxy-12-methyl-11-methylsulfonyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 133 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and methanesulfonyl chloride. LC-MS calc. for C₃₂H₄₁ClN₃O₇S₂ [M+H]⁺: m/z=678.2/680.2; Found: 678.4/680.3.

Example 136

(3R,6R,7S,8E,22S)-6′-Chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: 2-(allylamino)-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide

This compound was prepared using procedures analogous to those described for Example 43 Step 2 using (3R)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 43 Step 1). LC-MS calc. for C₃₄H₄₅ClN₃O₅S [M+H]⁺: m/z=642.28/644.28; Found: 642.9/644.8.

Step 2: (3R,6R,7S,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide. LC-MS calc. for C₃₂H₄₁ClN₃O₅S [M+H]⁺: m/z=614.24/616.24; Found: 614.8/616.7. ¹H NMR (600 MHz, DMSO-d₆) δ 7.60 (d, J=8.5 Hz, 1H), 7.22 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.16 (d, J=1.8 Hz, 1H), 6.96 (s, 1H), 6.85 (d, J=8.2 Hz, 1H), 5.74 (s, 1H), 5.58 (dd, J=15.8, 6.0 Hz, 1H), 4.08-3.85 (m, 3H), 3.48 (d, J=14.3 Hz, 2H), 3.38 (dd, J=14.6, 7.9 Hz, 1H), 3.29-3.24 (m, 2H), 3.20 (s, 3H), 3.15 (dt, J=14.5, 5.0 Hz, 1H), 2.83-2.76 (m, 1H), 2.75-2.68 (m, 1H), 2.64-2.56 (m, 1H), 2.41-2.29 (m, 1H), 2.01 (ddt, J=13.7, 9.0, 4.5 Hz, 2H), 1.91-1.77 (m, 3H), 1.75-1.41 (m, 4H), 1.32 (s, 3H), 1.23 (s, 3H).

Example 137

(3R,6R,7S,8E,22S)-6′-Chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 136) and formaldehyde aqueous solution (37%). LC-MS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.25/630.25; Found: 628.7/630.5. ¹H NMR (600 MHz, CDCl₃) δ 7.66 (d, J=8.5 Hz, 1H), 7.53-7.43 (m, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 6.92-6.85 (m, 1H), 5.83 (s, 1H), 5.54 (dd, J=15.6, 5.3 Hz, 1H), 5.45-5.19 (m, 1H), 4.07 (q, J=11.9 Hz, 2H), 3.71 (d, J=14.8 Hz, 1H), 3.63 (d, J=5.1 Hz, 1H), 3.35 (s, 4H), 3.07 (dd, J=15.1, 10.3 Hz, 1H), 2.78 (dqt, J=22.2, 10.8, 5.1 Hz, 5H), 2.28 (s, 3H), 2.22 (t, J=7.7 Hz, 1H), 2.03-1.89 (m, 6H), 1.89-1.80 (m, 2H), 1.76 (q, J=8.9 Hz, 2H), 1.63 (ddd, J=18.1, 11.7, 5.4 Hz, 2H), 1.49-1.39 (m, 2H).

Example 138

(3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

Step 1: (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24-]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (Intermediate 6) and 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (Example 116 Step 3) in Step 3. LC-MS calc. for C₃₉H₄₉ClN₃O₈S [M+H]⁺: m/z=754.29/756.28; Found: 754.0/756.4.

Step 2: (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

(3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (40 mg, 0.05 mmol) was stirred in 2 N HCl in EtOAc (3 mL) at r.t. overnight. The reaction was diluted with EtOAc, washed with saturated aqueous NaHCO₃ solution and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (35 mg, 100% yield) which was used for the next step without further purification. LC-MS calc. for C₃₄H₄₁ClN₃O₆S [M+H]⁺: m/z=654.23/656.23; Found 654.0/656.2.

Step 3: (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (35 mg, 0.05 mmol) in DCE (2 mL) was added two drops of formaldehyde aqueous solution (37% wt %, ca. 22 mg, 0.26 mmol HCHO). After 30 min., sodium cyanoborohydride (16.8 mg, 0.27 mmol) was added in one portion, and stirred at r.t. for 4 h. The reaction was diluted with DCM and water, and filtered through a pad of Celite. The organic layer was washed with saturated aqueous NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H₂O (t_R=24 min) to afford (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (14 mg, 39% yield) as a white product. LC-MS calc. for C₃₅H₄₃ClN₃O₆S [M+H]⁺: m/z=668.26/670.25; Found: 668.0/670.3.

Step 4: (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one

To a solution of (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (14.0 mg, 0.02 mmol) in MeOH (0.5 mL) and THF (0.2 mL) was added a solution of potassium carbonate (28.95 mg, 0.21 mmol) in water (0.5 mL) at r.t. After 16 h, LC-MS indicated the completion of reaction. The reaction was extracted with DCM, washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (10 mg, 76% yield), which was sufficiently pure without further purifications. LC-MS calc. for C₃₃H₄₁ClN₃O₅S [M+H]⁺: m/z=626.25/628.24; Found: 626.0/628.2. ¹H NMR (600 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.98 (app d, J=8.3 Hz, 2H), 5.70 (app s, 1H), 5.64-5.55 (m, 1H), 4.12 (d, J=12.2 Hz, 1H), 4.07 (d, J=12.1 Hz, 1H), 4.00 (t, J=7.8 Hz, 1H), 3.73 (d, J=14.7 Hz, 1H), 3.51 (app s, 1H), 3.33 (d, J=14.8 Hz, 1H), 3.05 (dd, J=15.2, 10.0 Hz, 1H), 2.90-2.64 (m, 4H), 2.49 (s, 1H), 2.42 (s, 3H), 2.31-2.23 (m, 1H), 2.18-2.09 (m, 3H), 2.04-1.91 (m, 5H), 1.88-1.78 (m, 1H), 1.75-1.60 (m, 3H), 1.49-1.39 (m, 1H).

Example 139

[(3R,6R,7R,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 138) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₆H₄₆ClN₄O₆S [M+H]⁺: m/z=697.27/699.27; Found 697.9/699.7. ¹H NMR (600 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 5.75 (s, 1H), 5.57 (s, 1H), 5.38-5.31 (m, 1H), 5.01 (s, 1H), 4.12-4.02 (m, 2H), 3.78 (d, J=14.5 Hz, 1H), 3.67 (s, 1H), 3.26 (d, J=14.6 Hz, 1H), 3.02 (dd, J=15.2, 9.9 Hz, 2H), 2.92 (d, J=13.5 Hz, 5H), 2.80-2.71 (m, 2H), 2.52 (s, 1H), 2.37 (s, 3H), 2.27 (s, 1H), 2.22 (t, J=7.7 Hz, 1H), 2.15 (d, J=20.7 Hz, 1H), 2.07-1.98 (m, 4H), 1.98-1.90 (m, 3H), 1.90-1.76 (m, 4H), 1.41 (t, J=12.7 Hz, 2H).

Example 140

2-[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (20 mg, 0.03 mmol, Example 32) in THF (0.25 mL) was added NaH (5.3 mg, 0.13 mmol, 60% suspension on mineral oil). The reaction was stirred at 0° C. for 30 min., and 2-bromo-N,N-dimethyl-acetamide (33 mg, 0.20 mmol) was added. The reaction was slowly warmed to r.t. over 4 h. The reaction was quenched with saturated NH₄Cl and diluted with EtOAc (3.0 mL). The organic layer separated, washed with water and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC on a C18 column with H₂O:MeCN (20% to 100%) to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide (12 mg, 52% yield). LC-MS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.2/688.2; Found: 686.8/688.8.

Example 141

2-[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide

This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36). LC-MS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.2/688.2; Found: 686.7/688.8.

Example 142

2-[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide

This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 40). LC-MS calc. for C₃₅H₄₃ClN₃O₇S [M+H]⁺: m/z=684.2/686.2; Found: 684.7/686.9.

Example 143

2-[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide

This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 38). LC-MS calc. for C₃₅H₄₃ClN₃O₇S [M+H]⁺: m/z=684.2/686.2; Found: 684.7/687.0.

Example 144

(3R,6R,7S,8E,12R,22S)-6′-Chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

Step 1: (3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 0.60 mmol, Intermediate 3) in DMF (5 mL) was added TBSCl (224 mg, 1.49 mmol) and imidazole (203 mg, 2.98 mmol). The resulting solution was stirred at 20° C. overnight. The reaction was quenched with water (15 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 75%) to afford (3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (315 mg, 85% yield) as a white solid. LC-MS calc. for C₃₂H₄₆ClN₂O₄SiS [M+H]⁺: m/z=617.3/619.3; Found 617.5/619.8.

Step 2: tert-butyl N-allyl-N-[(1R)-2-[[(3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate

A solution of (3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (315 mg, 0.51 mmol), (2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid (233 mg, 1.02 mmol, Example 121 Step 1) in DCM (3 mL) was added DMAP (206 mg, 2.04 mmol) and EDCI (195 mg, 1.02 mmol) at r.t. The mixture was stirred for 3 h. The reaction was diluted with DCM (10 mL), washed with 1 N HCl (3 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford tert-butyl N-allyl-N-[(1R)-2-[[(3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (264 mg, 62% yield) as a white solid. LC-MS calc. for C₄₃H₆₃ClN₃O₇SiS [M+H]⁺: m/z=828.4/830.4; Found 828.9/830.9.

Step 3: tert-butyl N-allyl-N-[(1R)-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate

To a stirred solution of tert-butyl N-allyl-N-[(1R)-2-[[(3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (230 mg, 0.28 mmol) in THF (10 mL) was added TBAF (725 mg, 2.78 mmol, 1 M in THF, pre-treated with molecular sieve). The resulting solution was stirred at 20° C. overnight. The reaction was quenched with sat. NH₄Cl aq. Solution (10 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 60%) to afford tert-butyl N-allyl-N-[(1R)-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (190 mg, 95% yield). LC-MS calc. for C₃₇H₄₉ClN₃O₇S [M+H]⁺: m/z=714.3/716.3; Found 714.8/717.0.

Step 4: tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate

A solution of tert-butyl N-allyl-N-[(1R)-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (260 mg, 0.36 mmol) in DCE (200 mL) was bubbled with N₂ for 30 min. 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethylaminosulfonyl)phenyl]-methyleneruthenium(II)dichloride (Zhan-catalyst-1B) (53.42 mg, 0.07 mmol) was added and the reaction mixture was further bubbled with N₂ for 30 min, and was heated to 40° C. under N₂ for 3 h. LC-MS analysis indicated the completion of reaction. The reaction was cool to r.t. while being exposed to air. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Hetpanes (2% to 50%) to afford two products: P1 (the earlier eluted product, 110 mg, 44.0% yield) as a light brown colored solid and P2 (the latter eluted product, 90 mg, 0.13 mmol, 36% yield) as a light brown colored solid.

P1 was assigned to the trans-isomer tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.3/688.3; Found: 686.8/688.3.

And P2 was assigned to the cis-isomer tert-butyl (3R,6R,7S,8Z,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.3/688.3; Found: 686.8/688.3.

Step 5: (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

A solution of tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate (110.0 mg, 0.16 mmol, P1 from Step 4) in DCE (2 mL) was added phosphoric acid (3.0 mL, 51 mmol) and the resulting solution was stirred at 20° C. overnight. LC-MS analysis indicated the completion of reaction. The reaction was quenched with aq. 1M NaOH solution (20 mL) and extracted with DCM (10 mL×2). The combined organic layers were concentrated under reduced pressure to afford (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (87 mg, 92% yield) as a light brown colored solid. LC-MS calc. for C₃₀H₃₇ClN₃O₅S [M+H]⁺: m/z=586.2/588.2; Found: 586.7/588.6.

Step 6: (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution (37%). LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.2/602.2; Found: 600.6/602.8. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (s, 1H), 7.01 (d, J=28.3 Hz, 2H), 6.69 (d, J=141.3 Hz, 2H), 6.20 (s, 1H), 5.63 (d, J=15.5 Hz, 1H), 5.43-5.24 (m, 1H), 4.11 (s, 1H), 4.05-3.69 (m, 3H), 3.59-3.46 (m, 1H), 3.25-3.06 (m, 2H), 2.79 (d, J=83.6 Hz, 5H), 2.31 (s, 3H), 2.24-2.19 (m, 1H), 2.08-1.93 (m, 3H), 1.83 (s, 3H), 1.59 (d, J=56.9 Hz, 4H), 1.44 (d, J=7.6 Hz, 2H).

Example 145

[(3R,6R,7S,8E,12R,22S)-6′-Chloro-11,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₄H₄₄ClN₄O₆S [M+H]⁺: m/z=671.3/673.3; Found: 671.7/673.9. ¹H NMR (300 MHz, CDCl₃) δ 7.65 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.3 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.13-6.88 (m, 3H), 5.84-5.46 (m, 2H), 5.30 (d, J=4.3 Hz, 1H), 4.32-3.97 (m, 3H), 3.67 (d, J=14.5 Hz, 2H), 3.42-3.28 (m, 2H), 2.95 (d, J=6.1 Hz, 6H), 2.79 (p, J=6.2, 4.7 Hz, 3H), 2.64 (s, 3H), 2.54-2.36 (m, 2H), 2.16-1.73 (m, 7H), 1.68-1.48 (m, 3H), 1.35 (s, 3H).

Example 146

[(3R,6R,7S,8E,12R,22S)-6′-Chloro-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-(dimethylcarbamoyloxy)-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-

This compound was prepared using procedures analogous to those described for Example 34 using tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-1-carboxylate (P1 Example 144 Step 4) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₈H₅₀ClN₄O₈S [M+H]⁺: m/z=757.30/759.30; Found: 758.04/760.12.

Step 2: [(3R,6R,7S,8E,12R,22S)-6′-chloro-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0-3,6.0-19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 144 Step 5 using tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-(dimethylcarbamoyloxy)-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate and phosphoric acid. LC-MS calc. for C₃₃H₄₂ClN₄O₆S [M+H]⁺: m/z=657.24/659.24; Found: 657.73/659.70. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (dd, J=8.6, 4.5 Hz, 1H), 7.43-7.33 (m, 1H), 7.29 (s, 1H), 7.20-7.06 (m, 3H), 6.94 (dd, J=8.4, 4.6 Hz, 1H), 5.76-5.52 (m, 2H), 5.15 (t, J=4.6 Hz, 1H), 4.23-3.97 (m, 2H), 3.63 (dd, J=14.5, 9.7 Hz, 2H), 3.54-3.25 (m, 5H), 2.86 (s, 3H), 2.80-2.72 (m, 4H), 2.67-2.47 (m, 3H), 2.23 (t, J=7.4 Hz, 2H), 2.02-1.75 (m, 6H), 1.47 (d, J=6.7 Hz, 4H).

Example 147

[(3R,6R,7S,8E,12S,22S)-6′-Chloro-11,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: tert-butyl (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate and tert-butyl (3R,6R,7S,8Z,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate

The compounds were prepared using procedures analogous to those described for Example 32 Step 1-3 using (3S)6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) and (2S)-2-[allyl(tert butoxycarbonyl)amino]propanoic acid (Example 85 Step 1) in Step 1. The reaction mixture was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (3% to 50%) to afford two products: P1 (the earlier eluted product) was assigned to the Z-isomer tert-butyl (3R,6R,7S,8Z,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate and P2 (the latter eluted product) was assigned to the E-isomer tert-butyl (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.2/688.2; Found: 686.7/688.1.

Step 2: (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 144 Step 5 using tert-butyl(3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate (P2 Step 1) and phosphoric acid (85% solution in water). LC-MS calc. for C₃₀H₃₇ClN₃O₅S [M+H]⁺: m/z=586.2/588.2; Found: 586.6/588.6.

Step 3: (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

The compounds were prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution (37%). LC-MS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.2/602.2; Found: 600.8/602.6.

Step 4: [(3R,6R,7S,8E,12S,22S)-6′-chloro-11,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

The compounds were prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C₃₄H₄₄ClN₄O₆S [M+H]⁺: m/z=671.26/673.26; Found: 671.7/673.8.

Example 148

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-hydroxyethyl)piperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 g, 4.66 mmol, Example 32) in Step 1 and 2-piperazin-1-ylethanol in Step 2. LC-MS calc. for C₃₈H₅₀ClN₄O₈S [M+H]⁺: m/z=757.30/759.30; Found: 757.7/759.7. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 6.98 (dd, J=7.6, 5.2 Hz, 2H), 5.91-5.78 (m, 1H), 5.71 (dd, J=15.7, 4.9 Hz, 1H), 5.33 (d, J=9.1 Hz, 1H), 4.12 (dt, J=13.9, 9.6 Hz, 4H), 3.80-3.67 (m, 2H), 3.67-3.61 (m, 2H), 3.47 (d, J=4.4 Hz, 1H), 3.41 (s, 1H), 3.37 (d, J=14.6 Hz, 1H), 3.21 (dd, J=15.0, 9.3 Hz, 2H), 2.87-2.67 (m, 5H), 2.61-2.55 (m, 3H), 2.45-2.33 (m, 3H), 1.99 (dd, J=24.2, 8.9 Hz, 4H), 1.89-1.72 (m, 4H), 1.64 (t, J=9.4 Hz, 2H), 1.50 (d, J=12.7 Hz, 1H), 1.45 (s, 3H), 1.37 (s, 3H).

Example 149

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(4-methylpiperazin-1-yl)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 2-(4-methylpiperazin-1-yl)ethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C₃₉H₅₃ClN₅O₇S [M+H]⁺: m/z=770.34/772.34; Found: 770.7/772.7. ¹H NMR (300 MHz, CDCl₃) δ 7.71 (d, J=8.5 Hz, 1H), 7.39 (d, J=8.3 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (s, 2H), 6.93 (d, J=8.3 Hz, 1H), 6.82 (d, J=8.3 Hz, 1H), 6.49 (s, 1H), 6.18 (d, J=15.2 Hz, 1H), 5.58 (d, J=15.6 Hz, 1H), 5.18 (s, 1H), 4.20-4.02 (m, 4H), 3.66 (dd, J=34.7, 13.8 Hz, 3H), 3.30 (dd, J=17.0, 9.0 Hz, 2H), 3.01 (d, J=14.9 Hz, 5H), 2.80 (d, J=12.3 Hz, 7H), 2.39 (s, 3H), 2.32-2.18 (m, 2H), 1.88 (ddd, J=27.1, 21.1, 12.4 Hz, 6H), 1.59 (dd, J=18.3, 8.8 Hz, 3H), 1.39 (d, J=2.5 Hz, 6H).

Example 150

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(4-hydroxy-1-piperidyl)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-aminoethyl)piperidin-4-ol to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₂ClN₄O₈S [M+H]⁺: m/z=771.32/773.32; Found: 771.8/773.8. 1H NMR (300 MHz, CDCl₃) δ 7.73 (d, J=8.5 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.18 (dd, J=8.4, 2.1 Hz, 2H), 7.14-7.06 (m, 2H), 6.88 (d, J=8.2 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 6.41-6.26 (m, 1H), 5.50 (d, J=15.8 Hz, 1H), 5.14 (s, 1H), 4.30 (dd, J=14.9, 4.9 Hz, 1H), 4.23-4.08 (m, 2H), 4.04 (d, J=12.6 Hz, 2H), 3.84 (dd, J=15.6, 10.5 Hz, 2H), 3.77-3.63 (m, 3H), 3.30 (dd, J=39.0, 12.7 Hz, 3H), 2.97 (dt, J=25.5, 13.4 Hz, 5H), 2.85-2.32 (m, 4H), 2.19 (dd, J=17.7, 8.8 Hz, 2H), 1.94 (dt, J=22.0, 14.6 Hz, 6H), 1.85-1.68 (m, 4H), 1.67-1.48 (m, 3H), 1.37 (d, J=8.6 Hz, 6H).

Example 151

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-triox-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-1-methylpyrrolidin-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using (3S)-1-methylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.3/729.3; Found: 727.5/729.2. ¹H NMR (300 MHz, CDCl₃) δ 7.71 (d, J=8.5 Hz, 1H), 7.31 (dd, J=8.3, 2.0 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=4.2, 2.2 Hz, 2H), 6.87 (d, J=8.2 Hz, 1H), 6.42-6.12 (m, 1H), 5.47 (dd, J=15.8, 2.6 Hz, 1H), 5.08 (s, 1H), 4.47-4.28 (m, 2H), 4.13-4.00 (m, 3H), 3.87 (d, J=11.6 Hz, 1H), 3.77-3.59 (m, 2H), 3.21 (d, J=14.3 Hz, 1H), 3.07-2.85 (m, 6H), 2.80-2.66 (m, 7H), 2.48 (ddd, J=14.3, 7.1, 3.1 Hz, 1H), 2.21-2.13 (m, 2H), 2.05-1.85 (m, 3H), 1.77 (td, J=9.3, 8.9, 3.0 Hz, 2H), 1.59-1.48 (m, 1H), 1.36 (s, 3H), 1.33 (s, 3H).

Example 152

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-1-methylpyrrolidin-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using (3R)-1-methylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.3/729.3; Found: 727.6/729.3. ¹H NMR (300 MHz, CDCl₃) δ 7.71 (d, J=8.4 Hz, 1H), 7.32 (dd, J=8.1, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.11-7.03 (m, 2H), 6.87 (d, J=8.2 Hz, 1H), 6.27 (dd, J=14.3, 6.9 Hz, 1H), 5.63-5.38 (m, 1H), 5.06 (s, 1H), 4.31 (td, J=13.4, 12.5, 5.2 Hz, 2H), 4.19-3.97 (m, 3H), 3.81-3.57 (m, 3H), 3.22 (d, J=14.4 Hz, 1H), 3.03-2.33 (m, 17H), 2.18 (q, J=8.9, 7.3 Hz, 1H), 2.04-1.72 (m, 5H), 1.54 (p, J=9.2 Hz, 1H), 1.37 (s, 3H), 1.34 (s, 3H).

Example 153

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-1-methylpyrrolidin-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 3-hydroxyazetidine-1-carboxylate to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₈S [M+H]⁺: m/z=700.24/702.24; Found: 700.3/702.0. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, J=8.5 Hz, 1H), 7.48-7.31 (m, 1H), 7.20-7.02 (m, 2H), 6.99-6.75 (m, 2H), 6.26 (s, 1H), 5.64 (d, J=15.2 Hz, 1H), 5.09 (s, 1H), 4.55 (s, 1H), 4.43-4.16 (m, 2H), 4.10-4.00 (m, 4H), 3.81 (d, J=12.8 Hz, 1H), 3.70 (d, J=14.7 Hz, 1H), 3.62-3.44 (m, 1H), 3.41-3.34 (m, 2H), 3.01 (q, J=7.4 Hz, 2H), 2.75 (d, J=10.5 Hz, 4H), 2.20 (q, J=7.3, 5.5 Hz, 1H), 1.99-1.75 (m, 4H), 1.61 (q, J=9.3 Hz, 1H), 1.40-1.27 (m, 9H).

Example 154

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-(dimethylamino)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3S)-N,N-dimethylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.3/743.3; Found: 741.4/743.2. ¹H NMR (499 MHz, DMSO-d₆) δ 7.67 (dd, J=8.6, 3.4 Hz, 1H), 7.27 (dt, J=8.6, 2.0 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.10 (dd, J=8.2, 2.0 Hz, 1H), 6.92-6.79 (m, 2H), 6.22 (s, 1H), 5.71-5.21 (m, 2H), 5.10 (d, J=32.3 Hz, 1H), 4.02 (d, J=5.9 Hz, 2H), 3.87 (d, J=9.4 Hz, 1H), 3.57 (d, J=13.5 Hz, 6H), 3.13-2.99 (m, 2H), 2.86-2.64 (m, 4H), 2.29 (d, J=35.6 Hz, 5H), 2.13-1.91 (m, 4H), 1.86 (d, J=7.5 Hz, 4H), 1.67 (dd, J=21.5, 12.4 Hz, 3H), 1.45 (q, J=12.9, 10.8 Hz, 2H), 1.22 (s, 3H), 1.12 (s, 3H).

Example 155

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using N′,N′-dimethylethane-1,2-diamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₈ClN₄O₇S [M+H]⁺: m/z=715.29/717.29; Found: 715.4/717.2. 1H NMR (499 MHz, DMSO-d₆) δ 7.67 (d, J=8.6 Hz, 1H), 7.28 (dd, J=8.5, 2.4 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.15-7.00 (m, 2H), 6.95 (d, J=2.1 Hz, 1H), 6.85 (d, J=8.1 Hz, 1H), 6.28 (s, 1H), 5.48 (dd, J=16.1, 3.7 Hz, 1H), 4.92 (s, 1H), 4.10-3.95 (m, 2H), 3.89 (dd, J=14.0, 7.7 Hz, 1H), 3.77 (s, 1H), 3.55 (d, J=14.2 Hz, 2H), 3.27-3.12 (m, 4H), 3.12-3.00 (m, 2H), 2.86-2.56 (m, 7H), 2.44-2.24 (m, 2H), 2.15-1.90 (m, 2H), 1.84 (dd, J=14.0, 7.6 Hz, 3H), 1.67 (ddd, J=43.0, 21.1, 12.2 Hz, 3H), 1.45 (dt, J=26.0, 9.4 Hz, 2H), 1.21 (s, 3H), 1.13 (s, 3H).

Example 156

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(methylamino)azetidine-1-carboxylate

Step 1: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-[tert-butoxycarbonyl(methyl)amino]azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using tert-butyl N-(azetidin-3-yl)-N-methyl-carbamate to replace 1-(2-methoxyethyl)piperazine in Step 2. The reaction mixture was concentrated under reduced pressure and the residue was directly used for the next step. LC-MS: calcd. for C₄₁H₅₄ClN₄O₉S [M+H]⁺: m/z=813.3/815.3; Found: 813.7/815.5.

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(methylamino)azetidine-1-carboxylate

To a solution of [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0-3,6.0-19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-[tert-butoxycarbonyl(methyl)amino]azetidine-1-carboxylate (30.0 mg, 0.04 mmol) in IPA (1 mL) and DCM (0.10 mL) was added phosphoric acid (0.5 mL, 8.6 mmol). The resulting solution was vigorously stirred at 20° C. for 3 h. The reaction mixture was quenched with 1M NaOH aqueous solution and extracted with DCM (2×2 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 μm) with MeOH/H₂O (15% to 100%) to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(methylamino)azetidine-1-carboxylate (16.8 mg, 63.9% yield) as a white solid. LCMS calc. for C₃₆H₄₆ClN₄O₇S [M+H]⁺: m/z=713.28/715.28; Found: 713.4/715.3. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.53-7.37 (m, 1H), 7.22-7.05 (m, 3H), 7.00-6.78 (m, 2H), 5.67 (dd, J=15.9, 4.2 Hz, 1H), 5.11 (s, 1H), 4.32-4.00 (m, 6H), 3.85-3.66 (m, 3H), 3.59 (s, 2H), 3.39 (t, J=17.0 Hz, 3H), 3.22-3.07 (m, 3H), 2.79 (s, 3H), 2.56-2.35 (m, 3H), 2.23 (t, J=7.6 Hz, 1H), 2.09-1.72 (m, 6H), 1.45 (s, 3H), 1.33 (s, 3H).

Example 157

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(methylamino)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-(2-aminoethyl)-N-methyl-carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C₃₅H₄₆ClN₄O₇S [M+H]⁺: m/z=701.28/703.28; Found 701.4/703.3. ¹H NMR (499 MHz, DMSO-d₆) δ 7.65 (dd, J=8.8, 4.1 Hz, 1H), 7.27 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.06 (dd, J=8.2, 1.9 Hz, 1H), 7.02-6.87 (m, 2H), 6.84 (d, J=8.1 Hz, 1H), 6.55-6.15 (m, 1H), 5.65-4.77 (m, 2H), 4.00 (s, 2H), 3.89 (d, J=6.0 Hz, 2H), 3.66-3.50 (m, 2H), 3.19 (dd, J=24.7, 13.1 Hz, 3H), 3.11-2.93 (m, 3H), 2.80 (d, J=18.4 Hz, 2H), 2.76-2.59 (m, 4H), 2.29 (d, J=8.7 Hz, 1H), 2.00 (ddd, J=21.8, 12.3, 6.1 Hz, 2H), 1.90-1.76 (m, 3H), 1.76-1.56 (m, 3H), 1.49-1.34 (m, 2H), 1.23-1.18 (m, 3H), 1.12 (s, 3H).

Example 185

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 2,2-dimethylmorpholine-4-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 2,2-dimethylmorpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₅ClN₃O₈S [M+H]⁺: m/z=742.29/744.29; Found: 742.6/744.6. 1H NMR (499 MHz, DMSO-d6) δ 7.64 (d, J=8.6 Hz, 1H), 7.25 (ddd, J=8.5, 6.1, 2.3 Hz, 2H), 7.18 (d, J=2.4 Hz, 1H), 7.06-6.92 (m, 2H), 6.51 (s, 1H), 5.67 (s, 1H), 5.33 (td, J=4.5, 2.2 Hz, 1H), 5.18 (s, 1H), 4.18-4.03 (m, 3H), 4.01-3.86 (m, 1H), 3.64-3.49 (m, 4H), 3.31-3.15 (m, 2H), 2.83-2.62 (m, 3H), 2.41-2.14 (m, 1H), 2.05-1.94 (m, 4H), 1.83 (d, J=4.7 Hz, 3H), 1.68 (ddt, J=44.8, 18.3, 8.4 Hz, 3H), 1.55-1.43 (m, 3H), 1.39 (s, 2H), 1.22 (s, 3H), 1.14-1.07 (m, 5H).

Example 159

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(2-methoxyethyl)-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 2-methoxy-N-methyl-ethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₇ClN₃O₈S [M+H]⁺: m/z=716.27/718.27; Found: 716.6/718.6. ¹H NMR (499 MHz, DMSO-d₆) δ 7.69-7.62 (m, 1H), 7.33-7.23 (m, 2H), 7.20 (dd, J=5.6, 2.4 Hz, 2H), 6.94 (s, 2H), 5.73 (d, J=39.4 Hz, 1H), 5.39-5.05 (m, 1H), 4.23-3.83 (m, 3H), 3.66-3.52 (m, 2H), 3.46 (s, 3H), 3.25 (d, J=12.2 Hz, 4H), 3.16-3.07 (m, 1H), 2.97 (d, J=21.7 Hz, 1H), 2.91-2.63 (m, 5H), 2.60 (s, 1H), 2.47-2.20 (m, 2H), 2.01 (dt, J=18.3, 7.8 Hz, 3H), 1.86 (s, 3H), 1.78-1.59 (m, 3H), 1.57-1.42 (m, 2H), 1.42-1.33 (m, 2H), 1.20-1.12 (m, 2H).

Example 160

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (2S)-2-(methoxymethyl)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (2S)-2-(methoxymethyl)pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.28; Found: 742.5/744.5. ¹H NMR (499 MHz, DMSO-d₆) δ 7.64 (d, J=8.5 Hz, 1H), 7.28-7.21 (m, 2H), 7.19-7.16 (m, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.98-6.94 (m, 1H), 6.65 (s, 1H), 5.72-5.67 (m, 1H), 5.21-5.15 (m, 1H), 4.09 (t, J=15.3 Hz, 2H), 3.94 (d, J=15.4 Hz, 1H), 3.86-3.83 (m, 1H), 3.56 (d, J=14.9 Hz, 1H), 3.28-3.15 (m, 7H), 2.80-2.72 (m, 2H), 2.04-1.94 (m, 5H), 1.83-1.77 (m, 6H), 1.49-1.46 (m, 2H), 1.42-1.38 (m, 2H), 1.28-1.22 (m, 10H).

Example 161

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (2R)-2-(methoxymethyl)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (2R)-2-(methoxymethyl)pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.28; Found: 742.5/744.5.

Example 162

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-ethoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3S)-3-ethoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.28; Found: 742.6/744.6. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.34 (t, J=7.2 Hz, 1H), 7.13 (dt, J=8.6, 2.2 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 6.99 (s, 1H), 6.84 (dd, J=8.3, 4.0 Hz, 1H), 6.13 (s, 1H), 5.70 (dt, J=14.7, 6.4 Hz, 1H), 5.17 (d, J=4.6 Hz, 1H), 4.08-3.93 (m, 4H), 3.84 (d, J=13.0 Hz, 1H), 3.67 (d, J=14.4 Hz, 1H), 3.50-3.42 (m, 7H), 3.25 (d, J=14.3 Hz, 1H), 3.15-3.01 (m, 1H), 2.75 (q, J=5.2 Hz, 2H), 2.37-2.30 (m, 1H), 2.21 (t, J=7.6 Hz, 1H), 2.02-1.86 (m, 5H), 1.81-1.75 (m, 3H), 1.62-1.54 (m, 1H), 1.34-1.15 (m, 11H).

Example 163

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-(methylamino)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-methyl-N-[(3S)-pyrrolidin-3-yl]carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.3/729.3; Found: 727.5/729.3. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.40 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.89 (d, J=8.3 Hz, 1H), 6.81 (d, J=2.2 Hz, 1H), 6.29 (td, J=10.4, 9.0, 4.9 Hz, 1H), 5.64 (dt, J=15.9, 2.7 Hz, 1H), 5.09 (s, 1H), 4.36 (d, J=12.4 Hz, 1H), 4.17-3.97 (m, 3H), 3.84 (d, J=13.4 Hz, 1H), 3.76-3.07 (m, 14H), 2.98-2.89 (m, 1H), 2.78 (d, J=8.6 Hz, 3H), 2.34-2.11 (m, 3H), 1.92-1.85 (m, 5H), 1.61 (d, J=6.6 Hz, 1H), 1.38 (s, 3H), 1.32 (s, 3H).

Example 164

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(methylamino)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.3/729.3; Found: 727.3/729.1. ¹H NMR (499 MHz, DMSO-d₆) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.20-7.13 (m, 1H), 7.10-6.99 (m, 1H), 6.91-6.73 (m, 2H), 6.22-6.17 (m, 1H), 5.54-5.46 (m, 1H), 4.91 (s, 1H), 4.11-3.94 (m, 3H), 3.90-3.78 (m, 2H), 3.70-3.65 (m, 4H), 3.01 (dd, J=16.0, 10.5 Hz, 2H), 2.88-2.67 (m, 4H), 2.67-2.55 (m, 3H), 2.29 (dq, J=15.3, 7.5, 6.3 Hz, 1H), 2.22-2.07 (m, 2H), 2.03-1.92 (m, 2H), 1.89-1.81 (m, 3H), 1.70-1.63 (m, 3H), 1.47-1.34 (m, 1H), 1.24 (s, 3H), 1.18 (s, 3H), 1.08 (d, J=8.4 Hz, 2H) ppm.

Example 165

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-fluoroazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 3-Fluoroazetidine hydrochloride and Hunig's Base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₂ClFN₃O₇S [M+H]⁺: m/z=702.23/704.23; Found: 702.7/704.7. ¹H NMR (300 MHz, CDCl₃) δ 9.13 (s, 1H, NH), 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.02-6.98 (m, 1H), 6.96 (d, J=1.8 Hz, 1H), 5.88-5.79 (m, 1H), 5.70 (dd, J=15.6, 4.9 Hz, 1H), 5.38 (m, 1H), 5.23 (m, 2H), 4.14 (m, 4H), 3.74 (dd, J=14.1, 8.3 Hz, 2H), 3.37 (d, J=14.5 Hz, 2H), 3.22 (dd, J=15.0, 9.3 Hz, 1H), 2.79 (d, J=4.1 Hz, 3H), 2.41-2.33 (m, 1H), 2.16 (s, 4H), 2.01 (dd, J=16.7, 9.0 Hz, 3H), 1.83 (d, J=8.4 Hz, 2H), 1.64 (dt, J=18.8, 9.3 Hz, 2H), 1.46 (s, 3H), 1.37 (s, 3H).

Example 166

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3,3-difluoropyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 3,3-Difluoropyrrolidine hydrochloride and Hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₃ClF₂N₃O₇S [M+H]⁺: m/z=734.24/736.24; Found: 734.7/735.7. ¹H NMR (600 MHz, DMSO-d₆) δ 7.64 (d, J=8.5 Hz, 1H), 7.25 (d, J=8.3 Hz, 2H), 7.18 (s, 1H), 7.05-6.99 (m, 1H), 6.91 (s, 1H), 6.69-6.48 (m, 1H), 5.92-5.62 (m, 2H), 4.15-3.98 (m, 4H), 3.81 (m, 2H), 2.80 (d, J=16.8 Hz, 2H), 2.75-2.64 (m, 6H), 2.44 (s, 2H), 2.06-1.93 (m, 3H), 1.84 (d, J=4.0 Hz, 2H), 1.72 (s, 1H), 1.65 (s, 2H), 1.52-1.44 (m, 2H), 1.38 (s, 3H), 1.22 (s, 3H).

Example 167

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxycarbamate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (30.0 mg, 0.10 mmol, Example 32) in MeCN (3 mL) was added 1,1′-carbonyldiimidazole (24.23 mg, 0.30 mmol). The mixture was stirred at 45° C. for 3 h. LCMS showed that the starting material was consumed. The mixture was concentrated, and the residue was re-dissolved in MeCN (1 mL) and water (1 mL). To the solution was added methoxyamine which was in-situ generated from methoxyamine hydrochloride (10.15 mg, 0.22 mmol) by treatment with 2 drops of 2N NaOH solution. The mixture was stirred at 45° C. overnight. The mixture was cooled down to r.t., 2 drops of 2 N HCl in EA was added and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H₂O/ACN (20-100%) to afford the desired product [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]N-methoxycarbamate (7.8 mg, 26.8% yield). LCMS calc. for C₃₃H₄₁ClN₃O₈S [M+H]⁺: m/z=674.22/675.23; Found: 674.3/674.2; ¹H NMR (300 MHz, CDCl₃) δ 9.13 (s, 1H, NH), 7.68 (d, J=8.5 Hz, 1H), 7.52 (dt, J=8.5, 2.5 Hz, 1H), 7.19 (d, J=8.5 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.07-6.97 (m, 2H), 5.78 (t, J=5.8 Hz, 1H), 4.15 (m, 3H), 4.02-3.83 (m, 2H), 3.75 (d, J=8.2 Hz, 2H), 3.50-3.23 (m, 3H), 2.88-2.70 (m, 3H), 2.45-2.33 (m, 1H), 2.10-1.95 (m, 3H), 1.91 (dd, J=12.9, 6.4 Hz, 2H), 1.87-1.80 (m, 3H), 1.69-1.59 (m, 2H), 1.58-1.49 (m, 2H), 1.44 (d, J=3.4 Hz, 3H), 1.38 (d, J=6.2 Hz, 3H).

Example 168

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (2S)-2-[(dimethylamino)methyl]pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethyl-1-[(2S)-pyrrolidin-2-yl]methanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₂ClN₄O₇S [M+H]⁺: m/z=755.32/757.31; Found: 755.5/757.4. ¹H NMR (600 MHz, DMSO-d₆) δ 9.11 (s, 1H, NH), 7.70 (d, J=8.6 Hz, 1H), 7.32 (td, J=8.0, 2.1 Hz, 2H), 7.25 (d, J=2.2 Hz, 1H), 7.08 (d, J=8.3 Hz, 1H), 7.01 (d, J=19.4 Hz, 1H), 5.75 (s, 2H), 5.24 (s, 1H), 4.17 (dd, J=27.1, 12.1 Hz, 3H), 3.99 (d, J=13.3 Hz, 1H), 3.59 (m, 3H), 3.36-3.22 (m, 5H), 3.15 (s, 1H), 2.92 (s, 3H), 2.87 (s, 3H), 2.85-2.71 (m, 4H), 2.05 (dt, J=12.0, 7.2 Hz, 2H), 1.93 (m, 4H), 1.80 (dd, J=24.4, 7.6 Hz, 2H), 1.69 (m, 2H), 1.62-1.49 (m, 2H), 1.43 (s, 3H), 1.28 (s, 3H).

Example 169

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,2-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (2R)-2-[(dimethylamino)methyl]pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethyl-1-[(2R)-pyrrolidin-2-yl]methanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₂ClN₄O₇S [M+H]⁺: m/z=755.32/757.31; Found: 755.6/757.5. ¹H NMR (600 MHz, DMSO-d₆) δ 9.14 (s, 1H, NH), 7.65 (d, J=8.5 Hz, 1H), 7.26 (d, J=8.4 Hz, 2H), 7.19 (d, J=1.5 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 6.92 (s, 1H), 5.84-5.66 (m, 2H), 5.12 (s, 1H), 4.10 (dd, J=23.8, 12.3 Hz, 3H), 3.96 (dt, J=28.1, 14.1 Hz, 1H), 3.62-3.53 (m, 2H), 3.32-3.20 (m, 6H), 3.14-3.10 (m, 1H), 2.88 (t, J=8.8 Hz, 3H), 2.86-2.82 (m, 3H), 2.80 (dd, J=12.3, 4.1 Hz, 2H), 2.76-2.69 (m, 2H), 2.05-1.96 (m, 2H), 1.86 (m, 6H), 1.76-1.69 (m, 2H), 1.65 (dd, J=18.7, 9.5 Hz, 1H), 1.52-1.46 (m, 1H), 1.38 (d, J=8.7 Hz, 3H), 1.23 (s, 3H).

Example 170

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 8-oxa-3-azabicyclo[3.2.1]octane-3-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (1R,5 S)-3-oxa-8-azabicyclo[3.2.1]octane hydrochloride and N,N-diisopropylethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₄₇ClN₃O₈S [M+H]⁺: m/z=740.27/742.27; Found: 740.5/742.3. ¹H NMR (600 MHz, DMSO-d₆) δ 7.63 (t, J=8.3 Hz, 1H), 7.25 (d, J=8.2 Hz, 2H), 7.19 (s, 1H), 6.98 (m, 2H), 6.60 (d, J=77.3 Hz, 1H), 5.84-5.51 (m, 2H), 4.26 (m, 2H), 4.09 (dd, J=38.2, 12.5 Hz, 2H), 4.03-3.85 (m, 1H), 3.71-3.46 (m, 4H), 3.25 (s, 3H), 3.06-2.96 (m, 1H), 2.80 (d, J=16.6 Hz, 1H), 2.76-2.64 (m, 2H), 2.05-1.94 (m, 3H), 1.83 (s, 3H), 1.75 (t, J=20.1 Hz, 2H), 1.68-1.57 (m, 4H), 1.52-1.44 (m, 2H), 1.24 (s, 6H).

Example 171

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15,6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl](9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazine-8-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine; dihydrochloride and diisopropylethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₀ClN₄O₈S [M+H]⁺: m/z=769.3/771.3; Found 769.5/771.5. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.4, 2.2 Hz, 1H), 7.18 (d, J=8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 5.90-5.62 (m, 2H), 5.43-5.27 (m, 1H), 4.16-4.00 (m, 4H), 3.95-3.63 (m, 6H), 3.40 (dd, J=22.9, 15.5 Hz, 2H), 3.21 (dd, J=15.4, 9.0 Hz, 2H), 3.06 (t, J=12.7 Hz, 1H), 2.84-2.62 (m, 6H), 2.38 (qd, J=8.9, 3.4 Hz, 2H), 2.25 (q, J=9.2, 7.1 Hz, 2H), 1.99 (tdd, J=14.5, 11.1, 6.4 Hz, 3H), 1.89-1.78 (m, 3H), 1.65 (q, J=9.1 Hz, 2H), 1.44 (s, 3H), 1.37 (s, 3H).

Example 172

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using morpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₅ClN₃O₈S [M+H]⁺: m/z=714.26/716.26; Found: 714.7/716.7. ¹H NMR (600 MHz, CDCl₃) δ 9.03 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.97 (dd, J=17.3, 5.2 Hz, 2H), 5.91-5.63 (m, 2H), 5.35 (s, 1H), 4.27-4.03 (m, 3H), 3.87-3.11 (m, 12H), 2.77 (dd, J=11.1, 5.2 Hz, 3H), 2.39 (dd, J=8.7, 3.3 Hz, 1H), 2.09-1.91 (m, 3H), 1.81 (ddd, J=29.9, 18.4, 9.7 Hz, 3H), 1.70-1.58 (m, 3H), 1.44 (s, 3H), 1.36 (s, 3H).

Example 173

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₅ClN₃O₇S [M+H]⁺: m/z=698.26/700.26; Found: 698.4/700.4. ¹H NMR (500 MHz, CDCl₃) δ 9.07 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52-7.44 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.98 (dd, J=5.3, 3.0 Hz, 2H), 5.77 (ddd, J=20.5, 16.0, 8.3 Hz, 2H), 5.37-5.33 (m, 2H), 5.30 (s, 1H), 4.07 (dd, J=13.7, 5.9 Hz, 1H), 3.84-3.65 (m, 2H), 3.51-3.44 (m, 2H), 3.37 (d, J=14.9 Hz, 2H), 3.21 (dd, J=14.9, 9.3 Hz, 1H), 2.85-2.71 (m, 3H), 2.36 (dd, J=9.0, 3.7 Hz, 1H), 2.26-2.17 (m, 2H), 2.01 (d, J=6.5 Hz, 4H), 1.89-1.80 (m, 6H), 1.65 (d, J=5.7 Hz, 2H), 1.43 (s, 3H), 1.35 (s, 3H).

Example 174

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using azetidine hydrochloride and hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₁ClN₃O₇S [M−H]⁺: m/z=682.24/684.24; Found: 682.7/684.7. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.41 (d, J=28.7 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 7.07 (d, J=1.6 Hz, 1H), 6.99 (s, 1H), 6.88 (s, 1H), 6.02 (s, 1H), 5.69 (dd, J=15.6, 5.6 Hz, 1H), 5.34 (d, J=2.9 Hz, 1H), 5.16 (s, 1H), 4.02 (ddd, J=21.9, 18.8, 7.6 Hz, 6H), 3.82 (s, 1H), 3.68 (d, J=14.5 Hz, 1H), 3.49 (s, 1H), 3.39-2.96 (m, 2H), 2.81-2.72 (m, 2H), 2.63 (d, J=10.3 Hz, 1H), 2.34 (qd, J=9.5, 3.2 Hz, 1H), 2.26-2.18 (m, 2H), 2.03-1.96 (m, 4H), 1.91 (dd, J=8.8, 4.0 Hz, 2H), 1.82-1.74 (m, 3H), 1.38 (s, 3H), 1.25 (s, 3H).

Example 175

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methylpiperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (2R)-2-methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.29/729.28; Found: 727.5/729.5. ¹H NMR (600 MHz, CDCl₃) δ 9.65 (s, 1H), 7.63 (dd, J=34.1, 7.2 Hz, 1H), 7.41 (d, J=25.4 Hz, 1H), 7.19-7.04 (m, 2H), 6.93 (d, J=35.6 Hz, 2H), 5.85 (dd, J=202.2, 33.8 Hz, 1H), 5.48-5.05 (m, 1H), 4.31-3.64 (m, 7H), 3.61-3.41 (m, 1H), 3.31 (d, J=14.6 Hz, 1H), 3.19-2.98 (m, 2H), 2.76 (ddd, J=22.2, 17.3, 4.6 Hz, 5H), 2.34 (d, J=7.6 Hz, 2H), 2.27-2.18 (m, 1H), 2.03-1.88 (m, 4H), 1.84-1.70 (m, 4H), 1.63 (d, J=9.9 Hz, 2H), 1.38 (s, 3H), 1.26 (d, J=8.7 Hz, 3H), 1.10 (s, 3H).

Example 176

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-methylpiperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (2S)-2-methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.29/729.28; Found: 727.5/729.5. ¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.48 (d, J=7.1 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.09 (dd, J=6.9, 2.2 Hz, 1H), 6.97 (d, J=8.1 Hz, 2H), 5.71 (s, 2H), 5.35 (dd, J=5.7, 3.9 Hz, 2H), 4.13 (t, J=11.9 Hz, 2H), 4.03 (dd, J=22.2, 8.6 Hz, 2H), 3.83-3.64 (m, 2H), 3.44 (d, J=14.9 Hz, 1H), 3.35 (d, J=14.6 Hz, 1H), 3.26-3.12 (m, 1H), 3.00 (d, J=15.0 Hz, 1H), 2.82-2.72 (m, 4H), 2.54 (s, 1H), 2.38 (s, 1H), 2.26-2.15 (m, 1H), 1.97 (dd, J=42.5, 8.6 Hz, 4H), 1.86-1.74 (m, 4H), 1.63 (dd, J=19.1, 9.7 Hz, 2H), 1.48 (t, J=12.2 Hz, 1H), 1.42 (s, 3H), 1.35 (s, 3H), 1.07 (s, 3H).

Example 177

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-pyridyl)piperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-pyridyl)piperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₄₁H₄₉ClN₅O₇S [M+H]⁺: m/z=790.3/792.3; Found: 790.3/792.3. ¹H NMR (600 MHz, CDCl₃) δ 9.13 (s, 1H), 8.28 (d, J=4.8 Hz, 1H), 7.82-7.73 (m, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.94 (d, J=2.0 Hz, 1H), 6.90-6.77 (m, 2H), 6.01-5.67 (m, 2H), 5.56-5.21 (m, 2H), 4.29-4.02 (m, 3H), 3.83-3.70 (m, 6H), 3.51-3.31 (m, 2H), 3.21 (dd, J=15.1, 9.7 Hz, 1H), 2.84-2.73 (m, 4H), 2.48-2.31 (m, 1H), 2.28-2.19 (m, 1H), 2.10-1.91 (m, 4H), 1.83 (ddd, J=25.5, 18.9, 9.2 Hz, 3H), 1.72-1.59 (m, 2H), 1.44 (s, 3H), 1.36 (s, 3H).

Example 178

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15λ{circumflex over ( )}6-thia-1,14-diazatetracyclo[14.7.2.0{circumflex over ( )}3,6.0{circumflex over ( )}19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(3-pyridyl)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 3-(2-aminoethyl)pyridine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₄₆ClN₄O₇S [M+H]⁺: m/z=749.28/751.28; Found: 749.5/751.4. ¹H NMR (500 MHz, DMSO-d₆) δ 8.58 (s, 2H), 7.96 (d, J=7.4 Hz, 1H), 7.62 (dd, J=22.2, 7.3 Hz, 2H), 7.33-7.23 (m, 2H), 7.19 (d, J=1.9 Hz, 1H), 7.12 (t, J=5.6 Hz, 1H), 7.06-6.96 (m, 2H), 6.92 (s, 1H), 5.81-5.26 (m, 2H), 5.01 (d, J=91.1 Hz, 1H), 4.11 (dd, J=43.7, 12.2 Hz, 3H), 3.90 (dd, J=14.3, 5.9 Hz, 2H), 2.95-2.60 (m, 6H), 2.17-1.45 (m, 10H), 1.40 (s, 3H), 1.24 (s, 6H).

Example 179

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(2,2-difluoroethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 2,2-difluoroethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₄H₄₁ClF₂N₃O₇S [M+H]⁺: m/z=708.23/710.23; Found: 708.4/710.3. ¹H NMR (500 MHz, DMSO-d₆) δ 11.66 (s, 1H), 7.65 (d, J=8.4 Hz, 1H), 7.44 (d, J=7.2 Hz, 1H), 7.35-7.13 (m, 4H), 7.05 (t, J=19.8 Hz, 2H), 6.51 (s, 1H), 6.27-5.57 (m, 2H), 5.33 (t, J=4.7 Hz, 1H), 5.04 (s, 1H), 4.33-3.72 (m, 3H), 2.85-2.64 (m, 3H), 2.15-1.44 (m, 10H), 1.39 (s, 2H), 1.24 (s, 8H).

Example 180

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(2-morpholinoethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 4-(2-aminoethyl)morpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₈H₅₀ClN₄O₈S [M+H]⁺: m/z=757.31/759.30; Found: 757.5/759.2.

Example 181

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-isopropylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using isopropylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.26/688.26; Found: 686.8/688.8. ¹H NMR (600 MHz, CDCl₃) δ 8.97 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.08 (d, J=1.7 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.82-5.60 (m, 2H), 5.15 (s, 1H), 4.64 (d, J=7.0 Hz, 1H), 4.13 (dd, J=26.0, 12.2 Hz, 3H), 3.80 (s, 3H), 3.52-3.07 (m, 3H), 2.86-2.63 (m, 3H), 2.35 (d, J=40.1 Hz, 1H), 2.07-1.71 (m, 7H), 1.64 (d, J=10.1 Hz, 1H), 1.42 (s, 3H), 1.37 (s, 3H), 1.17 (d, J=6.3 Hz, 6H).

Example 182

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-isobutylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using isobutylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₇ClN₃O₇S [M+H]⁺: m/z=700.27/702.27; Found: 700.8/702.6. ¹H NMR (600 MHz, CDCl₃) δ 9.00 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=10.3, 1.9 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.88-5.57 (m, 2H), 5.20 (s, 1H), 4.91 (t, J=5.6 Hz, 1H), 4.27-4.04 (m, 3H), 3.85-3.64 (m, 2H), 3.52-3.28 (m, 2H), 3.23-3.12 (m, 1H), 3.01 (dd, J=13.5, 6.9 Hz, 2H), 2.77 (dd, J=10.5, 5.2 Hz, 3H), 2.37 (dd, J=8.7, 3.9 Hz, 1H), 2.08-1.70 (m, 7H), 1.62 (d, J=9.6 Hz, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 0.92 (d, J=6.7 Hz, 6H).

Example 183

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(cyclopropylmethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 46 using cyclopropylmethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₅ClN₃O₇S [M+H]⁺: m/z=698.27/700.27; Found: 698.3/700.1.

Example 184

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-cyclobutylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using cyclobutylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₅ClN₃O₇S [M+H]⁺: m/z=698.27/700.27; Found: 698.4/700.3. ¹H NMR (600 MHz, CDCl₃) δ 9.00 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=10.3, 1.9 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.88-5.57 (m, 2H), 5.20 (s, 1H), 4.91 (t, J=5.6 Hz, 1H), 4.27-4.04 (m, 3H), 3.85-3.64 (m, 2H), 3.52-3.28 (m, 2H), 3.23-3.12 (m, 1H), 3.01 (dd, J=13.5, 6.9 Hz, 2H), 2.77 (dd, J=10.5, 5.2 Hz, 3H), 2.37 (dd, J=8.7, 3.9 Hz, 1H), 2.08-1.70 (m, 7H), 1.62 (d, J=9.6 Hz, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 0.92 (d, J=6.7 Hz, 6H).

Example 185

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-tetrahydropyran-4-ylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using 4-aminotetrahydropyran to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]: m/z=728.28/730.28; Found: 728.3/730.0. ¹H NMR (600 MHz, DMSO-d₆) δ 11.66 (s, 1H), 7.65 (d, J=8.5 Hz, 1H), 7.40-6.73 (m, 7H), 6.53 (s, 1H), 5.51 (dd, J=178.9, 11.3 Hz, 2H), 5.02 (s, 1H), 4.28-3.72 (m, 6H), 3.55 (s, 1H), 2.73 (dd, J=24.8, 16.6 Hz, 3H), 2.12-1.49 (m, 12H), 1.43-1.09 (m, 11H).

Example 186

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-isopropylpiperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 1-isopropylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₂ClN₄O₇S [M+H]⁺: m/z=755.32/757.31; Found: 755.5/757.4. ¹H NMR (600 MHz, CDCl₃) δ 12.87 (s, 1H), 9.15 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.47 (d, J=7.6 Hz, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.86 (s, 1H), 5.90 (t, J=20.4 Hz, 2H), 5.43-5.18 (m, 1H), 4.47-4.01 (m, 5H), 3.89-3.28 (m, 9H), 3.25-2.59 (m, 6H), 2.29 (dt, J=15.3, 8.3 Hz, 2H), 2.17-1.91 (m, 4H), 1.89-1.80 (m, 4H), 1.35 (s, 10H).

Example 187

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(oxetan-3-yl)piperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using 1-(oxetan-3-yl)piperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₀ClN₄O₈S [M+H]⁺: m/z=769.30/71.29; Found: 769.7/771.6. ¹H NMR (600 MHz, CDCl₃) δ 9.13 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52-7.40 (m, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.01-5.74 (m, 2H), 5.54-5.25 (m, 4H), 4.77 (ddd, J=42.9, 9.0, 4.2 Hz, 3H), 4.31-4.07 (m, 4H), 3.93 (dd, J=33.3, 27.0 Hz, 3H), 3.82-3.29 (m, 7H), 3.19 (dd, J=15.2, 10.0 Hz, 1H), 3.03-2.57 (m, 7H), 2.44-2.18 (m, 5H), 1.45 (s, 6H).

Example 188

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-cyclopropylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using cyclopropylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₇S [M+H]⁺: m/z=684.24/686.24; Found: 684.4/686.1. ¹H NMR (300 MHz, CDCl₃) δ 9.04 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.11-6.89 (m, 3H), 5.67 (dd, J=16.0, 3.5 Hz, 2H), 5.10 (d, J=55.9 Hz, 1H), 4.32-3.97 (m, 3H), 3.90-3.01 (m, 6H), 2.93-2.16 (m, 5H), 2.08-1.72 (m, 7H), 1.64 (s, 1H), 1.43 (s, 3H), 1.36 (s, 3H), 0.72 (dd, J=6.7, 5.0 Hz, 2H), 0.54 (s, 2H).

Example 189

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methylpiperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.30/729.29; Found: 727.6/729.2. ¹H NMR (499 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.54-7.41 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.13-7.04 (m, 1H), 6.98 (t, J=6.1 Hz, 2H), 6.17-5.55 (m, 2H), 5.32 (s, 2H), 4.12 (dd, J=25.4, 12.1 Hz, 3H), 3.85-3.08 (m, 9H), 2.93-2.64 (m, 3H), 2.60-2.14 (m, 9H), 2.09-1.92 (m, 5H), 1.82 (s, 2H), 1.43 (s, 3H), 1.36 (s, 3H).

Example 190

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-hydroxypiperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using piperidin-4-ol to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.28/730.28; Found: 728.4/729.9. ¹H NMR (500 MHz, DMSO-d₆) δ 11.69 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.20 (ddd, J=109.1, 20.0, 12.8 Hz, 6H), 6.57 (s, 1H), 5.74 (s, 2H), 5.20 (s, 1H), 4.77 (d, J=3.5 Hz, 1H), 3.92 (ddd, J=188.7, 35.2, 15.1 Hz, 8H), 2.96-2.68 (m, 4H), 1.84 (dd, J=111.2, 52.7 Hz, 11H), 1.31 (t, J=57.5 Hz, 10H).

Example 191

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(2-methoxyethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 2-methoxyethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₅ClN₃O₈S [M+H]⁺: m/z=702.26/704.26; Found: 702.4/704.3. ¹H NMR (500 MHz, DMSO-d₆) δ 11.72 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.40-7.19 (m, 3H), 7.05 (d, J=48.1 Hz, 3H), 6.57 (s, 1H), 5.95-5.33 (m, 2H), 5.07 (s, 1H), 4.39-3.76 (m, 4H), 3.59 (d, J=14.9 Hz, 2H), 3.28 (s, 3H), 3.16 (s, 2H), 2.96-2.64 (m, 3H), 2.16-1.50 (m, 9H), 1.44 (s, 2H), 1.25 (d, J=43.6 Hz, 7H).

Example 192

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(oxetan-3-yl)carbamate

This compound was prepared using procedures analogous to those described for Example 46 using oxetan-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₈S [M+H]⁺: m/z=700.24/702.24; Found: 700.3/702.3. ¹H NMR (600 MHz, CDCl₃) δ 8.97 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.49 (dd, J=26.7, 25.2 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (d, J=13.5 Hz, 2H), 7.01 (d, J=8.3 Hz, 1H), 5.94-5.64 (m, 2H), 5.56-5.12 (m, 4H), 4.98-4.79 (m, 3H), 4.56 (d, J=6.0 Hz, 2H), 4.13 (dd, J=27.7, 12.2 Hz, 3H), 3.75 (dd, J=53.1, 12.3 Hz, 2H), 3.53-3.10 (m, 2H), 2.90-2.65 (m, 3H), 2.49-2.28 (m, 1H), 2.29-2.14 (m, 2H), 2.01 (d, J=5.4 Hz, 4H), 1.86 (d, J=10.0 Hz, 1H), 1.43 (s, 3H), 1.37 (s, 3H).

Example 193

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(1-piperidyl)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-aminoethyl)-piperidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₉H₅₂ClN₄O₇S [M+H]⁺: m/z=755.33/757.32; Found: 755.5/757.4. ¹H NMR (600 MHz, CDCl₃) δ 12.22 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.08 (s, 1H), 7.03-6.86 (m, 2H), 5.81 (s, 1H), 5.63 (dd, J=15.4, 4.6 Hz, 1H), 5.42-5.24 (m, 2H), 5.18 (s, 1H), 4.12 (dd, J=24.6, 12.2 Hz, 3H), 4.04-3.79 (m, 2H), 3.78-3.55 (m, 5H), 3.50-2.98 (m, 5H), 2.93-2.53 (m, 6H), 2.49-2.28 (m, 1H), 2.28-2.12 (m, 2H), 2.08-1.96 (m, 6H), 1.40 (s, 4H), 1.36 (s, 5H).

Example 194

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[2-(methylamino)ethyl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 using N¹,N²-dimethylethane-1,2-diamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₆H₄₈ClN₄O₇S [M+H]⁺: m/z=715.30/717.29; Found: 715.5/717.5. ¹H NMR (500 MHz, DMSO-d₆) δ 11.61 (s, 1H), 8.42 (s, 2H), 7.65 (d, J=8.3 Hz, 1H), 7.26 (dd, J=8.4, 2.3 Hz, 2H), 7.19 (d, J=2.0 Hz, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.95 (s, 1H), 5.69 (s, 2H), 5.29 (dd, J=49.6, 44.7 Hz, 1H), 4.32-3.87 (m, 3H), 3.56 (d, J=14.5 Hz, 2H), 2.82 (ddd, J=56.1, 35.7, 24.1 Hz, 9H), 2.59 (s, 3H), 2.16-1.57 (m, 8H), 1.39 (s, 4H), 1.23 (d, J=10.5 Hz, 6H).

Example 195

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-methoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 using (3S)-3-methoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.27/730.27; Found: 728.5/730.5. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.36 (d, J=8.5 Hz, 1H), 7.13 (dd, J=8.4, 2.4 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 6.97 (d, J=2.2 Hz, 1H), 6.85 (d, J=8.2 Hz, 1H), 6.10 (br, 1H), 5.70 (ddd, J=15.8, 10.4, 5.4 Hz, 1H), 5.22-5.14 (m, 1H), 4.12-3.92 (m, 4H), 3.86 (d, J=16.1 Hz, 2H), 3.66 (t, J=13.7 Hz, 2H), 3.52-3.40 (m, 4H), 3.34 (s, 3H), 3.28 (s, 2H), 3.09 (q, J=12.3 Hz, 2H), 2.78-2.70 (m, 4H), 2.31 (d, J=8.0 Hz, 1H), 2.01-1.92 (m, 4H), 1.80-1.72 (m, 3H), 1.36 (s, 3H), 1.31 (s, 3H).

Example 196

(3R,6R,12S,22S)-6′-Chloro-11,12-dimethyl-15,15-dioxo-spiro[8,20-dioxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-10,13-dione

Step 1: tert-butyl 2-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate

To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.42 mmol, Intermediate 3 Step 2) in THF (15 mL) was added potassium tert-butoxide (93.86 mg, 0.84 mmol) at 20° C. The mixture was stirred at r.t. for 30 min., and t-butyl bromoacetate (163.15 mg, 0.84 mmol) was then added. The resulting mixture was stirred at r.t. overnight. LCMS showed full conversion of starting material. The reaction was quenched by water (5 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (3% to 40%) to afford tert-butyl 2-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (280 mg, 80.5% yield) as a white solid. LCMS calc. for C₄₆H₅₆ClN₂O₈S [M+H]⁺: m/z=831.34/833.34; Found: 831.06/832.45.

Step 2: 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid

To a solution of tert-butyl 2-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (280.0 mg, 0.34 mmol) in DCM (3 mL) was added TFA (3.0 mL, 39.2 mmol) at 40° C. The reaction mixture was stirred for 4 h. LCMS analysis indicated the completion of reaction. The reaction was diluted with EtOAc (10 mL), and adjusted to 7-8 pH with saturated aqueous Na₂CO₃ solution. The layers were separated, and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solution was concentrated under reduced pressure and the residue was purified by flash chromatography system on a silica gel column (12 g) with EtOAc/Heptanes (3% to 60%) to afford 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (152 mg, 84.4% yield) as a white solid. LCMS calc. for C₂₆H₃₂ClN₂O₆S [M+H]⁺: m/z=535.16/537.16; Found: 534.8/536.6.

Step 3: methyl 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate

To a stirred solution of 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (195.0 mg, 0.36 mmol) in DMF (5 mL) was added K₂CO₃ (100.59 mg, 0.73 mmol) and iodomethane (103.46 mg, 0.73 mmol). The resulting mixture was stirred at r.t. for 4 h. LCMS showed full conversion of starting material. EtOAc (10 mL) was added and the layers were separated, then the aqueous layer was adjusted pH to 1-2 with aq. HCl (1 N), and extracted with EtOAc (20 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Hetpanes (2% to 50%) to afford methyl 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (159 mg, 79.5% yield) as a white solid. LCMS calc. for C₂₇H₃₄ClN₂O₆S [M+H]⁺: m/z=549.17/551.17; Found: 548.9/550.6.

Step 4: methyl 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate

A mixture of (2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoic acid (77.73 mg, 0.38 mmol), methyl 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (70.0 mg, 0.13 mmol), EDCI (73.32 mg, 0.38 mmol) and DMAP (77.4 mg, 0.76 mmol) in DCM (3 mL) was stirred at r.t. overnight. LCMS analysis indicated the completion of reaction. The reaction was diluted with DCM (10 mL), washed with 1 N HCl (2 mL) and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (3% to 60%) to afford methyl 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (75 mg, 80.1% yield) as a white solid. LCMS calc. for C₃₆H₄₉ClN₃O₉S [M+H]⁺: m/z=734.28/736.28; Found: 733.9/736.3.

Step 5: 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid

To a stirred solution of methyl 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (75.0 mg, 0.10 mmol) in THF (0.50 mL) and methanol (0.50 mL) was added lithium hydroxide monohydrate (12.87 mg, 0.31 mmol) in water (0.50 mL). The resulting mixture was stirred at r.t. for 4 h. LCMS showed full conversion of starting material. THF and MeOH were partially removed on a rotary evaporator, and the aqueous layer was adjusted pH to 1-2 with aq. HCl (1 N) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to afford 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (64 mg, 87% yield) as a white solid. LCMS calc. for C₃₅H₄₇ClN₃O₉S [M+H]⁺: m/z=720.26/722.26; Found: 720.0/721.6.

Step 6: 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-[[(2S)-2-(methylamino)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid

2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]-sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-cyclobutyl]methoxy]acetic acid (64.0 mg, 0.09 mmol) was dissolved in 2N HCl in EtOAc solution (0.0 mL, 0.09 mmol), and stirred at r.t. for 6 h. The reaction was concentrated under reduced pressure, and the residue was added lithium hydroxide monohydrate (3.73 mg, 0.09 mmol) in THF (0.50 mL), water (0.50 mL) and methanol (0.50 mL). After 2 h, LCMS analysis indicated the completion of reaction. The reaction mixture was concentrated under reduced pressure to afford 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-[[(2S)-2-(methylamino)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (51 mg, 92.6% yield) as a white solid. LCMS calc. for C₃₀H₃₉ClN₃O₇S [M+H]⁺: m/z=620.22/622.22; Found: 619.9/622.1.

Step 7: (3R,6R,12S,22S)-6′-chloro-11,12-dimethyl-15,15-dioxo-spiro[8,20-dioxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-10,13-dione

To a stirred solution of 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-[[(2S)-2-(methylamino)-propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-cyclobutyl]methoxy]acetic acid (26.0 mg, 0.04 mmol) in DMF (2 mL) was added HATU (31.88 mg, 0.08 mmol) and DIPEA (0.01 mL, 0.08 mmol) at 20° C. After 1 h, LCMS analysis indicated the full conversion of starting material to the desired product. The reaction was quenched by water (5 mL), and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 60%). The desired fractions were collected, and further purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H₂O (20 to 100%) to afford (3R,6R,12S,22S)-6′-chloro-11,12-dimethyl-15,15-dioxo-spiro[8,20-dioxa-15-thia-1,11,14-triazatetracyclo-[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-10,13-dione (6.2 mg, 0.0103 mmol, 24.56% yield) as a white solid. LCMS calc 602.20/604.20; Found 602.28/604.25.

Example 197

(3R,6R,12S,22S)-6′-Chloro-12-methyl-15,15-dioxo-spiro[8,20-dioxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-16,18,24-triene-22,1′-tetralin]-10,13-dione

This compound was prepared using procedures analogous to those described for Example 196 Step 4-7 using (2S)-2-(tert-butoxycarbonylamino)propanoic acid to replace (2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoic acid in Step 4. LCMS calc. for C₂₉H₃₅ClN₃O₆S [M+H]⁺: m/z=588.19/590.19; Found 588.6/590.6. ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.22 (s, 1H), 7.13 (dd, J=8.2, 2.2 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.80 (d, J=8.1 Hz, 1H), 5.48-5.23 (m, 1H), 4.39 (d, J=8.6 Hz, 1H), 4.06-3.82 (m, 4H), 3.75 (d, J=14.2 Hz, 2H), 3.46 (s, 2H), 3.34 (d, J=14.4 Hz, 1H), 3.09 (d, J=13.5 Hz, 1H), 2.81 (d, J=25.2 Hz, 2H), 1.97 (s, 3H), 1.72 (ddd, J=42.0, 16.7, 8.4 Hz, 5H), 1.37 (d, J=7.2 Hz, 5H).

Example 198

[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: [(1R)-1-[(1R,2R)-2-[[(3S)-7-[[2-(allylamino)-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 42 Step 2 using [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (Intermediate 10) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 42 Step 1). LC-MS: calc. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.3/701.3; Found: 699.5/701.5.

Step 2: [(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using [(1R)-1-[(1R,2R)-2-[[(3S)-7-[[2-(allylamino)-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate. LCMS calc. for C₃₄H₄₄ClN₄O₆S [M+H]⁺: m/z=671.3/673.3; Found: 671.9/673.8.

Example 199

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate

Step 1: [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (680.0 mg, 1.11 mmol, Example 43) in pyridine (0.89 mL, 11.07 mmol) was added phenyl chloroformate (0.69 mL, 5.54 mmol). The mixture was stirred at r.t. for 1 h. LCMS showed the full conversion of the starting material into the desired product. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on a silica gel column with EA:Hep (50% to 100%) to afford [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (810 mg, 99.6% yield).

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate

To a solution of [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (40.0 mg, 0.05 mmol) in MeCN (1 mL) was added morpholine (47.46 mg, 0.54 mmol). Reaction was stirred for 14 h at 75° C. LCMS showed the conversion of the starting material into the desired product. The mixture was concentrated and purified by prep-HPLC on a C18 column (15% to 100% MeCN/H₂O) to afford [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] morpholine-4-carboxylate (15 mg, 37.9% yield). LCMS calcd. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.29/729.29; Found 727.4/729.4. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.53-7.43 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 6.83 (s, 1H), 5.86 (s, 1H), 5.70 (d, J=15.7 Hz, 1H), 5.39 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 3.72 (d, J=5.6 Hz, 6H), 3.50 (m, 6H), 3.35 (d, J=14.8 Hz, 1H), 3.09 (dd, J=15.0, 10.9 Hz, 1H), 2.87-2.73 (m, 3H), 2.29 (s, 3H), 1.99 (d, J=12.4 Hz, 2H), 1.83 (q, J=10.1, 9.5 Hz, 2H), 1.68 (dt, J=18.6, 9.5 Hz, 1H), 1.45 (d, J=12.8 Hz, 1H), 1.31 (d, J=24.9 Hz, 6H), 1.12 (s, 3H).

Example 200

[(3R,6R,7R,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

To a solution of [(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (10.0 mg, 0.01 mmol, Example 197) in DCE (0.50 mL) was added 37% formaldehyde aqueous solution (0.01 mL, 0.30 mmol). The mixture was stirred at r.t. for 2 h., then NaBH₃CN (11.27 mg, 0.30 mmol) in methanol (0.10 mL) was added. The reaction mixture was stirred at r.t. for 6 h. The reaction was quenched by sat. NH₄Cl aqueous solution (5 mL), and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column with MeCN/H₂O (20% to 100%) to afford [(3R,6R,7R,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (6.3 mg, 61.7% yield) as a white solid. LCMS calc. for C₃₅H₄₆ClN₄O₆S [M+H]⁺: m/z=685.3/687.3; Found 685.8/687.3. ¹H NMR (600 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=15.5 Hz, 1H), 7.18 (dd, J=8.6, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.83 (s, 1H), 5.92 (dt, J=12.7, 6.0 Hz, 1H), 5.41-5.25 (m, 1H), 5.07 (s, 1H), 4.08 (t, J=16.8 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.36 (s, 1H), 3.06 (dd, J=15.2, 10.7 Hz, 1H), 2.92 (s, 4H), 2.84-2.72 (m, 3H), 2.52 (s, 1H), 2.28 (s, 2H), 2.22 (t, J=7.7 Hz, 1H), 2.08-1.90 (m, 5H), 1.83 (s, 3H), 1.72-1.61 (m, 3H), 1.43 (t, J=13.1 Hz, 2H), 1.32 (d, J=12.4 Hz, 3H), 1.26 (d, J=8.6 Hz, 3H).

Example 201

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-cyclobutylcarbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclobutylamine to replace morpholine. LCMS calc. for C₃₇H₄₈ClN₄O₆S [M+H]⁺: m/z=711.30/713.30; Found: 711.7/713.8. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 5.89 (d, J=15.5 Hz, 1H), 5.67 (d, J=14.4 Hz, 1H), 5.44 (s, 1H), 5.28 (d, J=17.7 Hz, 1H), 4.14 (dt, J=35.4, 10.4 Hz, 3H), 3.70 (d, J=14.7 Hz, 1H), 3.39 (dd, J=28.7, 14.8 Hz, 2H), 3.14-2.97 (m, 1H), 2.81 (dd, J=15.8, 8.0 Hz, 5H), 2.46-2.13 (m, 5H), 2.09-1.89 (m, 5H), 1.89-1.77 (m, 4H), 1.77-1.52 (m, 4H), 1.45 (d, J=12.6 Hz, 1H), 1.35 (s, 3H), 1.11 (s, 3H).

Example 202

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32) in Step 2 and (3S)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.27/730.27; Found: 728.4/730.1. ¹H NMR (300 MHz, CDCl₃) δ 9.12 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.2 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (s, 1H), 6.99-6.95 (m, 1H), 5.83 (dd, J=5.9, 3.4 Hz, 1H), 5.73 (dd, J=15.7, 5.2 Hz, 1H), 5.33 (q, J=4.3, 3.9 Hz, 1H), 4.91 (s, 1H), 4.12 (t, J=6.3 Hz, 2H), 4.09-4.04 (m, 1H), 3.78 (s, 2H), 3.69 (d, J=8.3 Hz, 1H), 3.50-3.32 (m, 2H), 3.23 (dd, J=15.1, 9.3 Hz, 1H), 2.90 (s, 3H), 2.81-2.76 (m, 3H), 2.40 (dd, J=8.9, 3.5 Hz, 1H), 2.24 (dd, J=9.5, 5.5 Hz, 1H), 2.04 (d, J=8.6 Hz, 1H), 1.95 (d, J=10.1 Hz, 2H), 1.87-1.74 (m, 5H), 1.71-1.62 (m, 3H), 1.51 (d, J=12.6 Hz, 1H), 1.44 (s, 3H), 1.37 (s, 3H).

Example 203

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using methylamine (40% in water) to replace morpholine. LCMS calc. for C₃₄H₄₄ClN₄O₆S [M+H]⁺: m/z=671.27/673.27; Found: 671.7/673.6. ¹H NMR (499 MHz, DMSO-d₆) δ 7.63 (dd, J=8.5, 2.5 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.19-7.07 (m, 2H), 6.88-6.84 (m, 2H), 6.07 (br, 1H), 5.81-5.66 (m, 1H), 5.17-5.12 (m, 1H), 3.58-3.49 (m, 1H), 3.31-3.25 (m, 6H), 3.19-3.06 (m, 1H), 2.86-2.64 (m, 4H), 2.60 (d, J=4.6 Hz, 2H), 2.55 (s, 3H), 2.37 (dt, J=3.8, 2.0 Hz, 1H), 2.00 (dt, J=12.2, 3.9 Hz, 1H), 1.85 (s, 3H), 1.77-1.61 (m, 3H), 1.48-1.44 (m, 1H), 1.35 (s, 3H), 1.28-1.10 (m, 5H).

Example 204

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-ethylcarbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using ethylamine (66-72% in water) to replace morpholine. LCMS calc. for C₃₅H₄₆ClN₄O₆S [M+H]⁺: m/z=685.28/687.28; Found: 685.7/687.7. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.88 (s, 1H), 5.90 (d, J=15.4 Hz, 1H), 5.68 (d, J=15.7 Hz, 1H), 5.28 (s, 1H), 5.21 (s, 1H), 4.12 (dd, J=36.0, 12.1 Hz, 2H), 3.70 (d, J=14.5 Hz, 1H), 3.50-3.35 (m, 2H), 3.27 (dd, J=13.5, 7.0 Hz, 2H), 3.16-2.97 (m, 1H), 2.81 (dd, J=14.7, 8.2 Hz, 4H), 2.28 (s, 4H), 2.06-1.92 (m, 4H), 1.85 (s, 4H), 1.63 (dd, J=18.6, 9.6 Hz, 1H), 1.45 (d, J=12.8 Hz, 1H), 1.35 (s, 3H), 1.22 (dd, J=16.2, 9.0 Hz, 3H), 1.11 (s, 3H).

Example 205

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(cyclopropylmethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclopropyl methylamine to replace morpholine. LCMS calc. for C₃₇H₄₈ClN₄O₆S [M+H]⁺: m/z=711.30/713.30; Found: 711.8/713.8. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.89 (s, 1H), 5.93 (d, J=15.4 Hz, 1H), 5.68 (d, J=15.4 Hz, 1H), 5.40 (s, 1H), 5.26 (s, 1H), 4.12 (dd, J=36.4, 12.1 Hz, 2H), 3.70 (d, J=14.8 Hz, 1H), 3.39 (dd, J=25.6, 14.9 Hz, 3H), 3.17-2.98 (m, 3H), 2.92-2.68 (m, 4H), 2.29 (s, 4H), 1.99 (d, J=11.2 Hz, 4H), 1.87 (d, J=16.2 Hz, 4H), 1.63 (dd, J=18.8, 9.3 Hz, 1H), 1.45 (d, J=12.4 Hz, 1H), 1.35 (s, 3H), 1.10 (d, J=10.9 Hz, 3H), 0.57-0.47 (m, 2H), 0.27 (q, J=4.7 Hz, 2H).

Example 206

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-(cyclopropylmethyl)carbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclopropylamine to replace morpholine. LCMS calc. for C₃₆H₄₆ClN₄O₆S [M+H]⁺: m/z=697.28/699.28; Found: 697.7/699.8. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.85 (d, J=1.7 Hz, 1H), 5.85 (s, 1H), 5.68 (d, J=16.0 Hz, 1H), 5.43 (s, 1H), 5.29 (s, 1H), 4.11 (dd, J=35.5, 12.1 Hz, 2H), 3.70 (d, J=14.2 Hz, 1H), 3.38 (dd, J=25.8, 14.4 Hz, 2H), 3.15-2.99 (m, 2H), 2.96-2.73 (m, 4H), 2.67 (s, 1H), 2.29 (s, 4H), 2.07-1.89 (m, 4H), 1.85 (d, J=8.6 Hz, 4H), 1.63 (d, J=8.2 Hz, 1H), 1.45 (d, J=12.5 Hz, 1H), 1.36 (s, 3H), 1.11 (s, 3H), 0.77 (d, J=5.4 Hz, 2H), 0.59 (d, J=4.8 Hz, 2H).

Example 207

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-isopropylcarbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using propan-2-amine to replace morpholine. LCMS calc. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.30/701.30; Found: 699.8/701.7. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.6, 2.1 Hz, 1H), 7.09 (d, J=1.9 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 5.89 (d, J=15.6 Hz, 1H), 5.68 (d, J=14.9 Hz, 1H), 5.24 (s, 1H), 5.12 (s, 1H), 4.12 (dd, J=35.8, 12.1 Hz, 2H), 3.86 (dd, J=13.6, 6.5 Hz, 1H), 3.70 (d, J=14.6 Hz, 1H), 3.39 (dd, J=28.1, 14.5 Hz, 2H), 3.13-2.99 (m, 1H), 2.80 (t, J=10.4 Hz, 6H), 2.28 (s, 3H), 2.08-1.91 (m, 3H), 1.84 (d, J=4.3 Hz, 3H), 1.63 (dd, J=18.9, 9.6 Hz, 1H), 1.45 (d, J=13.0 Hz, 1H), 1.35 (s, 3H), 1.23 (dd, J=11.4, 6.6 Hz, 7H), 1.11 (s, 3H).

Example 208

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazine-8-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 by replacement of morpholine with (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine which was prepared in THF solution as following: a solution of (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride (500.0 mg, 2.32 mmol) in methanol (1 mL) was treated NaOMe (105.9 mg, 1.96 mmol) for 30 min. at r.t., concentrated under reduced pressure, re-dissolved in THF (1 mL) and filtered. LCMS calc. for C₄₀H₅₃ClN₅O₇S [M+H]⁺: m/z=782.33/784.33; Found 782.5/784.4. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (dd, J=7.8, 4.1 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.81 (s, 1H), 5.91-5.62 (m, 2H), 5.40 (s, 1H), 4.22-4.00 (m, 4H), 3.88-3.65 (m, 5H), 3.48-3.22 (m, 4H), 3.10 (q, J=13.6, 11.8 Hz, 3H), 2.89-2.70 (m, 7H), 2.28 (d, J=9.6 Hz, 6H), 1.99 (d, J=12.2 Hz, 4H), 1.91-1.75 (m, 4H), 1.35 (s, 3H), 1.10 (s, 3H).

Example 209

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 42 Step 2 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (Intermediate 9) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 42 Step 1). LCMS calc. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.3/701.3; Found: 699.9/701.8.

Step 2: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 26 Step 4 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate. LCMS calc. for C₃₄H₄₄ClN₄O₆S [M+H]⁺: m/z=671.3/673.3; Found: 671.8/673.2.

Example 210

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 27 using [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (Example 204) and acetaldehyde. LCMS calc. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.30/701.30; Found: 699.69/701.66. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.84 (d, J=2.0 Hz, 1H), 5.90 (dd, J=15.5, 8.3 Hz, 1H), 5.67 (d, J=15.5 Hz, 1H), 5.28 (s, 1H), 4.12 (dd, J=37.4, 12.1 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.41 (dd, J=20.8, 15.1 Hz, 2H), 3.12 (s, 3H), 3.00 (d, J=7.3 Hz, 3H), 2.93-2.74 (m, 4H), 2.73-2.58 (m, 1H), 2.29-2.14 (m, 2H), 1.99 (d, J=10.6 Hz, 4H), 1.91-1.74 (m, 4H), 1.66 (dd, J=18.7, 9.3 Hz, 2H), 1.41 (d, J=7.3 Hz, 5H), 1.18 (s, 3H), 1.06 (t, J=7.1 Hz, 3H).

Example 211

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-11-propyl-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 27 using [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (Example 204) and propionaldehyde. LCMS calc. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.30/701.30; Found: 699.7/701.7. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (d, J=1.9 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.84 (d, J=1.9 Hz, 1H), 5.93 (dd, J=15.4, 8.5 Hz, 1H), 5.65 (d, J=15.7 Hz, 1H), 5.28 (s, 1H), 4.12 (dd, J=37.7, 12.1 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.41 (t, J=16.2 Hz, 3H), 3.08 (dd, J=20.9, 10.1 Hz, 4H), 3.02-2.90 (m, 4H), 2.78 (dt, J=15.9, 14.5 Hz, 4H), 2.48-2.36 (m, 1H), 2.22 (d, J=8.4 Hz, 1H), 1.99 (d, J=10.9 Hz, 3H), 1.83 (dd, J=8.8, 4.5 Hz, 3H), 1.68-1.59 (m, 2H), 1.48 (dt, J=11.9, 6.1 Hz, 3H), 1.38 (s, 3H), 1.16 (s, 3H), 0.90 (t, J=7.3 Hz, 3H).

Example 212

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using (3S)-tetrahydrofuran-3-amine to replace morpholine. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.29/729.29; Found: 727.4/729.5. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.02-6.87 (m, 2H), 6.09 (t, J=11.5 Hz, 1H), 5.90 (s, 1H), 5.66 (d, J=16.1 Hz, 1H), 5.19 (s, 1H), 4.40-4.13 (m, 4H), 4.04 (d, J=12.1 Hz, 1H), 3.95 (d, J=9.5 Hz, 1H), 3.85-3.60 (m, 3H), 3.42 (d, J=13.5 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.10-2.67 (m, 6H), 2.43-2.13 (m, 4H), 2.09-1.70 (m, 5H), 1.61 (q, J=9.0 Hz, 1H), 1.33 (d, J=38.8 Hz, 5H), 1.12 (s, 3H).

Example 213

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using N,N,N′-trimethylethylenediamine to replace morpholine. LCMS calc. for C₃₈H₅₃ClN₅O₆S [M+H]⁺: m/z=742.33/744.33; Found: 742.8/744.8. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (dd, J=8.3, 2.3 Hz, 1H), 6.84 (d, J=2.3 Hz, 1H), 6.06-5.85 (m, 1H), 5.78-5.65 (m, 1H), 5.31 (d, J=16.4 Hz, 1H), 4.16 (d, J=12.2 Hz, 1H), 4.11-4.00 (m, 1H), 3.78-3.56 (m, 2H), 3.51-3.23 (m, 3H), 3.15-2.86 (m, 10H), 2.88-2.73 (m, 6H), 2.64-2.38 (m, 1H), 2.35-2.17 (m, 6H), 2.01 (dt, J=10.8, 5.6 Hz, 3H), 1.66 (q, J=8.9, 8.5 Hz, 1H), 1.51-1.23 (m, 6H), 1.13 (d, J=3.5 Hz, 3H).

Example 214

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using 3-dimethylamino azetidine 2HCl salt and Hunig's base to replace morpholine. LCMS calc. for C₃₈H₅₁ClN₅O₆S [M+H]⁺: m/z=740.32/742.31; Found: 740.6/742.6. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.6, 2.3 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 6.82 (s, 1H), 6.05-5.78 (m, 1H), 5.68 (dd, J=15.7, 2.8 Hz, 1H), 5.25 (s, 1H), 4.22-3.99 (m, 3H), 3.99-3.85 (m, 3H), 3.71 (d, J=14.7 Hz, 2H), 3.38 (dd, J=14.9, 8.9 Hz, 2H), 3.20-2.67 (m, 6H), 2.32-2.15 (m, 8H), 2.04-1.90 (m, 3H), 1.83 (dq, J=9.4, 4.9 Hz, 3H), 1.65 (q, J=9.4 Hz, 1H), 1.52-1.23 (m, 6H), 1.12 (d, J=6.4 Hz, 3H).

Example 215

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using (3R)-3-methoxypyrrolidine to replace morpholine. LCMS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.33/743.33; Found: 741.5/743.5. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.63-7.45 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.96 (dd, J=8.4, 1.1 Hz, 1H), 6.85 (dd, J=5.4, 2.2 Hz, 1H), 6.00-5.62 (m, 2H), 5.40-5.25 (m, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.12-3.94 (m, 2H), 3.86 (d, J=13.2 Hz, 1H), 3.72 (d, J=14.7 Hz, 1H), 3.67-3.26 (m, 8H), 3.09 (ddd, J=14.7, 11.0, 3.2 Hz, 1H), 2.82 (ddd, J=15.4, 10.3, 5.9 Hz, 6H), 2.28 (s, 3H), 1.95 (dddd, J=46.8, 27.6, 9.1, 5.6 Hz, 6H), 1.79-1.54 (m, 1H), 1.50-1.23 (m, 6H), 1.11 (s, 3H).

Example 216

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using azetidine hydrochloride salt and Hunig's base to replace morpholine. LCMS calc. for C₃₆H₄₆ClN₄O₆S [M+H]⁺: m/z=697.27/699.27; Found: 697.4/699.5. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.52-7.42 (m, 1H), 7.24-7.05 (m, 2H), 7.01-6.90 (m, 1H), 6.86 (s, 1H), 5.92 (s, 1H), 5.72-5.60 (m, 1H), 5.22 (s, 1H), 4.39-3.87 (m, 4H), 3.72 (d, J=14.6 Hz, 1H), 3.47 (d, J=15.0 Hz, 1H), 3.34 (d, J=14.8 Hz, 1H), 3.15-2.98 (m, 1H), 2.89 (s, 2H), 2.78 (d, J=10.5 Hz, 3H), 2.28 (s, 6H), 1.99 (d, J=12.0 Hz, 2H), 1.84 (d, J=15.0 Hz, 4H), 1.65 (q, J=9.5 Hz, 1H), 1.30 (d, J=22.5 Hz, 5H), 1.17-0.98 (m, 4H).

Example 217

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 Step 2 using 3-methoxyazetidine hydrochloride salt and Hunig's base to replace morpholine. LCMS calc. for C₃₇H₄₈ClN₄O₇S [M+H]⁺: m/z=727.29/729.29; Found: 727.4/729.5. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.82 (d, J=2.2 Hz, 1H), 5.86 (s, 1H), 5.67 (d, J=15.9 Hz, 1H), 5.26 (s, 1H), 4.24 (s, 3H), 4.18 (d, J=12.2 Hz, 1H), 4.05 (d, J=12.1 Hz, 1H), 3.97 (d, J=7.9 Hz, 2H), 3.72 (d, J=14.7 Hz, 1H), 3.37 (d, J=14.7 Hz, 3H), 3.35-3.27 (m, 3H), 3.07 (dd, J=15.0, 11.1 Hz, 1H), 2.81 (s, 5H), 2.88-2.73 (m, 1H), 2.28 (s, 3H), 2.01 (s, 1H), 1.82 (s, 4H), 1.65 (q, J=9.4 Hz, 1H), 1.37 (s, 3H), 1.27 (d, J=4.3 Hz, 1H), 1.11 (s, 3H).

Example 218

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.30/743.30; Found: 741.4/743.3. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.84 (d, J=2.2 Hz, 1H), 5.85-5.77 (m, 1H), 5.76-5.67 (m, 1H), 5.36 (s, 1H), 5.00 (s, 1H), 4.18 (d, J=12.2 Hz, 1H), 4.10-4.03 (m, 2H), 3.74 (d, J=15.1 Hz, 2H), 3.46 (d, J=14.8 Hz, 1H), 3.37 (d, J=14.7 Hz, 1H), 3.15-3.08 (m, 1H), 3.06-2.95 (m, 3H), 2.82 (t, J=9.4 Hz, 4H), 2.28 (s, 6H), 1.99 (d, J=11.0 Hz, 2H), 1.90-1.61 (m, 9H), 1.35 (s, 3H), 1.27 (s, 3H).

Example 219

(3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-11-ethyl-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43, Step 3) and acetaldehyde. LCMS calc. for C₃₃H₄₃ClN₃O₅S [M+H]⁺: m/z=628.25/630.25; Found: 628.4/630.4. ¹H NMR (600 MHz, DMSO-d₆) δ 7.64 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.4, 2.4 Hz, 1H), 7.25-7.15 (m, 3H), 7.10 (d, J=8.1 Hz, 1H), 6.76 (s, 1H), 5.72 (s, 1H), 5.33 (t, J=5.0 Hz, 1H), 4.88-4.84 (m, 1H), 3.99 (t, J=10.4 Hz, 2H), 3.51 (s, 1H), 3.02 (s, 2H), 2.80 (d, J=16.8 Hz, 1H), 2.72 (dd, J=11.1, 6.1 Hz, 1H), 2.54 (s, 4H), 2.00 (dt, J=19.0, 7.0 Hz, 5H), 1.85 (s, 5H), 1.85-1.81 (m, 1H), 1.64 (d, J=8.2 Hz, 2H), 1.56 (s, 1H), 1.46 (p, J=7.2 Hz, 2H), 1.39 (s, 2H), 1.30 (s, 2H), 1.15 (s, 1H), 0.86 (t, J=6.8 Hz, 3H).

Example 220

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]N-tetrahydropyran-4-ylcarbamate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 4-aminotetrahydropyran in Step 2. LCMS calcd. for C₃₉H₅₂ClN₄O₇S [M+H]⁺: m/z=755.32/757.32; Found: 755.5/757.6. ¹H NMR (600 MHz, DMSO-d₆) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.19 (dd, J=9.9, 5.1 Hz, 2H), 6.96 (dd, J=14.4, 7.0 Hz, 2H), 5.59 (s, 1H), 4.99 (d, J=4.0 Hz, 1H), 4.11 (d, J=12.3 Hz, 1H), 4.05 (d, J=11.6 Hz, 1H), 3.68 (s, 3H), 3.58-3.12 (m, 9H), 2.82-2.76 (m, 1H), 2.72 (q, J=8.4 Hz, 2H), 2.65 (s, 7H), 2.43 (s, 1H), 1.98 (dt, J=13.8, 4.6 Hz, 1H), 1.83 (h, J=6.0, 4.9 Hz, 3H), 1.71 (q, J=8.6 Hz, 2H), 1.63-1.53 (m, 1H), 1.48 (dd, J=14.5, 7.6 Hz, 1H), 1.31 (s, 3H), 1.27-1.21 (m, 2H), 1.19 (s, 3H).

Example 221

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and morpholine in Step 2. LCMS calc. for C₃₈H₄₉ClN₄O₇S [M+H]⁺: m/z=741.3/743.37; Found 741.6/741.6. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.59-7.47 (m, 1H), 7.24-7.07 (m, 2H), 7.05-6.90 (m, 2H), 5.89 (s, 1H), 5.64 (d, J=16.5 Hz, 1H), 5.36 (s, 1H), 4.19 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.0 Hz, 1H), 3.70 (d, J=13.1 Hz, 6H), 3.35 (d, J=14.6 Hz, 3H), 3.09 (s, 6H), 2.81 (m, 10H), 2.31 (d, J=9.3 Hz, 1H), 2.07-1.94 (m, 3H), 1.84 (t, J=9.2 Hz, 2H), 1.31 (s, 6H).

Example 222

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 4-methoxypiperidine in Step 2. LCMS calc. for C₄₀H₅₄ClN₄O₇S [M+H]⁺: m/z=769.34/771.34; Found 769.7/771.8. ¹H NMR (300 MHz, CDCl₃) δ 7.63 (dd, J=19.7, 8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.24-7.06 (m, 3H), 7.00 (d, J=8.4 Hz, 1H), 5.86 (s, 2H), 5.61 (s, 1H), 4.19 (d, J=12.1 Hz, 1H), 5.32 (s, 2H), 4.06 (d, J=12.1 Hz, 1H), 3.90 (m, 16H), 3.70 (d, J=14.7 Hz, 1H), 3.35 (d, J=16.0 Hz, 7H), 3.11 (s, 1H), 1.97 (t, J=10.3 Hz, 1H), 1.80 (dt, J=18.6, 8.5 Hz, 1H), 1.67-1.54 (m, 1H), 1.36-1.21 (m, 10H).

Example 223

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(methylamino)azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (30.0 mg, Example 219) in Step 1 and tert-butyl N-(azetidin-3-yl)-N-methyl-carbamate (74.67 mg, 0.40 mmol) in Step 2. The reaction mixture was concentrated under reduced pressure The residue was dissolved in IPA (0.50 mL) and DCM (0.50 mL), and treated with phosphoric acid (0.5 mL, 8.6 mmol). The resulting mixture was stirred for 16 h., and quenched with sat. NaHCO₃(a_q) (1 mL). The mixture was extracted with DCM (1 mL×3). The organic layer was concentrated and the residue was purified by prep-HPLC on a C18 column with MeCN/H₂O (15% to 100%) to afford the title compound (6 mg, 20.2% yield). LCMS calc. for C₃₅H₅₁ClN₅O₆S [M+H]⁺: m/z=740.32/742.32; Found 740.5/742.6. ¹H NMR (600 MHz, DMSO-d₆) δ 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.09 (d, J=8.4 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.72 (s, 1H), 6.41 (t, J=12.5 Hz, 1H), 5.80 (d, J=15.7 Hz, 1H), 5.11 (s, 1H), 3.99 (q, J=12.2 Hz, 3H), 3.74-3.65 (m, 2H), 3.56 (d, J=14.5 Hz, 1H), 3.31-3.24 (m, 1H), 3.03 (dd, J=15.2, 11.1 Hz, 1H), 2.96 (dd, J=12.6, 6.8 Hz, 1H), 2.83-2.76 (m, 1H), 2.70 (ddd, J=17.2, 11.3, 6.2 Hz, 2H), 2.51 (s, 1H), 2.32 (q, J=8.8 Hz, 1H), 2.24 (s, 3H), 1.99 (ddt, J=17.6, 12.2, 5.6 Hz, 2H), 1.93-1.77 (m, 3H), 1.73-1.63 (m, 3H), 1.41 (s, 3H), 1.32-1.28 (m, 1H), 1.30-1.18 (m, 10H), 0.86 (t, J=6.9 Hz, 1H).

Example 224

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and N,N-dimethylazetidin-3-amine in Step 2. LCMS calc. for C₃₉H₅₃ClN₅O₆S [M+H]⁺: m/z=754.33/756.43; Found 756.5/758.6. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.63-7.45 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (dd, J=9.3, 2.2 Hz, 1H), 6.94 (d, J=8.4 Hz, 1H), 6.80 (s, 1H), 6.18 (s, 1H), 5.69 (d, J=14.6 Hz, 1H), 5.18 (s, 1H), 4.38 (s, 1H), 4.16 (d, J=12.3 Hz, 1H), 4.03 (d, J=10.9 Hz, 2H), 3.86 (s, 1H), 3.71 (d, J=14.6 Hz, 1H), 3.36 (d, J=14.7 Hz, 1H), 3.25-3.09 (m, 1H), 3.01 (m, 15H), 2.79 (m, 4H), 2.20 (d, J=16.2 Hz, 7H), 1.98 (d, J=12.3 Hz, 1H), 1.64 (q, J=9.3 Hz, 1H), 1.46 (d, J=30.9 Hz, 3H), 1.23 (q, J=7.8, 7.2 Hz, 3H).

Example 225

[(3R,6R,7S,8E,22S)-6′-Chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)piperazine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C₄₁H₅₇ClN₅O₇S [M+H]⁺: m/z=798.36/800.36; Found: 799.1/801.1.

Example 226

[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 2 and (3S)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.30/743.30; Found: 741.4/743.3. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (d, J=8.5 Hz, 1H), 7.19 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.03-6.95 (m, 1H), 6.89-6.75 (m, 1H), 5.94-5.62 (m, 2H), 5.38 (s, 1H), 4.97 (s, 1H), 4.18 (d, J=12.1 Hz, 1H), 4.13-3.96 (m, 2H), 3.90-3.62 (m, 4H), 3.41 (dd, J=25.6, 15.3 Hz, 2H), 3.06 (dd, J=39.0, 17.3 Hz, 4H), 2.81 (t, J=12.5 Hz, 5H), 2.26 (d, J=14.2 Hz, 5H), 2.12-1.56 (m, 10H), 1.35 (s, 4H), 1.27 (s, 2H).

Example 227

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 40) in Step 1 and methylamine (40% in water) in Step 2. LCMS calc. for C₃₃H₃₉ClN₃O₇S [M+H]⁺: m/z=656.22/658.22; Found: 656.6/658.5. ¹H NMR (300 MHz, CDCl₃) δ 9.02 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.37 (d, J=1.6 Hz, 1H), 7.17 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.81-5.56 (m, 2H), 5.09 (d, J=6.6 Hz, 1H), 4.46 (s, 1H), 4.14 (s, 2H), 4.07 (dd, J=13.3, 5.2 Hz, 1H), 3.95 (dd, J=13.0, 7.5 Hz, 1H), 3.67 (t, J=10.3 Hz, 1H), 3.60 (d, J=7.4 Hz, 1H), 3.30 (d, J=14.6 Hz, 1H), 3.17 (dd, J=15.3, 4.7 Hz, 1H), 2.76 (d, J=4.8 Hz, 4H), 2.72-2.61 (m, 1H), 2.56 (dd, J=16.5, 8.3 Hz, 1H), 2.05-1.85 (m, 3H), 1.81 (dd, J=10.7, 7.7 Hz, 1H), 1.70 (dd, J=11.7, 7.0 Hz, 2H), 1.62 (d, J=12.4 Hz, 2H), 1.55-1.30 (m, 3H), 1.22 (ddd, J=13.3, 11.2, 4.6 Hz, 2H).

Example 228

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate

Step 1: 1-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-cyclobutanecarboxamide

A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.0 g, 5.96 mmol), 1-allyloxycyclobutanecarboxylic acid (3.26 g, 20.87 mmol), DMAP (5.83 g, 47.71 mmol) and EDC (5.72 g, 29.82 mmol) in DCM (30 mL) was stirred at 30° C. for 2 h. LCMS showed the conversion of the starting material into the desired product. The mixture was quenched with sat. NH₄Cl(aq) (20 mL) and extracted with DCM (20 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was dissolved in THF (10 mL), water (10 mL) and methanol (10 mL), and treated with LiOH (1.29 g, 30.79 mmol). The mixture was stirred at 30° C. overnight, and quenched with 1M HCl (20 mL). The mixture was extracted with EtOAc (20 mL×3). The combined organic layers were washed with sat. NaHCO₃(aq) (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EA:Hep (5% to 30%) to afford 1-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-cyclobutanecarboxamide (2.35 g, 71.4% yield).

Step 2: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-13-one

A solution of 1-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-cyclobutanecarboxamide (2.35 g, 3.66 mmol) in DCE (2.5 L) was bubbled with N₂ gas for 15 min., then Hoveyda-Grubbs II (0.46 g, 0.73 mmol) was added and the mixture was bubbled with N₂ gas for an additional 15 min. The mixture was stirred for 2 h. at 40° C. under N₂. LCMS showed the conversion of the starting material into the desired product. The mixture was then exposed to air and stirred for 30 min before it was concentrated under reduced pressure. The reside was purified by flash chromatography on a silica gel column eluting with EA:Hep (10% to 60%) to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (1.49 g, 66.3% yield).

Step 3: [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl](3R)-3-ethoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one in Step 1 and (3R)-3-ethoxypyrrolidine in Step 2. LCMS calc. for C₃₉H₄₉ClN₃O₈S [M+H]⁺: m/z=754.29/756.29; Found: 754.4/756.4. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (dd, J=8.5, 4.3 Hz, 1H), 7.51 (d, J=8.2 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 7.10-6.91 (m, 3H), 5.96 (s, 1H), 5.62 (ddd, J=15.6, 9.3, 5.4 Hz, 1H), 5.17 (d, J=4.8 Hz, 1H), 4.08 (m, 4H), 3.76-3.60 (m, 3H), 3.59-3.32 (m, 3H), 3.32-3.12 (m, 2H), 2.81-2.63 (m, 2H), 2.44 (m, 1H), 2.09 (dd, J=58.7, 11.5 Hz, 7H), 1.82 (t, J=8.0 Hz, 3H), 1.63 (q, J=9.4 Hz, 1H), 1.33-1.18 (m, 9H), 1.09 (dd, J=8.8, 6.3 Hz, 3H).

Example 229

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3S)-3-methoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and (3R)-3-methoxypyrrolidine HCl and DIPEA in Step 2. LCMS calc. for C₃₉H₅₃ClN₅O₆S [M+H]⁺: m/z=740.28/742.27; Found: 740.4/742.5. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (dd, J=8.5, 5.3 Hz, 1H), 7.48 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (d, J=8.8 Hz, 1H), 7.13-6.99 (m, 2H), 6.97 (dd, J=8.3, 2.6 Hz, 1H), 5.80 (d, J=15.9 Hz, 1H), 5.64 (td, J=15.6, 13.8, 5.0 Hz, 1H), 5.23 (s, 1H), 4.23-4.01 (m, 3H), 3.75-3.46 (m, 2H), 3.47-3.29 (m, 5H), 3.29-3.08 (m, 1H), 2.78 (s, 3H), 2.67-2.48 (m, 1H), 2.42 (d, J=7.4 Hz, 2H), 2.35-2.17 (m, 1H), 2.10 (q, J=10.4, 9.9 Hz, 1H), 1.97 (dd, J=14.7, 6.0 Hz, 2H), 1.87 (dd, J=27.0, 5.2 Hz, 2H), 1.70-1.40 (m, 2H), 1.29 (d, J=16.4 Hz, 3H), 1.10 (d, J=6.6 Hz, 8H).

Example 230

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]-N,N-1,3-(2-ethoxy)propylene carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and 3-ethoxyazetidine in Step 2. LCMS calc. for C₃₈H₄₇ClN₃O₈S [M+H]⁺: m/z=740.27/742.27; Found: 740.4/742.4; ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.05 (dd, J=13.4, 2.3 Hz, 2H), 6.94 (d, J=8.3 Hz, 1H), 5.83 (s, 1H), 5.60 (dd, J=15.7, 5.4 Hz, 1H), 5.12 (s, 1H), 4.28-3.98 (m, 7H), 3.67 (m, 3H), 3.48-3.37 (m, 4H), 3.29 (d, J=14.5 Hz, 1H), 2.76 (d, J=5.0 Hz, 2H), 2.27-2.16 (m, 3H), 2.10-1.93 (m, 7H), 1.80-1.64 (m, 6H), 1.21-1.18 (m, 3H).

Example 231

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15λ6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethyl-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and dimethylamine (2.0 M in THF) in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₇S [M+H]⁺: m/z=684.24/686.24; Found: 684.3/686.2; ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.04 (dd, J=18.7, 2.2 Hz, 2H), 6.93 (d, J=8.3 Hz, 1H), 6.10-5.97 (m, 1H), 5.62 (dd, J=15.7, 5.8 Hz, 1H), 5.13 (t, J=5.0 Hz, 1H), 4.07 (d, J=3.8 Hz, 1H), 3.99 (dd, J=14.0, 6.3 Hz, 1H), 3.80-3.68 (m, 2H), 3.65 (s, 1H), 3.51 (d, J=14.1 Hz, 1H), 3.24 (d, J=14.4 Hz, 1H), 3.14 (dd, J=15.0, 8.8 Hz, 1H), 2.94-2.82 (m, 6H), 2.75-2.69 (m, 3H), 2.67 (s, 3H), 2.14-1.92 (m, 6H), 1.76-1.66 (m, 6H).

Example 232

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N,N-1,3-propylene carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and azetidine hydrochloride and DIPEA in Step 2. LCMS calc. for C₃₇H₄₅ClN₃O₆S [M+H]⁺: m/z=696.24/698.24; Found: 696.3/698.4; ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.15 (dd, J=8.5, 2.3 Hz, 2H), 7.09-7.00 (m, 2H), 6.91 (d, J=8.3 Hz, 1H), 5.63 (dd, J=15.4, 5.8 Hz, 1H), 5.37-5.31 (m, 1H), 5.12 (s, 1H), 4.10-3.88 (m, 7H), 3.66-3.64 (m, 2H), 3.24-3.20 (m, 1H), 2.76 (s, 2H), 2.40-2.31 (m, 4H), 2.21-2.08 (m, 5H), 2.06-1.93 (m, 6H), 1.76-1.62 (m, 7H).

Example 233

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and N,N,N′-trimethylethylenediamine in Step 2. LCMS calc. for C₃₈H₅₀ClN₄O₇S [M+H]⁺: m/z=741.30/743.30; Found: 741.4/743.3; ¹H NMR (300 MHz, CDCl₃) δ 7.71 (d, J=8.5 Hz, 1H), 7.46 (d, J=8.2 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 2H), 7.09 (s, 1H), 6.94 (d, J=8.3 Hz, 1H), 6.41 (s, 1H), 6.07 (s, 1H), 5.66 (d, J=15.0 Hz, 1H), 5.34 (d, J=11.5 Hz, 1H), 4.98 (s, 1H), 4.69 (s, 1H), 4.20-4.00 (m, 4H), 3.71 (d, J=15.5 Hz, 3H), 3.50 (d, J=14.1 Hz, 2H), 3.37-3.26 (m, 2H), 3.03-2.95 (m, 4H), 2.85 (s, 3H), 2.78 (s, 2H), 2.74 (s, 1H), 2.41 (s, 3H), 2.23-2.20 (m, 4H), 1.99-1.87 (m, 4H), 1.82-1.75 (m, 4H).

Example 234

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₈H₄₇ClN₃O₈S [M+H]⁺: m/z=740.27/742.27; Found: 740.4/742.2. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.05 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.66 (d, J=2.8 Hz, 2H), 5.30-5.19 (m, 1H), 4.89 (s, 1H), 4.20 (d, J=12.1 Hz, 1H), 4.12 (s, 1H), 4.08 (d, J=3.4 Hz, 1H), 4.01 (dd, J=8.6, 4.8 Hz, 1H), 3.76 (d, J=5.9 Hz, 2H), 3.70 (d, J=7.5 Hz, 1H), 3.66 (s, 1H), 3.56 (d, J=13.8 Hz, 1H), 3.38 (s, 1H), 3.32 (d, J=6.5 Hz, 2H), 2.86 (s, 3H), 2.79-2.72 (m, 4H), 2.04-1.70 (m, 12H), 1.67-1.49 (m, 4H).

Example 235

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C₃₇H₄₅ClN₃O₈S [M+H]⁺: m/z=726.26/728.26; Found: 726.4.4/728.6. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (dq, J=12.6, 8.1 Hz, 2H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.18-7.00 (m, 3H), 5.88 (tdd, J=16.8, 10.4, 5.5 Hz, 1H), 5.64 (s, 2H), 5.38-5.01 (m, 3H), 4.77 (dt, J=13.4, 7.0 Hz, 2H), 4.25-4.02 (m, 3H), 3.97-3.84 (m, 1H), 3.83-3.52 (m, 3H), 3.29 (d, J=20.3 Hz, 3H), 3.06 (s, 3H), 2.78 (s, 4H), 2.57-2.05 (m, 3H), 2.09-1.77 (m, 2H), 1.60 (dd, J=20.4, 10.9 Hz, 2H), 1.47-1.23 (m, 5H).

Example 236

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C₃₉H₄₉ClN₃O₈S [M+H]⁺: m/z=754.29/756.29; Found: 754.4/756.5. ¹H NMR (300 MHz, CDCl₃) δ 8.81 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.1 Hz, 1H), 7.21-6.92 (m, 4H), 5.64 (s, 2H), 5.25 (s, 1H), 4.25-4.05 (m, 2H), 4.01 (d, J=10.4 Hz, 6H), 3.73 (dd, J=30.6, 14.2 Hz, 1H), 3.56 (d, J=13.7 Hz, 1H), 3.48-3.29 (m, 8H), 2.84-2.68 (m, 7H), 2.56-2.44 (m, 1H), 2.45-2.20 (m, 1H), 2.24-1.98 (m, 1H), 2.04-1.83 (m, 1H), 1.82 (q, J=10.4, 7.9 Hz, 4H), 1.57 (s, 1H), 1.29 (d, J=16.1 Hz, 3H).

Example 237

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and (3S)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C₃₇H₄₅ClN₃O₈S [M+H]⁺: m/z=726.26/728/26; Found: 726.4/728.4.

Example 238

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 3-methoxyazetidine hydrochloride and DIPEA in Step 2. LCMS calc. for C₃₈H₄₈ClN₄O₇S [M+H]⁺: m/z=739.2/741.2; Found: 739.4/741.5. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.4, 2.3, 1H), 7.23-7.18 (m, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.00 (dd, J=8.3, 1.0 Hz, 1H), 6.87 (d, J=2.2 Hz, 1H), 5.72-5.67 (m, 2H), 5.24 (br, 1H), 4.23-4.06 (m, 4H), 3.96 (d, J=8.3 Hz, 1H), 3.73 (d, J=14.8 Hz, 1H), 3.45-3.40 (m, 2H), 3.33 (s, 3H), 3.12 (dd, J=14.9, 10.6 Hz, 1H), 2.89-2.66 (m, 5H), 2.44 (s, 3H), 2.35-2.15 (m, 4H), 2.04-1.92 (m, 4H), 1.85-1.64 (m, 7H), 1.34-1.30 (m, 3H).

Example 239

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.3,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C₄₀H₅₂ClN₄O₇S [M+H]⁺: m/z=767.32/769.32; Found: 767.5/769.8. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 5.72 (s, 2H), 5.33 (s, 1H), 4.27 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.2 Hz, 1H), 3.73 (d, J=14.7 Hz, 1H), 3.55-3.40 (m, 4H), 3.36 (d, J=14.4 Hz, 1H), 3.13 (t, J=12.8 Hz, 1H), 2.90 (d, J=11.8 Hz, 3H), 2.89-2.63 (m, 7H), 2.58-2.43 (m, 1H), 2.42 (s, 3H), 2.36-2.05 (m, 1H), 2.01 (s, 2H), 2.00-1.84 (m, 1H), 1.85-1.52 (m, 8H), 1.44 (t, J=12.0 Hz, 1H), 1.36-1.20 (m, 4H).

Example 240

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C₃₈H₄₈ClN₄O₇S [M+H]⁺: m/z=739.29/741.29; Found: 739.5/741.5.

Example 241

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3S)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₉H₄₉ClN₃O₈S [M+H]⁺: m/z=753.31/755.31; Found: 753.4/755.4. ¹H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=8.6 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.24-7.16 (m, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 5.72 (d, J=2.7 Hz, 2H), 5.33 (s, 1H), 4.96 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.10-3.98 (m, 2H), 3.85-3.67 (m, 5H), 3.50-3.41 (m, 1H), 3.36 (d, J=14.8 Hz, 1H), 3.13 (dd, J=15.0, 10.5 Hz, 1H), 2.94 (d, J=8.5 Hz, 3H), 2.79 (q, J=6.1, 5.7 Hz, 4H), 2.72 (s, 2H), 2.43 (s, 3H), 2.08-1.92 (m, 7H), 1.85-1.62 (m, 7H), 1.46 (d, J=12.9 Hz, 1H).

Example 242

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₉H₅₀ClN₄O₇S [M+H]⁺: m/z=753.31/755.31; Found: 753.4/755.4. ¹H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.3 Hz, 1H), 5.72 (d, J=1.8 Hz, 2H), 5.40-5.29 (m, 1H), 4.97 (s, 1H), 4.17 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 2H), 3.86-3.74 (m, 3H), 3.71 (s, 2H), 3.50-3.40 (m, 1H), 3.36 (d, J=14.7 Hz, 1H), 3.12 (dd, J=15.0, 10.6 Hz, 1H), 2.95 (d, J=8.1 Hz, 3H), 2.79 (q, J=5.8, 5.1 Hz, 4H), 2.71 (s, 1H), 2.43 (s, 3H), 2.09-1.89 (m, 7H), 1.89-1.76 (m, 4H), 1.75-1.61 (m, 4H), 1.46 (d, J=13.0 Hz, 1H).

Example 243

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3R)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C₃₈H₄₈ClN₄O₇S [M+H]⁺: m/z=739.29/741.29; Found: 739.3/741.3.

Example 244

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-ethoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 3-ethoxyazetidine; hydrochloride and DIPEA in Step 2. LCMS calc. for C₃₉H₅₀ClN₄O₇S [M+H]⁺: m/z=753.30/755.30; Found: 753.6/755.3. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.72-5.66 (m, 2H), 5.24 (br, 1H), 4.22-4.13 (m, 6H), 3.73 (d, J=14.7 Hz, 1H), 3.48-3.33 (m, 4H), 3.12 (dd, J=15.0, 10.5 Hz, 1H), 2.84-2.71 (m, 4H), 2.44 (s, 3H), 2.32-2.27 (m, 3H), 2.06-1.95 (m, 4H), 1.85-1.80 (m, 3H), 1.67-1.61 (m, 2H), 1.45 (t, J=11.8 Hz, 1H), 1.27-1.16 (m, 8H).

Example 245

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 4-methoxypiperidine in Step 2. LC-MS: calc. for C₄₀H₅₂ClN₄O₇S [M+H]⁺: m/z=767.32/769.32; Found 767.4/769.4.

Example 246

(3R,6R,7S,8E,22S)-7′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one

This compound was prepared using procedures analogous to those described for Example 32 Step 1-3 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 12) and 2-allyloxy-2-methyl-propanoic acid (Example 30 Stepl). LC-MS: calc. for C₃₀H₃₆ClN₂O₇S [M+H]⁺: m/z=603.2/605.2; Found: 603.2/605.2. HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H₂O (with 0.1% TFA) 2 min, 5% to 95% 6 min, 95% 2 min. λ=220 nm. tR=6.813 min. ¹H NMR (499 MHz, DMSO-d₆) δ 11.71 (s, 1H), 7.55 (d, J=8.5 Hz, 1H), 7.38-7.20 (m, 1H), 7.15-7.00 (m, 2H), 6.97 (dd, J=8.5, 2.3 Hz, 1H), 6.89 (t, J=2.4 Hz, 1H), 5.67-5.37 (m, 2H), 4.69 (d, J=4.1 Hz, 1H), 4.33-4.17 (m, 3H), 4.05 (d, J=12.1 Hz, 1H), 3.97-3.82 (m, 2H), 3.59 (d, J=14.5 Hz, 1H), 3.45 (t, J=15.4 Hz, 2H), 3.17 (dd, J=14.5, 7.4 Hz, 1H), 2.60 (q, J=7.8, 6.0 Hz, 1H), 2.34-2.20 (m, 1H), 2.17-1.95 (m, 2H), 1.84 (tdt, J=25.5, 16.6, 7.4 Hz, 3H), 1.73-1.51 (m, 2H), 1.36 (s, 3H), 1.23 (s, 3H).

Example 247

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-135,5-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate

To a stirred solution of (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (22.0 mg, 0.04 mmol, Example 246) in MeCN (10 ml) was added CDI (18.11 mg, 0.11 mmol). The mixture was stirred at 45° C. for 2 h. LCMS analysis indicated the starting material was fully consumed. Dimethylamine in THF (35 uL, 0.07 mmol, 2.0 N) was added. The reaction mixture was stirred at 45° C. for 2 h. HCl (1.0 M, 2 mL) was added. The mixture was extracted with DCM (5 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C₁₈ column to afford [(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate (5.8 mg, 23.6% yield) as a white solid. LCMS calc. for C₃₃H₄₁ClN₃O₈S [M−H]⁺: m/z=674.2/676.2; Found: 674.4/676.4. ¹H NMR (499 MHz, DMSO-d₆) δ 11.69 (s, 1H), 7.57 (d, J=8.5 Hz, 1H), 7.33-7.18 (m, 1H), 7.05-6.94 (m, 3H), 6.88 (d, J=2.2 Hz, 1H), 5.66 (s, 2H), 5.10 (t, J=3.5 Hz, 1H), 4.35-4.15 (m, 3H), 4.07 (d, J=12.1 Hz, 1H), 3.94 (d, J=13.7 Hz, 1H), 3.63 (d, J=14.5 Hz, 1H), 3.41 (d, J=14.5 Hz, 1H), 3.25 (d, J=6.7 Hz, 2H), 2.92 (s, 3H), 2.83 (s, 3H), 2.69 (q, J=7.9 Hz, 1H), 2.43 (s, 1H), 2.11-1.97 (m, 1H), 1.89-1.79 (m, 2H), 1.77-1.60 (m, 3H), 1.37 (s, 3H), 1.21 (s, 3H).

Example 248

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl]morpholine-4-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and morpholine in Step 2. LC-MS: calc. for C₃₅H₄₃ClN₃O₉S [M+H]⁺: m/z=716.2/718.2; Found: 716.3/718.3. ¹H NMR (300 MHz, CDCl₃) δ 7.78 (d, J=7.5 Hz, 1H), 7.57 (dd, J=8.4, 1.1 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.13-7.01 (m, 2H), 6.94 (ddd, J=8.4, 2.3, 1.2 Hz, 1H), 5.97-5.64 (m, 2H), 5.34 (t, J=4.3 Hz, 1H), 4.57 (td, J=11.5, 10.4, 6.4 Hz, 1H), 4.40-3.94 (m, 5H), 3.80-3.62 (m, 4H), 3.54-3.26 (m, 4H), 3.03-2.87 (m, 1H), 2.80 (d, J=7.1 Hz, 3H), 2.08-1.80 (m, 6H), 1.65 (dd, J=12.2, 6.6 Hz, 2H), 1.46 (s, 3H), 1.37 (s, 3H).

Example 249

(3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one

This compound was prepared using procedures analogous to those described for Example 32 Step 1-3 using (3R)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 15) and 2-allyloxy-2-methyl-propanoic acid (Example 30 Stepl). LC-MS: calc. for C₃₀H₃₆ClN₂O₇S [M+H]⁺: m/z=603.2/605.2; Found: 603.2/605.2. ¹H NMR (300 MHz, CDCl₃) δ 7.60-7.45 (m, 2H), 7.25-7.14 (m, 3H), 7.02 (dd, J=8.4, 1.4 Hz, 1H), 5.86-5.51 (m, 2H), 4.38-4.29 (m, 1H), 4.17 (d, J=12.1 Hz, 2H), 4.09-3.96 (m, 2H), 3.84-3.52 (m, 6H), 3.28 (dd, J=14.8, 7.3 Hz, 1H), 2.94 (ddt, J=24.3, 16.0, 7.8 Hz, 2H), 2.80-2.68 (m, 1H), 2.40 (q, J=9.1 Hz, 1H), 2.14-1.78 (m, 4H), 1.42 (s, 3H), 1.39 (s, 3H).

Example 250

[(3R,6R,7S,8E,22R)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 1 and dimethylamine in THF solution (2.0 N) in Step 2. LC-MS: calc. for C₃₃H₄₁ClN₃O₈S [M+H]⁺: m/z=674.2/676.2; Found: 674.3/676.3. ¹H NMR (300 MHz, CDCl₃) δ 7.50 (d, J=8.5 Hz, 1H), 7.43 (dd, J=8.3, 2.0 Hz, 1H), 7.27-7.21 (m, 1H), 7.16 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.94 (dd, J=8.3, 0.9 Hz, 1H), 6.09 (ddd, J=15.8, 6.4, 4.1 Hz, 1H), 5.69 (dd, J=15.7, 5.5 Hz, 1H), 5.25 (t, J=4.2 Hz, 1H), 4.31 (d, J=11.8 Hz, 1H), 4.13 (d, J=11.8 Hz, 1H), 4.02-3.95 (m, 2H), 3.80-3.71 (m, 1H), 3.66 (d, J=11.6 Hz, 2H), 3.50-3.38 (m, 2H), 3.03 (s, 3H), 2.95 (s, 3H), 2.72 (s, 5H), 2.37 (qd, J=9.0, 2.9 Hz, 1H), 2.04 (qt, J=7.5, 3.0 Hz, 1H), 1.84 (q, J=9.0 Hz, 2H), 1.71-1.57 (m, 1H), 1.40 (s, 3H), 1.33 (s, 3H).

Example 251

Methyl N-[(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

Step 1: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1000.0 mg, 1.4 mmol, Intermediate 3 Step 3) in DCM (20 mL) was added copper sulfate (669.41 mg, 4.19 mmol) followed by the addition of (S)-2-methylpropane-2-sulfinamide (254.16 mg, 2.1 mmol). The reaction mixture was stirred at r.t. overnight. The reaction was filtered through a pad of Celite and washed with DCM. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Hep (3% to 60%) to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (980 mg, 85.6% yield). LCMS calcd. for C₄₄H₅₃ClN₃O₆S₂ [M+H]⁺: m/z=818.31/820.30; Found: 819.0/821.0.

Step 2: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a cooled (−78° C.) solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (980.0 mg, 1.2 mmol) in THF (20 mL) was added dropwise vinylmagnesium bromide (1.8 mL, 1.8 mmol, 1.0M THF solution) over 10 min. After addition, the reaction mixture was allowed to warm to r.t. over 1 h. LCMS showed full conversion of starting material and the formation of desired product. The reaction was quenched with sat. NH₄Cl(aq) (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was dried over NaSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (3% to 100%) to afford two products: P1 (the earlier eluted product, 410 mg, 40.4%) which was assigned to (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and P2 (the latter eluted product, 190 mg, 18.7%) which was assigned to (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LCMS calcd. for C₄₆H₅₇ClN₃O₆S₂ [M+H]⁺: m/z=846.34/848.33; Found: 847.1/849.2.

Step 3. (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

(3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (400.0 mg, 0.47 mmol, P1 Step 2) in 1,4-dioxane (10 mL) was treated with 6 M HCl in IPA solution (1.5 mL, 9.45 mmol). The reaction mixture was stirred for 1 h. LCMS showed full consume of starting material. The reaction was quenched with sat. NaHCO₃(a_q) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to yield (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (312 mg, 88.9% yield) which was used in the next step without further purification. LCMS calc. for C₄₂H₄₈ClN₃O₅S [M+H]⁺: m/z=742.31/744.31; Found: 742.7/744.1.

Step 4. (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (312.0 mg, 0.42 mmol) in DCM (5 mL) was added methyl chloroformate (0.05 mL, 0.63 mmol) and triethylamine (0.09 mL, 0.67 mmol). The mixture was stirred for 4 h. The reaction was quenched with MeOH (lmL) and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (3% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (252 mg, 74.9% yield). LCMS calc. for C₄₄H₅₁ClN₃O₇S [M+H]⁺: m/z=800.31/802.31; Found: 800.8/803.0.

Step 5: methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate

Methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (180.0 mg, 0.22 mmol) was dissolved in 2,2,2-trifluoroacetic acid (2.0 mL, 25.96 mmol) and DCM (8 mL). The mixture was stirred at r.t. overnight 16 h. The mixture was quenched by sat. NaHCO₃(a_q) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (10% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (116 mg, 92.1% yield). LCMS calc. for C₂₈H₃₅ClN₃O₅S [M+H]⁺: m/z=560.20/562.20; Found: 560.8/562.7.

Step 6: methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl) sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate

To a solution of methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (48.0 mg, 0.09 mmol) and 2-allyloxy-2-methyl-propanoic acid (24.71 mg, 0.17 mmol, Example 30 Step 1) in DCM (2 mL) was added sequentially DMAP (41.88 mg, 0.34 mmol), and EDCI (32.86 mg, 0.17 mmol). The mixture was stirred at r.t. overnight. The mixture was diluted with DCM (1 mL) and washed with 1 M HCl(aq) (1 mL). The organic layer was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (10% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl) sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (51 mg, 86.7% yield). LCMS calc. for C₃₅H₄₆ClN₄O₆S [M+H]⁺: m/z=685.28/687.28; Found: 685.8/687.2.

Step 7: methyl N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

A solution of methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl) sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (51.07 mg, 0.07 mmol) in DCE (60 mL) was bubbled with N₂ gas for 10 min., then Hoveyda-Grubbs 11 (9.33 mg, 0.01 mmol) was added. The reaction mixture was re-bubbled with N₂ for an additional 10 min. The mixture was then stirred at 40° C. under N₂ overnight. The reaction was exposed to air for 30 min. before concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (5% to 60%), and further purified by prep-HPLC H₂O:MeCN (10% to 100%) to afford methyl N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate (9 mg, 18.4% yield). LCMS calc. for C₃₃H₄₁ClN₃O₇S [M+H]⁺: m/z=658.24/660.23; Found: 658.68/660.8. HPLC: C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: MeCN/H₂O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=6.741 min. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.09-6.98 (m, 4H), 5.62 (dd, J=15.4, 7.2 Hz, 1H), 4.11-3.92 (m, 3H), 3.81-3.72 (m, 5H), 3.54 (d, J=14.6 Hz, 1H), 3.33 (d, J=14.5 Hz, 1H), 3.16 (t, J=12.2 Hz, 1H), 2.79 (s, 2H), 2.57 (s, 1H), 2.22 (q, J=6.8, 6.0 Hz, 1H), 2.04-1.89 (m, 4H), 1.65 (s, 3H), 1.50-1.23 (m, 7H), 0.89 (t, J=6.5 Hz, 1H).

Example 252

Methyl N-[(3R,6R,7R,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

Step 1: ethyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate

This compound was prepared using procedures analogous to those described for Example 251 Step 4 using ethyl chloroformate to replace methyl chloroformate. LCMS calc. for C₄₅H₅₃ClN₃O₇S [M+H]⁺: m/z=814.33/816.33; Found: 815.0/816.9.

Step 2: ethyl N-methyl-N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate

To a solution of ethyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (371.0 mg, 0.46 mmol) in DMF (6 mL) was added sodium hydride (60%, dispersion in paraffin liquid) (54.66 mg, 1.37 mmol), followed by iodomethane (0.11 mL, 1.82 mmol). The reaction was stirred at r.t. for 4 h. The reaction was quenched with sat. NH₄Cl (aq) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude product which was used in the next step without further purification. LCMS calc. for C₄₆H₅₅ClN₃O₇S [M+H]⁺: m/z=828.34/830.33; Found: 828.8/830.2.

Step 3: methyl N-[(3R,6R,7R,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using ethyl N-methyl-N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate in Step 5 and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1) in Step 6. LCMS calcd. for C₃₅H₄₅ClN₃O₇S (M+H)⁺: m/z=686.27/688.26; Found: 686.3/688.3. HPLC: C18 column (4.6×150 mm, 5 μm); flow rate=1 mL/min; mobile phase: MeCN/H₂O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=8.004 min.

Example 253

Ethyl N-methyl-N-[(3R,6R,7R,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

Step 1: ethyl N-methyl-N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using ethyl N-methyl-N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (Example 252, Step 2) in Step 5 and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 43 Step 1) in Step 6. LCMS calcd. for C₃₅H₄₆ClN₄O₆S (M+H)⁺: m/z=685.27/686.26; Found: 685.3/687.3.

Step 2: ethyl N-methyl-N-[(3R,6R,7R,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 138 Step 3 using ethyl N-methyl-N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate and formaldehyde aqueous solution (37%). LCMS calcd. for C₃₆H₄₈ClN₄O₆S [M+H]⁺: m/z=699.30/701.30; Found: 699.4/701.5.

Example 254

Methyl N-methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

Step 1: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-aminoallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

This compound was prepared using procedures analogous to those described for Example 251 Step 3 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (P2 Example 251 Step 2). LCMS calc. for C₄₂H₄₈ClN₃O₅S [M+H]⁺: m/z=742.31/744.31; Found: 742.7/744.1.

Step 2: 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide

To a solution of 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide (0.82 g, 1.1 mmol) in DCM (10 mL) was added trifluoroacetic anhydride (0.28 mL, 2.21 mmol) and triethylamine (0.62 mL, 4.42 mmol). The mixture was stirred for 16 h. The reaction was concentrated under reduced pressure to afford 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide (1.6 g) which was used in the next step without further purification. LCMS calc. for C₄₄H₄₈ClF₃N₃O₆S [M+H]⁺: m/z=838.29/840.29; Found: 838.8/840.0.

Step 3: 2,2,2-trifluoro-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide

This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide in Step 5 and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1) in Step 6. LCMS calc. for C₃₃H₃₈ClF₃N₃O₆S [M+H]⁺: m/z=696.21/698.21; Found: 696.3/698.3.

Step 4: (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one

To a solution of 2,2,2-trifluoro-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide (134.0 mg, 0.19 mmol) in methanol (10 mL) and water (5 mL) was added potassium carbonate (265.62 mg, 1.92 mmol). The mixture was stirred at 50° C. overnight. The mixture was quenched with NH₄Cl(aq) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (10% to 100%) to afford (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (120 mg). LCMS calc. for C₃₁H₃₉ClN₃O₅S [M+H]⁺: m/z=600.22/602.22; Found: 600.5/602.5.

Step 5: methyl N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one and methyl chloroformate. LCMS calc. for C₃₃H₄₀ClN₃O₇S [M+H]⁺: m/z=658.23/660.22; Found: 658.4/660.4.

Step 6: methyl N-methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 252 Step 2 using methyl N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate and iodomethane. LCMS calc. for C₃₄H₄₃ClN₃O₇S [M+H]⁺: m/z=672.25/674.25; Found: 672.4/674.4; HPLC: C18 column (4.6×150 mm, 5 μm); flow rate=1 mL/min; mobile phase: MeCN/H₂O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=7.321 min. ¹H NMR (600 MHz, DMSO-d₆) δ 7.65 (d, J=8.5 Hz, 1H), 7.30 (s, 1H), 7.23-7.18 (m, 2H), 7.09 (s, 1H), 6.85 (s, 1H), 6.66 (s, 1H), 5.63 (s, 1H), 5.33 (t, J=4.9 Hz, 1H), 4.17 (s, 1H), 3.96 (d, J=12.7 Hz, 1H), 3.89 (s, 1H), 3.70 (s, 1H), 3.52 (s, 3H), 2.80-2.70 (m, 1H), 2.65 (s, 2H), 2.00 (tt, J=13.1, 5.7 Hz, 3H), 1.86 (s, 2H), 1.80 (s, 3H), 1.54 (d, J=9.6 Hz, 1H), 1.46 (t, J=7.1 Hz, 2H), 1.29 (d, J=6.4 Hz, 1H), 1.26-1.19 (m, 4H), 1.14 (d, J=10.6 Hz, 3H), 0.86 (t, J=6.8 Hz, 3H).

Example 255

N-Methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide

Step 1: N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide

This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and acetyl chloride. LCMS calcd. for C₃₃H₄₁ClN₃O₆S [M+H]⁺: m/z=642.24/644.24; Found: 642.4/642.3.

Step 2: N-methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dime thyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide

This compound was prepared using procedures analogous to those described for Example 252 Step 2 using N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide and iodomethane. LCMS calcd. for C₃₄H₄₃ClN₃O₆S (M+H)⁺: m/z=656.26/658.25; Found: 656.4/658.5. ¹H NMR (600 MHz, CDCl₃) δ 7.75-7.70 (m, 1H), 7.60-7.38 (m, 1H), 7.16 (dd, J=8.7, 2.4 Hz, 1H), 7.13-7.06 (m, 2H), 7.02 (s, 1H), 6.91 (s, 1H), 5.82 (s, 1H), 5.39 (s, 1H), 5.25 (s, 1H), 5.03 (s, 1H), 4.18 (d, J=13.7 Hz, 2H), 4.07 (s, 3H), 3.94 (dd, J=13.6, 8.5 Hz, 1H), 3.70 (s, 2H), 3.23 (d, J=14.3 Hz, 1H), 2.79 (d, J=5.9 Hz, 1H), 2.78-2.69 (m, 4H), 2.52-2.32 (m, 1H), 2.24-2.19 (m, 3H), 2.06-1.94 (m, 4H), 1.92-1.87 (m, 1H), 1.86-1.81 (m, 4H), 1.45 (d, J=9.8 Hz, 2H), 0.87 (h, J=7.5, 6.5 Hz, 3H).

Example 256

N-Methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]methanesulfonamide

Step 1: N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]methanesulfonamide

This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and methanesulfonyl chloride. LCMS calcd. for C₃₂H₄₁ClN₃O₇S₂ (M+H)⁺: m/z=678.21/680.20; found: 678.4/660.1.

Step 2: N-methyl-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),7,19(24)-tetraene-22,1′-tetralin]-7-yl]methanesulfonamide

This compound was prepared using procedures analogous to those described for Example 252 Step 2 using N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]methanesulfonamide and iodomethane. LCMS calcd. for C₃₃H₄₃ClN₃O₇S₂ [M+H]⁺: m/z=692.22/692.42; found: 692.7/694.7. ¹H NMR (300 MHz, CDCl₃) δ 8.81 (s, 1H), 7.64 (d, J=8.6 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.21-6.91 (m, 4H), 5.84 (dd, J=15.3, 8.7 Hz, 1H), 5.33 (s, 1H), 4.17 (s, 3H), 3.95 (s, 2H), 3.69-3.52 (m, 3H), 3.37 (d, J=14.4 Hz, 1H), 3.23 (s, 1H), 2.75 (m, 8H), 2.37-1.61 (m, 5H), 1.45 (d, J=12.0 Hz, 6H), 1.36-1.23 (m, 3H).

Example 257

1,1,3-Trimethyl-3-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]urea

Step 1: 1,1-dimethyl-3-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,1′-tetralin]-7-yl]urea

This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and N,N-dimethylcarbamoyl chloride. LCMS calcd. for C₃₄H₄₄ClN₄O₆S (M+H)⁺: m/z=671.27/673.26; found: 671.5/673.4.

Step 2: 1,1,3-trimethyl-3-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,1′-tetralin]-7-yl]urea

This compound was prepared using procedures analogous to those described for Example 252 Step 2 using 1,1-dimethyl-3-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]urea and iodomethane. LCMS calcd. for C₃₅H₄₆ClN₄O₆S [M+H]⁺: m/z=685.28/687.28; found: 685.7/687.7. ¹H NMR (500 MHz, CDCl₃) δ 9.07 (s, 1H), 7.67-7.55 (m, 2H), 7.18-7.10 (m, 1H), 7.03 (s, 2H), 6.84 (d, J=8.4 Hz, 1H), 5.89 (d, J=10.0 Hz, 1H), 5.56 (d, J=15.1 Hz, 1H), 5.42 (s, 1H), 4.14 (d, J=10.7 Hz, 3H), 4.06 (d, J=11.8 Hz, 1H), 4.01-3.89 (m, 3H), 3.86 (d, J=12.9 Hz, 2H), 3.47 (d, J=15.2 Hz, 2H), 3.26 (d, J=19.2 Hz, 2H), 2.98 (d, J=14.6 Hz, 1H), 2.66 (s, 2H), 2.58 (s, 3H), 2.37 (d, J=8.4 Hz, 1H), 2.13 (s, 1H), 2.06-1.99 (m, 2H), 1.85 (s, 3H), 1.44 (d, J=14.9 Hz, 4H), 1.31 (s, 6H).

Example 258

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using 3,3-difluoroazetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₆H₄₅ClN₃O₆S [M+H]⁺: m/z=720.26/722.26; Found: 720.5/722.6.

Example 259

(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-7-[2-(4-methylpiperazin-1-yl)ethoxy]-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using methylpiperazine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₈H₅₂ClN₄O₆S [M+H]⁺: m/z=727.32/729.32; Found: 727.5/729.7; ¹H NMR (600 MHz, DMSO-d6) δ 7.63-7.59 (m, 1H), 7.30 (dd, J=8.3, 2.1 Hz, 1H), 7.24 (dd, J=8.5, 2.3 Hz, 1H), 7.20 (d, J=2.3 Hz, 1H), 7.07-7.04 (m, 2H), 5.56 (dd, J=15.7, 7.2 Hz, 1H), 5.36 (s, 1H), 4.07 (dt, J=27.4, 13.7 Hz, 3H), 3.91-3.85 (m, 2H), 3.32 (m, 6H), 3.15 (m, 3H), 2.80-2.76 (m, 2H), 2.74 (s, 4H), 2.65 (dd, J=3.9, 1.9 Hz, 1H), 2.47-2.38 (m, 2H), 2.34-2.23 (m, 1H), 2.04-1.93 (m, 3H), 1.91-1.76 (m, 5H), 1.74-1.69 (m, 1H), 1.61-1.55 (m, 2H), 1.47 (d, J=6.6 Hz, 1H), 1.38 (s, 3H), 1.26 (s, 3H).

Example 260

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R)-3-methoxypyrrolidin-1-yl]ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using (R)-3-methoxypyrrolidine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₈H₅₁ClN₃O₇S [M+H]⁺: m/z=728.31/730.30; Found: 728.5/730.7; ¹H NMR (300 MHz, DMSO-d₆) δ 9.95 (s, 1H, NH), 7.61 (d, J=8.5 Hz, 1H), 7.32-7.17 (m, 3H), 7.03 (t, J=7.7 Hz, 2H), 5.57 (dd, J=15.7, 6.8 Hz, 1H), 5.46-5.31 (m, 1H), 4.08 (m, 3H), 3.87 (dd, J=14.2, 5.8 Hz, 1H), 3.68-3.58 (m, 3H), 3.32 (m, 6H), 3.23 (m, 4H), 3.20-3.08 (m, 4H), 2.79-2.62 (m, 3H), 2.28-2.18 (m, 1H), 1.96 (dd, J=18.5, 9.0 Hz, 2H), 1.84 (s, 4H), 1.77-1.61 (m, 2H), 1.58 (d, J=8.2 Hz, 2H), 1.37 (s, 3H), 1.24 (s, 3H).

Example 261

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3-methoxyazetidin-1-yl)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using -methoxyazetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₉ClN₃O₇S [M+H]⁺: m/z=714.29/716.29; Found: 714.5/716.7; ¹H NMR (300 MHz, DMSO-d₆) δ 7.61 (d, J=8.5 Hz, 1H), 7.31-7.15 (m, 3H), 7.02 (dd, J=9.3, 5.7 Hz, 2H), 5.56 (dd, J=15.6, 6.1 Hz, 1H), 5.48 (s, 1H), 4.36 (s, 1H), 4.27-4.13 (m, 2H), 4.11-4.02 (m, 2H), 3.90 (m, 2H), 3.63 (s, 1H), 3.53 (d, J=8.2 Hz, 2H), 3.32 (m, 5H), 3.22 (d, J=7.3 Hz, 4H), 3.19-3.09 (m, 2H), 2.76 (dd, J=21.0, 12.7 Hz, 2H), 2.66 (s, 1H), 2.41 (s, 2H), 1.96 (d, J=13.3 Hz, 1H), 1.84 (d, J=4.1 Hz, 4H), 1.71 (d, J=8.3 Hz, 1H), 1.55 (d, J=7.0 Hz, 2H), 1.37 (s, 3H), 1.24 (s, 3H).

Example 262

(3R,6R,7S,8E,22S)-7-[2-(Azetidin-1-yl)ethoxy]-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using azetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₇ClN₃O₆S [M+H]⁺: m/z=684.28/686.28; Found: 684.4/686.2; ¹H NMR (300 MHz, CDCl₃) δ 10.60 (s, 1H, NH), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.01-6.96 (m, 1H), 6.87 (t, J=4.3 Hz, 1H), 6.01 (dd, J=15.7, 3.9 Hz, 1H), 5.70 (dd, J=15.6, 5.4 Hz, 1H), 4.14-3.94 (m, 5H), 3.76 (dd, J=14.2, 5.2 Hz, 3H), 3.57-3.45 (m, 3H), 3.38 (d, J=14.9 Hz, 3H), 3.11 (dd, J=15.0, 11.0 Hz, 2H), 2.76 (M, 4H), 2.28 (d, J=7.5 Hz, 1H), 2.23-2.05 (m, 2H), 2.00 (dd, J=14.1, 5.9 Hz, 4H), 1.81 (dd, J=16.2, 8.1 Hz, 2H), 1.73-1.58 (m, 2H), 1.50 (d, J=10.2 Hz, 3H), 1.34 (s, 3H).

Example 263

(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-15,15-dioxo-7-[2-(1-piperidyl)ethoxy]spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using piperidine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₅₁ClN₃O₆S [M+H]⁺: m/z=712.31/714.31; Found: 712.4/714.3; ¹H NMR (300 MHz, CDCl₃) δ 9.53 (s, 1H, NH), 7.67 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.1 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.02-6.98 (m, 1H), 6.94 (t, J=3.4 Hz, 1H), 5.89 (dd, J=15.6, 3.3 Hz, 1H), 5.64 (dd, J=15.6, 6.1 Hz, 1H), 4.12 (d, J=5.8 Hz, 2H), 4.03 (dd, J=13.0, 5.2 Hz, 2H), 3.71 (d, J=15.0 Hz, 6H), 3.36 (d, J=14.5 Hz, 4H), 3.18 (dd, J=15.1, 9.6 Hz, 1H), 2.79 (d, J=4.0 Hz, 5H), 2.27-2.18 (m, 1H), 2.02-1.77 (m, 12H), 1.66 (dd, J=17.9, 8.9 Hz, 2H), 1.47 (s, 3H), 1.36 (s, 3H).

Example 264

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R)-3-fluoropyrrolidin-1-yl]ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using (3R)-3-fluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₈ClFN₃O₆S [M+H]⁺: m/z=716.3/718.3. Found: 716.4/718.2. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.47 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.83 (d, J=2.2 Hz, 1H), 6.08-5.89 (m, 1H), 5.75 (dd, J=15.6, 6.7 Hz, 1H), 5.36 (d, J=53.3 Hz, 1H), 4.66-4.24 (m, 2H), 4.20-3.96 (m, 4H), 3.84-3.69 (m, 3H), 3.46 (qd, J=24.9, 22.1, 13.2 Hz, 7H), 3.14 (dd, J=15.0, 10.7 Hz, 2H), 2.85-2.65 (m, 3H), 2.36-2.09 (m, 5H), 1.89-1.66 (m, 5H), 1.49 (s, 3H), 1.32 (s, 3H).

Example 265

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3S)-3-fluoropyrrolidin-1-yl]ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using (3S)-3-fluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₈ClFN₃O₆S [M+H]⁺: m/z=716.3/718.3. Found: 716.4/718.2. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.48 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.89 (d, J=2.2 Hz, 1H), 6.08-5.84 (m, 1H), 5.72 (dd, J=15.7, 6.3 Hz, 1H), 5.33 (d, J=53.0 Hz, 1H), 4.26 (t, J=9.1 Hz, 2H), 4.17-4.02 (m, 4H), 3.77 (t, J=14.1 Hz, 3H), 3.59-3.33 (m, 7H), 3.16 (dd, J=15.1, 10.3 Hz, 2H), 2.82-2.74 (m, 3H), 2.28 (ddd, J=35.2, 19.4, 11.1 Hz, 5H), 1.95-1.64 (m, 5H), 1.49 (s, 3H), 1.35 (s, 3H).

Example 266

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,155-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-3-methoxypyrrolidine hydrochloride in Step 2. LC-MS: calc. for C₃₆H₄₃ClN₃O₉S [M+H]⁺: m/z=728.2/730.2; Found: 728.5/730.5. ¹H NMR (300 MHz, CDCl₃) δ 7.56 (d, J=8.5 Hz, 1H), 7.48 (ddd, J=7.8, 5.4, 2.1 Hz, 1H), 7.05 (dd, J=4.8, 2.2 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.92 (dd, J=8.4, 2.2 Hz, 1H), 6.85 (d, J=2.1 Hz, 1H), 6.15-5.77 (m, 1H), 5.77-5.51 (m, 1H), 5.23 (d, J=8.3 Hz, 1H), 4.24 (dtd, J=31.1, 11.4, 8.1 Hz, 3H), 4.11-3.91 (m, 4H), 3.74-3.62 (m, 4H), 3.44 (q, J=7.4, 6.2 Hz, 3H), 3.36 (s, 3H), 3.32 (s, 2H), 3.20-3.09 (m, 1H), 2.79 (q, J=7.2 Hz, 2H), 2.06-1.95 (m, 3H), 1.85-1.77 (m, 2H), 1.60 (p, J=9.2 Hz, 1H), 1.42 (s, 3H), 1.33 (s, 3H).

Example 267

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[methoxy(methyl)amino]ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using N,O-dimethylhydroxylamine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₅H₄₇ClFN₃O₆S [M+H]⁺: m/z=688.3/690.3; Found: 688.3/690.3. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.03-6.92 (m, 2H), 5.87 (d, J=16.2 Hz, 1H), 5.66 (dd, J=15.6, 6.5 Hz, 1H), 5.36 (d, J=1.0 Hz, 1H), 4.37 (s, 3H), 4.18-3.99 (m, 4H), 3.84 (s, 3H), 3.74 (d, J=5.3 Hz, 1H), 3.68 (s, 1H), 3.62-3.54 (m, 1H), 3.47-3.32 (m, 4H), 3.20 (dd, J=15.0, 9.5 Hz, 1H), 3.09 (s, 3H), 2.79 (d, J=4.5 Hz, 3H), 2.32-2.21 (m, 1H), 2.01-1.90 (m, 3H), 1.79 (q, J=9.4, 8.9 Hz, 2H), 1.47 (s, 3H), 1.37 (s, 3H).

Example 268

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(diethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using diethylamine in THF (2.0 M) to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₅₁ClFN₃O₆S [M+H]⁺: m/z=700.3/702.3. Found: 700.3/702.3.

Example 269

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R,4S)-3,4-difluoropyrrolidin-1-yl]ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using (3S,4R)-3,4-difluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₇ClF₂N₃O₆S [M+H]⁺: m/z=734.3/736.3. Found: 734.3/736.3.

Example 270

(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-7-(2-morpholinoethoxy)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 using morpholine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C₃₇H₄₉ClN₃O₇S [M+H]⁺: m/z=714.29/716.29; Found: 714.7/716.8.

Example 271

(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-7-(2-morpholinoethoxy)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and morpholine in Step 5. LCMS calc. for C₃₇H₄₉ClN₃O₇S [M+H]⁺: m/z=714.29/716.29; Found: 714.7/716.8. ¹H NMR (300 MHz, CDCl₃) δ 9.43 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.05-6.93 (m, 2H), 5.92 (dt, J=15.7, 4.5 Hz, 1H), 5.73 (dd, J=15.7, 8.5 Hz, 1H), 4.10 (d, J=2.0 Hz, 2H), 3.99 (m, 2H), 3.87 (d, J=6.5 Hz, 1H), 3.71 (dt, J=24.9, 14.9 Hz, 6H), 3.36-3.22 (m, 4H), 3.01 (m, 3H), 2.79 (m, 2H), 2.45 (m, 1H), 2.40-2.32 (m, 1H), 2.24 (m, 1H), 1.99 (m, 3H), 1.84 (m, 3H), 1.71-1.62 (m, 1H), 1.47 (m, 1H), 1.41 (d, J=15.2 Hz, 6H), 1.35-1.25 (m, 2H).

Example 272

(3R,6R,7R,8E,22S)-6′-Chloro-7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and 3,3-difluoroazetidine hydrochloride in Step 5. LCMS calc. for C₃₆H₄₅ClF₂N₃O₆S [M+H]⁺: m/z=720.27/722.27; Found: 720.7/722.7. ¹H NMR (300 MHz, CDCl₃) δ 9.47 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 6.93 (d, J=2.2 Hz, 1H), 5.91 (dt, J=15.7, 4.6 Hz, 1H), 5.71 (dd, J=15.7, 8.6 Hz, 1H), 4.11 (s, 2H), 3.99 (m, 2H), 3.91 (m, 1H), 3.87 (d, J=6.5 Hz, 1H), 3.77 (d, J=14.4 Hz, 1H), 3.70 (dd, J=8.6, 4.9 Hz, 1H), 3.60 (m, 2H), 3.52 (m, 3H), 3.27 (m, 2H), 3.07 (dd, J=15.1, 10.1 Hz, 1H), 2.78 (m, 2H), 2.46 (t, J=9.1 Hz, 1H), 2.31 (dt, J=15.5, 9.8 Hz, 1H), 2.11-1.92 (m, 3H), 1.91-1.79 (m, 2H), 1.68 (m, 2H), 1.50 (m, 1H), 1.41 (d, J=11.1 Hz, 6H), 1.30 (m, 2H).

Example 273

(3R,6R,7R,8E,22S)-6′-Chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and dimethylamine in THF (2 M) in Step 5. LCMS calc. for C₃₅H₄₇ClN₃O₆S [M+H]⁺: m/z=672.3/674.3; Found: 672.4/674.3. ¹H NMR (600 MHz, DMSO-d₆) δ 9.24 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.19 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 6.82 (d, J=2.3 Hz, 1H), 6.08 (d, J=13.9 Hz, 1H), 5.43 (dd, J=16.0, 8.7 Hz, 1H), 4.14-4.03 (m, 3H), 3.74-3.66 (m, 2H), 3.61 (d, J=14.6 Hz, 1H), 3.54 (m, 1H), 3.47 (m, 2H), 3.24 (m, 3H), 3.11 (dd, J=15.3, 10.2 Hz, 1H), 2.79 (m, 7H), 2.73 (m, 1H), 2.39 (d, J=1.9 Hz, 1H), 2.10 (m, 1H), 1.98 (m, 4H), 1.85 (m, 2H), 1.73-1.69 (m, 1H), 1.47 (m, 1H), 1.35 (s, 3H), 1.23 (s, 3H).

Example 274

(3R,6R,7R,8E,22S)-6′-Chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and pyrrolidine in Step 5. LCMS calc. for C₃₇H₄₈ClN₃O₆S [M+H]⁺: m/z=698.3/700.3; Found: 698.4/700.3. ¹H NMR (600 MHz, DMSO-d₆) δ 9.37 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.23-7.16 (m, 1H), 7.05-6.99 (m, 1H), 6.83 (d, J=2.2 Hz, 1H), 6.07 (d, J=16.2 Hz, 1H), 5.44 (dd, J=15.9, 8.8 Hz, 1H), 4.09 (m, 3H), 3.67 (m, 1H), 3.61 (d, J=14.6 Hz, 1H), 3.55-3.41 (m, 6H), 3.19-2.95 (m, 5H), 2.89-2.64 (m, 3H), 2.13-2.06 (m, 1H), 1.99 (m, 6H), 1.84 (m, 4H), 1.71 (m, 2H), 1.47 (d, J=7.9 Hz, 1H), 1.36 (s, 3H), 1.23 (s, 3H).

Example 275

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3-fluoroazetidin-1-yl)ethoxy]-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3-fluoroazetidine hydrochloride in Step 5. LCMS calc. for C₃₇H₄₉ClFN₄O₅S [M+H]⁺: m/z=715.31/717.31; Found: 715.4/717.4.

Example 276

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R)-3-fluoropyrrolidin-1-yl]ethoxy]-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and (3R)-3-fluoropyrrolidine hydrochloride in Step 5. LCMS calc. for C₃₈H₅₁ClFN₄O₅S [M+H]⁺: m/z=729.32/731.31; Found: 729.5/731.5.

Example 277

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[4-(2-methoxyethyl)-1,4-diazepan-1-yl]ethoxy]-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 1-(2-methoxyethyl)-1,4-diazepane in Step 5. LCMS calc. for C₄₂H₆₁ClN₅O₆S [M+H]⁺: m/z=798.40/800.40; Found: 798.5/800.5.

Example 278

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of isobutoxycarbonyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (40.0 mg, 0.05 mmol, Example 65 Step 3) in THF (4 mL) was added triethylamine (0.07 mL, 0.50 mmol). The mixture was stirred at r.t. for 5 min, followed by adding of 3,3-difluoroazetidine hydrochloride (65.2 mg, 0.50 mmol). The mixture was then stirred at r.t. for an additional 4 h. LCMS showed that the starting material was consumed. The reaction was quenched by 1N HCl (2 mL), and extracted with DCM (3 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H₂O/ACN (20-100%) to afford (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (9 mg, 21% yield). LCMS calc. for C₃₆H₄₃ClF₂N₃O₇S [M+H]⁺: m/z=734.2; Found: 734.5. ¹H NMR (300 MHz, CDCl₃) δ 9.08 (s, 1H), 7.72-7.58 (m, 1H), 7.52 (m, 1H), 7.37 (dd, J=4.3, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.12 (d, J=2.9 Hz, 1H), 7.02 (dd, J=8.5, 3.4 Hz, 1H), 5.85-5.48 (m, 2H), 4.66 (m, 2H), 4.39 (m, 2H), 4.27-4.07 (m, 3H), 4.03-3.90 (m, 2H), 3.88-3.64 (m, 3H), 3.52 (m, 1H), 3.42-3.28 (m, 2H), 2.89-2.63 (m, 3H), 2.41 (m, 1H), 2.11-1.76 (m, 6H), 1.72-1.53 (m, 2H), 1.49-1.33 (m, 6H).

Example 279

(3R,6R,7S,8E,22S)-7-[2-(Azetidin-1-yl)-2-oxo-ethoxy]-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using azetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₆H₄₅ClN₃O₇S [M+H]⁺: m/z=698.2; Found: 698.3. ¹H NMR (300 MHz, CDCl₃) δ 9.17 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.3 Hz, 1H), 7.13 (m, 2H), 7.00 (m, 1H), 6.83 (d, J=8.2 Hz, 1H), 5.77 (m, 1H), 5.61 (dd, J=15.7, 6.4 Hz, 1H), 4.48-4.26 (m, 2H), 4.23-4.03 (m, 5H), 4.01-3.65 (m, 5H), 3.46-3.33 (m, 2H), 3.26 (m, 2H), 2.80 (m, 2H), 2.33 (m, 2H), 2.06-1.91 (m, 3H), 1.86 (m, 2H), 1.64 (s, 3H), 1.43 (d, J=20.2 Hz, 6H).

Example 280

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3-methoxyazetidin-1-yl)-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using 3-methoxyazetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₇H₄₇ClN₃O₇S [M+H]⁺: m/z=728.2; Found: 728.3. 1H NMR (300 MHz, CDCl₃) δ 9.17 (s, 1H), 7.67 (dd, J=8.5, 3.9 Hz, 1H), 7.52 (dd, J=8.4, 1.9 Hz, 1H), 7.20-7.10 (m, 2H), 7.08-6.94 (m, 2H), 6.83 (d, J=8.3 Hz, 1H), 5.85-5.46 (m, 2H), 4.65-4.39 (m, 1H), 4.39-4.17 (m, 3H), 4.15-3.84 (m, 6H), 3.82-3.67 (m, 2H), 3.55 (q, J=6.9 Hz, 1H), 3.45-3.33 (m, 2H), 3.31 (d, J=10.4 Hz, 3H), 3.23 (d, J=15.0 Hz, 1H), 2.83-2.69 (m, 2H), 2.45-2.29 (m, 1H), 2.29-2.14 (m, 1H), 2.07-1.78 (m, 7H), 1.59-1.50 (m, 1H), 1.52-1.33 (m, 6H).

Example 281

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3-fluoroazetidin-1-yl)-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using 3-fluoroazetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₆H₄₄ClFN₃O₇S [M+H]⁺: m/z=716.2; Found: 716.3. ¹H NMR (300 MHz, CDCl₃) δ 9.16 (d, J=22.6 Hz, 1H), 7.67 (t, J=7.7 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.23-7.11 (m, 2H), 7.11-6.93 (m, 2H), 6.83 (d, J=7.8 Hz, 1H), 5.94-5.52 (m, 2H), 5.33 (d, J=57.0 Hz, 1H), 4.89-4.57 (m, 1H), 4.46 (m, 2H), 4.25-4.01 (m, 5H), 3.94-3.54 (m, 4H), 3.49-3.09 (m, 3H), 2.79 (m, 2H), 2.36 (m, 1H), 2.12-1.76 (m, 5H), 1.65 (m, 3H), 1.56-1.34 (m, 6H).

Example 282

2-[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15λ6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-tetrahydropyran-4-yl-acetamide

This compound was prepared using procedures analogous to those described for Example 278 using 4-aminotetrahydropyran to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₈H₄₉ClN₃O₈S [M+H]⁺: m/z=742.29/744.28; Found: 742.4/744.3; ¹H NMR (300 MHz, CDCl₃) δ 7.65 (d, J=8.4 Hz, 1H), 7.43 (s, 1H), 7.15 (d, J=8.7 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.03 (d, J=2.1 Hz, 1H), 6.89 (s, 1H), 6.46 (s, 1H), 5.60 (dd, J=15.4, 6.6 Hz, 1H), 4.10-3.78 (m, 10H), 3.68 (d, J=14.4 Hz, 1H), 3.40-3.36 (m, 5H), 2.75 (d, J=18.9 Hz, 3H), 2.37 (d, J=9.6 Hz, 1H), 1.91-1.84 (m, 9H), 1.66 (d, J=9.1 Hz, 1H), 1.50-1.48 (m, 2H), 1.39 (s, 3H), 1.35 (s, 3H).

Example 283

(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-15,15-dioxo-7-(2-oxo-2-pyrrolidin-1-yl-ethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using pyrrolidine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₆H₄₃ClF₂N₃O₇S [M+H]⁺: m/z=712.2; Found: 712.4. ¹H NMR (300 MHz, CDCl₃) δ 9.16 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.23-7.16 (m, 1H), 7.11 (d, J=2.3 Hz, 1H), 7.08-6.95 (m, 2H), 5.74 (dt, J=15.7, 4.6 Hz, 1H), 5.62 (dd, J=15.7, 6.7 Hz, 1H), 4.19 (m, 2H), 4.13 (m, 2H), 4.01 (d, J=14.0 Hz, 1H), 3.92-3.84 (m, 2H), 3.70 (d, J=14.6 Hz, 1H), 3.51 (m, 3H), 3.41 (m, 1H), 3.29 (dd, J=14.9, 8.4 Hz, 1H), 2.87-2.63 (m, 3H), 2.44 (dt, J=9.6, 4.8 Hz, 1H), 1.92 (m, 8H), 1.60 (m, 2H), 1.42 (d, J=9.5 Hz, 6H).

Example 284

2-[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15λ6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-[(3R)-tetrahydrofuran-3-yl]acetamide

This compound was prepared using procedures analogous to those described for Example 278 using (3R)-tetrahydrofuran-3-amine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.3/730.3; Found: 728.4/730.4. ¹H NMR (300 MHz, CDCl₃) δ 9.38 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.3 Hz, 1H), 7.11 (d, J=2.3 Hz, 1H), 7.05-6.98 (m, 2H), 6.89 (d, J=7.7 Hz, 1H), 5.80 (ddd, J=16.0, 6.9, 3.3 Hz, 1H), 5.63 (dd, J=15.8, 5.9 Hz, 1H), 4.56 (ddt, J=10.5, 7.5, 3.2 Hz, 1H), 4.19-3.95 (m, 6H), 3.87-3.74 (m, 6H), 3.42-3.20 (m, 3H), 2.80 (dt, J=12.3, 6.4 Hz, 3H), 2.41-2.19 (m, 2H), 2.09-1.80 (m, 7H), 1.67 (t, J=9.3 Hz, 1H), 1.47 (s, 3H), 1.39 (s, 3H).

Example 285

2-[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15λ6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-[(3S)-tetrahydrofuran-3-yl]acetamide

This compound was prepared using procedures analogous to those described for Example 278 using (3S)-tetrahydrofuran-3-amine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₇H₄₇ClN₃O₈S [M+H]⁺: m/z=728.3/730.3; Found: 728.4/730.4. ¹H NMR (300 MHz, CDCl₃) δ 9.44 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.4, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.2 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 7.04-6.98 (m, 2H), 5.81 (ddd, J=15.9, 6.7, 3.6 Hz, 1H), 5.66 (dd, J=15.9, 6.1 Hz, 1H), 5.35-5.27 (m, 1H), 4.58 (tt, J=7.3, 3.7 Hz, 1H), 4.19-3.94 (m, 6H), 3.88-3.65 (m, 6H), 3.47-3.21 (m, 3H), 2.78 (dt, J=19.1, 5.7 Hz, 3H), 2.45-2.23 (m, 2H), 2.10-1.80 (m, 7H), 1.67 (t, J=9.3 Hz, 1H), 1.46 (s, 3H), 1.39 (s, 3H).

Example 286

[(3R,6R,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (35.0 mg, 0.05 mmol, Example 34) in ethyl acetate (3 mL) was added platinum(IV) oxide (2.36 mg, 0.01 mmol). The mixture was then purged by H₂ gas in balloon for 2 times, and stirred at r.t. for 2 h under H₂ atmosphere. LCMS showed that most of the starting material was consumed. The mixture was filtered through Celite and concentrated under reduced pressure. The resulting residue was then purified by prep-HPLC on a C18 column using H₂O/ACN (20-100%) to provide [(3R,6R,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (7.4 mg, 21.1% yield) as a white solid. LCMS calc. for C₃₄H₄₃ClN₃O₇S [M+H]⁺: m/z=674.26/677.26; Found: 674.7/679.6; ¹H NMR (600 MHz, DMSO-d6) δ 7.61 (q, J=8.0 Hz, 1H), 7.31-7.16 (m, 4H), 7.00 (dt, J=17.3, 8.5 Hz, 1H), 4.76-4.64 (m, 1H), 4.14-4.09 (m, 1H), 4.06-4.00 (m, 1H), 3.54-3.43 (m, 3H), 3.25 (t, J=14.6 Hz, 2H), 3.10-2.96 (m, 2H), 2.85-2.74 (m, 3H), 2.74-2.65 (m, 3H), 2.58 (d, J=14.1 Hz, 2H), 2.24 (s, 1H), 1.96-1.89 (m, 2H), 1.85-1.73 (m, 3H), 1.73-1.52 (m, 5H), 1.49-1.35 (m, 2H), 1.28 (s, 3H), 1.23 (d, J=16.5 Hz, 3H).

Example 287

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3,3-difluoroazetidine hydrochloride in Step 5. LCMS calc. for C₃₇H₄₈ClF₂N₄O₅S [M+H]⁺: m/z=733.30/735.30; Found: 733.3/735.1. ¹H NMR (300 MHz, CDCl₃) δ 7.74-7.45 (m, 2H), 7.22-7.18 (m, 2H), 7.09 (s, 1H), 7.03-6.89 (m, 1H), 6.02 (s, 1H), 5.71-5.46 (m, 1H), 5.36 (s, 1H), 4.23-3.94 (m, 4H), 3.87 (d, J=18.4 Hz, 1H), 3.69 (s, 3H), 3.33 (d, J=15.2 Hz, 2H), 3.06 (s, 1H), 2.79 (s, 3H), 2.46 (s, 2H), 2.25 (t, J=7.7 Hz, 2H), 1.64 (d, J=7.4 Hz, 1H), 1.46 (s, 3H), 1.33 (s, 16H).

Example 288

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3,3-difluoropyrrolidine hydrochloride in Step 5. LCMS calc. for C₃₈H₅₀ClF₂N₄O₅S [M+H]⁺: m/z=747.32/749.31; Found: 747.4/749.3. ¹H NMR (300 MHz, CDCl₃) δ 7.71-7.49 (m, 1H), 7.39-7.12 (m, 4H), 7.08-6.84 (m, 1H), 6.00 (s, 2H), 5.61 (d, J=17.9 Hz, 2H), 5.37 (s, 2H), 3.72 (d, J=14.2 Hz, 4H), 3.52 (s, 3H), 3.11 (s, 1H), 2.80 (s, 1H), 2.62 (m, 15H), 2.54 (s, 2H), 2.39-2.21 (m, 3H), 2.04 (s, 5H), 1.66 (d, J=7.4 Hz, 2H).

Example 289

(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-15,15-dioxo-7-[2-(1-piperidyl)ethoxy]spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and piperidine in Step 5. LCMS calc. for C₃₉H₅₄ClN₄O₅S [M+H]⁺: m/z=725.35/727.35; Found: 725.3/727.6. ¹H NMR (300 MHz, CDCl₃) δ 11.57 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.09 (d, J=2.3 Hz, 2H), 7.02-6.88 (m, 2H), 5.95 (d, J=45.7 Hz, 2H), 5.60 (d, J=15.9 Hz, 1H), 5.42-5.28 (m, 1H), 4.20-4.00 (m, 3H), 3.72 (dd, J=24.6, 13.3 Hz, 4H), 3.31 (d, J=14.6 Hz, 1H), 3.06 (s, 2H), 2.53 (s, 3H), 2.38-2.20 (m, 2H), 2.00 (d, J=7.1 Hz, 1H), 1.84 (s, 3H), 1.69-1.24 (m, 23H).

Example 290

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R,4R)-3,4-difluoropyrrolidin-1-yl]-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using (3R,4R)-3,4-difluoropyrrolidine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C₃₇H₄₅ClF₂N₃O₇S [M+H]⁺: m/z=748.3/750.3; Found: 748.4/750.4. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, J=8.5 Hz, 1H), 7.49 (dt, J=8.4, 1.7 Hz, 1H), 7.18 (dt, J=8.5, 1.8 Hz, 1H), 7.09 (t, J=1.8 Hz, 1H), 7.05-6.95 (m, 2H), 5.82-5.53 (m, 2H), 5.19 (ddd, J=50.3, 15.9, 4.2 Hz, 2H), 4.11-3.64 (m, 12H), 3.44-3.22 (m, 3H), 2.84-2.69 (m, 3H), 2.37 (dd, J=9.2, 3.1 Hz, 1H), 2.03-1.78 (m, 7H), 1.63 (d, J=17.3 Hz, 1H), 1.42 (s, 3H), 1.37 (s, 3H).

Example 291

(3R,6R,7S,8E,22S)-6′-Chloro-7-[2-[(3R,4S)-3,4-difluoropyrrolidin-1-yl]-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15λ6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 278 using (3R,4S)-3,4-difluoropyrrolidine to replace 3,3-difluoroazetidine hydrochloride. C₃₇H₄₅ClF₂N₃O₇S [M+H]⁺: m/z=748.3/750.3; Found: 748.4/750.4. ¹H NMR (300 MHz, CDCl₃) δ 7.65 (dd, J=8.5, 2.7 Hz, 1H), 7.48 (dt, J=8.4, 1.7 Hz, 1H), 7.18 (dt, J=8.5, 1.9 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 7.00 (ddd, J=8.4, 4.1, 1.7 Hz, 2H), 5.85-5.56 (m, 2H), 5.26-4.95 (m, 2H), 4.17-3.66 (m, 12H), 3.45-3.17 (m, 3H), 2.85-2.66 (m, 3H), 2.38 (dq, J=10.6, 5.4, 3.0 Hz, 1H), 2.07-1.78 (m, 7H), 1.64 (t, J=8.7 Hz, 1H), 1.43 (s, 3H), 1.38 (s, 3H).

Example 292

[(3R,6R,7S,8E,22S)-6′-Chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1:2-methyl-2-(1-methylallyloxy)propanoic acid

To a solution of but-3-en-2-ol (410.0 mg, 5.69 mmol) and DIPEA (1.98 mL, 11.37 mmol) in MeCN (5 mL) was added 2-bromo-2-methyl-propanoic acid (636.18 mg, 3.81 mmol). The reaction mixture was stirred at 50° C. overnight. Upon completion, the solvent was removed under reduced pressure. The residue was dissolved in DCM (10 mL) and washed with 1 N HCl solution (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to yield 2-methyl-2-(1-methylallyloxy)propanoic acid (450 mg, 50.0% yield), which was used for the next reaction without further purification. TLC: R_f=0.1 (Heptane:EtOAc=1:1).

Step 2:[1-[(1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-(1-methylallyloxy)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-methyl-2-(1-methylallyloxy)propanoate

To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]-methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (180.0 mg, 0.36 mmol, Intermediate 3) and 2-methyl-2-(1-methylallyloxy)propanoic acid (169.81 mg, 1.07 mmol) in DCM (4 mL) was added 4-(dimethylamino)pyridine (262.28 mg, 2.15 mmol), followed by the addition of EDCI (274.37 mg, 1.43 mmol). The reaction mixture was stirred at r.t. overnight. The reaction was diluted with DCM (5 mL) and washed with 1N HCl solution (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to yield [1-[(1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-(1-methylallyloxy)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-methyl-2-(1-methylallyloxy)propanoate (295 mg, 103.4% yield), which was used for the next reaction without further purification. LCMS calc. for C₄₃H₅₈ClN₂O₈S [M+H]⁺: m/z=783.34/785.34; Found: 783.6/785.5.

Step 3: N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-2-(1-methylallyloxy)propanamide

To a solution of [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-(1-methylallyloxy)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-methyl-2-(1-methylallyloxy)propanoate (295.0 mg, 0.38 mmol) in THF (0.50 mL), methanol (0.50 mL) and water (0.50 mL) was added lithium hydroxide monohydrate (158.15 mg, 3.77 mmol). The reaction mixture was stirred at 45° C. for 2 h. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with sat. NaHCO₃ solution (5 mL) and brine (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-30%) to afford the desired product N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-2-(1-methylallyloxy)propanamide (124 mg, 51.2% yield). LCMS calc. for C₃₄H₄₄ClN₂O₆S [M+H]⁺: m/z=643.24/645.24; Found: 643.4/645.3.

Step 4: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]-methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-2-(1-methylallyloxy)propanamide (124.0 mg, 0.19 mmol) in DCE (90 mL) was bubbled with N₂ for 20 min. Then Zhan catalyst (28.26 mg, 0.04 mmol) was added and was bubbled with N₂ for another 5 min. The reaction mixture was stirred at 45° C. for 2 h. The solvent was removed under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes with 0.2% HOAc (5-65%) to afford two products: P1 (18 mg, the earlier eluted product) and P2 (74 mg, the latter eluted product). The first fraction P1 was assigned to cis-isomer (3R,6R,7 S, 8Z,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (18 mg, 15.2% yield). The P2 was assigned to the trans-isomer (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (74 mg, 62.4% yield). LCMS calc. for C₃₂H₄₀ClN₂O₆S [M+H]⁺: m/z=615.22/617.22; Found: 615.3/617.2.

Step 5: [(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (15.0 mg, 0.02 mmol) in MeCN (1 mL) was added CDI (11.86 mg, 0.07 mmol). The reaction mixture was stirred at 45° C. for 2 h., and then cooled to r.t. Dimethylamine (0.025 mL, 0.05 mmol) (2.0 M in THF solution) was added. The reaction mixture was stirred at r.t. for 2 h. The reaction was concentrated under reduced pressure. The residue was purified by Prep-HPLC on a C18 column eluting with ACN/H₂O (20%-100%) to afford a mixture of the two desired products: Fraction 1 (3.8 mg) contained about 39% of Product 2 (Product 1/Product 2=55:35, Rt (P1)=8.02 min, Rt (P2)=8.18 min), and Fraction 2 (3.6 mg) contained 30% of Product 1 (Product 1/Product 2=29:67, Rt (P1)=8.02 min, Rt (P2)=8.18 min). [(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (3.8 mg, 21.8% yield). LCMS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.26/688.26; Found: 686.4/688.4. ¹H NMR (600 MHz, DMSO-d₆) δ 7.64 (dd, J=8.6, 4.5 Hz, 1H), 7.29-7.26 (m, 1H), 7.25 (d, J=2.5 Hz, 1H), 7.24 (d, J=2.4 Hz, 1H), 7.18 (dd, J=5.9, 2.4 Hz, 1H), 7.04 (s, 1H), 5.66 (d, J=14.2 Hz, 1H), 5.17 (s, 1H), 4.19 (s, 1H), 4.00 (d, J=12.2 Hz, 1H), 3.59 (d, J=14.3 Hz, 3H), 3.12 (s, 1H), 2.98 (s, 1H), 2.85 (s, 2H), 2.75 (s, 6H), 2.62 (s, 1H), 2.03-1.95 (m, 2H), 1.89-1.79 (m, 3H), 1.77-1.69 (m, 2H), 1.66-1.59 (m, 1H), 1.52-1.50 (m, 1H), 1.47-1.40 (m, 1H), 1.32 (s, 6H), 1.24 (s, 3H).

Example 293

[(3R,6R,7S,8E,22S)-6′-Chloro-7,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarbonyl]oxysodium

To a suspension of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1450.0 mg, 2.03 mmol, Intermediate 3 Step 3) in 1-butanol (5 mL) and 2-methylbut-2-ene (5.0 mL, 47.2 mmol) was added sodium chlorite (458.34 mg, 4.05 mmol) and the solution of sodium phosphate monobasic monohydrate (559.45 mg, 4.05 mmol) in water (5 mL). The reaction was stirred at r.t. for 3 h. LCMS showed reaction was completed. The reaction was quenched with aq. 10% Na₂S₂O₃ (5 mL) and the mixture was extracted with ethyl acetate (2 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was used directly without further purification. LCMS calc. for C₄₀H₄₂ClN₂O₇S [M−H]⁻: m/z=730.24/732.24; Found: 730.8/732.7.

Step 2: (JR, 2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-N-methoxy-N-methyl-cyclobutanecarboxamide

To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarbonyl]oxysodium (300.0 mg, 0.40 mmol) and N,O-dimethylhydroxylamine hydrochloride (77.69 mg, 0.80 mmol) in DCM (4 mL) was added DIPEA (0.28 mL, 1.59 mmol), followed by the addition of 1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (302.86 mg, 0.80 mmol) at 0° C. The reaction mixture was stirred at r.t. for 2 h. The reaction was diluted with DCM (5 mL) and washed with 1 N HCl solution (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-50%) to afford the desired product (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-N-methoxy-N-methyl-cyclobutanecarboxamide (232 mg, 75.2% yield). LCMS calc. for C₄₂H₄₉ClN₃O₇S [M+H]⁺: m/z=774.29/776.29; Found: 774.5/776.3.

Step 3: (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of methylmagnesium chloride THF solution (3 M in THF, 1.0 mL, 3 mmol) was added a solution of (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-N-methoxy-N-methyl-cyclobutanecarboxamide (232.0 mg, 0.30 mmol) in THF (2 mL) dropwise at 0° C. After addition, the reaction mixture was stirred at r.t. for 2 h. The reaction was quenched with aq. NH₄Cl solution (5 mL) at 0° C. and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford the crude (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg) which contaminated with some inorganic salt and was used for the next reaction without further purification. LCMS calc. for C₄₁H₄₆ClN₂O₆S [M+H]⁺: m/z=729.27/731.27; Found: 729.5/731.4.

Step 4: (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.41 mmol) in DCM (3 mL) was added Anisole (0.3 mL, 2.76 mmol) and TFA (3.0 mL, 39.2 mmol). The reaction mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with sat. NaHCO₃ solution (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-70%) to afford the desired product (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (220 mg). LCMS calc. for C₂₅H₃₀ClN₂O₄S [M+H]⁺: m/z=489.15/491.15; Found: 489.2/491.4.

Step 5: (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methylspiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a solution of vinylmagnesium bromide THF solution (1.0 M in THF, 4.5 mL, 4.5 mmol) was added a solution of (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (220.0 mg, 0.45 mmol) in THF (1 mL) dropwise at 0° C. After addition, the reaction mixture was stirred at r.t. for 2 h. The reaction was quenched by aq. NH₄Cl (5 mL) and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-70%) to afford the desired product (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (85 mg, 36.5% yield). LCMS calc. for C₂₇H₃₃ClN₂O₄S [M+H]⁺: m/z=517.18/519.18; Found: 517.2/519.3.

Step 6: [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-allyloxy-2-methyl-propanoate

To a mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]-cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (85.0 mg, 0.16 mmol) and 2-allyloxy-2-methyl-propanoic acid (71.1 mg, 0.49 mmol, Example 30 Step 1) in DCM (1 mL) was added DMAP (120.5 mg, 0.99 mmol), followed by the addition of EDCI (126.05 mg, 0.66 mmol). The reaction mixture was stirred at r.t. overnight, and then diluted with DCM (5 mL). The mixture was and washed with 1N HCl solution (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to yield [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-allyloxy-2-methyl-propanoate (136 mg) which was directly used for the next reaction without further purification. LCMS calc. for C₄₁H₅₄ClN₂O₈S [M+H]⁺: m/z=769.32/771.32; Found: 769.5/771.5.

Step 7: 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide

To a solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-allyloxy-2-methyl-propanoate (136.0 mg, 0.18 mmol) in THF (0.50 mL), methanol (0.50 mL) and water (0.50 mL) was added lithium hydroxide monohydrate (74.24 mg, 1.77 mmol). The reaction mixture was stirred at 45° C. for 6 h. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with 1N HCl solution (5 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-60%) to afford the desired product 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (83 mg, 73.0% yield). LCMS calc. for C₃₄H₄₄ClN₂O₆S [M+H]⁺: m/z=643.25/645.25; Found: 643.4/645.5.

Step 8: (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-7,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

To a solution of 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (83.0 mg, 0.13 mmol) in DCE (80 mL) was bubbled with N₂ for 20 min. Then Zhan catalyst (18.92 mg, 0.03 mmol) was added and was bubbled with N₂ for another 5 min. The reaction mixture was stirred at 45° C. for 2h. Upon completion, the solvent was removed under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-60%), and further purified with Prep-HPLC on a C18 column eluting with ACN/H₂O (20%-100%) to afford the desired product (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-7,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.6 mg, 3.3% yield). LCMS calc. for C₃₂H₄₀ClN₂O₆S [M+H]⁺: m/z=615.23/617.23; Found: 615.4/617.5. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, J=8.5 Hz, 1H), 7.47 (s, 1H), 7.18 (d, J=9.2 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.95 (s, 1H), 6.89 (d, J=2.2 Hz, 1H), 6.05 (s, 1H), 5.78 (d, J=15.4 Hz, 1H), 4.09 (s, 3H), 3.85-3.67 (m, 2H), 3.46 (d, J=14.5 Hz, 1H), 3.39-3.29 (m, 1H), 3.02 (d, J=14.2 Hz, 1H), 2.74 (d, J=19.5 Hz, 3H), 2.03-1.89 (m, 3H), 1.81 (t, J=8.5 Hz, 2H), 1.69 (s, 4H), 1.41 (s, 3H), 1.36 (s, 3H), 1.24 (d, J=7.2 Hz, 3H).

Step 9: [(3R,6R,7S,8E,22S)-6′-chloro-7,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-7,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and dimethylcarbamoyl chloride. LCMS calc. for C₃₅H₄₅ClN₃O₇S [M+H]⁺: m/z=686.26/688.26; Found: 686.4/688.4. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=8.5 Hz, 1H), 7.48 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.93 (d, J=2.1 Hz, 1H), 6.04 (d, J=15.8 Hz, 1H), 5.85-5.71 (m, 1H), 4.09 (d, J=3.7 Hz, 2H), 3.92-3.83 (m, 1H), 3.78 (d, J=14.6 Hz, 1H), 3.59 (d, J=15.1 Hz, 1H), 3.34 (d, J=14.3 Hz, 1H), 3.10 (dd, J=15.1, 10.8 Hz, 1H), 2.94 (d, J=5.1 Hz, 6H), 2.79 (s, 2H), 2.24 (t, J=9.1 Hz, 1H), 2.01 (d, J=6.3 Hz, 2H), 1.85 (d, J=8.9 Hz, 1H), 1.65 (d, J=8.8 Hz, 7H), 1.61 (s, 3H), 1.43 (s, 3H), 1.36 (s, 3H).

Example 294

[(3R,6R,7S,8E,15S,25S)-6′-Chloro-16,18,18-trioxo-spiro[23-oxa-18-thia-1,11,17-triazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa-8,19,21,27-tetraene-25,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 292 Step 2-5 using (2S)-1-allylpyrrolidine-2-carboxylic acid HCl (Example 100 Step 2) and (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) in Step 2, and dimethylcarbamoyl chloride in Step 5. LCMS calc. for C₃₅H₄₄ClN₅O₆S [M+H]⁺: m/z=683.26/685.26; Found: 683.4/685.4. ¹H NMR (300 MHz, DMSO-d₆) δ 8.96 (s, 1H), 7.62 (dd, J=8.6, 1.8 Hz, 1H), 7.29 (dd, J=8.5, 2.3 Hz, 1H), 7.16 (dd, J=3.7, 2.1 Hz, 2H), 6.99 (dd, J=8.1, 1.8 Hz, 1H), 6.76 (dd, J=8.2, 1.7 Hz, 1H), 5.88 (dd, J=15.6, 3.0 Hz, 1H), 5.18 (d, J=10.9 Hz, 1H), 5.08-4.93 (m, 1H), 4.05 (d, J=12.2 Hz, 1H), 3.92 (d, J=12.3 Hz, 1H), 3.75-3.58 (m, 3H), 3.57-3.42 (m, 3H), 3.17 (s, 1H), 3.14-3.08 (m, 1H), 3.05 (d, J=4.4 Hz, 1H), 2.96 (d, J=6.6 Hz, 1H), 2.78-2.70 (m, 1H), 2.66 (s, 3H), 2.51 (s, 3H), 2.41 (t, J=8.0 Hz, 2H), 2.33-2.24 (m, 1H), 2.15-1.85 (m, 5H), 1.79-1.59 (m, 5H), 1.38 (d, J=10.2 Hz, 1H).

Example 295

[(3R,6R,7S,8E,22S)-6′-Chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3S)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C₃₈H₄₈ClN₄O₇S [M+H]⁺: m/z=739.29/741.29; Found: 739.3/741.4.

Example 296

(23S)-6′-Chloro-16,16-dioxo-spiro[21-oxa-16-thia-1,6,12,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-9(27),10,17,19,25-pentaene-23,1′-tetralin]-7,14-dione

Step 1: ethyl 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetate

To a mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1.0 g, 6.49 mmol) and cesium carbonate (4.25 g, 12.97 mmol) in DMF (35 mL) was added t-butyl bromoacetate (1.9 g, 9.73 mmol) dropwise. The mixture was stirred at r.t. overnight. The mixture was diluted with ethyl acetate (50 mL), washed with water (30 mL×3). The organic layer was dried over Na₂SO₄, filtered, and concentrated. The residue was purified with reverse phase HPLC (0.01% ammonia in water and acetonitrile) to get ethyl 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetate (370.5 mg, 20.6% yield) as a pale yellow oil. LCMS calc. for C₁₃H₂₁N₂O₄ [M+H]⁺: m/z=269.14; Found: 269.1. ¹H NMR (400 MHz, CDCl₃-d) δ 1.26 (t, J=7.2 Hz, 3H), 1.47 (s, 9H), 3.69 (s, 2H), 4.17 (q, J=6.8 Hz, 2H), 4.77 (s, 2H), 6.30 (d, J=2.4 Hz, 1H), 7.41 (d, J=2.4 Hz, 1H).

Step 2: 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid

To a stirred solution of ethyl 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetate (128.0 mg, 0.48 mmol) in THF (1 mL), water (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (22.02 mg, 0.52 mmol). The resulting mixture was stirred at r.t. overnight. LCMS indicated the consumption of starting material and the formation of desired product. Water (5 mL) was added followed by 5 mL of DCM. The pH of aqueous layer was adjusted to 2-3 by adding 0.1 M HCl. The layers were separated, and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid (115 mg) as a light yellow solid. LCMS calc. for C₁₁H₁₅N₂O₄S [M−H]⁻: m/z=239.1; Found: 239.2.

Step 3: tert-butyl 3-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate

To a stirred solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.0 g, 1.62 mmol, Intermediate 2) in DCM (3 mL) was added tert-butyl 3-formylpyrrolidine-1-carboxylate (0.39 g, 1.94 mmol). The resulting mixture was then cooled to 0° C. TFA (1.24 mL, 16.15 mmol) was added to this solution followed by sodium borohydride (1.22 g, 32.3 mmol). The resulting mixture was further stirred at 0° C. for 30 min., then slowly warmed up to r.t. LCMS showed the consumption of starting material and the formation of desired product. MeOH (2 mL) was added to quench the reaction. Water (10 mL) was added followed by 10 mL of DCM. The pH of aqueous layer was adjusted to 7-8 by adding saturated sodium bicarbonate solution. The layers were separated, and the aqueous layer was extracted with DCM (10 mL×2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to afford tert-butyl 3-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (660 mg, 50.9% yield) which was used in next step without further purification. LCMS calc. for C₄₄H₅₃ClN₃O₇S [M+H]⁺: m/z=802.3/804.3; Found: 802.5/804.6.

Step 4: (3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide

To a stirred solution oftert-butyl 3-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (0.66 g, 0.82 mmol) in DCM (10 mL) was added TFA slowly. The resulting mixture was kept stirring at r.t. overnight. The reaction was slowly poured into 100 mL of saturated sodium carbonate solution under an ice bath. Then the mixture was extracted with DCM (50 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to afford (3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (400 mg) as a white solid. The crude product was used in next step without further purification. LCMS calc. for C₂₃H₂₉ClN₃O₃S [M+H]⁺: m/z=462.2/464.2; Found: 462.6/464.5.

Step 5: tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate

To a solution of (3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (160.0 mg, 0.35 mmol) in methanol (5 mL) was added di-tert butyl dicarbonate (113.38 mg, 0.52 mmol). The resulting mixture was stirred at r.t. LCMS indicated the consumption of starting material and the formation of desired product. Water (20 mL) was added and extracted with DCM (20 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (103 mg, 52.9% yield) as a colorless oil. LCMS calc. for C₂₈H₃₇ClN₃O₅S [M+H]⁺: m/z=562.2/564.2; Found: 562.5/564.7.

Step 6: tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate

To a stirred solution of tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (80.0 mg, 0.14 mmol) in DCM (2 mL) was added 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid (68.39 mg, 0.28 mmol) followed by EDCI (0.06 mL, 0.28 mmol) and DMAP (69.55 mg, 0.57 mmol). The resulting mixture was stirred at r.t. overnight. The reaction was quenched by adding 5 mL of 1 M HCl (5 mL) and extracted with DCM (5 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H₂O (20% to 100%) to afford tert-butyl 3-[[(3S)-7-[[2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (62 mg, 55.5% yield) as a white solid. LCMS calc. for C₃₉H₅₁ClN₅O₈S [M+H]⁺: m/z=784.3/786.3; Found: 784.5/786.5.

Step 7: 2-[3-[2-oxo-2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]pyrazol-1-yl]acetic acid

To a stirred solution of tert-butyl 3-[[(3S)-7-[[2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (62.0 mg, 0.08 mmol) in DCM (2 mL) was added phosphoric acid (0.05 mL, 0.79 mmol). The resulting mixture was stirred at r.t. for 24 h. The solution was slowly poured into a 30 mL of saturated sodium bicarbonate solution and the pH of aqueous layer was adjusted to ˜4-5 by adding 1 M HCl. The mixture was extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H₂O (20% to 100%) to afford 2-[3-[2-oxo-2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]pyrazol-1-yl]acetic acid (31 mg, 50.0% yield) as a white solid. LCMS calc. for C₃₀H₃₅ClN₅O₆S [M+H]⁺: m/z=628.2/630.2; Found: 628.4/630.5.

Step 8: (23S)-6′-chloro-16,16-dioxo-spiro[21-oxa-16-thia-1,6,12,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-9(27),10,17,19,25-pentaene-23,1′-tetralin]-7,14-dione

To a stirred solution of 2-[3-[2-oxo-2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]pyrazol-1-yl]acetic acid (31.0 mg, 0.05 mmol) in DMF (25 mL) was added HATU (56.3 mg, 0.15 mmol) followed by DIPEA (0.03 mL, 0.15 mmol). The resulting solution was stirred at r.t. for 2 h. Water (50 mL) was added, and extracted with ethyl acetate (25 mL×3). The combined organic layers were washed with water (25 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H₂O (20% to 100%) to afford (23 S)-6′-chloro-16,16-dioxo-spiro[21-oxa-16-thia-1,6,12,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-9(27), 10,17,19,25-pentaene-23,1′-tetralin]-7,14-dione (9.1 mg, 30.2% yield) as a white solid. LCMS calc. for C₃₀H₃₃ClN₅O₅S [M+H]⁺: m/z=610.2/612.2; Found: 610.4/612.3.

Example 297

(23S)-6′-Chloro-16,16-dioxo-spiro[21-oxa-thia-1,6,9,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-10,12(27),17,19,25-pentaene-23,1′-tetralin]-7,14-dione

Step 1: 2-[1-(2-ethoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid

This compound was prepared using procedures analogous to those described for Example 296 Step 1-2 using tert-butyl 2-(1H-pyrazol-3-yl)acetate and ethyl bromoacetate in Step 1. LCMS calc. for C₉H₁₄N₂₀₄ [M+H]⁺: m/z=213.1; Found: 213.2.

Step 2: ethyl 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetate

This compound was prepared using procedures analogous to those described for Example 296 Step 6-7 using 2-[1-(2-ethoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid to replace 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid in Step 6. LCMS calc. for C₃₂H₃₉ClN₅O₆S [M+H]⁺: m/z=656.2/658.2; Found: 656.4/658.4.

Step 3: 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetic acid

To a solution of ethyl 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetate (25.0 mg, 0.04 mmol) in methanol (0.50 mL) and THF (0.50 mL) was added lithium hydroxide monohydrate (4.8 mg, 0.11 mmol) in water (0.50 mL). The resulting solution was stirred at 40° C. for 2 h. The reaction mixture was quenched with 1M HCl aqueous solution to pH 5-6 and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure to afford 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetic acid (21 mg, 87.7% yield) as a white solid. LC-MS: calc. for C₃₀H₃₅ClN₅O₆S [M+H]⁺: m/z=628.1/630.2; Found: 628.3/630.2.

Step 4: (23S)-6′-chloro-16,16-dioxo-spiro[21-oxa-thia-1,6,9,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-10,12(27),17,19,25-pentaene-23,1′-tetralin]-7,14-dione

This compound was prepared using procedures analogous to those described for Example 296 Step. LCMS calc. for C₃₀H₃₃ClN₅O₅S [M+H]⁺: m/z=610.2/612.2; Found 610.2/612.2.

Example 298

[(3R,6R,7S,8E,22R)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C₃₅H₄₃ClN₃O₉S [M+H]⁺: m/z=716.23/718.23; Found: 716.0/718.1. ¹H NMR (300 MHz, Chloroform-d) δ 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.49 (d, J=8.5 Hz, 1H), 7.25 (d, J=2.3 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (dd, J=8.4, 1.1 Hz, 1H), 5.93-5.83 (m, 1H), 5.67 (dd, J=15.6, 5.9 Hz, 1H), 4.92-4.74 (m, 5H), 4.33 (d, J=11.8 Hz, 1H), 4.16 (d, J=11.8 Hz, 1H), 4.05-3.93 (m, 3H), 3.66 (td, J=15.5, 14.8, 4.6 Hz, 4H), 3.34 (dd, J=15.0, 5.2 Hz, 1H), 3.16 (s, 3H), 2.96 (dd, J=9.1, 6.0 Hz, 1H), 2.83-2.70 (m, 2H), 2.47-2.35 (m, 1H), 2.16-2.05 (m, 1H), 1.88 (q, J=10.6, 9.9 Hz, 2H), 1.65 (d, J=9.5 Hz, 2H), 1.43 (s, 3H), 1.35 (s, 3H).

Example 299

[(3R,6R,7S,8E,22R)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₆H₄₅ClN₃O₉S [M+H]⁺: m/z=730.25/732.25; Found: 730.0/732.2. ¹H NMR (300 MHz, Chloroform-d) δ 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.26 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.93-5.82 (m, 1H), 5.67 (dd, J=15.7, 5.6 Hz, 1H), 5.34 (s, 1H), 4.96 (s, 1H), 4.33 (d, J=11.8 Hz, 1H), 4.16 (d, J=11.8 Hz, 1H), 4.10-3.91 (m, 4H), 3.80 (s, 2H), 3.74-3.50 (m, 5H), 3.37 (d, J=5.1 Hz, 1H), 2.95 (s, 3H), 2.90-2.82 (m, 1H), 2.81-2.69 (m, 1H), 2.48-2.36 (m, 1H), 2.26 (ddd, J=13.1, 8.9, 4.8 Hz, 1H), 2.17-2.00 (m, 2H), 1.89 (dq, J=19.4, 9.4 Hz, 3H), 1.66 (t, J=9.4 Hz, 2H), 1.44 (s, 3H), 1.35 (s, 3H).

Example 300

[(3R,6R,7S,8E,22R)-6′-Chloro-12,12-dimethyl-13,15,15-trio-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C₃₇H₄₇ClN₃O₉S [M+H]⁺: m/z=744.26/746.26; Found: 744.1/746.2. ¹H NMR (300 MHz, Chloroform-d) δ 7.59-7.44 (m, 2H), 7.26 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.12 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.86 (d, J=16.0 Hz, 1H), 5.66 (d, J=16.1 Hz, 1H), 5.34 (s, 1H), 4.33 (d, J=11.8 Hz, 1H), 4.17 (d, J=11.9 Hz, 1H), 4.10-3.88 (m, 5H), 3.75-3.59 (m, 4H), 3.46 (d, J=11.9 Hz, 1H), 3.35 (dd, J=15.0, 5.4 Hz, 1H), 3.05-2.95 (m, 1H), 2.88 (d, J=17.0 Hz, 3H), 2.76 (dt, J=16.3, 3.8 Hz, 1H), 2.50-2.34 (m, 1H), 2.15-1.99 (m, 1H), 1.88 (dd, J=21.4, 10.2 Hz, 4H), 1.66 (t, J=9.0 Hz, 6H), 1.43 (s, 3H), 1.35 (s, 3H).

Example 301

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and (3R)-N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C₃₆H₄₅ClN₃O₉S [M+H]⁺: m/z=730.25/732.25; Found: 730.1/732.1. ¹H NMR (300 MHz, CDCl₃) δ 9.10 (s, 1H), 7.60-7.48 (m, 2H), 7.06-6.99 (m, 2H), 6.93 (dt, J=8.5, 1.6 Hz, 1H), 6.86 (d, J=2.1 Hz, 1H), 5.87-5.63 (m, 2H), 5.27 (d, J=16.4 Hz, 2H), 4.91 (s, 1H), 4.36-4.00 (m, 7H), 3.84-3.68 (m, 5H), 3.49-3.32 (m, 2H), 3.23 (dd, J=15.0, 8.9 Hz, 1H), 2.91 (s, 3H), 2.41 (qd, J=9.3, 3.3 Hz, 1H), 2.27 (dtd, J=13.3, 8.4, 4.8 Hz, 1H), 2.09-1.98 (m, 2H), 1.91-1.77 (m, 3H), 1.66 (q, J=9.4 Hz, 1H), 1.44 (s, 3H), 1.36 (s, 3H).

Example 302

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-tetrahydrofuran-3-amine in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₉S [M+H]⁺: m/z=716.23/718.23; Found: 716.52/718.09. ¹H NMR (300 MHz, CDCl₃) δ 9.05 (s, 1H), 7.54 (t, J=14.5 Hz, 2H), 7.14 (s, 1H), 7.05 (d, J=8.3 Hz, 1H), 6.95 (dd, J=8.4, 2.0 Hz, 1H), 6.88 (d, J=1.9 Hz, 1H), 5.83-5.64 (m, 2H), 5.18 (s, 1H), 4.26 (m, 3H), 4.16-4.07 (m, 2H), 4.03-3.95 (m, 1H), 3.86 (d, J=5.8 Hz, 2H), 3.77 (d, J=13.5 Hz, 2H), 3.44 (t, J=12.4 Hz, 2H), 3.22 (d, J=6.9 Hz, 3H), 2.79 (d, J=6.4 Hz, 1H), 2.40 (s, 1H), 2.32-2.20 (m, 1H), 2.11-1.99 (m, 2H), 1.83 (dd, J=32.2, 8.6 Hz, 4H), 1.69-1.60 (m, 1H), 1.44 (s, 3H), 1.39 (s, 3H).

Example 303

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C₃₅H₄₁ClN₃O₉S [M−H]⁻: m/z=714.2/716.2; Found 713.8/715.8. ¹H NMR (300 MHz, CDCl₃) δ 7.56 (dd, J=8.4, 2.1 Hz, 2H), 7.05 (dd, J=8.3, 1.8 Hz, 2H), 6.95 (dd, J=8.6, 2.2 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.74 (t, J=8.0 Hz, 2H), 5.28 (d, J=4.6 Hz, 1H), 4.89-4.73 (m, 3H), 4.43-3.98 (m, 6H), 3.87-3.69 (m, 3H), 3.50-3.20 (m, 3H), 3.12 (s, 3H), 2.50-2.32 (m, 1H), 2.25 (t, J=7.6 Hz, 1H), 2.17-1.76 (m, 7H), 1.46 (s, 3H), 1.37 (s, 3H).

Example 304

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C₃₇H₄₇ClN₃O₉S [M+H]⁺: m/z=744.26/746.26; Found: 744.2/746.2. ¹H NMR (300 MHz, CDCl₃) δ 9.04 (s, 1H), 7.60-7.46 (m, 2H), 7.09-6.99 (m, 2H), 6.93 (dd, J=8.4, 2.2 Hz, 1H), 6.86 (d, J=2.1 Hz, 1H), 5.84-5.63 (m, 2H), 5.31 (t, J=4.3 Hz, 1H), 4.39-3.92 (m, 9H), 3.76 (t, J=12.2 Hz, 2H), 3.52-3.34 (m, 4H), 3.27 (d, J=8.8 Hz, 1H), 2.85 (s, 3H), 2.51-2.35 (m, 1H), 2.12-1.98 (m, 2H), 1.81 (q, J=12.0, 10.8 Hz, 4H), 1.65 (d, J=6.8 Hz, 4H), 1.44 (s, 3H), 1.36 (s, 3H).

Example 305

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-tetrahydropyran-4-yl-carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and tetrahydropyran-4-amine in Step 2. LCMS calc. for C₃₆H₄₅ClN₃O₉S [M+H]⁺: m/z=730.25/732.25; Found: 730.2/732.2. ¹H NMR (300 MHz, CDCl₃) δ 9.02 (s, 1H), 7.61-7.53 (m, 2H), 7.15 (s, 1H), 7.05 (d, J=8.3 Hz, 1H), 6.94 (dd, J=8.4, 2.1 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 5.79-5.67 (m, 2H), 5.18 (s, 1H), 4.30 (d, J=7.7 Hz, 1H), 4.22 (d, J=16.7 Hz, 2H), 4.14 (d, J=12.0 Hz, 2H), 4.02 (d, J=11.3 Hz, 2H), 3.84-3.74 (m, 2H), 3.54-3.43 (m, 4H), 3.19 (m, 2H), 2.83-2.72 (m, 1H), 2.41 (s, 1H), 2.04 (dd, J=10.7, 6.1 Hz, 2H), 2.00-1.80 (m, 6H), 1.54 (dd, J=12.4, 3.9 Hz, 2H), 1.45 (s, 3H), 1.39 (s, 3H).

Example 306

[(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methoxy-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N,O-dimethylhydroxylamine hydrochloride in Step 1. LCMS calc. for C₃₃H₄₁ClN₃O₉S [M+H]⁺: m/z=690.22/692.22; Found: 690.0/692.0. ¹H NMR (300 MHz, CDCl₃) δ 9.05 (s, 1H), 7.56 (dd, J=8.4, 2.0 Hz, 2H), 7.10 (d, J=2.2 Hz, 1H), 7.04 (dd, J=8.4, 0.9 Hz, 1H), 6.94 (dd, J=8.5, 2.2 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.82-5.61 (m, 2H), 5.35-5.17 (m, 1H), 4.30-3.99 (m, 5H), 3.77 (dd, J=14.7, 6.0 Hz, 2H), 3.71 (s, 3H), 3.51-3.30 (m, 3H), 3.19 (s, 3H), 2.80 (d, J=7.9 Hz, 1H), 2.47 (tt, J=8.9, 4.9 Hz, 1H), 2.01-1.81 (m, 4H), 1.66 (q, J=9.6 Hz, 2H), 1.45 (s, 3H), 1.38 (s, 3H).

Example 307

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and N,N,N′-trimethylethylenediamine in Step 2. LCMS calc. for C₃₆H₄₉ClN₄O₈S [M+H]⁺: m/z=731.28/733.28; Found: 731.2/733.3. ¹H NMR (300 MHz, CDCl₃) δ 7.57 (d, J=8.4 Hz, 2H), 7.04 (d, J=8.1 Hz, 2H), 6.95 (dd, J=8.3, 1.9 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 5.80 (d, J=37.2 Hz, 2H), 5.26 (s, 1H), 4.32 (s, 1H), 4.25-4.17 (m, 2H), 4.13 (d, J=12.2 Hz, 2H), 3.79 (d, J=14.5 Hz, 2H), 3.44 (d, J=14.7 Hz, 2H), 3.26 (s, 2H), 3.02 (s, 3H), 2.94 (s, 4H), 2.51-2.34 (m, 2H), 2.05 (d, J=8.3 Hz, 2H), 1.97-1.77 (m, 4H), 1.65 (s, 2H), 1.47 (m, 3H), 1.37 (s, 3H), 1.28 (s, 3H).

Example 308

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-3-ethoxypyrrolidine in Step 2. LCMS calc. for C₃₇H₄₇ClN₃O₉S [M+H]⁺: m/z=744.26/746.26; Found: 744.15/746.26; ¹H NMR (300 MHz, CDCl₃) δ 9.49-9.09 (m, 1H), 7.55 (dd, J=8.4, 3.0 Hz, 2H), 7.02 (d, J=6.3 Hz, 2H), 6.93 (d, J=8.4 Hz, 1H), 6.86 (d, J=1.9 Hz, 1H), 5.82 (d, J=14.2 Hz, 1H), 5.73-5.62 (m, 1H), 5.27 (s, 1H), 4.29 (d, J=10.0 Hz, 1H), 4.25-4.15 (m, 2H), 4.08 (dd, J=16.0, 9.3 Hz, 3H), 3.82-3.72 (m, 2H), 3.71-3.61 (m, 4H), 3.42 (dd, J=13.4, 5.8 Hz, 4H), 3.25-3.17 (m, 1H), 2.83 (s, 1H), 2.38 (d, J=8.2 Hz, 1H), 2.13-1.98 (m, 4H), 1.86 (dd, J=14.6, 5.6 Hz, 3H), 1.67-1.60 (m, 1H), 1.45 (s, 3H), 1.35 (s, 3H), 1.29-1.22 (m, 3H).

Example 309

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and 3-methoxyazetidine in Step 2. LCMS calc. for C₃₅H₄₃ClN₃O₉S [M+H]⁺: m/z=716.23/718.23; Found: 716.2/718.3. ¹H NMR (300 MHz, CDCl₃) δ 9.12 (s, 1H), 7.55 (d, J=8.4 Hz, 2H), 7.02 (d, J=8.3 Hz, 2H), 6.93 (dd, J=8.5, 2.0 Hz, 1H), 6.86 (d, J=1.9 Hz, 1H), 5.79 (d, J=15.5 Hz, 1H), 5.70-5.60 (m, 1H), 5.21 (s, 1H), 4.31-4.27 (m, 1H), 4.20 (d, J=8.4 Hz, 3H), 4.13 (s, 1H), 4.10-4.01 (m, 2H), 3.91 (d, J=6.8 Hz, 1H), 3.75 (t, J=12.1 Hz, 2H), 3.42 (s, 2H), 3.38 (s, 1H), 3.31 (s, 3H), 3.22 (dd, J=14.9, 8.9 Hz, 2H), 2.79 (d, J=6.1 Hz, 1H), 2.37 (d, J=5.7 Hz, 1H), 2.09-1.98 (m, 2H), 1.95-1.78 (m, 3H), 1.68-1.59 (m, 1H), 1.45 (s, 3H), 1.36 (s, 3H).

Example 310

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(dimethylamino)pyrrolidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-N,N-dimethylpyrrolidin-3-amine in Step 2. LCMS calc. for C₃₇H₄₈ClN₄O₈S [M+H]⁺: m/z=743.28/745.28; Found: 743.2/745.2. ¹H NMR (300 MHz, CDCl₃) δ 9.20 (s, 1H), 7.53 (dd, J=16.3, 8.7 Hz, 2H), 7.03 (d, J=8.3 Hz, 1H), 6.97-6.88 (m, 2H), 6.86 (d, J=2.0 Hz, 1H), 6.00-5.73 (m, 2H), 5.30 (s, 1H), 4.33 (d, J=11.4 Hz, 1H), 4.29-4.13 (m, 4H), 4.09 (d, J=12.0 Hz, 1H), 3.88 (d, J=14.8 Hz, 1H), 3.75 (d, J=12.1 Hz, 3H), 3.63 (s, 2H), 3.44 (d, J=14.7 Hz, 2H), 3.17-3.06 (m, 1H), 2.87 (d, J=18.8 Hz, 7H), 2.45-2.24 (m, 3H), 2.18 (s, 1H), 2.02 (d, J=14.3 Hz, 1H), 1.88 (s, 3H), 1.71-1.62 (m, 1H), 1.44 (s, 3H), 1.35 (s, 3H).

Example 311

[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate

This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and N,N-dimethylazetidin-3-amine dihydrochloride salt and Hunig's base in Step 2. LCMS calc. for C₃₆H₄₆ClN₄O₈S [M+H]⁺: m/z=729.26/731.26; Found: 729.2/731.5. ¹H NMR (300 MHz, CDCl₃) δ 7.53 (dd, J=18.2, 10.3 Hz, 2H), 7.02 (d, J=8.2 Hz, 1H), 6.97-6.89 (m, 2H), 6.86 (d, J=1.7 Hz, 1H), 6.10 (s, 1H), 5.71 (s, 1H), 5.30 (s, 1H), 4.34 (d, J=11.2 Hz, 2H), 4.26 (d, J=12.1 Hz, 2H), 4.20 (d, J=10.9 Hz, 2H), 4.07 (d, J=12.0 Hz, 1H), 3.80 (d, J=14.7 Hz, 2H), 3.73 (s, 2H), 3.43 (d, J=14.4 Hz, 2H), 3.02 (s, 2H), 2.83 (s, 6H), 2.27 (s, 1H), 2.02 (d, J=14.1 Hz, 2H), 1.85 (s, 3H), 1.65 (d, J=9.2 Hz, 2H), 1.36 (s, 3H), 1.27 (s, 3H).

Example 312

[(3R,6R,7S,8E,22S)-6′-Chloro-10,10-dideuterio-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

Step 1: 2-(1,1-dideuterioallyloxy)-2-methyl-propanoic acid

A suspension of lithium aluminium deuteride (2.0 g, 46.5 mmol) in ether (20 mL) was cooled at −78° C. under N₂. 2-Propenoyl chloride (4.0 mL, 39.44 mmol) in ether (20 mL) was added dropwise over 1 h. at −78° C. The mixture was then allowed to slowly warm to r.t. and stirred overnight. The mixture was carefully quenched at −10° C. with water (4 mL), followed by 15% NaOH (4 mL). The mixture was diluted with water (12 mL), and stirred for 1 h. The mixture was filtered. The filtrate was dried over Na₂SO₄, filtered and the solvent was partially removed under reduced pressure. The crude product (0.25 g, 4.19 mmol) and 2-bromo-2-methyl-propanoic acid (1.0 g, 5.99 mmol) was dissolved in MeCN (3 mL). DIPEA (2.3 g, 18 mmol) was added and the mixture was stirred at 50° C. overnight. The mixture was quenched with 1 M HCl (20 mL) and extracted with EtOAc (20 mL×2). The organic layer was concentrated. The residue was purified with flash chromatography on a silica gel column with EtOAc:Heptane (0% to 40%) to afford 2-(1,1-dideuterioallyloxy)-2-methyl-propanoic acid (500 mg, 40.% yield).

Step 2: (3R,6R,7S,8E,22S)-6′-Chloro-10,10-dideuterio-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one

This compound was prepared using procedures analogous to those described for Example 32 Step 1-2 using 2-(1,1-dideuterioallyloxy)-2-methyl-propanoic acid to replace 2-allyloxy-2-methyl-propanoic acid in Step 1. LCMS calc. for C₃₁H₃₆D2ClN₂O₆S [M+H]⁺: m/z=603.23/604.23; Found: 602.9.1/604.4.

Step 3: [(3R,6R,7S,8E,22S)-6′-Chloro-10,10-dideuterio-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate

This compound was prepared using procedures analogous to those described for Example 34. LCMS calc. for C₃₄H₄₁D₂ClN₃O₇S [M+H]⁺: m/z=674.26/675.26; Found: 674.1/675.4.

Example 313

(3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one

Step 1: (3R,6R,7S,8E,22S)-7-(2-bromoethoxy)-7′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25), 17, 19(24)-tetraene-22,4′-chromane]-13-one

To a solution of (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (130 mg, 0.22 mmol, Example 246) in toluene (4 mL) was added 2,6-ditert-butylpyridine (412 mg, 2.2 mmol) followed by 2-bromoethyl trifluoromethanesulfonate (554 mg, 2.2 mmol). The resulting mixture was stirred at 90° C. overnight. The reaction was quenched with 1N HCl aq. solution (1 mL) and extracted with EtOAc. The combined organic extracts were washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (3% to 60%) to afford (3R,6R,7S,8E,22S)-7-(2-bromoethoxy)-7′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (105 mg, 68.6% yield) as a white solid. LC-MS: calc. for C₃₂H₃₉BrClN₂O₇S [M+H]⁺: m/z=709.1/711.1; Found: 709.0/710.8.

Step 2. (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one

To a stirred solution of (3R,6R,7S,8E,22S)-7-(2-bromoethoxy)-7′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (30 mg, 0.04 mmol) in DMSO (1 mL) was added potassium iodide (35 mg, 0.21 mmol) and dimethylamine (2 M in THF) (9.5 mg, 0.21 mmol). The resulting solution was stirred at 35° C. for 1 h. The reaction mixture was directly purified by prep-HPLC on C18 column (30×250 mm, 10 μm) with MeOH/H₂O (15% to 100%) to afford (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (11 mg, 38.6% yield) as a white solid. LC-MS calc. for C₃₄H₄₅ClN₃O₇S [M+H]⁺: m/z=674.26/676.26; Found: 674.2/676.4.

Example 314

(3R,6R,7S,8E,22S)-7′-chloro-7-[2-(diethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one

This compound was prepared using procedures analogous to those described for Example 313 Step 2 using diethylamine (2 M in THF) to replace dimethylamine (2 M in THF). LC-MS calc. for C₃₆H₄₉ClN₃O₇S [M+H]: m/z=702.29/704.29; Found: 702.0/703.5.

Example 315

(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one

This compound was prepared using procedures analogous to those described for Example 313 Step 2 using pyrrolidine to replace dimethylamine (2 M in THF). LC-MS calc. for C₃₆H₄₇ClN₃O₇S [M+H]: m/z=700.27/702.27; Found: 700.2/702.6.

Single-Crystal X-ray Analysis of Example 34

A saturated solution of Example 34 in ethanol/methyl tert-butyl ether (4/1) was stored at 23-25° C., and after 4 days, cubic crystals were observed. A crystal of approximate dimensions 0.197 mm×0.250 mm×0.345 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured.

The total exposure time was 3.45 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using an orthorhombic unit cell yielded a total of 26210 reflections to a maximum θ angle of 75.55° (0.80 Å resolution), of which 8525 were independent (average redundancy 3.074, completeness=98.9%, R_int=4.77%, R_sig=4.89%) and 7840 (91.96%) were greater than 2σ(F²). The final cell constants of a=9.1529(13) Å, b=11.1812(17) Å, c=41.054(7) Å, volume=4201.5(11) ų, are based upon the refinement of the XYZ-centroids of 9678 reflections above 20 σ(I) with 6.463⁰<2θ<150.8°. Data were corrected for absorption effects using the Multi-Scan method (SADAB S). The ratio of minimum to maximum apparent transmission was 0.838. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.5830 and 0.7240.

FIG. 1 shows an ORTEP representation of the compound of Example 34. The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P 21 21 21, with Z=4 for the formula unit, C₄₀H₆₀ClN₃O₁₀S. The final anisotropic full-matrix least-squares refinement on F² with 504 variables converged at R1=7.06%, for the observed data and wR2=20.53% for all data. The goodness-of-fit was 1.151. The largest peak in the final difference electron density synthesis was 0.445 e/ų and the largest hole was −0.447 e/ų with an RMS deviation of 0.091 e⁻/ų. On the basis of the final model, the calculated density was 1.281 g/cm³ and F (000), 1736 e⁻.

TABLE E1
Sample and crystal data for Example 34.
	Identification code	Example 34
	Chemical formula	C40H60ClN3O10S
		(includes 3 ethanols)
	Formula weight	810.42 g/mol
	Temperature	150(2) K
	Wavelength	1.54178 Å
	Crystal size	0.197 × 0.250 × 0.345 mm
	Crystal system	orthorhombic
	Space group	P 21 21 21
	Unit cell	a = 9.1529(13) Å	α = 90°
	dimensions	b = 11.1812(17) Å	β = 90°
		c = 41.054(7) Å	γ = 90°
	Volume	4201.5(11) Å3
	Z	4
	Density (calculated)	1.281 g/cm3
	Absorption	1.752 mm−1
	coefficient
	F(000)	1736

TABLE E2
Data collection and structure refinement for Example 34.
Theta range for data	2.15 to 75.55°
collection
Index ranges	−11 <= h <= 11, −13 <= k <= 13,
	−51 <= 1 <= 51
Reflections collected	26210
Independent reflections	8525 [R(int) = 0.0477]
Coverage of independent	98.9%
reflections
Absorption correction	Multi-Scan
Max. and min. transmission	0.7240 and 0.5830
Structure solution technique	direct methods
Structure solution program	XT, VERSION 2014/5
Refinement method	Full-matrix least-squares on F2
Refinement program	SHELXL-2018/3 (Sheldrick, 2018)
Function minimized	Σ w(Fo2 − Fc2)2
Data/restraints/parameters	8525/0/504
Goodness-of-fit on F2	1.151
Δ/σmax	0.001
Final R indices	7840 data; I > 2σ(I)	R1 = 0.0706,
		wR2 = 0.2010
	all data	R1 = 0.0740,
		wR2 = 0.2053
Weighting scheme	w = 1/[σ2(Fo2) + (0.1199P)2 +
	1.8325P] where P = (Fo2 + 2Fc2)/3
Absolute structure	0.002 (11)
parameter
Extinction coefficient	0.0048(6)
Largest diff. peak and hole	0.445 and −0.447 eÅ−3
R.M.S. deviation from	0.091 eÅ−3
mean

The binding affinity of each compound was measured via a fluorescence polarization competition assay, in which the compound competes for the same binding site with the ligand, and thus leads to a dose-dependent anisotropy reduction. The tracer ligand utilized was a fluorescein isothiocyanate labelled peptide (FITC-ARIAQELRRIGDEFNETYTR) derived from Bim (GenScript).

The assay was carried out in black half-area 96-well NBS plate (Corning), containing 15 nM of MCL-1 (BPS Bioscience), 5 nM of FITC-Bim and 3-fold serial diluted test compounds in a total volume of 50 μL of assay buffer (20 mM HEPES, 50 mM NaCl, 0.002% Tween 20, 1 mM TCEP, and 1% DMSO). The reaction plate was incubated for 1 hour at room temperature. The change of anisotropy is measured with an Envision multimode plate reader (PerkinElmer) at emission wavelength 535 nm. Fluorescence polarization was calculated in mP unit and the percentage inhibition was calculated by % inhibition=100×(mP_DMSO−mP)/(mP_DMSO−mP_PC), in which mPDMSO is the DMSO control, and mPpc is the positive control. IC₅₀ values were determined from a 10-point dose response curve by fitting the percent inhibition against compound concentration using the GraphPad Prism software. The inhibition constant K_i was subsequently calculated according to the Nikolovska-Coleska's equation (Anal. Biochem., 2004, 332, 261),

$K_i=\frac{{\left[I\right]}_{50}}{\frac{{\left[L\right]}_{50}}{K_d}+\frac{{\left[P\right]}_0}{K_d}+1}$

• • where [I]₅₀ is the concentration of the free inhibitor at 50% inhibition, [L]₅₀ is the concentration of the free labeled ligand at 50% inhibition, [P]₀ is the concentration of the free protein at 0% inhibition, and K_d is the dissociation constant of the protein-ligand complex. See Table F.

Caspase 3/7 Activity Assay

Dispense 10 μL aliquot of prepared H929 cells (1:1 ratio of cells:Trypan Blue (#1450013, Bio-Rad)) onto cell counting slide (#145-0011, Bio-Rad) and obtain cell density and cell viability using cell counter (TC20, Bio-Rad). Remove appropriate volume of resuspended cells from culture flask to accommodate 2000 cells/well @ 5 μL/well. Transfer H929 cells to 50 mL conical (#430290, Corning) for each of the FBS concentration to be assayed (10%, 0.1%). Spin down at 1000 rpm for 5 min. using tabletop centrifuge (SPINCHRON 15, Beckman). Discard supernatant and resuspend cell pellet in modified RPMI 1640 (#10-040-CV, Corning) cell culture media containing sodium pyruvate (100 mM) (#25-000-CL, Corning), HEPES buffer (1 M) (#25-060-CL, Corning) and glucose (200 g/L) (A24940-01, Gibco) with appropriate FBS (F2422-500ML, Sigma) concentration to a cell density of 400,000 cells/mL. Dispense 5 μL of resuspended H929 cells per well in 384-well small volume TC treated plate (#784080, Greiner Bio-one) using standard cassette (#50950372, Thermo Scientific) on Multidrop Combi (#5840310, Thermo Scientific) in laminar flow cabinet. Dispense compounds onto plates using digital liquid dispenser (D300E, Tecan). Incubate plates in humidified tissue culture incubator @ 37° C. for 4 hours. Add 5 μL of prepared Caspase-Glo® 3/7 detection buffer (G8093, Promega) to each well of 384-well plate using small tube cassette (#24073295, Thermo Scientific) on Combi multi-drop, incubate @ RT for 30-60 min. Read plates with microplate reader (PheraStar, BMG Labtech) using 384 well luminescence mode.

Cell Viability Assay (H929 10 FBS)

Dispense 10 μL aliquot of prepared H929 cells (1:1 ratio of cells:Trypan Blue (#1450013, Bio-Rad)) onto cell counting slide (#145-0011, Bio-Rad) and obtain cell density and cell viability using cell counter (TC20, Bio-Rad). Remove appropriate volume of resuspended cells from culture flask to accommodate 4000 cells/well @ 10 μL/well. Transfer H929 cells to 50 mL conical (#430290, Corning). Spin down at 1000 rpm for 5 min using tabletop centrifuge (SPINCHRON 15, Beckman). Discard supernatant and resuspend cell pellet in modified RPMI 1640 (#10-040-CV, Corning) cell culture media containing 10% FBS (F2422-500 ML, Sigma), sodium pyruvate (100 mM) (#25-000-CL, Corning), HEPES buffer (1 M) (#25-060-CL, Corning) and glucose (200 g/L) (A24940-01, Gibco) to a cell density of 400,000 cells/mL. Dispense 10 μL of resuspended H929 cells per well in 384-well small volume TC treated plate (#784080, Greiner Bio-one) using standard cassette (#50950372, Thermo Scientific) on Multi-drop Combi (#5840310, Thermo Scientific) in laminar flow cabinet. Dispense compounds onto plates using digital liquid dispenser (D300E, Tecan). Incubate plates in humidified tissue culture incubator @ 37° C. for 24 hours. Add 10 μL of prepared CellTiTer-Glo® detection buffer (G7570, Promega) or ATPlite 1 Step detection reagent (#6016731, Perkin Elmer) to each well of 384-well plate using small tube cassette (#24073295, Thermo Scientific) on Combi multi drop, incubate @ RT for 30-60 min. Read plates with microplate reader (PheraStar, BMG Labtech) using 384 well luminescence mode.

Cytotoxicity Studies in NCI-H929 Cells

Cytotoxicity studies were conducted in NCI-H929 multiple myeloma cell line. Cells were maintained in RPMI 1640 (Corning Cellgro, Catalog #: 10-040-CV) supplemented with 10% v/v FBS (GE Healthcare, Catalog #: SH30910.03), 10 mM HEPES (Corning, Catalog #: 25-060-CI), 1 mM sodium pyruvate (Corning Cellgro, Catalog #: 25-000-CI and 2500 mg/L glucose (Gibco, Catalog #: A24940-01). Cells were seeded in 96-well plates at a density of 75000 cells/well. Compounds dissolved in DMSO were plated in duplicate using a digital dispenser (Tecan D300E) and tested on a 9-point 3-fold serial dilution. Cells were incubated for 24 hr in a 37° C. incubator at 5% CO₂. Cell viability was measured using the Cell Counting Kit-8 (CCK-8, Jojindo, CK04-13) as per manufacturer's instructions. Cells were incubated for 4 hours at 37° C. 5% CO₂ following addition of reagent and OD₄₅₀ values were measured with a microplate reader (iMark microplate reader, Bio-Rad). Background from media only wells were averaged and subtracted from all readings. OD₄₅₀ values were then normalized to DMSO controls to obtain percentage of viable cells, relative to DMSO vehicle control and plotted in Graphpad Prism ([Inhibitor] vs. normalized response−Variable slope; equation: Y=100/(1+(X{circumflex over ( )}HillSlope)/(IC₅₀{circumflex over ( )}HillSlope))) to determine ICso values (the concentration of compound inhibiting half of the maximal activity).

TABLE F
Cell free Mcl-1:Bim affinity assay (Mcl-1 Bim) and
Cell viability assay (H929_10FBS)
Ex.		H929_10FBS
No.	BIM_Ki (nM)	IC50 (nM)
1	45.6	#
2	179	#
3	143	#
4	207	#
5	37.3	#
6	35.7	#
7	227	NT
8	424	#
9	1640	#
10	1430	#
11	503	#
12	15.8	#
13	22	#
14	222	NT
15	8.7	#
16	9	#
17	7.4	#
18	1.4	#
19	9.3	#
20	21.8	#
21	53.3	#
22	57	#
23	73.6	#
24	6.0	#
25	9.0	#
26	++	#
27	++	#
28	+++	#
29	+++	##
30	+++	##
31	++	#
32	+++	###
33	+++	###
34	+++	###
35	++	#
36	+++	##
37	+++	###
38	+++	###
39	+++	##
40	+++	###
41	+++	###
42	++	###
43	++	#
44	+++	###
45	+++	###
46	+++	###
47	+++	###
48	+++	###
49	+++	###
50	+++	###
51	+++	###
52	+++	###
53	+++	###
54	+++	###
55	+++	###
56	+++	###
57	+++	###
58	+++	###
59	+++	###
60	+++	###
61	+++	###
62	+++	###
63	+++	###
64	+++	###
65	+++	###
66	+++	###
67	++	#
68	++	#
69	++	#
70	++	#
71	++	#
72	++	#
73	++	#
74	+++	#
75	++	#
76	++	#
77	++	#
78	++	#
79	++	#
80	++	#
81	++	#
82	++	#
83	++	#
84	++	#
85	++	#
86	++	#
87	+++	##
88	+++	##
89	++	#
90	+++	#
91	++	#
92	+++	##
93	++	#
94	+++	#
95	++	#
96	+++	#
97	+++	#
98	++	#
99	++	#
100	++	#
101	+++	#
102	++	#
103	+++	#
104	+++	#
105	++	#
106	++	##
107	++	##
108	++	#
109	++	#
110	++	#
111	++	#
112	++	#
113	+++	##
114	+++	##
115	++	#
116	++	##
117	++	#
118	++	#
119	++	##
120	++	##
121	++	#
122	++	#
123	++	##
124	++	##
125	+++	#
126	++	#
127	++	##
128	++	#
129	++	#
130	++	#
131	++	#
132	++	###
133	++	#
134	++	#
135	++	#
136	++	#
137	++	##
138	++	##
139	++	##
140	+++	###
141	+++	###
142	+++	##
143	+++	###
144	++	#
145	+++	###
146	++	###
147	+++	###
148	+++	###
149	+++	###
150	+++	##
151	+++	###
152	+++	###
153	+++	###
154	+++	###
155	+++	###
156	+++	###
157	+++	###
158	+++	###
159	+++	###
160	+++	###
161	+++	##
162	+++	###
163	+++	###
164	+++	###
165	+++	###
166	+++	###
167	+++	###
168	+++	###
169	+++	###
170	+++	##
171	+++	###
172	+++	###
173	+++	###
174	+++	###
175	+++	###
176	+++	###
177	++	###
178	+++	###
179	+++	###
180	+++	###
181	+++	###
182	+++	###
183	+++	###
184	+++	###
185	+++	###
186	+++	###
187	+++	###
188	+++	###
189	+++	###
190	+++	###
191	+++	###
192	+++	###
193	++	###
194	+++	###
195	+++	###
196	++	#
197	++	#
198	+++	###
199	+++	###
200	++	###
201	+++	###
202	+++	###
203	+++	###
204	+++	###
205	++	###
206	+++	###
207	+++	###
208	++	###
209	+++	###
210	+++	###
211	+++	###
212	+++	###
213	+++	###
214	+++	###
215	+++	###
216	+++	###
217	+++	###
218	+++	###
219	++	###
220	+++	###
221	+++	###
222	+++	###
223	+++	###
224	+++	###
225	++	###
226	+++	###
227	+++	###
228	+++	###
229	+++	###
230	+++	###
231	+++	###
232	+++	###
233	+++	###
234	+++	###
235	+++	###
236	+++	###
237	+++	###
238	+++	###
239	+++	###
240	+++	###
241	+++	###
242	+++	###
243	+++	###
244	+++	###
245	+++	###
246	++	#
247	+++	###
248	+++	#
249	++	#
250	+++	###
251	++	#
252	++	#
253	++	#
254	++	#
255	++	#
256	++	#
257	++	#
258	+++	###
259	+++	###
260	+++	###
261	+++	###
262	+++	###
263	+++	###
264	+++	###
265	++	###
266	+++	###
267	++	##
268	+++	###
269	+++	###
270	+++	###
271	+++	###
272	+++	###
273	+++	##
274	+++	##
275	++	###
276	+++	##
277	++	#
278	+++	###
279	+++	###
280	+++	###
281	+++	###
282	+++	###
283	+++	###
284	+++	###
285	+++	###
286	++	#
287	+++	###
288	++	#
289	++	#
290	+++	###
291	+++	##
292	+++	###
293	+++	###
294	++	###
295	++	#
296	++	###
297	++	#
298	+++	##
299	+++	##
300	+++	##
301	+++	###
302	+++	###
303	+++	###
304	+++	###
305	+++	###
306	+++	###
307	+++	###
308	+++	###
309	+++	##
310	+++	###
311	+++	###
312	+++	###
313	NT	NT
314	NT	NT
315	NT	NT
+++ Ki < 1 nM; ++ Ki = 1 nM-100 nM; ### IC50 < 500 nM; ## IC50 < 1000 nM; # IC50 > 1000 nM; NT = not tested

In some embodiments, the invention is directed to the following aspects:

• Aspect 1. A compound of Formula I:

• • or a pharmaceutically acceptable salt or solvate thereof;
  • wherein
  • Z is CH or N;
  • Q is —O—, —S—, —S(O)—, or —S(O)₂—;
  • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —NR^2B—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—NR^2B, —S—CR^2BR^2C—CR²R^2A, or —CR²R^2A—CR^2BR^2C—S—;
  • L¹ is absent or is optionally substituted —C₁-C₆alkylene-;
  • L² is absent or is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁴ is absent, or is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; or is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • L⁵ is absent, or is —C₁-C₆ alkylene-, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein said C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene, arylene, heteroarylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, —(CR⁷R⁸)_sO(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR⁹(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sS(O)₂(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sOC(O)NR^9A(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)O(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AC(O)NR^9B(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AS(O)(CR⁷R⁸)_t—, —(CR⁷R⁸)_sNR^9AS(O)₂(CR⁷R⁸)_t—; —(CR⁷R⁸)_s—CR^4A═CR^4B—(CR⁷R⁸)_t—, —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)_t—; —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-O—, or —(CR⁷R⁸)_sC(═O)(CR⁷R⁸)t-NR⁶—;
  • each n is independently 0-3;
  • each m is independently 0-2;
  • each p is independently 0-4;
  • each q is independently 0-4;
  • each s is independently 0-3;
  • each t is independently 0-4;
  • each R is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, -cycloalkyl, —OR^a, —SR^a, —C(O)R^b, —C(O)OR^a, —NR^cR^d, —C(O)NR^cR^d, or —S(O)₂R^a; wherein said —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₁-C₆alkoxy, or -cycloalkyl is optionally substituted;
  • each R¹ is independently -D, -halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OR^a, —SR^a, —NR^cR^d, —C(O)R^b, —OC(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)₂R^a; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein said —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted;
  • each R², R^2A, or R^2a is independently H, D, halo, OR^a, optionally substituted C₁-C₆alkyl, or R² and R^2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
  • each R^2B and R^2C is independently H, D, optionally substituted C₁-C₆alkyl, or R^2B and R^2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
  • R³ is H, D, —C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, heterocycloalkyl, C(O)R^b, C(O)OR^a, or C(O)NR^cR^d; wherein said C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R³ is —C₁-C₆alkyl substituted at the C₁ carbon atom with —OR^3A wherein R^3A is C₁-C₆alkyl, —PO₃H, —C(O)OR^2C, or —C(O)NR^3AR^3B wherein R^3A and R^3B are each independently H, D, optionally substituted C₁-C₆alkyl;
  • each R⁴ or R⁷ is independently H, D, halo, —OH, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —OR^a, —SR^a, —NR^cR^d, —NR^aR^c, —C(O)R^b, —OC(O)R^a, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b, or —S(O)₂R^b, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkenyl, or heterocycloalkyl is optionally substituted;
  • each R^4A or R^4B is independently H, D, -Me, —CF₃ or —F;
  • each R⁵ or R⁸ is independently H, D, fluoro, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • or R⁴ and R⁵ together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • or an R⁴ and an R⁵ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • or R⁷ and R⁸ together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted;
  • or an R⁷ and an R⁸ attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
  • each R⁶ or R⁹ is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b or —S(O)₂R^b, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted;
  • or R⁹ together with either an R⁷ or an R⁸ forms an optionally substituted heterocyclic alkylene;
  • each R^6A, R^6B, R^9A, or R^9B is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • or R^6A and R^6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
  • or R^9A and R^9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
  • each R^a is independently H, D, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —P(OR^c)₂, —P(O)R^cR^b, P(O)OR^cOR^b, —S(O)R^b, —S(O)NR^cR^d, —S(O)₂R^b, —S(O)₂NR^cR^d, —B(OR^c)(OR^b), SiR^b₃, —C₁-C₁₀alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • each R^b, is independently H, D, —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said —C₁-C₆ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
  • each R^c or R^d is independently H, D, —C₁-C₁₀ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted;
  • or R^c and R^d, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.
• Aspect 2. The compound according to aspect 1 having the Formula IA-0,

• • or a pharmaceutically acceptable salt or solvate thereof;wherein
  • Z is CH or N;
  • Q is —O—, —S—, —S(O)—, or —S(O)₂—;
  • the moiety —W¹—W²—W³ is —CR²R^2A—CR²R^2A—CR²R^2A—, —O—CR^2BR²CR²R^2A—, —CR²R^2A—CR^2BR^2C—O—, —NR^2B—CR^2BR^2C—CR²R^2A—, —CR²R^2A—CR^2BR^2C—NR^2B, —S—CR^2BR^2C—CR²R^2A—, or —CR²R^2A—CR^2BR^2C—S—;
  • L¹ is optionally substituted —C₁-C₆alkylene-;
  • L² is optionally substituted 3-7 membered cycloalkylene, optionally substituted 4-7 membered heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁴ is absent, or is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O)—, —C(═O)NR^6A—,—NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—; or is —(CR⁴R⁵)_p—(CR^4A═CR^4B)—(CR⁴R⁵)_q—O—;
  • L⁵ is absent, or is —C₁-C₆ alkylene-, —C₂-C₆ alkenylene-, —C₂-C₆ alkynylene-, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein said C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene groups are optionally substituted;
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, —S(O)₂(CR⁷R⁸)_t—, —NR^9AC(O)(CR⁷R⁸)_t—, —C(O)NR^9A(CR⁷R⁸)_t—, —R^9AC(O)O(CR⁷R⁸)_t—, —NR^9AC(O)NR^9B(CR⁷R⁸)_t—, —NR^9AS(O)(CR⁷R⁸)_t—, —NR^9AS(O)₂(CR⁷R⁸)_t—; —CR^4A═CR^4B—(CR⁷R⁸)_t—, —C(═O)(CR⁷R⁸)_t—; —C(═O)(CR⁷R⁸)_t—O—, or —C(═O)(CR⁷R⁸)t-NR⁶—;
  • each n is independently 0-3;
  • each m is independently 0-2;
  • each p is independently 0-4;
  • each q is independently 0-4;
  • each s is independently 0-3;
  • each t is independently 0-4;
  • each R is independently D, halo, —CN, —NO₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkoxy, C₃-C₆cycloalkyl, —OR^a, —SR^a, —C(O)R^b, —C(O)OR^a, —NR^cR^d, —C(O)NR^cR^d, or —S(O)₂R^a; wherein said C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkoxy, or C₃-C₆cycloalkyl is optionally substituted;
  • each R¹ is independently D, halo, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OR^a, —SR^a, —NR^cR^d, —C(O)R^b, —OC(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)₂R^a; aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, is optionally substituted;
  • each R², R^2A, or R^2a is independently H, D, halo, —OR^a, optionally substituted —C₁-C₆alkyl, or R² and R^2A, that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted 3-7 membered cycloalkyl ring;
  • R^2B and R^2C are each independently H, D, optionally substituted C₁-C₆alkyl, or R^2B and R^2C may, together with the carbon atom to which they are both attached, form an optionally substituted 3-7 membered cycloalkyl ring;
  • R³ is H, D, —C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, 3-7 membered cycloalkyl, -4-7 membered heterocycloalkyl, —C(O)R^b, —C(O)OR^a, or —C(O)NR^cR^d; wherein said C₁-C₆alkyl, —C₃-C₆alkenyl, —C₃-C₆alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted; or R³ is —C₁-C₆alkyl substituted at the C₁ carbon atom with —OR^3A wherein R^3A is C₁-C₆alkyl, —PO₃H, —C(O)OR^2C, or —C(O)NR^3AR^3B wherein R^3A and R^3B are each independently H, D, optionally substituted C₁-C₆alkyl;
  • each R⁴ or R⁷ is independently H, D, halo, —OH, —CN, —NO₂, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, 3-7 membered cycloalkyl, —OR^a, —SR^a, —NR^cR^d, —NR^aR^c, —C(O)R^b, —OC(O)R^a, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b, —S(O)₂R^b, aryl, heteroaryl, or heterocycloalkyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • each R^4A or R^4B is independently H, D, -Me, —CF₃ or —F;
  • each R⁵ or R⁸ is independently H, D, fluoro, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —C(O)R^c, —C(O)OR^c, —C(O)NR^cR^d, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • or R⁴ and R⁵ together with the C atom to which they are attached form a cycloalkyl or heterocycloalkyl ring, each optionally substituted;
  • or R⁷ and R⁸ together with the C atom to which they are attached form a cycloalkyl or heterocycloalkyl ring, each optionally substituted;
  • each R⁶ or R⁹ is independently H, D, —C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, —C(O)R^b, —C(O)OR^a, —C(O)NR^cR^d, —S(O)R^b or —S(O)₂R^b, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, —OC₁-C₆alkyl, -aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
  • each R^6A, R^6B, R^9A, or R^9B is independently H, D, C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, wherein said C₁-C₆alkyl, —C₂-C₆alkenyl, —C₂-C₆alkynyl, 3-7 membered cycloalkyl, or 4-7 membered heterocycloalkyl is optionally substituted;
  • or R^6A and R^6B together with the atoms to which they are attached form an optionally substituted heterocycloalkyl ring;
  • or R^9A and R^9B together with the N atom to which they are attached form an optionally substituted heterocycloalkyl ring;
  • each R^a is independently H, D, —C(O)R^b, —C(O)OR^e, —C(O)NR^cR^d, —P(OR^c)₂, —P(O)R^cR^b, P(O)OR^cOR^b, —S(O)R^b, —S(O)NR^cR^d, —S(O)₂R^b, —S(O)₂NR^cR^d, —B(OR^c)(OR^b), —SiR^b₃, —C₁-C₁₀alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
  • each R^b is independently H, D, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, wherein said C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
  • each R^c or R^d is independently H, D, C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, is optionally substituted;
  • or R^c and R^d, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic-4-10 membered heterocycloalkyl group.
• Aspect 3. The compound according to either aspect 1 or aspect 2, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA:

wherein W¹ is —CH₂— and W³ is —O—, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —S—, or W¹ is —S— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —NR^2B—, or W¹ is —NR^2B— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—.

• Aspect 4. The compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-1:

• Aspect 5. The compound according to aspect 4, wherein W¹ is —CH₂— or —O—.
• Aspect 6. A compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-2:

• Aspect 7. The compound according to aspect 6, wherein W³ is —CH₂— or —O—.
• Aspect 8. The compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-3:

wherein W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—.

• Aspect 9. The compound according to any one of aspects 1-8, wherein L¹ is optionally substituted C₁alkylene.
• Aspect 10. The compound according to aspect 9, wherein L¹ is —CH₂—.
• Aspect 11. The compound according to any one of aspects 1-10, wherein L² is optionally substituted cycloalkylene or optionally substituted heterocycloalkylene.
• Aspect 12. The compound according to aspect 11, wherein L¹ is —CH₂—; and L² is optionally substituted cyclobutylene or optionally substituted pyrrolidine.
• Aspect 13. The compound according to any one of aspects 1-12, wherein said compound is a compound of Formula IA-4:

• • or a pharmaceutically acceptable salt or solvate thereof; wherein
  • W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—;
  • L³ is absent, or is —(CR⁴R⁵)_p—, —(CR⁴R⁵)_pO—, —S(O)—, —S(O)₂—, —C(═O)—, —C(═O)O—, —C(═O)NR^6A—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁴ is absent, or —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—,—NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁵ is absent, or is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, —S(O)₂(CR⁷R⁸)_t—, —NR^9AC(O)(CR⁷R⁸)_t—, —C(O)NR^9A(CR⁷R⁸)_t—, —R^9AC(O)O(CR⁷R⁸)_t—, —NR^9AC(O)NR^9B(CR⁷R⁸)_t—, —NR^9AS(O)(CR⁷R⁸)_t—, —NR^9AS(O)₂(CR⁷R⁸)_t—; —CR^4A═CR^4B—(CR⁷R⁸)_t—, —C(═O)(CR⁷R⁸)_t—; —C(═O)(CR⁷R⁸)t-O—, or —C(═O)(CR⁷R⁸)t-NR⁶—.
• Aspect 14. The compound according to any one of aspects 1-13, or a pharmaceutically acceptable salt or solvate thereof; wherein
  • L³ absent;
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(O)₂—;
  • L⁵ is absent; and
  • L⁶ is absent, or is —(CR⁷R⁸)_s—, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, —S(O)₂(CR⁷R⁸)_t—, —NR^9AC(O)(CR⁷R⁸)_t—, —C(O)NR^9A(CR⁷R⁸)_t—, —R^9AC(O)O(CR⁷R⁸)_t—, —NR^9AC(O)NR^9B(CR⁷R⁸)_t—, —NR^9AS(O)(CR⁷R⁸)_t—, —NR^9AS(O)₂(CR⁷R⁸)_t—; —CR^4A═CR^4B—(CR⁷R⁸)_t—, —C(═O)(CR⁷R⁸)_t—; —C(═O)(CR⁷R⁸)t-O—, or —C(═O)(CR⁷R⁸)t-NR⁶—.
• Aspect 15. The compound according to any one of aspects 1-14, wherein
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—; and
  • L⁶ is absent, —O(CR⁷R⁸)_t—, or —NR⁹(CR⁷R⁸)_t—.
• Aspect 16. The compound according to any one of aspects 1-15, wherein
  • p=¹;
  • q=1-4; and
  • t=1.
• Aspect 17. The compound according to any one of aspects 1-13, or a pharmaceutically acceptable salt or solvate thereof; wherein
  • L³ absent;
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is absent, —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —NR⁶—, —OC(═O)—, —C(═O)O—, —NR^6AC(O), —C(═O)NR^6A—, —NR^6AC(O)R^6B—, —OC(═O)N(R^6A)—, —NR^6AC(O)O—, —S(═O)NR^6A—, —NR^6AS(O)—, —S(═O)₂NR^6A—, or —NR^6AS(═O)₂—;
  • L⁵ is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and
  • L⁶ is absent, or is —(CR⁷R⁸)_s—.
• Aspect 18. The compound according to any one of aspects 1-13 or 17, wherein
  • L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q—, wherein Q¹ is —CR^4A═CR^4B—, —O—, —S—, —S(O)—, —S(O)₂—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)N(R^6A)—, or —NR^6AC(O)O—;
  • L⁵ is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene is optionally substituted; and
  • L⁶ is absent, or is —(CR⁷R⁸)_s—.
• Aspect 19. The compound according to any one of aspects 1 to 14, or a pharmaceutically acceptable salt or solvate thereof; wherein L⁴ is —(CR⁴R⁵)_pQ¹(CR⁴R⁵)_q— wherein p=1; q=1-3, Q¹ is absent, or —CR^4A═CR^4B—; L⁶ is (CR⁷R⁸)_s wherein s=1-2, —O(CR⁷R⁸)_t—, —NR⁹(CR⁷R⁸)_t—, —S(CR⁷R⁸)_t—, —S(O)(CR⁷R⁸)_t—, or —S(O)₂(CR⁷R⁸)_t—, wherein t=1.
• Aspect 20. The compound according to any one of aspects 1-14 or 19, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is a compound of Formula IA-8:

• • wherein X is O, NR⁹, CR⁷R⁸, S, S(O), SO₂;
  • R is halo or C₁-C₆alkyl;
  • represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵, an (E)-carbon-carbon double bond, or a (Z)-carbon-carbon double bond;
  • R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, P(OR)₂, P(O)R^cR^b, P(O)OR^cOR^b, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, S(O)₂NR^cR^d, B(OR^c)(OR^b), SiR^b₃, C₁-C₁₀alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₁₀alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
  • R^c* is R^c wherein R^c is H, D, —C₁-C₁₀ alkyl, —C₂-C₆ alkenyl, —C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, —OC₁-C₆alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.
• Aspect 21. The compound according to aspect 20, wherein represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵.
• Aspect 22. The compound according to aspect 20, wherein represents a carbon-carbon double bond substituted with R^4A and R^4B.
• Aspect 23. The compound according to aspect 22, wherein represents a (E)-carbon-carbon double bond substituted with R^4A and R^4B.
• Aspect 24. The compound according to any one of aspects 20-23, wherein X is —O—, —NR⁹—, or —CR⁷R⁸—.
• Aspect 25. The compound according to any one of aspects 20-24, wherein R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, —S(O)₂R^b, or optionally substituted C₁-C₁₀alkyl; and R^c* is R^c wherein R^c is H or optionally substituted C₁-C₁₀alkyl.
• Aspect 26. The compound according to any one of aspects 20-25, wherein R is —C₁.
• Aspect 27. The compound according to any one of aspects 20-26, wherein each R⁴ and R⁵ is independently H or C₁-C₆alkyl.
• Aspect 28. The compound according to any one of aspects 1-14 or 19, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is a compound of Formula IA-5:

• • wherein X is —O—, —NR⁹—, —CR⁷R⁸—, —S—, —S(O)—, —SO₂—; R is halo or C₁-C₆alkyl;
  • represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵, an (E)-carbon-carbon double bond substituted with R^4A and R^4B, or a (Z)-carbon-carbon double bond substituted with R^4A and R^4B; and R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)OR^c, —C(O)NR^cR^d, P(OR)₂, P(O)R^cR^b, P(O)OR^cOR^b, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, S(O)₂NR^cR^d, B(OR^c)(OR^b), SiR^b₃, C₁-C₁₀alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C₁-C₁₀ alkyl, C₂-C₁₀alkenyl, C₂-C₁₀ alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted.
• Aspect 29. The compound according to aspect 28, wherein represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R⁴ and R⁵.
• Aspect 30. The compound according to aspect 28, wherein represents a carbon-carbon double bond substituted with R^4A and R^4B.
• Aspect 31. The compound according to any one of aspects 28-30 wherein X is —O—, —NR⁹—, or —CR⁷R⁸—.
• Aspect 32. The compound according to any one of aspects 28-31, wherein R^a* is R^a wherein R^a is H, —C(O)R^b, —C(O)NR^cR^d, optionally substituted C₁-C₁₀alkyl, optionally substituted C₂-C₁₀alkenyl, optionally substituted C₂-C₁₀ alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.
• Aspect 33. The compound according to aspect 30, having the structure IA-6:

•  or a pharmaceutically acceptable salt or solvate thereof;
  • wherein X is —O—, —NR⁹—, or —CR⁷R⁸—; and
  • W¹ is —CH₂— and W³ is O, or W¹ is —O— and W³ is —CH₂—, or W¹ is —CH₂— and W³ is —CH₂—.
• Aspect 34. The compound according to any one of aspects 28-33, wherein each R⁴ or R⁵ is independently H, D, or C₁-C₆alkyl.
• Aspect 35. The compound according to any one of aspects 20-34, wherein X is —CR⁷R⁸—.
• Aspect 36. The compound according to any one of aspects 20-34, wherein X is —O—.
• Aspect 37. The compound according to any one of aspects 20-34, wherein X is —NR⁹—.
• Aspect 38. The compound according to aspect 37, wherein X is —NR⁹— wherein R⁹ is H; optionally substituted —C₁-C₆alkyl; optionally substituted —C(O)OC₁-C₆alkyl; optionally substituted —SO₂C₁-C₆alkyl; optionally substituted —C(O)C₁-C₆alkyl; optionally substituted —C(O)NR^cR^d; or wherein R⁹ together with either R⁷ or R⁸ form an optionally substituted C₁-C₆alkylene group.
• Aspect 39. The compound according to aspect 38, wherein X is —NR⁹— wherein R⁹ is H; —C₁-C₆alkyl, optionally substituted with deuterium; —C(O)OC₁-C₆alkyl; —SO₂C₁-C₆alkyl; —C(O)C₁-C₆alkyl; or wherein R⁹ together with either R⁷ or R⁸ form a C₁-C₆alkylene group.
• Aspect 40. The compound according to aspect 39, wherein X is —NR⁹— wherein R⁹ is H; —CH₃; —CH₂CH₃, —CH₂CH₂CH₃, -CD₃, —C(O)OCH₃; —C(O)OC(CH₃)₃, —SO₂CH₃; or —C(O)CH₃.
• Aspect 41. The compound according to anyone of aspects 20-40, wherein each R⁷ and each R⁸ is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C₁-C₆alkyl;
  • or R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring;
  • or R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
• Aspect 42. The compound of aspect 41, wherein each R⁷ and each R⁸ is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C₁-C₆alkyl;
  • or wherein R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring;
  • or R⁷ and R⁸ attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.
• Aspect 43. The compound of aspect 42, wherein R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring;
  • or R⁷ and R⁸ attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.
• Aspect 44. The compound of aspect 42, wherein R⁷ or R⁸ are each independently H, —CH₃, -cyclopropyl, —CH₂CH₃, or —CH(CH₃)₂.
• Aspect 45. The compound of aspect 42, wherein R⁷ and R⁸ attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
• Aspect 46. The compound of aspect 41, wherein each R⁷ and each R⁸ is independently H, or a —C₁-C₆alkyl group optionally substituted with —OH; optionally substituted —OC₁-C₆alkyl; optionally substituted —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10; or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, optionally substituted —C₁-C₆alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.
• Aspect 47. The compound of aspect 46, wherein the —C₁-C₆alkyl group is optionally substituted with —OH; —OC₁-C₆alkyl; —(CH₂CH₂O)_oC₁-C₆alkyl wherein o is 1-10; or —C(O)NR^c1R^d1 wherein R^c1 and R^d1 are independently H, C₁-C₆alkyl, or 4-7 membered heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form a monocyclic or multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo; —OC₁-C₆alkyl; or —C₁-C₆alkyl optionally substituted with —OH or —OC₁-C₆alkyl.
• Aspect 48. The compound of any one of aspects 28-47, wherein R^a* is R^a wherein R^a is H.
• Aspect 49. The compound of any one of aspects 28-47, wherein R^a* is R^a wherein R^a is —C(O)R^b.
• Aspect 50. The compound of any one of aspects 28-47, wherein R^a* is R^a wherein R^a is —C(O)R^b wherein R^b is optionally substituted —C₁-C₆alkyl.
• Aspect 51. The compound of aspect 50, wherein R^a* is R^a wherein R^a is —C(O)R^b wherein R^b is —C₁-C₆alkyl.
• Aspect 52. The compound of aspect 51, wherein R^a* is R^a wherein R^a is —C(O)R^b wherein R^b is —CH₃.
• Aspect 53. The compound of any one of aspects 28-47, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d.
• Aspect 54. The compound of any one of aspects 28-47, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; optionally substituted —OC₁-C₆alkyl; optionally substituted cycloalkyl; optionally substituted —C₁-C₆alkyl, or optionally substituted heterocycloalkyl.
• Aspect 55. The compound of aspect 54, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; optionally substituted 3-7 membered cycloalkyl; —OC₁-C₆alkyl; —C₁-C₆alkyl (optionally substituted with deuterium, halo, optionally substituted cycloalkyl, optionally substituted —OC₁-C₆alkyl, —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or optionally substituted —C₁-C₆alkyl, optionally substituted 4-7 membered heterocycloalkyl, or optionally substituted 5-6 membered heteroaryl); or optionally substituted 4-7 membered heterocycloalkyl.
• Aspect 56. The compound aspect 54, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d are independently H; 3-7 membered cycloalkyl; —C₁-C₆alkyl (optionally substituted with deuterium, halo, —OC₁-C₆alkyl, cycloalkyl, —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or —C₁-C₆alkyl, 4-7 membered heterocycloalkyl (optionally substituted with halo, —C₁-C₆alkyl, —OH, or —OC₁-C₆alkyl), or -5-6 membered heteroaryl), —OC₁-C₆alkyl; or -4-7 membered heterocycloalkyl optionally substituted with —C₁-C₆alkyl or —OH.
• Aspect 57. The compound of any one of aspects 33-39, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.
• Aspect 58. The compound of aspect 47, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl group optionally substituted with -halo, —OH, optionally substituted -4-7 membered heterocycle, optionally substituted 5-6 membered heteroaryl, optionally substituted —OC₁-C₆alkyl, optionally substituted —C₁-C₆alkyl; or —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or optionally substituted C₁-C₆alkyl.
• Aspect 59. The compound of aspect 28-47, wherein R^a* is R^a wherein R^a is —C(O)NR^cR^d wherein R^c and R^d, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic-4-10 membered heterocycloalkyl group optionally substituted with -halo, —OH, -4-7 membered heterocycle, 5-6 membered heteroaryl, —OC₁-C₆alkyl, —C₁-C₆alkyl (optionally substituted with —OH, —OC₁-C₆alkyl, or NR^c1R^d1 wherein R^c1 and R^d1 are independently H or C₁-C₆alkyl); or —NR^c1R^d1 wherein R^c1 and R^d1 are independently H or C₁-C₆alkyl.
• Aspect 60. The compound according to any one of aspects 28-47, wherein R^a* is R^a wherein R^a is optionally substituted —C₁-C₁₀alkyl.
• Aspect 61. The compound of aspect 60, wherein R^a* is R^a wherein R^a is —C₁-C₁₀alkyl optionally substituted with —C(O)NR^c1R^d1, wherein R^c1 and R^d1 are independently H, optionally substituted C₁-C₆alkyl, or optionally substituted heterocyclyl; or wherein or R^c1 and R^d1 together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic-4-10 membered heterocycloalkyl group; —NR^c1R^d1 wherein R^c1 and R^d1 are independently H, optionally substituted C₁-C₆alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; optionally substituted heteroaryl; —C(O)OH; or optionally substituted -heterocycloalkyl.
• Aspect 62. The compound of aspect 61, wherein R^a* is R^a wherein R^a is —C₁-C₁₀alkyl optionally substituted with —C(O)NR^c1R^d1, wherein R^c1 and R^d1 are independently H, C₁-C₆alkyl (optionally substituted with —OC₁-C₆alkyl), or 4-7 membered heterocycloalkyl; or wherein or R^c1 and R^d1, together with the N atom to which they are both attached, form a monocyclic or multicyclic-4-10 membered heterocycloalkyl group (optionally substituted with halo, —OC₁-C₆alkyl, or —C₁-C₆alkyl (optionally substituted with —OH or —OC₁-C₆alkyl)); —NR^c1R^d1 wherein R^c1 and R^d1 are independently H, or optionally substituted C₁-C₆alkyl; —C₄-C₅heteroaryl; —C(O)OH; or -4-7 membered heterocycloalkyl optionally substituted with halo, C₁-C₆alkyl, or —OC₁-C₆alkyl.
• Aspect 63. The compound according to any one of aspects 28-62, wherein the compound has the structure (IA-7):

• • wherein W¹ is —CH₂— and W³ is —O—; or W¹ is —O— and W³ is —CH₂—; or W¹ is —CH₂— and W³ is —CH₂—.
• Aspect 64. The compound according to aspect 63, wherein W¹ is —CH₂— and W³ is —CH₂—.
• Aspect 65. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is:
• (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7R,8E,12 S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(dimethylamino)pyrrolidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methyl-1,4-diazepane-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-propyl-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-1-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-ethoxyazetidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)-1,4-diazepane-1-carboxylate;
• [(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate;
• (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• (3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-1,3-propylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N-methyl-N[2-(dimethylamino)ethyl] carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate;
• 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-tetrahydropyran-4-yl-acetamide;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-6′-chloro-7,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• [(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
• [(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methoxy-N-methyl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate;
• [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate;
• [(3R,6R,7S,8E,22S)-6′-Chloro-10,10-dideuterio-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
• (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
• (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(diethyl amino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
• (3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
• [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate; or
• [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate.
• Aspect 66. A pharmaceutical composition comprising a compound according to any one of aspects 1 to 65 and a pharmaceutically acceptable excipient.
• Aspect 67. A method of inhibiting an MCL-1 enzyme comprising contacting the MCL-1 enzyme with an effective amount of a compound of any one of aspects 1 to 65.
• Aspect 68. A method of treating a disease or disorder associated with aberrant MCL-1 activity in a subject comprising administering to the subject, a compound of any one of aspects 1 to 65.
• Aspect 69. The method of aspect 68, wherein the disease or disorder associated with aberrant MCL-1 activity is colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.

Claims

1. A compound of Formula IA-5:

2. The compound according to claim 1, wherein represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5.

3. The compound according to claim 1, wherein represents a carbon-carbon double bond substituted with R4A and R4B.

4. The compound according to claim 1, wherein X is —O—, —NR9—, or —CR7R8—.

5. The compound according to claim 1, wherein Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)NRcRd, optionally substituted C1-C10alkyl, optionally substituted C2-C10alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

6. The compound according to claim 1, having the structure IA-6:

7. The compound according to claim 6, wherein each R4 or R5 is independently H or C1-C6alkyl.

8. The compound according to claim 6, wherein X is —CR7R8—.

9. The compound according to claim 6, wherein X is —O—.

10. The compound according to claim 6, wherein X is —NR9—.

11. The compound according to claim 10, wherein X is —NR9— wherein R9 is H; optionally substituted —C1-C6alkyl; optionally substituted —C(O)OC1-C6alkyl; optionally substituted —SO2C1-C6alkyl; optionally substituted —C(O)C1-C6alkyl; optionally substituted —C(O)NRcRd; or wherein R9 together with either R7 or R8 form an optionally substituted C1-C6alkylene group.

12. The compound according to claim 6, wherein each R7 and each R8 is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C1-C6alkyl; or R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring;or R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.

13. The compound of claim 12, wherein R7 or R8 are each independently H, —CH3, -cyclopropyl, —CH2CH3, or —CH(CH3)2.

14. The compound of claim 12, wherein R7 and R8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.

15. The compound of claim 14, wherein each R7 and each R8 is independently H, or a —C1-C6alkyl group optionally substituted with —OH; optionally substituted —OC1-C6alkyl; optionally substituted —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted —C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.

16. The compound of claim 1, wherein Ra* is Ra wherein Ra is H.

17. The compound of claim 1, wherein Ra* is Ra wherein Ra is —C(O)Rb.

18. The compound of claim 1, wherein Ra* is Ra wherein Ra is —C(O)NRcRd.

19. The compound of claim 18, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd are independently H; optionally substituted —OC1-C6alkyl; optionally substituted cycloalkyl; optionally substituted —C1-C6alkyl, or optionally substituted heterocycloalkyl.

20. The compound of claim 18, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.

21. The compound according to claim 1, wherein Ra* is Ra wherein Ra is optionally substituted —C1-C10alkyl.

22. The compound according to claim 6, wherein the compound has the structure (IA-7):

23. The compound according to claim 22, wherein W1 is —CH2— and W3 is —CH2—.

24. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is: (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;(3R,6R,7R,8E,12 S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;(3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one;(3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;(3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;(3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(dimethylamino)pyrrolidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methyl-1,4-diazepane-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-propyl-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-1-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-ethoxyazetidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)-1,4-diazepane-1-carboxylate;[(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate;(3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-1,3-propylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N-methyl-N[2-(dimethylamino)ethyl] carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate;2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-tetrahydropyran-4-yl-acetamide;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;[(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate[(3R,6R,7S,8E,22S)-6′-chloro-7,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate[(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate; or[(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate.

25. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

26. A method of inhibiting an MCL-1 enzyme comprising contacting the MCL-1 enzyme with an effective amount of a compound of claim 1.

27. A method of treating a disease or disorder associated with aberrant MCL-1 activity in a subject comprising administering to the subject, a compound of claim 1.

28. The method of claim 27, wherein the disease or disorder associated with aberrant MCL-1 activity is colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.